Datasets:

tasksource

/

nli4ct

like 1

Follow

tasksource 14

Single

Results

NCT02260531

the percentage of participants achieving complete response (CR) or partial response (PR) was 6x higher in the HER2-positive group in the primary trial, than in the ER+ and/or PR+ group.

Contradiction

{'Clinical Trial ID': 'NCT02260531', 'Intervention': ['INTERVENTION 1: ', ' Cohort 1 - Cabozantinib, Trastuzumab for HER2+', ' HER2-positive', ' Cabozantinib- orally administered daily per treatment cycle', ' Trastuzumab- IV administered once per cycle', ' MRI- Baseline, Cycle 2 Day 1, and every 2 cycles', ' Magnetic Resonance Angiography (MRA ), Baseline, Cycle 2 Day 1,', ' Cabozantinib: One, 60 mg tablet daily of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.', ' Trastuzumab: For HER2-Positive participants only. Administered by IV on day 1 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.', 'INTERVENTION 2: ', ' Cohort 2 - Cabozantinib for ER+ and/or PR+', ' Hormone receptor-positive (ER+ and/or PR+)', ' Cabozantinib- orally administered daily per treatment cycle', ' MRI- Baseline, Cycle 2 Day 1, and every 2 cycles', ' Magnetic Resonance Angiography (MRA ), Baseline, Cycle 2 Day 1,', ' Cabozantinib: One, 60 mg tablet daily of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.'], 'Eligibility': ['Inclusion Criteria:', ' Patients must have histologically or cytologically confirmed invasive breast cancer, with stage IV disease.', " New or progressive CNS lesions, as assessed by the patient's treating physician.", ' For patients who have received prior cranial radiation, no increase in corticosteroid dose in the week prior to the baseline brain MRI', ' Discontinued prior therapy (with the exception of trastuzumab for patients with HER2+ breast cancer)', ' Recovery to baseline or Grade 1 CTCAE v.4.0 from toxicities related to any prior treatments, unless AE(s) are clinically nonsignificant and/or stable on supportive therapy;', ' The subject has an ECOG performance status of 0 or 1', ' Patients must have normal organ and marrow function and laboratory values as follows within 14 days before the first dose of cabozantinib', ' Sexually active subjects (men and women) must agree to use medically accepted barrier methods of contraception (e.g., male or female condom) during the course of the study and for 4 months after the last dose of study drug(s)', ' Subjects of childbearing potential must not be pregnant at screening.', ' Patients on bisphosphonates may continue receiving bisphosphonate therapy during study. Patients wanting to initiate bisphosphonate therapy may do so.', ' The subject has had an assessment of all known disease sites eg, by computerized tomography (CT) scan, magnetic resonance imaging (MRI), bone scan as appropriate, within 28 days before the first dose of cabozantinib', 'Exclusion Criteria:', ' The subject has received cabozantinib or another c-Met inhibitor (please note ARQ 197 is not considered a MET inhibitor for purposes of this study given data to suggest it inhibits tubulin)', ' The subject has uncontrolled, significant intercurrent or recent illness', ' Leptomeningeal disease as the only site of CNS involvement', ' Known contraindication to MRI with gadolinium contrast, such as cardiac pacemaker, shrapnel, or ocular foreign body', ' More than 2 seizures over the last 4 weeks prior to study entry', ' Grade 1 or higher CNS hemorrhage on baseline brain MRI, or history of grade 2 or higher CNS hemorrhage within 12 months', ' Has experienced clinically-significant GI bleeding within 6 months before first dose of cabozantinib; hemoptysis of 0.5 teaspoon (2.5ml) of red blood within 3 months before the first dose of cabozantinib; any other signs indicative of pulmonary hemorrhage within 3 months before the first dose of cabozantinib', ' The subject has tumor in contact with, invading or encasing any major blood vessels', ' The subject has evidence of tumor invading the GI tract (esophagus, stomach, small or large bowel, rectum or anus), or any evidence of endotracheal or endobronchial tumor within 28 days before the first dose of cabozantinib', ' The subject requires concomitant treatment, in therapeutic doses, with anticoagulants. Low dose aspirin ( 81 mg/day), low-dose warfarin ( 1 mg/day), and prophylactic LMWH are permitted.', ' The subject has prothrombin time (PT)/INR or partial thromboplastin time (PTT) test 1.3 × the laboratory ULN within 7 days before the first dose of cabozantinib.', ' Inability to swallow intact tablets', ' Pregnant or lactating females', ' Diagnosis of another malignancy within 2 years before the first dose of cabozantinib, except for superficial skin cancers, or localized, low grade tumors deemed cured and not treated with systemic therapy', ' Subjects with clinically relevant ongoing complications from prior radiation therapy are not eligible', ' The subject is known to be positive for the human immunodeficiency virus (HIV)', ' Subjects with clinically relevant ongoing complications from prior surgery are not eligible', ' QTcF > 500 msec on average of screening EKGs performed within 28 days of first dose of cabozantinib. Three EKGs must be performed at screening. If the average of these three consecutive results for QTcF is > 500 msec, the subject is ineligible.', ' Active infection requiring IV antibiotics at Day 1 of cycle 1', ' No prior lapatinib within 7 days prior to initiation of protocol treatment', ' Receive concurrent investigational agents while on study', ' Receive any concurrent chemotherapy, radiotherapy, or hormonal therapy while on study', ' Previously identified allergy or hypersensitivity to components of the cabozantinib formulations', ' The subject requires chronic concomitant treatment with strong CYP3A4 inducers'], 'Results': ['Outcome Measurement: ', ' CNS Objective Response Rate (ORR)', ' The central nervous system (CNS) ORR was defined as the percentage of participants achieving complete response (CR) or partial response (PR) based on RECIST 1.1 criteria in the evaluation CNS lesions on treatment: CR is complete disappearance of all target lesions and PR is at least a 30% decrease in the sum of longest diameter (LD) of target lesions, taking as reference baseline sum LD. PR or better overall response assumes at a minimum incomplete response/stable disease (SD) for the evaluation of non-target lesions and absence of new lesions.', ' Time frame: Disease assessments occurred every 6 cycles. Patients with stable or responsive disease after completion of 6 cycles could reduce frequency of assessments to every 3 cycles. Response was evaluated up to 25 months.', 'Results 1: ', ' Arm/Group Title: Cohort 1 - Cabozantinib, Trastuzumab for HER2+', ' Arm/Group Description: HER2-positive', ' Cabozantinib- orally administered daily per treatment cycle', ' Trastuzumab- IV administered once per cycle', ' MRI- Baseline, Cycle 2 Day 1, and every 2 cycles', ' Magnetic Resonance Angiography (MRA ), Baseline, Cycle 2 Day 1,', ' Cabozantinib: One, 60 mg tablet daily of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.', ' Trastuzumab: For HER2-Positive participants only. Administered by IV on day 1 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.', ' Overall Number of Participants Analyzed: 21', ' Measure Type: Number', ' Unit of Measure: percentage of participants 5 (.2 to 24)', 'Results 2: ', ' Arm/Group Title: Cohort 2 - Cabozantinib for ER+ and/or PR+', ' Arm/Group Description: Hormone receptor-positive (ER+ and/or PR+)', ' Cabozantinib- orally administered daily per treatment cycle', ' MRI- Baseline, Cycle 2 Day 1, and every 2 cycles', ' Magnetic Resonance Angiography (MRA ), Baseline, Cycle 2 Day 1,', ' Cabozantinib: One, 60 mg tablet daily of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.', ' Overall Number of Participants Analyzed: 7', ' Measure Type: Number', ' Unit of Measure: percentage of participants 14 (.4 to 58)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 6/21 (28.57%)', ' Diarrhea 1/21 (4.76%)', ' Dyspepsia 0/21 (0.00%)', ' Mucositis oral 0/21 (0.00%)', ' Nausea 0/21 (0.00%)', ' Vomiting 1/21 (4.76%)', ' Fatigue 1/21 (4.76%)', ' Portal vein thrombosis 0/21 (0.00%)', ' Ejection fraction decreased 1/21 (4.76%)', ' Alanine aminotransferase increased 0/21 (0.00%)', ' Aspartate aminotransferase increased 0/21 (0.00%)', ' Lipase increased 3/21 (14.29%)', 'Adverse Events 2:', ' Total: 4/7 (57.14%)', ' Diarrhea 0/7 (0.00%)', ' Dyspepsia 1/7 (14.29%)', ' Mucositis oral 1/7 (14.29%)', ' Nausea 0/7 (0.00%)', ' Vomiting 0/7 (0.00%)', ' Fatigue 1/7 (14.29%)', ' Portal vein thrombosis 1/7 (14.29%)', ' Ejection fraction decreased 0/7 (0.00%)', ' Alanine aminotransferase increased 1/7 (14.29%)', ' Aspartate aminotransferase increased 2/7 (28.57%)', ' Lipase increased 0/7 (0.00%)']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

7d7a9a69-533a-4480-b2e7-aa59eb8a738b

Single

Results

NCT00036270

In total Less than 10% of patients in the primary trial either had a disease relapse or died.

Entailment

{'Clinical Trial ID': 'NCT00036270', 'Intervention': ['INTERVENTION 1: ', ' Exemestane', ' Exemestane (Aromasin®) 25 mg QD for 5 years.', 'INTERVENTION 2: ', ' Tamoxifen Followed by Exemestane', ' Tamoxifen 20 mg QD; upon completing 2.5 years to 3 years of tamoxifen, participants were to be switched to exemestane 25 mg QD and then were to complete a total of 5 years endocrine therapy.'], 'Eligibility': ['Inclusion Criteria:', ' Histologically/cytologically confirmed adenocarcinoma of the breast, followed by adequate surgical resection and/or radiotherapy, and/or adjuvant chemotherapy, if indicated.', ' Stage T1-3 N0-2 Mo, Any TNM stage BC for whom adjuvant hormonal therapy is being considered.', 'Exclusion Criteria:', ' Those patients not deemed to have had potentially curative primary surgical treatment or one of the following criteria:', ' Inflammatory breast cancer', ' Histologically positive supraclavicular nodes', ' Ulceration/infiltration of local skin metastasis', ' Neoadjuvant chemotherapy', ' Ductal carcinoma in situ (DCIS) or lobular carcinoma in situ (LCIS) without invasion', ' ER and PR negative primary tumor or ER/PR unknown status.'], 'Results': ['Outcome Measurement: ', ' Disease Free Survival (DFS): Number of Events (Disease Relapse or Death) From Baseline up to 2.75 Years', ' Number of events (disease relapse or death) to time of observation for DFS. DFS defined as time from randomization to earliest documentation of disease relapse or death from any cause in postmenopausal, receptor positive, node negative or node positive breast cancer patients for adjuvant treatment with exemestane compared with adjuvant tamoxifen therapy at 2.75 years. Disease relapse: primary tumor recurrence (locoregional or distant) and ipsilateral or contralateral breast cancer (CBC). Intercurrent death: death without disease relapse.', ' Time frame: Baseline (Month 0) up to 2.75 years', 'Results 1: ', ' Arm/Group Title: Exemestane', ' Arm/Group Description: Exemestane (Aromasin ) 25 mg QD for 5 years.', ' Overall Number of Participants Analyzed: 4898', ' Measure Type: Number', ' Unit of Measure: Events (disease relapse or death) 352', 'Results 2: ', ' Arm/Group Title: Tamoxifen Followed by Exemestane', ' Arm/Group Description: Tamoxifen 20 mg QD; upon completing 2.5 years to 3 years of tamoxifen, participants were to be switched to exemestane 25 mg QD and then were to complete a total of 5 years endocrine therapy.', ' Overall Number of Participants Analyzed: 4868', ' Measure Type: Number', ' Unit of Measure: Events (disease relapse or death) 388'], 'Adverse Events': ['Adverse Events 1:', ' Total: 784/4814 (16.29%)', ' Anaemia * 5/4814 (0.10%)', ' Anaemia vitamin B12 deficiency * 1/4814 (0.02%)', ' Coagulopathy * 1/4814 (0.02%)', ' Febrile neutropenia * 0/4814 (0.00%)', ' Haemorrhagic anaemia * 0/4814 (0.00%)', ' Iron deficiency anaemia * 1/4814 (0.02%)', ' Leukocytosis * 1/4814 (0.02%)', ' Leukopenia * 1/4814 (0.02%)', ' Lymphadenopathy * 1/4814 (0.02%)', ' Neutropenia * 0/4814 (0.00%)', 'Adverse Events 2:', ' Total: 831/4852 (17.13%)', ' Anaemia * 12/4852 (0.25%)', ' Anaemia vitamin B12 deficiency * 0/4852 (0.00%)', ' Coagulopathy * 0/4852 (0.00%)', ' Febrile neutropenia * 2/4852 (0.04%)', ' Haemorrhagic anaemia * 1/4852 (0.02%)', ' Iron deficiency anaemia * 0/4852 (0.00%)', ' Leukocytosis * 0/4852 (0.00%)', ' Leukopenia * 1/4852 (0.02%)', ' Lymphadenopathy * 3/4852 (0.06%)', ' Neutropenia * 1/4852 (0.02%)']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

c6fc8336-7c74-443e-9548-3bbafe21fc37

Single

Eligibility

NCT01351376

Patients currently prescribed Diuretics are excluded from the primary trial.

Entailment

{'Clinical Trial ID': 'NCT01351376', 'Intervention': ['INTERVENTION 1: ', ' Placebo', ' CDT + inactive LLL', ' Low Level Laser Therapy: Placebo LLL combined with CDT', 'INTERVENTION 2: ', ' LLL Combined With CDT', ' CDT + active LLL', ' Low Level Laser: Active LLL combined with CDT'], 'Eligibility': ['Inclusion Criteria:', ' unilateral breast cancer with ipsilateral lumpectomy or mastectomy and lymph node dissection (sentinel biopsy or axillary dissection)', ' stage II or III unilateral secondary upper extremity lymphedema (as defined by the International Society of Lymphology)', ' girth 2 cm circumferential difference and/or volume 200 mL compared to the uninvolved upper extremity at any 4 cm segment', ' able to commit to a long term follow-up schedule', 'Exclusion Criteria:', ' active cancer/metastatic cancer', ' currently receiving or have plans for adjuvant radiation or chemotherapy', ' pregnant', ' presence of other extremity lymphedema (primary or secondary)', ' pacemaker', ' artificial joints in the upper quadrants', ' renal failure', ' arterial insufficiency', ' congestive heart failure', ' chronic inflammatory conditions', ' history of deep vein thrombosis (DVT) in the lymphedematous upper extremity', ' previous treatment with Low Level Laser (regardless of indication)', ' medication(s) known to affect body fluid balance', ' body mass index (BMI) > 40 (morbid obesity)'], 'Results': ['Outcome Measurement: ', ' Arm Volume', ' [Not Specified]', ' Time frame: 13 Months', 'Results 1: ', ' Arm/Group Title: Placebo', ' Arm/Group Description: CDT + inactive LLL', ' Low Level Laser Therapy: Placebo LLL combined with CDT', ' Overall Number of Participants Analyzed: 10', ' Mean (Standard Deviation)', ' Unit of Measure: cm^3 1.48 (1.01)', 'Results 2: ', ' Arm/Group Title: LLL Combined With CDT', ' Arm/Group Description: CDT + active LLL', ' Low Level Laser: Active LLL combined with CDT', ' Overall Number of Participants Analyzed: 11', ' Mean (Standard Deviation)', ' Unit of Measure: cm^3 1.58 (1.0)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 0/10 (0.00%)', 'Adverse Events 2:', ' Total: 0/11 (0.00%)']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

9035000f-d87b-439f-882a-e6e30694e391

Comparison

Intervention

NCT03210220

NCT00290745

Unlike the primary trial, the secondary trial does not test Gonadotrophin-releasing Hormone Analogues or medical devices.

Contradiction

{'Clinical Trial ID': 'NCT03210220', 'Intervention': ['INTERVENTION 1: ', ' Pecs Group', ' Ultrasound guided pectoral nerve block is performed right after induction, before surgery. The needle is advanced to the tissue plane between the pectoralis major and pectoralis minor muscle at the vicinity of the pectoral branch of the acromiothoracic artery, and 10 mL of 0.5% ropivacaine deposited. In a similar manner, 20 mL is deposited at the level of the third rib between the pectoralis minor muscle and the serratus anterior muscle .', 'INTERVENTION 2: ', ' Control Group', 'There is no block.'], 'Eligibility': ['Inclusion Criteria:', ' American Society of Anesthesiologists( ASA) I or II Scheduled for breast cancer surgery', 'Exclusion Criteria:', ' Sensitivity to local anesthetic, Bleeding disorders , Receiving anticoagulant, Body mass index (BMI) > 35/kg/m2 , Spine or chest wall deformity , Pregnancy'], 'Results': ['Outcome Measurement: ', ' Intraoperative Remifentanil Consumption', ' Intraoperative remifentanil consumption during surgery(whole intraoperative period)', ' Time frame: whole intraoperative period', 'Results 1: ', ' Arm/Group Title: Pecs Group', ' Arm/Group Description: Ultrasound guided pectoral nerve block is performed right after induction, before surgery. The needle is advanced to the tissue plane between the pectoralis major and pectoralis minor muscle at the vicinity of the pectoral branch of the acromiothoracic artery, and 10 mL of 0.5% ropivacaine deposited. In a similar manner, 20 mL is deposited at the level of the third rib between the pectoralis minor muscle and the serratus anterior muscle .', ' Overall Number of Participants Analyzed: 19', ' Mean (Standard Deviation)', ' Unit of Measure: μg/kg/h 6.75 (2.18)', 'Results 2: ', ' Arm/Group Title: Control Group', ' Arm/Group Description: There is no block.', ' Overall Number of Participants Analyzed: 20', ' Mean (Standard Deviation)', ' Unit of Measure: μg/kg/h 10.12 (3.68)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 0/19 (0.00%)', 'Adverse Events 2:', ' Total: 0/20 (0.00%)']}

{'Clinical Trial ID': 'NCT00290745', 'Intervention': ['INTERVENTION 1: ', ' Tamoxifen or Letrozole', ' tamoxifen or letrozole work in treating women with ductal carcinoma in situ', ' letrozole', ' tamoxifen citrate', ' conventional surgery', ' neoadjuvant therapy'], 'Eligibility': ['DISEASE CHARACTERISTICS:', ' Diagnosis of ductal carcinoma in situ (DCIS) on core biopsy', ' No evidence of contralateral breast disease or palpable masses on breast examination', ' No presence or suspicion of invasive cancer, including contralateral invasive cancer, on core biopsy and MRI', ' No documented ipsilateral axillary adenopathy', ' Planning to undergo lumpectomy or mastectomy', ' Estrogen receptor (ER)-positive tumor by immunohistochemistry', ' PATIENT CHARACTERISTICS:', ' Female patient', ' Premenopausal or postmenopausal', ' Postmenopausal is defined by any of the following:', ' No spontaneous menses for >= 1 year', ' Bilateral oophorectomy', ' Radiation castration and amenorrheic for >= 3 months', ' Follicle-stimulating hormone (FSH) > 20 IU/L AND off all hormonal therapy (e.g., hormone replacement therapy or birth control pills) for >= 1 month', ' Not pregnant or nursing', ' Negative pregnancy test', ' Fertile patients must use effective contraception', ' No co-morbidities contraindicating the use of tamoxifen, including any of the following:', ' Prior history of thrombotic events', ' History of hypercoagulable state', ' History of endometrial hyperplasia', ' Abnormal vaginal bleeding', ' No history of contrast dye-related allergies/reactions', ' No history of metal-containing prostheses or implants', ' PRIOR CONCURRENT THERAPY:', ' See Disease Characteristics'], 'Results': ['Outcome Measurement: ', ' Median Change in 6-month Tumor Volume Compared to Baseline Using Mammography', ' Change in size of Ductal Carcinoma in situ (DCIS) for participants on hormonal therapy, as determined by mammography are determined by (1) largest diameter of tumor, as visualized on mammography (2) extent of disease on mammography (3) quantification of mammographically-detected change from baseline to 6-month and used to generate the change in tumor volume of mammographic extent of disease from baseline. Since values were not normally distributed, the median change was calculated, and Wilcoxon sign rank tests were used to evaluate the significance of these changes', ' Time frame: Baseline and 6 months', 'Results 1: ', ' Arm/Group Title: Tamoxifen or Letrozole', ' Arm/Group Description: tamoxifen or letrozole work in treating women with ductal carcinoma in situ', ' letrozole', ' tamoxifen citrate', ' conventional surgery', ' neoadjuvant therapy', ' Overall Number of Participants Analyzed: 54', ' Median (Inter-Quartile Range)', ' Unit of Measure: change in tumor volume (mm) -5.0 (-10.4 to 0.4)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 0/0']}

522ca0ec-aeb0-4083-a274-ab58c2cddb8a

Single

Adverse Events

NCT01127763

There were 4% more cases (1 more case) of Dyspnea than Dehydration in the primary trial.

Entailment

{'Clinical Trial ID': 'NCT01127763', 'Intervention': ['INTERVENTION 1: ', ' RAD001+Carboplatin', ' Carboplatin (starting dose was initially AUC 6, later decreased to AUC 5, then AUC 4) every 3 weeks as IV infusion and RAD001 as 5 mg pill each day until disease progression or unacceptable toxicity.', 'RAD001', 'Carboplatin'], 'Eligibility': ['Inclusion Criteria:', ' Women with metastatic breast cancer (measurable or evaluable including bone metastases only)', ' Histologically confirmed triple negative breast cancer (estrogen receptor (ER)< 10%, progesterone receptor (PR) < 10 %, Her2neu IHC 0 or 1 or FISH negative)', ' Age >= 18 years', ' World Health Organization performance status <= 2', ' Adequate bone marrow function as shown by: absolute neutrophil count 1.5 x 10^9/L, Platelets 100 x 10^9/L, Hb >9 g/dL', ' Adequate liver function as shown by:', ' serum bilirubin 1.5 x upper limit of normal (ULN)', ' international normalized ratio (INR): Patients not on warfarin INR 1.5; Patients on warfarin INR 3; Patient on stable dose of low molecular weight heparin for >2 weeks at time of treatment is allowed.', ' alanine aminotransferase and aspartate aminotransferase 2.5x ULN ( 5x ULN in patients with liver metastases)', ' Adequate renal function: serum creatinine 1.5 x ULN', ' Fasting serum cholesterol 300 mg/dL OR 7.75 mmol/L AND fasting triglycerides 2.5 x ULN. NOTE: In case one or both of these thresholds are exceeded, the patient can only be included after initiation of appropriate lipid lowering medication.', ' Signed informed consent', ' Patients may have had 0-3 prior regimens for metastatic disease and prior bevacizumab (avastin) is allowed.', ' A baseline lung CT (or PET/CT)', ' O2 sat >= 90% in room air (if <90%, spirometry and diffusion capacity of lung for carbon monoxide (DLCO) above 50% of the normal predicted value of pulmonary function tests)', ' Negative serum pregnancy test within 7 days prior to starting treatment', 'Exclusion Criteria:', ' Patients currently receiving anticancer therapies or who have received anticancer therapies within 2 weeks of the start of study drug (including chemotherapy, radiation therapy, and biologics)', ' Patients, who have had a major surgery or significant traumatic injury within 4 weeks of start of study drug, patients who have not recovered from the side effects of any major surgery (defined as requiring general anesthesia) or patients that may require major surgery during the course of the study', ' Prior treatment with any investigational drug within the preceding 2 weeks', ' Patients receiving chronic, systemic treatment with corticosteroids or another immunosuppressive agent, except corticosteroids with a daily dosage equivalent to prednisone 20 mg. However, patients receiving corticosteroids must have been on a stable dosage regimen for a minimum of 4 weeks prior to the first treatment with RAD001. Topical or inhaled corticosteroids are allowed.', ' Patients should not receive immunization with attenuated live vaccines within one week of study entry or during study period', ' Uncontrolled brain or leptomeningeal metastases, including patients who continue to require glucocorticoids for brain or leptomeningeal metastases', ' Other malignancies within the past 3 years except for adequately treated carcinoma of the cervix or basal or squamous cell carcinomas of the skin.', ' Patients who have any severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the study such as:', ' Symptomatic congestive heart failure of New York heart Association Class III or IV', ' unstable angina pectoris, symptomatic congestive heart failure, myocardial infarction within 6 months of start of study drug, serious uncontrolled cardiac arrhythmia or any other clinically significant cardiac disease', ' severely impaired lung function as defined as spirometry and DLCO that is 50% of the normal predicted value and/or 02 saturation that is 88% or less at rest on room air', ' uncontrolled diabetes as defined by fasting serum glucose >1.5 x ULN', ' active (acute or chronic) or uncontrolled severe infections', ' liver disease such as cirrhosis, chronic active hepatitis or chronic persistent hepatitis. Note: A detailed assessment of Hepatitis B/C medical history and risk factors must be done at screening for all patients. HBV DNA and HCV RNA polymerase chain reaction testing are required at screening for all patients with a positive medical history based on risk factors and/or confirmation of prior HBV/HCV infection.', ' A known history of HIV seropositivity', ' Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of RAD001 (e.g., ulcerative disease, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome or small bowel resection)', ' Patients with an active, bleeding diathesis', ' Female patients who are pregnant or breast feeding, or adults of reproductive potential who are not using effective birth control methods. If barrier contraceptives are being used, these must be continued throughout the trial by both sexes. Hormonal contraceptives are not acceptable as a sole method of contraception. (Women of childbearing potential must have a negative urine or serum pregnancy test within 7 days prior to administration of RAD001)', ' Patients who have received prior treatment with an mTOR inhibitor (sirolimus, temsirolimus, everolimus).', ' Patients with a known hypersensitivity to RAD001 (everolimus) or other rapamycins (sirolimus, temsirolimus) or to its excipients', ' History of noncompliance to medical regimens', ' Patients unwilling to or unable to comply with the protocol', ' Ongoing alcohol or drug addiction'], 'Results': ['Outcome Measurement: ', ' Clinical Benefit Rate (Complete Response, Partial Response, and Stable Disease That Lasts More Than 6 Months)', ' Clinical benefit rate is defined as the number of patients with complete response (CR), partial response (PR), or stable disease (SD) that lasts at least 6 months. Response was assessed every 2 cycles of treatment (6 weeks) by computed tomography (CT), CT/positron emission tomography (PET), or magnetic resonance imaging (MRI). Overall response evaluation is based on Response Evaluation Criteria In Solid Tumors 1.0 (RECIST 1.0). Per RECIST 1.0 for target lesions: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.', ' Time frame: up to 1 year', 'Results 1: ', ' Arm/Group Title: RAD001+Carboplatin', ' Arm/Group Description: Carboplatin (starting dose was initially AUC 6, later decreased to AUC 5, then AUC 4) every 3 weeks as IV infusion and RAD001 as 5 mg pill each day until disease progression or unacceptable toxicity.', ' RAD001', ' Carboplatin', ' Overall Number of Participants Analyzed: 25', ' Measure Type: Number', ' Unit of Measure: percentage of patients 36 (21 to 57)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 5/25 (20.00%)', ' Hypertension 1/25 (4.00%)', ' Dehydration 1/25 (4.00%)', ' Infection With Normal Anc Or Grade 1 Or 2 Neutrophils 2/25 (8.00%)', ' Pain 1/25 (4.00%)', ' Dyspnea (Shortness Of Breath) 2/25 (8.00%)']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

46d65581-7a0a-423b-907e-662c1f5843cc

Comparison

Intervention

NCT02413008

NCT02725801

The intervention in the primary trial requires patients to receive multiple applications of treatment over a period of several weeks, whereas the interventions for the secondary trial are only apllied once.

Entailment

{'Clinical Trial ID': 'NCT02413008', 'Intervention': ['INTERVENTION 1: ', ' 0.005% Estriol Vaginal Gel', ' Route: Vaginal. Administration by an applicator inserted deep inside the vagina Dose: 1 g of gel, containing 50 Mcg of estriol Dosage schedule: Weeks 1-3: single daily application Weeks 4-12: twice weekly administration', 'INTERVENTION 2: ', ' Placebo Vaginal Gel', ' Route: Vaginal. Administration by an applicator inserted deep inside the vagina Dose: 1 g of gel. Dosage schedule: Weeks 1-3: single daily application Weeks 4-12: twice weekly administration', 'Placebo'], 'Eligibility': ['Inclusion Criteria:', ' Written informed consent prior to beginning specific protocol procedures.', ' Patients must have histological confirmation of breast adenocarcinoma with stage I-IIIA, documented at a local pathology department.', ' The breast tumors must be estrogen-receptor positive and/or progesterone receptor positive ( 1% of stained tumor cells by Immunohistochemistry (IHC) as determined by the local laboratory) with any Human Epidermal Growth Factor Receptor 2(HER2) status.', ' Postmenopausal status defined as: 12 months of spontaneous amenorrhea or 6 months of spontaneous amenorrhea with serum FSH levels > 40 Milli-international units per milliliter (mIU/ml) or 6 weeks postsurgical bilateral oophorectomy with or without hysterectomy.', ' Patient must be receiving the non-steroidal aromatase inhibitors anastrozole or letrozole as breast cancer treatment in the adjuvant setting for a minimum of 6 months.', ' Women suffering from moderate to severe vaginal dryness according to the FDA guidelines for drug development in postmenopausal women (Center for Drug Evaluation and Research, (CDER) Jan 2003). A moderate symptom will be considered if the symptom is present, bothersome and annoying, and a severe symptom will be considered if the symptom is present, bothersome and annoying, and interferes with the normal patient activity.', ' Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1.', ' Adequate bone marrow as defined by the following laboratory values:', ' Absolute Neutrophil Count (ANC) 1.5 x 109/L.', ' Platelets (plt) 100 x 109/L.', ' Hemoglobin (Hgb) 10 g/dl.', ' Patient has adequate organ function as defined by the following laboratory values:', ' Serum creatinine 1.5 x Upper Limit of Normal (ULN).', ' Bilirubin 1.5 × ULN.', ' Alkaline phosphatase 2 × ULN.', ' Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) 2 × ULN.', ' Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests and other study procedures.', 'Exclusion Criteria:', ' Stage IIIB-IV breast cancer or bilateral breast cancer.', ' Treatment with any other current anti-tumoral therapy (chemotherapy, anti-Her2…etc) besides the NSAI. Pamidronate or Alendronate are permitted.', ' Prior history of other malignancy within 5 years of study entry, aside from non-melanoma skin cancer or carcinoma-in-situ of the uterine cervix adequately treated.', ' Postmenopausal uterine bleeding. Vaginal bleeding of unknown etiology.', ' Patients with endometrial thickness equal to or greater than 4 mm measured by transvaginal ultrasound.', ' Patients who have received any type of vulvovaginal treatment in the 15 days prior to the start of the study.', ' Use of any hormone, natural (phytoestrogens) or herbal products for the treatment of menopausal symptoms within the last 3 months.', ' Current or previous history of thromboembolic disease or coagulopathies.', ' Severe cardiovascular or respiratory diseases in the previous 6 months.', ' Renal Impairment.', ' Hepatitis B and/or hepatitis C carriers (unless with normal hepatic function).', ' Known human immunodeficiency virus infection.', ' Known hypersensitivity to NSAI.', ' Other severe acute or chronic medical or psychiatric condition, or laboratory abnormality that would impart, in the judgment of the investigator, excess risk associated with study participation or study drug administration, or which, in the judgment of the investigator, would make the patient inappropriate for entry into this study.', ' Previous investigational treatment for any condition or participation in any clinical trial within 4 weeks of inclusion date.'], 'Results': ['Outcome Measurement: ', ' Variation in Serum Levels of Follicle Stimulating Hormone (FSH)', ' Change from Baseline (mean screening-baseline) to Week 12 in Serum Levels of Follicle Stimulating Hormone (FSH) compare to natural physiological variability (screening-baseline variation)', ' Time frame: from baseline to 12 weeks of treatment', 'Results 1: ', ' Arm/Group Title: 0.005% Estriol Vaginal Gel', ' Arm/Group Description: Route: Vaginal. Administration by an applicator inserted deep inside the vagina Dose: 1 g of gel, containing 50 Mcg of estriol Dosage schedule: Weeks 1-3: single daily application Weeks 4-12: twice weekly administration', ' Overall Number of Participants Analyzed: 50', ' Median (Inter-Quartile Range)', ' Unit of Measure: mIU/ml -2.8 (-13.1 to 7.4)', 'Results 2: ', ' Arm/Group Title: Placebo Vaginal Gel', ' Arm/Group Description: Route: Vaginal. Administration by an applicator inserted deep inside the vagina Dose: 1 g of gel. Dosage schedule: Weeks 1-3: single daily application Weeks 4-12: twice weekly administration', ' Placebo', ' Overall Number of Participants Analyzed: 11', ' Median (Inter-Quartile Range)', ' Unit of Measure: mIU/ml 1.4 (-5.4 to 15.7)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 1/50 (2.00%)', ' Lymphoma [1]1/50 (2.00%)', 'Adverse Events 2:', ' Total: 0/11 (0.00%)', ' Lymphoma [1]0/11 (0.00%)']}

{'Clinical Trial ID': 'NCT02725801', 'Intervention': ['INTERVENTION 1: ', ' One-port', ' intervention is placement of one-port tissue expander at time of reconstruction', ' Allergen one-port tissue expander placement: patients will be randomized to receive a one port or two port tissue expander for breast reconstruction', 'INTERVENTION 2: ', ' Two-port', ' intervention is placement of two-port tissue expander at time of reconstruction', ' AlloX2 two-port tissue expander placement: patients will be randomized to receive a one port or two port tissue expander for breast reconstruction'], 'Eligibility': ['Inclusion Criteria:', ' patient agrees to immediate tissue expander breast reconstruction', ' a suitable patient for tissue expander reconstruction', 'Exclusion Criteria:', ' not a surgical candidate for immediate breast reconstruction', ' age less than 18', ' patient declines tissue expander reconstruction', ' patient anticipated to need radiation therapy postoperatively'], 'Results': ['Outcome Measurement: ', ' Number of Participants With Successful Replacement of Tissue Expander With Permanent Implant', ' The number of patients that are able to undergo replacement of the tissue expander between the two arms will be compared', ' Time frame: 3 months', 'Results 1: ', ' Arm/Group Title: One-port', ' Arm/Group Description: intervention is placement of one-port tissue expander at time of reconstruction', ' Allergen one-port tissue expander placement: patients will be randomized to receive a one port or two port tissue expander for breast reconstruction', ' Overall Number of Participants Analyzed: 8', ' Measure Type: Count of Participants', ' Unit of Measure: Participants 8 100.0%', 'Results 2: ', ' Arm/Group Title: Two-port', ' Arm/Group Description: intervention is placement of two-port tissue expander at time of reconstruction', ' AlloX2 two-port tissue expander placement: patients will be randomized to receive a one port or two port tissue expander for breast reconstruction', ' Overall Number of Participants Analyzed: 12', ' Measure Type: Count of Participants', ' Unit of Measure: Participants 12 100.0%'], 'Adverse Events': ['Adverse Events 1:', ' Total: 1/8 (12.50%)', ' re-operation [1]1/8 (12.50%)', 'Adverse Events 2:', ' Total: 4/12 (33.33%)', ' re-operation [1]4/12 (33.33%)']}

f4ea6e98-75e1-43a0-8202-548bb7ceb66c

Single

Results

NCT00534417

The median TTP for patients in cohort one of the primary trial is NA.

Contradiction

{'Clinical Trial ID': 'NCT00534417', 'Intervention': ['INTERVENTION 1: ', ' Capecitabine and Fulvestrant', ' Capecitabine will be given on a continuous basis at a total dose of 1500 mg, given as 1000 mg po AM and 500 mg po PM in patients of body weight < 80 kg, and at a total dose of 2000 mg given as 1000 mg po bid in patients with a body weight of 80 kg.', ' Fulvestrant will be given at 500 mg on Day 1 followed by 250 mg on Days 15 and 29, then 250 mg every 28 days.'], 'Eligibility': ['Inclusion Criteria:', ' Provide written informed consent prior to study-specific screening procedures, with the understanding that the patient has the right to withdraw from the study at any time, without prejudice.', ' At least 18 years of age.', ' Post-menopausal female (ie, amenorrheic for at least 12 months prior to study entry). Post-menopausal status will be confirmed by drawing follicle stimulating hormone (FSH) and estradiol levels if < 2 years since last menses.', ' Ambulatory outpatient with Eastern Cooperative Oncology Group (ECOG)performance status of 0 to 2 at study entry.', ' Primary tumor human epidermal growth factor receptor 2 (HER-2) negative at study entry.(Investigator discretion will be used in instances of immuno-histochemistry [IHC] 2+.)', ' Histologically or cytologically confirmed MBC.', ' Primary tumor and/or metastatic lesion estrogen receptor + and/or progesterone receptor + by IHC.', ' At least one measurable or evaluable(non-measurable) lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria (see Appendix 11.6) which has not been irradiated (i.e., newly arising lesions in previously irradiated areas are accepted). Ascites, pleural effusion, and bone metastases are not considered measurable but are considered evaluable (non-measurable). Minimum indicator lesion size for measurable disease: 10 mm measured by spiral computed tomography (CT) or 20 mm measured by conventional techniques.', ' Adequate hematologic, renal, and hepatic function.', 'Hematologic values: Neutrophils (ANC) > 1.5 x 109/L; Platelet count > 100 x 109/L.', ' Renal function: estimated creatinine clearance > 30 mL/min as calculated with Cockcroft-Gault equation.', ' Note: In patients with moderate renal impairment (calculated creatinine clearance 30 to 50 mL/min) at baseline, a dose reduction to (-1) of the capecitabine starting dose is required.', ' Serum bilirubin < 1.5 x upper limit normal (ULN).', ' Alanine transaminase (ALT) or aspartate transaminase (AST) < 2.5 x ULN (or < 5 x ULN in the case of liver metastases).', ' Alkaline phosphatase < 2.5 x ULN (or < 5 x ULN in the case of liver metastases or < 10 x ULN in the case of bone disease).', ' International normalization ratio (INR) < 1.6.', ' Must have 1 prior regimen of endocrine therapy for metastatic breast cancer. This would include patients who have a recurrence while on adjuvant hormone therapy OR have first recurrence after adjuvant hormone therapy OR progressed after first line hormone therapy for metastatic breast cancer OR treatment naïve patients who present with metastatic breast cancer.', 'Exclusion Criteria:', ' Prior administration of capecitabine.', ' Prior administration of fulvestrant.', ' Prior chemotherapy for metastatic breast cancer.', ' Radiotherapy 2 weeks prior to registration, except if to a non-target lesion only or single-dose radiation for palliation. NOTE: Prior radiation to a target lesion(s) is permitted only if there has been clear progression of the lesion since radiation was completed.', ' Life expectancy <3 months.', ' Serious, uncontrolled, concurrent infection(s).', ' Prior unanticipated severe reaction to fluoropyrimidine therapy, or known hypersensitivity to 5-fluorouracil or known dihydropyrimidine dehydrogenase (DPD) deficiency.', ' Treatment for other carcinomas within the last 5 years, except cured non-melanoma skin and treated in-situ cervical cancer or superficial bladder tumors (stage Ta or Tis).', ' Participation in any investigational drug study within 4 weeks preceding the start of study treatment.', ' Clinically significant cardiac disease (e.g., congestive heart failure, symptomatic coronary artery disease and cardiac arrhythmias not well controlled with medication)or myocardial infarction within the last 12 months prior to study entry.', ' Active brain metastases. Patients with neurological symptoms must undergo a CT scan or magnetic resonance imaging (MRI) of the brain to exclude active brain metastasis. NOTE: Patients with treated brain metastases are eligible provided they have no evidence of disease and are off definitive therapy (including steroids) 3 months prior to study entry.', ' Central nervous system (CNS) disorders or psychiatric disability judged by the investigator to be clinically significant, precluding informed consent, or interfering with compliance of oral drug intake.', ' Known human immunodeficiency virus or chronic hepatitis B or C.', ' Other serious uncontrolled medical conditions that the investigator feels might compromise study participation.', ' Major surgery within 4 weeks of the start of study treatment, without complete recovery.', ' Lack of physical integrity of the upper GI tract or malabsorption syndrome.', ' Known, existing uncontrolled coagulopathy.', ' Any of the following laboratory values:', ' Abnormal hematologic values (neutrophils [ANC]: <1.5 × 109/L, platelet count: <100 × 109/L)', ' Impaired renal function (estimated creatinine clearance: <30 mL/min as calculated with Cockcroft-Gault equation). Note: In patients with moderate renal impairment (calculated creatinine clearance: 30 to 50 mL/min) at baseline, a dose reduction to (-1) of the capecitabine starting dose is required.', ' Serum bilirubin >1.5 × upper normal limit (ULN).', ' Alanine transaminase (ALT) or aspartate transaminase (AST) >2.5 × ULN (or >5 × ULN in the case of liver metastases).', ' Alkaline phosphatase > 2.5 × ULN (or >5 × ULN in the case of liver metastases or >10 × ULN in the case of bone disease).', ' International normalization ratio (INR) >1.6.', ' History of:', ' Bleeding diathesis,(ie, disseminated intravascular coagulation [DIC], clotting factor deficiency) or', ' Long-term anticoagulant therapy,(other than antiplatelet therapy and warfarin 1 mg qd for port prophylaxis).', ' History of hypersensitivity to active or inactive excipients of fulvestrant (ie, castor oil or Mannitol).', ' Unwillingness to give written informed consent.', ' Unwillingness to participate or inability to comply with the protocol for the duration of the study.'], 'Results': ['Outcome Measurement: ', ' Time to Progression (TTP)', ' Time to progression is defined as the time from treatment start until objective tumor progression. Progression is defined per Response Evaluation Criteria in Solid Tumors (RECIST)v1.0 guidelines as a measurable increase in the smallest diameter of any target lesion, progression of existing non-target lesions, or the appearance of 1 or more new lesions. The median time to progression is the parameter used to describe TTP.', ' Time frame: TTP was measured from day 1 of treatment until time of progression (assessed every 8 weeks), up to 29 months.', 'Results 1: ', ' Arm/Group Title: Capecitabine and Fulvestrant', ' Arm/Group Description: Capecitabine will be given on a continuous basis at a total dose of 1500 mg, given as 1000 mg po AM and 500 mg po PM in patients of body weight < 80 kg, and at a total dose of 2000 mg given as 1000 mg po bid in patients with a body weight of 80 kg.', ' Fulvestrant will be given at 500 mg on Day 1 followed by 250 mg on Days 15 and 29, then 250 mg every 28 days.', ' Overall Number of Participants Analyzed: 41', ' Median (95% Confidence Interval)', ' Unit of Measure: Months 26.94 [1] (7.26 to NA)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 9/41 (21.95%)', ' Neutropenia * 1/41 (2.44%)', ' Cardiac Tamponade * 1/41 (2.44%)', ' Pericardial Effusion * 1/41 (2.44%)', ' Abdominal Pain Upper * 1/41 (2.44%)', ' Colitis * 1/41 (2.44%)', ' Diarrhoea * 1/41 (2.44%)', ' Enteritis * 1/41 (2.44%)', ' Nausea * 1/41 (2.44%)', ' Vomiting * 1/41 (2.44%)', ' Adverse Drug Reaction * 1/41 (2.44%)', ' Pneumonia * 2/41 (4.88%)', ' Overdose * 1/41 (2.44%)']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

c3a618d6-2c2e-4ed6-bfe7-88d28ec18240

Single

Adverse Events

NCT00129935

There were more cases of embolisms in cohort 2 of the primary trial than cohort 1.

Entailment

{'Clinical Trial ID': 'NCT00129935', 'Intervention': ['INTERVENTION 1: ', ' Arm A: EC-T', ' Epirubicin with cyclophosphamide, followed by docetaxel (EC-T): Epirubicin 90 mg/ m2 in combination with cyclophosphamide 600 mg/m2 (EC) every 21 days for 4 cycles, followed by docetaxel 100 mg/m2 (T) every 21 days for 4 cycles.', ' Docetaxel', ' Epirubicin', 'Cyclophosphamide', 'INTERVENTION 2: ', ' Arm B: ET-X', ' Epirubicin and docetaxel followed by capecitabine (ET-X):Epirubicin 90 mg/m2 and docetaxel 75 mg/ m2 (ET) every 21 days for 4 cycles, followed by capecitabine 1,250 mg/m2 bid for 14 days, followed by a 7-day rest for 4 cycles.', ' Docetaxel', ' Capecitabine', 'Epirubicin'], 'Eligibility': ['Inclusion Criteria:', ' Written informed consent.', ' Histological diagnosis of operable invasive adenocarcinoma of the breast (T1-T3). Tumours must be HER2 negative. Time window between surgery and study randomization must be less than 60 days.', ' Surgery must consist of mastectomy or conservative surgery with axillary lymph node dissection. Margins free of disease and ductal carcinomas in situ (DCIS) are required. Lobular carcinoma is not considered a positive margin.', ' Positive axillary lymph nodes defined as at least 1 out of 10 nodes with presence of disease. If sentinel node technique is used, sentinel node can be the only node affected. Patients belonging to the following classifications are eligible: TNM pathologic stage N1a, TNM pathologic stage N2a, TNM pathologic stage N3a.', ' Status of hormone receptors in primary tumour. Results must be available before the end of adjuvant chemotherapy.', ' Patients must not present evidence of metastatic disease. Status of HER2 in primary tumour, known before randomization. Patients with immune histochemistry (IHC) 0 or +1 are eligible. For patients with IHC 2+, fluorescence in situ hybridization (FISH) is mandatory and result must be negative.', ' Age >= 18 and <= 70 years old.', ' Performance status (Karnofsky index) >= 80.', ' Normal electrocardiogram (EKG) in the 12 weeks prior to randomization. If needed, normal cardiac function must be confirmed by left ventricular ejection fraction (LVEF).', ' Laboratory results (within 14 days prior to randomization):', ' Hematology: neutrophils >= 1.5 x 10^9/l; platelets >= 100 x 10^9/l; hemoglobin >= 10 mg/dl;', ' Hepatic function: total bilirubin <= 1 upper normal limit (UNL); serum glutamic-oxaloacetic transaminase (SGOT) and Serum glutamic pyruvic transaminase (SGPT) <= 2.5 UNL; alkaline phosphatase <= 2.5 UNL. If values of SGOT and SGPT > 1.5 UNL are associated to alkaline phosphatase > 2.5 UNL, patient is not eligible;', ' Renal function: creatinine <= 175 mmol/l (2 mg/dl); creatinine clearance >= 60 ml/min;', ' Pharmacogenetics: one blood sample is needed for single nucleotide polymorphism (SNP) assessment.', ' Complete stage workup during the 12 weeks prior to randomization (mammograms are allowed within a 20 week window). All patients must have a bilateral mammogram, thorax x-ray, abdominal echography and/or computed tomography (CT)-scan. If bone pain, and/or alkaline phosphatase elevation, a bone scintigraphy is mandatory. This test is recommended for all patients. Other tests: as clinically indicated.', ' Patients able to comply with treatment and study follow-up.', ' Negative pregnancy test done in the 14 prior days to randomization.', 'Exclusion Criteria:', ' Prior systemic therapy for breast cancer.', ' Prior therapy with anthracyclines or taxanes (paclitaxel or docetaxel) for any malignancy.', ' Prior radiotherapy for breast cancer.', ' Bilateral invasive breast cancer.', ' Pregnant or lactating women. Adequate contraceptive methods must be used during chemotherapy and hormone therapy treatments.', ' Any T4 or M1 tumour.', ' Axillary lymph nodes: patients belonging to the following classifications are excluded: TNM pathologic stage N1b, TNM pathologic stage N1c, TNM pathologic stage N2b, TNM pathologic stage N3b, TNM pathologic stage N3c.', ' HER2 positive breast cancer (IHC 3+ or positive FISH result).', ' Pre-existing grade >= 2 motor or sensorial neurotoxicity (National Cancer Institute Common Toxicity Criteria version 2.0 [NCICTC v-2.0]).', ' Any other serious medical pathology, such as congestive heart failure; unstable angina; history of myocardial infarction during the previous year; uncontrolled hypertension or high risk arrhythmias.', ' History of neurological or psychiatric disorders, which could preclude the patients from free informed consent.', ' Active uncontrolled infection.', ' Active peptic ulcer; unstable diabetes mellitus.', ' Previous or current history of neoplasms different from breast cancer, except for skin carcinoma, cervical in situ carcinoma, or any other tumour curatively treated and without recurrence in the last 10 years; ductal in situ carcinoma in the same breast; lobular in situ carcinoma.', ' Chronic treatment with corticosteroids.', ' Contraindications for corticosteroid administration.', ' Concomitant treatment with raloxifene, tamoxifen or other selective estrogen receptor modulators (SERMs), either for osteoporosis treatment or for prevention. These treatments must stop before randomisation.', ' Concomitant treatment with other investigational products; participation in other clinical trials with a non-marketed drug in the 20 previous days before randomization.', ' Concomitant treatment with another therapy for cancer.', 'Males.'], 'Results': ['Outcome Measurement: ', ' Number of Participants With Disease-free Survival (DFS) Event', ' A participant was considered to have had a DFS event if there was evidence of local, regional or metastatic recurrence, second primary cancer (with the exception of carcinoma of squamous cells or basal cells of the skin, cervical carcinoma in situ or lobular or ductal carcinoma in situ of the breast) or death for any reason.', ' Time frame: 5 years', 'Results 1: ', ' Arm/Group Title: Arm A: EC-T', ' Arm/Group Description: Epirubicin with cyclophosphamide, followed by docetaxel (EC-T): Epirubicin 90 mg/ m2 in combination with cyclophosphamide 600 mg/m2 (EC) every 21 days for 4 cycles, followed by docetaxel 100 mg/m2 (T) every 21 days for 4 cycles.', ' Docetaxel', ' Epirubicin', ' Cyclophosphamide', ' Overall Number of Participants Analyzed: 669', ' Measure Type: Count of Participants', ' Unit of Measure: Participants 127 19.0%', 'Results 2: ', ' Arm/Group Title: Arm B: ET-X', ' Arm/Group Description: Epirubicin and docetaxel followed by capecitabine (ET-X):Epirubicin 90 mg/m2 and docetaxel 75 mg/ m2 (ET) every 21 days for 4 cycles, followed by capecitabine 1,250 mg/m2 bid for 14 days, followed by a 7-day rest for 4 cycles.', ' Docetaxel', ' Capecitabine', ' Epirubicin', ' Overall Number of Participants Analyzed: 715', ' Measure Type: Count of Participants', ' Unit of Measure: Participants 170 23.8%'], 'Adverse Events': ['Adverse Events 1:', ' Total: 111/669 (16.59%)', ' Leukocytes * [1]1/669 (0.15%)', ' Hemoglobin * [1]1/669 (0.15%)', ' Hemoglobin * [2]0/669 (0.00%)', ' CNS cerebrovascular ischemia * [1]0/669 (0.00%)', ' CNS cerebrovascular ischemia * [3]0/669 (0.00%)', ' Heart Failure * [1]3/669 (0.45%)', ' Thrombosis/embolism * [1]1/669 (0.15%)', ' Thrombosis/embolism * [3]0/669 (0.00%)', 'Adverse Events 2:', ' Total: 138/715 (19.30%)', ' Leukocytes * [1]0/715 (0.00%)', ' Hemoglobin * [1]0/715 (0.00%)', ' Hemoglobin * [2]1/715 (0.14%)', ' CNS cerebrovascular ischemia * [1]1/715 (0.14%)', ' CNS cerebrovascular ischemia * [3]1/715 (0.14%)', ' Heart Failure * [1]1/715 (0.14%)', ' Thrombosis/embolism * [1]3/715 (0.42%)', ' Thrombosis/embolism * [3]2/715 (0.28%)']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

932728c5-2e7f-401f-be64-e90597ff2ce2

Single

Results

NCT00291577

It is not possible for a participant of the primary trial to have a Time to Reach Maximum Plasma Concentration of 16, 17 or 20 hours

Entailment

{'Clinical Trial ID': 'NCT00291577', 'Intervention': ['INTERVENTION 1: ', ' Sunitinib in Combination With Docetaxel', ' Sunitinib (SU011248) orally (PO) for 2 weeks every 3 weeks (2 weeks on, then 1 week off = Schedule 2/1) starting on Day 2 (Cycle 2, Day 3 only for those subjects included in the Pharmacokinetic [PK] study); starting dose 37.5 milligrams (mg) daily (QD). Docetaxel (Taxotere) administered Day 1 of each cycle via intravenous (IV) infusion every 3 weeks; starting dose 75 mg/m2.'], 'Eligibility': ['Inclusion Criteria:', ' Breast cancer with evidence of unresectable, locally recurrent or metastatic disease', ' Candidate for treatment with docetaxel', 'Exclusion Criteria:', ' Prior chemotherapy in the advanced disease setting', ' Inflammatory breast cancer', ' HER2 positive disease'], 'Results': ['Outcome Measurement: ', ' Time to Reach Maximum Plasma Concentration (Tmax): Sunitinib (SU011248), Sunitinib Metabolite (SU012662), and Total Drug PK Parameters', ' Median Tmax = time for maximum plasma concentration (Cmax) for SU011248, SU012662, and combined SU011248 and SU012662 (total drug); collected C1D2, C2D3. Paired observation.', ' Time frame: 1, 2, 4, 6, 8, 12, 24 hours postdose', 'Results 1: ', ' Arm/Group Title: Sunitinib in Combination With Docetaxel', ' Arm/Group Description: Sunitinib (SU011248) orally (PO) for 2 weeks every 3 weeks (2 weeks on, then 1 week off = Schedule 2/1) starting on Day 2 (Cycle 2, Day 3 only for those subjects included in the Pharmacokinetic [PK] study); starting dose 37.5 milligrams (mg) daily (QD). Docetaxel (Taxotere) administered Day 1 of each cycle via intravenous (IV) infusion every 3 weeks; starting dose 75 mg/m2.', ' Overall Number of Participants Analyzed: 11', ' Median (Full Range)', ' Unit of Measure: hours SU011248 C1D2: 6.0 (4.0 to 24.0)', ' SU011248 C2D3: 6.0 (2.0 to 8.0)', ' SU012662 C1D2: 6.0 (2.0 to 24.0)', ' SU012662 C2D3: 6.0 (4.0 to 24.0)', ' Total drug C1D2: 6.0 (2.0 to 24.0)', ' Total drug C2D3: 6.0 (2.0 to 8.0)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 11/22 (50.00%)', ' Febrile neutropenia 4/22 (18.18%)', ' Leukopenia 1/22 (4.55%)', ' Neutropenia 2/22 (9.09%)', ' Stomatitis 1/22 (4.55%)', ' Fatigue 1/22 (4.55%)', ' Oedema peripheral 1/22 (4.55%)', ' Pyrexia 1/22 (4.55%)', ' Jaundice 1/22 (4.55%)', ' Back pain 1/22 (4.55%)', ' Musculoskeletal pain 1/22 (4.55%)', ' Cerebral haemorrhage 1/22 (4.55%)', ' Headache 1/22 (4.55%)']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

54ad9406-852c-40fc-bd0e-8e7e81eacc71

Comparison

Eligibility

NCT00201760

NCT00127933

Patients must have a triple negative infiltrating breast carcinoma to participate in the secondary trial or the primary trial.

Contradiction

{'Clinical Trial ID': 'NCT00201760', 'Intervention': ['INTERVENTION 1: ', ' Arm 1 Gemcitabine/Cisplatin/Trastuzumab', ' Gemcitabine 1000 mg/m2 iv over 30 minutes on days 1 and 8 Cisplatin 30 mg/m2 iv over 90 minutes on days 1 and 8 Trastuzumab 2 mg/kg iv over 30 minutes on days 1, 8 and 15 (if trastuzumab was not administered within the past 3 weeks, a loading dose of 4 mg/kg iv over 90 minutes will be given on the first day of cycle 1 only).', ' Gemcitabine: 1000 mg/m2 IV over 30 minutes on Days 1 and 8.', ' Trastuzumab: 2 mg/kg IV on days 1, 8 and 15. If Trastuzumab has not been administered within the 3 weeks before starting this treatment, the first dose of Trastuzumab given on Cycle 1, Day 1 will be 4 mg/kg followed by 2 mg/kg weekly.', ' Cisplatin: 30 mg/m2 IV on Day 1 and Day 8.', 'INTERVENTION 2: ', ' Arm 2 Gemcitabine / Trastuzumab', ' Gemcitabine 1000 mg/m2 iv over 30 minutes on days 1 and 8 Trastuzumab 2 mg/kg iv over 30 minutes on days 1, 8 and 15 (if trastuzumab was not administered within the past 3 weeks, a loading dose of 4 mg/kg iv over 90 minutes will be given on the first day of cycle 1 only).', ' Gemcitabine: 1000 mg/m2 IV over 30 minutes on Days 1 and 8.', ' Trastuzumab: 2 mg/kg IV on days 1, 8 and 15. If Trastuzumab has not been administered within the 3 weeks before starting this treatment, the first dose of Trastuzumab given on Cycle 1, Day 1 will be 4 mg/kg followed by 2 mg/kg weekly.'], 'Eligibility': ['Eligibility Criteria:', ' Must have invasive metastatic breast cancer', ' Tumor must be Her 2/neu 3+ by IHC (must be confirmed by Ohio State University pathology)or positive FISH', ' Histological confirmation of invasive breast cancer either from the original diagnosis and/or diagnosis of metastatic disease.', ' Tumor must be detectable clinically or radiographically (a positive bone scan is allowed as the only site of disease). Unidimensional measurements must be obtained whenever possible). Bone marrow only disease is not eligible for enrollment on this study.', ' No evidence of congestive heart failure, symptoms of coronary artery disease, serious cardiac arrhythmias, or evidence of prior myocardial infarction on EKG or ECHO. Patients must have normal LV function and LVEF(left ventricular ejection fraction)> 50% as demonstrated by either echo or muga within the proceeding 4 weeks.', ' Must have adequate renal and hepatic function documented by a serum creatinine < 1.5 x the institutional upper limit of normal (ULN), serum bilirubin <1.5 x ULN and liver enzymes (AST, ALT, or alkaline phosphatase) < 2 x ULN (< 5 x ULN if hepatic metastasis) within 21 days prior to registration.', ' Patients must have an ANC (absolute neutrophil count) > 1.5, platelets > 100,000, Hemoglobin >9.0 within 21 days of registration.', ' If patients are on bisphosphonates at the time of registration, with a stable creatinine over the preceding 2 months, then they may continue bisphosphonates during the study.', ' No more than one prior Trastuzumab/chemotherapy or Trastuzumab/biotherapy combination for metastatic disease. Additional Trastuzumab therapy may have been given in the adjuvant setting. Prior hormonal therapy is allowed for either adjuvant or metastatic disease.', ' Must be >3 weeks since administration of last chemotherapy prior to initiation of treatment on this trial. Prior trastuzumab may have been administered within one week of initiation of treatment on this trial if the last dose was 2 mg/kg. Any prior trastuzumab dosing greater than 2 mg/kg requires a 3 week washout period.', ' Patients may have received prior cisplatin or carboplatin for metastatic disease.', ' No CNS(central nervous system)metastasis disease.', ' No active infection at time of registration.', ' Pregnant or nursing women may not participate in trial.', ' Patients must be informed of the investigational nature of this study and sign and give written informed consent in accordance with institutional and federal guidelines.', ' ECOG (Eastern Cooperative Oncology Group)performance status < 2 at the time of registration.', ' Patients may participate in a non-treatment related protocol while participating in this study.', ' No other active malignancy is allowed. Adequately treated basal cell, squamous cell skin cancer, in situ cervical cancer, adequately treated stage I or II cancer from which the patient is currently in complete remission, or any other cancer from which the patient has been disease-free for 5 years is allowed.'], 'Results': ['Outcome Measurement: ', ' Disease Progression', ' Proportion of patients with metastatic breast cancer free of disease progression at 6 months following treatment', ' Time frame: 6 months', 'Results 1: ', ' Arm/Group Title: Arm 1 Gemcitabine/Cisplatin/Trastuzumab', ' Arm/Group Description: Gemcitabine 1000 mg/m2 iv over 30 minutes on days 1 and 8 Cisplatin 30 mg/m2 iv over 90 minutes on days 1 and 8 Trastuzumab 2 mg/kg iv over 30 minutes on days 1, 8 and 15 (if trastuzumab was not administered within the past 3 weeks, a loading dose of 4 mg/kg iv over 90 minutes will be given on the first day of cycle 1 only).', ' Gemcitabine: 1000 mg/m2 IV over 30 minutes on Days 1 and 8.', ' Trastuzumab: 2 mg/kg IV on days 1, 8 and 15. If Trastuzumab has not been administered within the 3 weeks before starting this treatment, the first dose of Trastuzumab given on Cycle 1, Day 1 will be 4 mg/kg followed by 2 mg/kg weekly.', ' Cisplatin: 30 mg/m2 IV on Day 1 and Day 8.', ' Overall Number of Participants Analyzed: 5', ' Measure Type: Count of Participants', ' Unit of Measure: Participants 1 20.0%', 'Results 2: ', ' Arm/Group Title: Arm 2 Gemcitabine / Trastuzumab', ' Arm/Group Description: Gemcitabine 1000 mg/m2 iv over 30 minutes on days 1 and 8 Trastuzumab 2 mg/kg iv over 30 minutes on days 1, 8 and 15 (if trastuzumab was not administered within the past 3 weeks, a loading dose of 4 mg/kg iv over 90 minutes will be given on the first day of cycle 1 only).', ' Gemcitabine: 1000 mg/m2 IV over 30 minutes on Days 1 and 8.', ' Trastuzumab: 2 mg/kg IV on days 1, 8 and 15. If Trastuzumab has not been administered within the 3 weeks before starting this treatment, the first dose of Trastuzumab given on Cycle 1, Day 1 will be 4 mg/kg followed by 2 mg/kg weekly.', ' Overall Number of Participants Analyzed: 5', ' Measure Type: Count of Participants', ' Unit of Measure: Participants 0 0.0%'], 'Adverse Events': ['Adverse Events 1:', ' Total: 1/5 (20.00%)', ' Nausea/vomiting/diarrhea 1/5 (20.00%)', ' Pneumonia 1/5 (20.00%)', 'Adverse Events 2:', ' Total: 0/5 (0.00%)', ' Nausea/vomiting/diarrhea 0/5 (0.00%)', ' Pneumonia 0/5 (0.00%)']}

{'Clinical Trial ID': 'NCT00127933', 'Intervention': ['INTERVENTION 1: ', ' HER2-Neu Negative', ' Dose and route per treatment cycle (Q3W):', ' Capecitabine: 825 mg/m2, orally, twice daily, days 1-14 Docetaxel: 75 mg/m2, IV infusion, day 1', ' HER2-neu negative: capecitabine + docetaxel', ' Duration: Four 3-week treatment cycles', 'INTERVENTION 2: ', ' HER2-Neu Positive', ' Dose and route per treatment cycle (Q3W):', ' Capecitabine: 825 mg/m2, orally, twice daily, days 1-14 Docetaxel: 75 mg/m2, IV infusion, day 1 Trastuzumab: loading dose 4 mg/kg, 90-min IV infusion; thereafter, 2 mg/kg, 30-min IV infusion, weekly', ' HER2-neu positive: capecitabine + docetaxel + trastuzumab', ' Duration: Four 3-week treatment cycles'], 'Eligibility': ['Inclusion Criteria:', ' women >=18 years of age;', ' newly diagnosed;', ' infiltrating (invasive) HER2-neu-negative or HER2-neu-positive breast cancer.', 'Exclusion Criteria:', ' evidence of metastatic disease, except ipsilateral (same side) axillary lymph nodes;', ' previous systemic or local primary treatment.'], 'Results': ['Outcome Measurement: ', ' Percentage of Participants Assessed for Pathological Complete Response (pCR) Plus Near Complete (npCR) in Primary Breast Tumor at Time of Definitive Surgery', ' Pathological complete response was defined as the absence of histological evidence of invasive breast cancer cells in the tissue specimen removed from the breast after 4 cycles of preoperative treatment. Near pCR (npCR) was defined as the presence of invasive tumor cells with a size of 5 mm or less in aggregate in the tissue specimen removed from the breast after 4 cycles of preoperative treatment. Only pathological assessments occurring prior to the first date of adjuvant treatment were included in the analysis of pCR rate.', ' Time frame: at the time of definitive surgery; after four 3-week cycles (3-4 months)', 'Results 1: ', ' Arm/Group Title: HER2-Neu Negative', ' Arm/Group Description: Dose and route per treatment cycle (Q3W):', ' Capecitabine: 825 mg/m2, orally, twice daily, days 1-14 Docetaxel: 75 mg/m2, IV infusion, day 1', ' HER2-neu negative: capecitabine + docetaxel', ' Duration: Four 3-week treatment cycles', ' Overall Number of Participants Analyzed: 101', ' Measure Type: Number', ' Unit of Measure: percentage of participants 15.8 (9.7 to 25.4)', 'Results 2: ', ' Arm/Group Title: HER2-Neu Positive', ' Arm/Group Description: Dose and route per treatment cycle (Q3W):', ' Capecitabine: 825 mg/m2, orally, twice daily, days 1-14 Docetaxel: 75 mg/m2, IV infusion, day 1 Trastuzumab: loading dose 4 mg/kg, 90-min IV infusion; thereafter, 2 mg/kg, 30-min IV infusion, weekly', ' HER2-neu positive: capecitabine + docetaxel + trastuzumab', ' Duration: Four 3-week treatment cycles', ' Overall Number of Participants Analyzed: 28', ' Measure Type: Number', ' Unit of Measure: percentage of participants 50.0 (31.9 to 71.3)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 15/122 (12.30%)', ' febrile neutropenia 4/122 (3.28%)', ' Neutropenia 0/122 (0.00%)', ' Angina unstable 1/122 (0.82%)', ' Coronary artery disease 1/122 (0.82%)', ' Myocardial infarction 1/122 (0.82%)', ' Diarrhoea 2/122 (1.64%)', ' Colitis 1/122 (0.82%)', ' Pyrexia 2/122 (1.64%)', ' Chest pain 1/122 (0.82%)', ' Pneumonia 1/122 (0.82%)', ' Catheter site cellulitis 1/122 (0.82%)', 'Adverse Events 2:', ' Total: 7/34 (20.59%)', ' febrile neutropenia 1/34 (2.94%)', ' Neutropenia 1/34 (2.94%)', ' Angina unstable 0/34 (0.00%)', ' Coronary artery disease 0/34 (0.00%)', ' Myocardial infarction 0/34 (0.00%)', ' Diarrhoea 0/34 (0.00%)', ' Colitis 0/34 (0.00%)', ' Pyrexia 0/34 (0.00%)', ' Chest pain 0/34 (0.00%)', ' Pneumonia 1/34 (2.94%)', ' Catheter site cellulitis 0/34 (0.00%)', ' Infection 1/34 (2.94%)']}

7021a4a9-b474-4568-a3b8-015a50c9d9cc

Single

Intervention

NCT00290745

There is no radiotherapy or educational part of the intervention used in the primary trial.

Entailment

{'Clinical Trial ID': 'NCT00290745', 'Intervention': ['INTERVENTION 1: ', ' Tamoxifen or Letrozole', ' tamoxifen or letrozole work in treating women with ductal carcinoma in situ', ' letrozole', ' tamoxifen citrate', ' conventional surgery', ' neoadjuvant therapy'], 'Eligibility': ['DISEASE CHARACTERISTICS:', ' Diagnosis of ductal carcinoma in situ (DCIS) on core biopsy', ' No evidence of contralateral breast disease or palpable masses on breast examination', ' No presence or suspicion of invasive cancer, including contralateral invasive cancer, on core biopsy and MRI', ' No documented ipsilateral axillary adenopathy', ' Planning to undergo lumpectomy or mastectomy', ' Estrogen receptor (ER)-positive tumor by immunohistochemistry', ' PATIENT CHARACTERISTICS:', ' Female patient', ' Premenopausal or postmenopausal', ' Postmenopausal is defined by any of the following:', ' No spontaneous menses for >= 1 year', ' Bilateral oophorectomy', ' Radiation castration and amenorrheic for >= 3 months', ' Follicle-stimulating hormone (FSH) > 20 IU/L AND off all hormonal therapy (e.g., hormone replacement therapy or birth control pills) for >= 1 month', ' Not pregnant or nursing', ' Negative pregnancy test', ' Fertile patients must use effective contraception', ' No co-morbidities contraindicating the use of tamoxifen, including any of the following:', ' Prior history of thrombotic events', ' History of hypercoagulable state', ' History of endometrial hyperplasia', ' Abnormal vaginal bleeding', ' No history of contrast dye-related allergies/reactions', ' No history of metal-containing prostheses or implants', ' PRIOR CONCURRENT THERAPY:', ' See Disease Characteristics'], 'Results': ['Outcome Measurement: ', ' Median Change in 6-month Tumor Volume Compared to Baseline Using Mammography', ' Change in size of Ductal Carcinoma in situ (DCIS) for participants on hormonal therapy, as determined by mammography are determined by (1) largest diameter of tumor, as visualized on mammography (2) extent of disease on mammography (3) quantification of mammographically-detected change from baseline to 6-month and used to generate the change in tumor volume of mammographic extent of disease from baseline. Since values were not normally distributed, the median change was calculated, and Wilcoxon sign rank tests were used to evaluate the significance of these changes', ' Time frame: Baseline and 6 months', 'Results 1: ', ' Arm/Group Title: Tamoxifen or Letrozole', ' Arm/Group Description: tamoxifen or letrozole work in treating women with ductal carcinoma in situ', ' letrozole', ' tamoxifen citrate', ' conventional surgery', ' neoadjuvant therapy', ' Overall Number of Participants Analyzed: 54', ' Median (Inter-Quartile Range)', ' Unit of Measure: change in tumor volume (mm) -5.0 (-10.4 to 0.4)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 0/0']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

24eced44-40b2-4365-abd3-42eb13220cf0

Comparison

Intervention

NCT01448447

NCT03252145

the primary trial is testing a radiotherapy intervention whereas the secondary trial is testing a novel hand-held medical device

Entailment

{'Clinical Trial ID': 'NCT01448447', 'Intervention': ['INTERVENTION 1: ', ' Sole Method', ' patients will be treated with HDR brachytherapy using Mammosite ML as the sole method for radiation delivery after lumpectomy for breast cancer or DCIS', ' Mammosite ML: 34 Gy / 10 fractions (3.4 Gy per fraction) 2 fractions / day (separated by at least 6 hours) Delivered in 5 consecutive working days', 'INTERVENTION 2: ', ' Boost', ' patients will be treated with HDR brachytherapy using Mammosite ML as a boost technique prior to standard external beam radiation after lumpectomy for breast cancer or DCIS', ' Mammosite ML: 5-10.2 Gy / 2-3 fractions (3.4 Gy per fraction) 2 fractions / day (separated by at least 6 hours) Delivered in 1-2 days Followed by whole breast radiation (25-28 daily tx)'], 'Eligibility': ['Inclusion Criteria:', ' Women,age of at least 45 years', ' Zubrod performance status of 0-2', ' AJCC Stage I-II (T1-T2, N0 M0) breast cancer', ' Maximum tumor dimension < 3 cm', ' Invasive ductal, medullary, papillary, tubular, colloid (mucinous) histologies', ' Unifocal breast cancer', ' Unilateral breast cancer (no synchronous or previous contralateral breast cancer)', ' Lumpectomy with negative surgical margins by at least 2 mm or re-excision specimen with negative surgical margins by at least 2 mm', ' Ductal Carcinoma In-Situ', ' Negative axillary lymph nodes for invasive breast cancer (sentinel node biopsy or standard level I-II dissection with > 6 nodes removed)', ' Time interval from final breast surgery to brachytherapy loading less than 8 weeks', ' At least 2 mm of breast tissue between the skin and the MammoSite® balloon surface(prefer > 5 mm)', ' If chemotherapy is planned, it must begin no earlier that 2 weeks following completion of radiation therapy. If chemotherapy is first, a minimum of 2 weeks from the last cycle must elapse prior to the start of radiation therapy.', ' Signed study-specific consent form', 'Exclusion Criteria:', ' Invasive lobular histology', ' Non-epithelial breast malignancies such as sarcoma or lymphoma', ' Multifocal or multicentric invasive carcinoma', ' Extensive intraductal component (EIC)', " Paget's disease of the nipple", ' Skin involvement by tumor, regardless of tumor size', ' Positive axillary lymph nodes', ' Distant metastases', ' Collagen vascular disease (scleroderma)', ' Pregnant or lactating women, due to potential exposure of the fetus to RT and unknown effects of RT on lactating females (negative pregnancy test for women of child-bearing age)', ' Any previously treated or synchronous contralateral breast carcinoma', ' Patients with psychiatric or addictive disorder that would preclude obtaining informed Consent', 'Men'], 'Results': ['Outcome Measurement: ', ' Ipsilateral Recurrence Rate', ' Local recurrence is defined as either invasive or non-invasive breast cancer recurrence within the target volume.', ' Elsewhere recurrence is defined as either invasive or non-invasive breast cancer recurrence outside of the target volume.', ' Local control rate will be evaluated by imaging techniques, physical exam and biopsy, if applicable.', ' Measured as a count of participants experiencing recurrence, i.e. each subject experiencing ipsilateral tumor recurrence within 5 years = 1, and each subject with no ipsilateral tumor recurrence within 5 years = 0', ' Time frame: 5 years', 'Results 1: ', ' Arm/Group Title: Sole Method', ' Arm/Group Description: patients will be treated with HDR brachytherapy using Mammosite ML as the sole method for radiation delivery after lumpectomy for breast cancer or DCIS', ' Mammosite ML: 34 Gy / 10 fractions (3.4 Gy per fraction) 2 fractions / day (separated by at least 6 hours) Delivered in 5 consecutive working days', ' Overall Number of Participants Analyzed: 9', ' Measure Type: Number', ' Unit of Measure: participants 0', 'Results 2: ', ' Arm/Group Title: Boost', ' Arm/Group Description: patients will be treated with HDR brachytherapy using Mammosite ML as a boost technique prior to standard external beam radiation after lumpectomy for breast cancer or DCIS', ' Mammosite ML: 5-10.2 Gy / 2-3 fractions (3.4 Gy per fraction) 2 fractions / day (separated by at least 6 hours) Delivered in 1-2 days Followed by whole breast radiation (25-28 daily tx)', ' Overall Number of Participants Analyzed: 0', ' Measure Type: Number', ' Unit of Measure: participants '], 'Adverse Events': ['Adverse Events 1:', ' Total: 0/20 (0.00%)', 'Adverse Events 2:', ' Total: ']}

{'Clinical Trial ID': 'NCT03252145', 'Intervention': ['INTERVENTION 1: ', ' Manual Lymph Drainage', ' Manual lymph drainage (MLD) treatment 3 times a week for 4 weeks to the lymphedematous upper limb', ' Manual Lymph Drainage (MLD): MLD is a practitioner-applied manual massage technique designed to decrease limb volume in patients with lymphedema by enhancing movement of lymph fluid, resulting in reductions in interstitial fluid.', 'INTERVENTION 2: ', ' Negative Pressure', ' PhysioTouch (negative pressure massage) treatment 3 times a week for 4 weeks to the lymphedematous upper limb', ' PhysioTouch: The PhysioTouch is a hand-held device that administers negative pressure under the treatment head, and gently pulls the underlying skin and subcutaneous tissue into the suction cup. This suction produces a stretch to the skin and in the subcutaneous tissue space. This action is thought to facilitate lymphatic flow from the interstitium into the lymphatic vessels, and mobilizes the superficial fascia.'], 'Eligibility': ['INCLUSION CRITERIA:', ' To be included women must be:', ' Be over 18 years of age;', ' Have had cancer treatment that included a surgical procedure, radiation therapy (RT), and/or chemotherapy (CTX);', ' Have completed active cancer treatment at least 1 year prior to study enrollment;', ' Have been diagnosed with lymphedema (LE) at least one year prior to study enrollment;', ' Have arm lymphedema on one side only;', ' Have confirmed LE based on bioimpedance measurements with an L-Dex® score of >7.1 (note - this is very mild lymphedema);', ' Have stable arm LE. LE will be considered "stable" if during the 3 months prior to study enrollment there was no arm infection requiring antibiotics, no change in ability to perform activities of daily living related to LE, and no subjective report of significant persistent changes in limb volume;', ' Be mentally and physically able to participate in the study;', ' Be able to attend the sessions at the University of California, San Francisco (UCSF) Parnassus campus;', ' Read and understand English;', ' Be able to understand a written informed consent document and the willingness to sign it', ' EXCLUSION CRITERIA', ' Women cannot have:', ' Bilateral upper extremity LE;', ' Current infection or lymphangitis involving the affected arm;', ' Current recurrence of their breast cancer (BC) (local or distant)', ' Pre-existing LE prior to their BC diagnosis;', ' A condition that precludes measurement of LE using Bioimpedance Spectroscopy (BIS), including pregnancy;', ' Current venous thrombosis in either upper extremity or be on current anticoagulant therapy;', ' Extremity edema due to heart failure'], 'Results': ['Outcome Measurement: ', ' Recruitment Rates', ' The recruitment rate is defined as the number of women who were screened and then enrolled on the study divided by the the total number of women screened overall.', ' Time frame: At 4 weeks', 'Results 1: ', ' Arm/Group Title: Manual Lymph Drainage', ' Arm/Group Description: Manual lymph drainage (MLD) treatment 3 times a week for 4 weeks to the lymphedematous upper limb', ' Manual Lymph Drainage (MLD): MLD is a practitioner-applied manual massage technique designed to decrease limb volume in patients with lymphedema by enhancing movement of lymph fluid, resulting in reductions in interstitial fluid.', ' Overall Number of Participants Analyzed: 13', ' Measure Type: Number', ' Unit of Measure: rate of recruitment 32.5', 'Results 2: ', ' Arm/Group Title: Negative Pressure', ' Arm/Group Description: PhysioTouch (negative pressure massage) treatment 3 times a week for 4 weeks to the lymphedematous upper limb', ' PhysioTouch: The PhysioTouch is a hand-held device that administers negative pressure under the treatment head, and gently pulls the underlying skin and subcutaneous tissue into the suction cup. This suction produces a stretch to the skin and in the subcutaneous tissue space. This action is thought to facilitate lymphatic flow from the interstitium into the lymphatic vessels, and mobilizes the superficial fascia.', ' Overall Number of Participants Analyzed: 15', ' Measure Type: Number', ' Unit of Measure: rate of recruitment 37.5'], 'Adverse Events': ['Adverse Events 1:', ' Total: 0/13 (0.00%)', 'Adverse Events 2:', ' Total: ']}

3e2dda3a-815f-4681-a470-009d9f9b30d6

Comparison

Intervention

NCT01653964

NCT02660788

The interventions in the primary trial and the secondary trial are similar, as they are testing the same medication, however they are not using the same doses.

Contradiction

{'Clinical Trial ID': 'NCT01653964', 'Intervention': ['INTERVENTION 1: ', ' Molecular Breast Imaging', ' Molecular breast imaging performed after injection of 4 mCi Tc-99m sestamibi and again after 8 mCi Tc-99m sestamibi.'], 'Eligibility': ['Inclusion Criteria:', ' Subgroup 1, Patients with breast lesions:', ' -At least one breast lesion detected by mammogram, ultrasound or breast MRI that measures < 20 mm in greatest dimension, presents as a mass, is considered suspicious or highly suggestive of malignancy according to the Breast Imaging Reporting and Data System Atlas criteria (BIRADS 4 or 5), and is scheduled for core-needle biopsy or surgical biopsy.', ' OR', ' -At least one breast lesion that measures between > 10 mm but < 20 mm in greatest dimension, presents as a mass, is biopsy-proven as malignant, and is scheduled for surgical resection.', ' AND', ' Age > 40 years', ' Negative pregnancy test, postmenopausal, or surgically sterilized', ' Subgroup 2, Patients without known breast lesions:', ' Negative screening mammogram performed at Mayo Clinic Rochester within 15 months prior to performance of study MBI', ' No signs or symptoms of breast disease', ' Age > 40 years', ' Negative pregnancy test, postmenopausal, or surgically sterilized', 'Exclusion Criteria:', ' Vacuum-assisted or excisional biopsy has been performed prior to the study MBI. Reason: these types of biopsies are more likely to remove all of the tumor', ' MBI is performed after biopsy and neo-adjuvant chemotherapy is planned prior to surgery. Reason: true tumor size will not be able to be ascertained from the final pathology findings', ' Breast implants. Reason: cases with breast implants will be easily identifiable on blinded interpretation to take place at the study end', ' Suspected that breasts will not fit in the MBI field of view. Reason: cases that require tiled views or additional views will be easily identifiable on blinded interpretation to take place at the study end', ' Only one breast remaining. Reason: unilateral cases will be easily identifiable on blinded interpretation to take place at the study end; injection timing is designed for bilateral views', ' Pregnancy test (if necessary) is not negative, or the patient is unable to complete the pregnancy test', ' Physically unable to sit upright and still remain still during two consecutive MBI studies over the course of a 2-hour period.'], 'Results': ['Outcome Measurement: ', ' Compare the Diagnostic Accuracy of 8 mCi Molecular Breast Imaging (MBI) With 4 mCi MBI.', ' [Not Specified]', ' Time frame: At time of study (within 2 days after exam) and when enrollment has been reached (approximately 24 months)', 'Results 1: ', ' Arm/Group Title: Molecular Breast Imaging', ' Arm/Group Description: Molecular breast imaging performed after injection of 4 mCi Tc-99m sestamibi and again after 8 mCi Tc-99m sestamibi.', ' Overall Number of Participants Analyzed: 34', ' Measure Type: Number', ' Unit of Measure: cancers detected 8 mCi: 30', '4 mCi: 29'], 'Adverse Events': ['Adverse Events 1:', ' Total: 0/82 (0.00%)']}

{'Clinical Trial ID': 'NCT02660788', 'Intervention': ['INTERVENTION 1: ', ' Control Arm', ' Mail', ' Standard Reminder Postcard', 'INTERVENTION 2: ', ' Family Physician Reminder Letter Arm', ' Mail', ' Standard Reminder Postcard', ' Family Physician Reminder Letter'], 'Eligibility': ['Inclusion Criteria:', ' Active family physicians (family physicians, general practitioners or primary care physicians) who have overdue women in their practice that meet the following criteria:', ' Previously been enrolled in the SMPBC and had a previous normal screening mammogram.', ' Have agreed to being contacted for research on the SMPBC questionnaire', ' Are 6-24 months overdue from their last screening mammogram', ' Live in BC', ' Have listed an active family physician as the contact to receive their mammography results', 'Exclusion Criteria:', ' Family physicians who do not work in primary care', ' Family physicians who do not have overdue women in their practice'], 'Results': ['Outcome Measurement: ', ' Percentage of Overdue Women Returning for Screening Mammography', ' Percentage of overdue women returning for screening mammography, measured from the date of randomization', ' Time frame: 6 months', 'Results 1: ', ' Arm/Group Title: Control Arm', ' Arm/Group Description: Mail', ' Standard Reminder Postcard', ' Overall Number of Participants Analyzed: 2749', ' Measure Type: Number', ' Unit of Measure: percentage of participants 24.0', 'Results 2: ', ' Arm/Group Title: Family Physician Reminder Letter Arm', ' Arm/Group Description: Mail', ' Standard Reminder Postcard', ' Family Physician Reminder Letter', ' Overall Number of Participants Analyzed: 2749', ' Measure Type: Number', ' Unit of Measure: percentage of participants 34.4'], 'Adverse Events': ['Adverse Events 1:', ' Total: 0/2749 (0.00%)', 'Adverse Events 2:', ' Total: 0/2749 (0.00%)']}

1a293e7c-691f-4f93-bab8-6bf5d9b3f904

Single

Results

NCT00444535

Less than 1/3 participants in the primary trial treated with Lapatinib achieved Progression-free Survival Rate After 6 months of Study Treatment.

Contradiction

{'Clinical Trial ID': 'NCT00444535', 'Intervention': ['INTERVENTION 1: ', ' Lapatinib + Bevacizumab', ' Lapatinib (1500 mg once daily taken orally) and bevacizumab (10 mg/kg intravenously [IV] every two weeks)'], 'Eligibility': ['Inclusion criteria:', ' Females that are at least 18 years of age.', ' Women of childbearing potential must have a negative serum pregnancy test at screening.', ' Documented evidence of HER2-overexpressing unresectable or metastatic breast cancer. Disease may/may not have been treated in metastatic setting.', ' Subjects are permitted (but not required) to have previously-treated brain metastases that are stable and asymptomatic.', ' Adequate hepatic, renal and cardiac function', ' ECOG score 0-1 and a life expectancy of at least 12 weeks.', ' Able to swallow oral medication', ' Signed informed consent', 'Exclusion criteria:', ' Pregnancy', ' Unstable or symptomatic CNS metastases', ' Major surgery within 28 days of enrollment (minor surgery within 7 days).', ' Prior anti-cancer treatment within 14 days of enrollment, or unresolved treatment-related toxicities.', ' A serious non-healing wound, ulcer, or bone fracture at baseline.', ' Class II, III or IV heart failure as defined by the NYHA functional classification system', ' History of significant vascular disease, arterial thrombosis, unstable INR, hypertensive crisis, or uncontrolled hypertension.', ' History of myocardial infarction, stenting procedure, or angioplasty within 6 months of enrollment.', ' History of abdominal fistulae, gastrointestinal perforation, or intra-abdominal abscess within 6 months of enrollment.', ' History of malabsorption syndrome, ulcerative colitis, or bowel obstruction.', ' Proteinuria', ' Requires concurrent anti-cancer treatment or investigational treatment.', ' Known hypersensitivity to either study medication', ' Received investigational treatment within 28 days or 5 half-lives, whichever is longer', ' Concurrent disease or circumstances that would lead the investigator would consider the subject an inappropriate candidate for the study', ' Requires medication that has been excluded during study participation'], 'Results': ['Outcome Measurement: ', ' Investigator-evaluated Crude Progression-free Survival Rate After 12 Weeks of Study Treatment', ' The PFS rate is defined as the percentage of subjects who have shown no evidence of disease progression or death from any cause following 12 weeks of treatment. Disease progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.', ' Since there is no independent reviewer, only the investigator response was reported.', ' Time frame: up to week 12', 'Results 1: ', ' Arm/Group Title: Lapatinib + Bevacizumab', ' Arm/Group Description: Lapatinib (1500 mg once daily taken orally) and bevacizumab (10 mg/kg intravenously [IV] every two weeks)', ' Overall Number of Participants Analyzed: 52', ' Measure Type: Count of Participants', ' Unit of Measure: Participants No disease progression by Week 12: 36 69.2%', ' Disease progression or death by Week 12: 16 30.8%'], 'Adverse Events': ['Adverse Events 1:', ' Total: 13/52 (25.00%)', ' Anaemia 1/52 (1.92%)', ' Blood loss anaemia 1/52 (1.92%)', ' Left ventricular dysfunction 1/52 (1.92%)', ' Abdominal pain 3/52 (5.77%)', ' Abdominal pain upper 1/52 (1.92%)', ' Diarrhoea 3/52 (5.77%)', ' Gastric haemorrhage 1/52 (1.92%)', ' Gastritis 1/52 (1.92%)', ' Lower gastrointestinal haemorrhage 1/52 (1.92%)', ' Nausea 1/52 (1.92%)', ' Vomiting 2/52 (3.85%)']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

a87e6e20-c7d0-4941-9933-204fab99b299

Single

Adverse Events

NCT01940497

There were more allergic reactions observed in cohort 1 of the primary trial than cohort 2.

Entailment

{'Clinical Trial ID': 'NCT01940497', 'Intervention': ['INTERVENTION 1: ', ' Trastuzumab (Vial): Adjuvant', ' Participants received trastuzumab 600 mg subcutaneously using a vial every 3 weeks (1 cycle) for 1 year (4 cycles in combination with adjuvant chemotherapy [consisting of doxorubicin, paclitaxel or docetaxel] and 14 cycles administered alone).', 'INTERVENTION 2: ', ' Trastuzumab (Vial): Neoadjuvant', ' Participants received trastuzumab 600 mg subcutaneously using a vial every 3 weeks (1 cycle) for 1 year (4 cycles in combination with neoadjuvant chemotherapy [consisting of doxorubicin, paclitaxel or docetaxel] and 14 cycles administered alone).'], 'Eligibility': ['Inclusion Criteria:', ' Histologically confirmed non-metastatic primary invasive adenocarcinoma of the breast. Stage of disease: T1-4 (T describes size of tumour from 1 to 4), N0-3 (N describes nearby lymph nodes), M0 (M describes distant metastasis)', ' HER2-positive disease immunohistochemistry (IHC) 3+ or in situ hybridization (ISH) positive', ' Eastern Cooperative Oncology Group (ECOG) performance status 0-1', ' Left ventricular ejection fraction (LVEF) of greater than or equal to (>=) 55 percent (%) measured by echocardiography (ECHO) or multiple gated acquisition (MUGA) scan prior to first dose of trastuzumab SC', ' Intact skin at site of SC injection on the thigh', 'Exclusion Criteria:', ' History of other malignancy, except for participants with curatively treated carcinoma in situ of the cervix or basal cell carcinoma and participants with other curatively treated malignancies, other than breast cancer, who have been disease-free for at least 5 years', ' Severe dyspnea at rest or requiring supplementary oxygen therapy', ' Concurrent serious diseases that may interfere with planned treatment, including severe pulmonary conditions/illness', ' Serious cardiac illness or medical conditions that would preclude the use of trastuzumab, specifically: history of documented congestive heart failure (CHF), high-risk uncontrolled arrhythmias, angina pectoris requiring medication, clinically significant valvular disease, evidence of transmural infarction on electrocardiogram (ECG), diagnosed poorly controlled hypertension', ' Known infection with human immunodeficiency virus (HIV), active hepatitis B virus (HBV) or hepatitis C virus (HCV)', ' Pregnant or lactating women', ' Concurrent enrolment in another clinical trial using an investigational anti-cancer treatment, including hormonal therapy, bisphosphonate therapy and immunotherapy, within 28 days prior to the first dose of study treatment', ' Known hypersensitivity to trastuzumab, murine proteins, to any of the excipients of Herceptin including hyaluronidase, or the adhesive of the SC device (for Cohort B), or a history of severe allergic or immunological reactions, for example, difficulty to control asthma', ' Inadequate bone marrow, hepatic or renal function', ' Hormonal treatment concomitant with chemotherapy (allowed in adjuvant phase with adjuvant trastuzumab SC)', ' Pre-existing motor or sensory neuropathy of Grade greater than (>) 1', ' Synchronous bilateral invasive breast cancer'], 'Results': ['Outcome Measurement: ', ' Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs)', ' An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. TEAEs were the AEs occurring from starting on the day of or after first administration of trastuzumab and within 28 days after last dose of trastuzumab. Data for this outcome measure were analyzed and reported by adjuvant versus neoadjuvant chemotherapy groups within each treatment arm.', ' Time frame: Day 1 up to 28 days after last dose of trastuzumab (up to approximately 1 year)', 'Results 1: ', ' Arm/Group Title: Trastuzumab (Vial): Adjuvant', ' Arm/Group Description: Participants received trastuzumab 600 mg subcutaneously using a vial every 3 weeks (1 cycle) for 1 year (4 cycles in combination with adjuvant chemotherapy [consisting of doxorubicin, paclitaxel or docetaxel] and 14 cycles administered alone).', ' Overall Number of Participants Analyzed: 95', ' Measure Type: Number', ' Unit of Measure: Percentage of Participants 98.9', 'Results 2: ', ' Arm/Group Title: Trastuzumab (Vial): Neoadjuvant', ' Arm/Group Description: Participants received trastuzumab 600 mg subcutaneously using a vial every 3 weeks (1 cycle) for 1 year (4 cycles in combination with neoadjuvant chemotherapy [consisting of doxorubicin, paclitaxel or docetaxel] and 14 cycles administered alone).', ' Overall Number of Participants Analyzed: 20', ' Measure Type: Number', ' Unit of Measure: Percentage of Participants 100.0'], 'Adverse Events': ['Adverse Events 1:', ' Total: 5/95 (5.26%)', ' Febrile neutropenia 0/95 (0.00%)', ' Neutropenia 0/95 (0.00%)', ' Atrial fibrillation 0/95 (0.00%)', ' Pleuropericarditis 0/95 (0.00%)', ' Vomiting 0/95 (0.00%)', ' Pryexia 0/95 (0.00%)', ' Anaphylactic shock 1/95 (1.05%)', ' Gastroenteritis 0/95 (0.00%)', ' Fibula fracture 1/95 (1.05%)', ' Tibia fracture 1/95 (1.05%)', ' Intervertebral disc protrusion 0/95 (0.00%)', 'Adverse Events 2:', ' Total: 3/20 (15.00%)', ' Febrile neutropenia 0/20 (0.00%)', ' Neutropenia 0/20 (0.00%)', ' Atrial fibrillation 1/20 (5.00%)', ' Pleuropericarditis 1/20 (5.00%)', ' Vomiting 0/20 (0.00%)', ' Pryexia 0/20 (0.00%)', ' Anaphylactic shock 0/20 (0.00%)', ' Gastroenteritis 1/20 (5.00%)', ' Fibula fracture 0/20 (0.00%)', ' Tibia fracture 0/20 (0.00%)', ' Intervertebral disc protrusion 1/20 (5.00%)']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

6c3427a8-27a1-459c-9fbc-175649210868

Single

Eligibility

NCT00101400

A female with Hemoglobin > 10.0 g/dl, Absolute neutrophil count 1,733/mm3, platelet count = 100,000/µl and total bilirubin < 1.2 x ULN are eligilbe for the primary trial.

Contradiction

{'Clinical Trial ID': 'NCT00101400', 'Intervention': ['INTERVENTION 1: ', ' Sorafenib (Nexavar, BAY43-9006)', ' Sorafenib 400 mg administered twice daily (b.i.d.)'], 'Eligibility': ['Inclusion Criteria:', ' Age > 18 years', ' Women with prior histologically documented diagnosis of breast cancer', ' Subjects with metastatic disease who have already received and failed at least one chemotherapy regimen for metastatic disease and, if ER/PgR +ve, have failed on at least adjuvant hormonal therapy', ' Subjects for whom trastuzumab treatment is not indicated, no longer effective or refused by the subjects', ' Four weeks since the last cytotoxic chemotherapy or clear evidence of progression on hormonal therapy', ' Subjects who have at least one measurable lesion by CT (Computed Tomography) scan or MRI (Magnetic Resonance Imaging) according to modified WHO Tumour Response Criteria', ' Subjects who have an Eastern Co-operative Oncology Group (ECOG) performance status of 0, 1 or 2', ' Adequate bone marrow, liver and renal function as assessed by the following laboratory evaluations:', ' Hemoglobin > 9.0 g/dl', ' Absolute neutrophil count (ANC) > 1,500/mm3', ' Platelet count = 100,000/µl', ' Total bilirubin =1.5 x the upper limit of normal.', ' Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST) = 2.5 x upper limit of normal (=5 x upper limit of normal for subjects with liver involvement of their cancer)', ' Amylase and lipase = 1.5 x the upper limit of normal', ' Serum creatinine = 3.0 x the upper limit of normal', ' Prothrombin Time (PT) or International Normalized Ratio (INR) and Partial Thromboplastin Time (PTT) < 1.5 x upper limit of normal (subjects who receive anti-coagulation treatment with an agent such as warfarin or heparin will be allowed to participate provided that no evidence of underlying abnormality in these parameters exists)', ' Subjects who give written informed consent prior to any study specific screening procedures with the understanding that the subject has the right to withdraw from the study at any time, without prejudice', ' Life expectancy of at least 12 weeks', ' Signed informed consent must be obtained prior to any study specific procedures', 'Exclusion Criteria:', ' Previous malignancy (except for cervical carcinoma in situ, adequately treated basal cell carcinoma, or superficial bladder tumours [Ta, Tis and T1] or other malignancies curatively treated > 2 years prior to entry)', ' Congestive heart failure > New York Heart Association (NYHA) Class II', ' Cardiac arrhythmia requiring anti-arrhythmic (excluding beta blockers or digoxin)', ' Active coronary artery disease or ischaemia', ' Active clinically serious bacterial or fungal infections (> grade 2 National Cancer Institute - Common Terminology Criteria for Adverse Events (NCI-CTCAE), Version 3)', ' Known History of Human Immunodeficiency Virus (HIV) infection or chronic hepatitis B or C', ' Metastatic brain or meningeal tumors unless the subject is > 6 months from definitive therapy, has a negative imaging study within 4 weeks of study entry and is clinically stable with respect to the tumor at the time of study entry. Also the patient must not be undergoing acute steroid therapy or taper (chronic steroid therapy is acceptable provided that the dose is stable for 1 month prior to and following screening radiographic study)', ' Subjects with seizure disorders requiring medication (such as steroid or anti-epileptics)', ' History of organ allograft', " Substance abuse, medical, psychological or social conditions that may interfere with the subject's participation in the study or evaluation of the study results", ' Known or suspected allergy to the investigational agent', ' Any condition that is unstable or which could jeopardize the safety of the subject and his/her compliance in the study. Pregnant or breast-feeding subjects. Women of childbearing potential must have a negative pregnancy test performed within seven days prior to the start of study drug. Women enrolled in this trial must use adequate barrier birth control measures during the course of the trial.', ' Excluded therapies include:', ' Anti-cancer chemotherapy, hormonal therapy or immunotherapy during the study or within 4 weeks of study entry. Mytomicin or nitroureas should not be given within 6 weeks of study entry', ' Significant surgery within 4 weeks prior to the start of study drug', ' Any bone marrow transplant or stem cell rescue within 4 months of the start of study drug', ' Radiotherapy during the study or within 3 weeks of the start of drug', ' Use of biologic response modifiers, such as Granulocyte-Colony Stimulating Factor (G-CSF), within 3 weeks of study entry', ' Investigational drug therapy outside of this trial during or within 30 days prior to start of the study drug', ' Concomitant treatment with ketoconazole, itraconazole, ritonavir, or use of grapefruit juice', ' Prior use of Raf-Kinase Inhibitors (RKI), Methyl Ethyl Ketone (MEK) or farnesyl transferase inhibitors', " Concomitant treatment or use of St. John's Wort", ' Prior use of bevacizumab and all other drugs that target Vascular Endothelial Growth Factor (VEGF)/VEGF receptors'], 'Results': ['Outcome Measurement: ', ' Number of Subjects With Response (Complete or Partial)', ' Number of subjects with metastatic breast cancer treated with single agent BAY43-9006 who had best overall response assessed as complete response (CR) or partial response (PR) as per Modified World Health Organization (WHO) Tumor Response Criteria.', ' Time frame: Until 30 days after termination of active therapy', 'Results 1: ', ' Arm/Group Title: Sorafenib (Nexavar, BAY43-9006)', ' Arm/Group Description: Sorafenib 400 mg administered twice daily (b.i.d.)', ' Overall Number of Participants Analyzed: 54', ' Measure Type: Number', ' Unit of Measure: participants Complete response (CR): 0', ' Partial response (PR): 1', ' Stable disease (SD): 20', ' Progressive disease (PD): 31', 'Not evaluated: 2'], 'Adverse Events': ['Adverse Events 1:', ' Total: 22/54 (40.74%)', ' Hemoglobin * 1/54 (1.85%)', ' Coagulation - Other * 1/54 (1.85%)', ' Supraventricular Arrhythmia, Supraventricular Tachycardia * 1/54 (1.85%)', ' Cardiac General - Other * 2/54 (3.70%)', ' Anorexia * 1/54 (1.85%)', ' Ascites * 2/54 (3.70%)', ' Nausea * 2/54 (3.70%)', ' Perforation, GI, Colon * 1/54 (1.85%)', ' Vomiting * 1/54 (1.85%)']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

883bec6a-bce2-4e60-9304-49a056e66df7

Comparison

Adverse Events

NCT02402764

NCT00490646

There were no cases of extravasation in either the primary trial or the secondary trial.

Contradiction

{'Clinical Trial ID': 'NCT02402764', 'Intervention': ['INTERVENTION 1: ', ' Selinexor Treatment', ' Ten patients were treated with oral selinexor 60 mg twice per week (on days 1 and 3) on a schedule of 3 weeks on and 1 week off, each four-week cycle.'], 'Eligibility': ['Inclusion Criteria:', ' Histologically confirmed triple negative breast cancer (TNBC), defined as negative immunohistochemical staining for estrogen and progesterone receptors ( 5% of nuclei positive by IHC) and receptor tyrosine-protein kinase erbB-2 (HER2) negative (IHC 0-1+ or HER2-neu negative according to American Society of Clinical Oncology; College of American Pathologists (ASCO-CAP) HER2 Test Guideline Recommendations)', ' Written informed consent in accordance with federal, local, and institutional guidelines', ' Body surface area 1.4 m^2', ' Age 18 years', ' Estimated life expectancy of >3 months at study entry', ' TNBC must be either locally recurrent or metastatic. Locally recurrent disease must not be amenable to surgical resection or radiation with curative intent.', ' Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) 1.1', ' Documented disease progression at study entry', ' Must have received at least 1 chemotherapy regimens in the setting of metastatic disease', ' Eastern Cooperative Oncology Group (ECOG) performance status of 2', ' Adequate hematological function: Absolute neutrophil count (ANC) > 1500/mm^3, platelets count >100,000mm^3', " Adequate hepatic function within 14 days prior to Cycle 1 Day 1 (C1D1): total bilirubin <2 times the upper limit of normal (ULN) (except patients with Gilbert's syndrome who must have a total bilirubin of < 3 times ULN) and aspartate aminotransferase (AST), alanine aminotransferase (ALT) 2.5 x ULN. In the case of known (radiological and/or biopsy documented) liver metastasis, AST/ALT 5.0 times ULN is acceptable.", ' Amylase and lipase 1.5 x ULN', ' Adequate renal function within 14 days prior to C1D1: estimated creatinine clearance of 30 mL/min', ' Women of child-bearing potential (WOCBP) must agree to use dual methods of contraception and have a negative serum pregnancy test at screening, and male participants must use an effective barrier method of contraception if sexually active with a female of child-bearing potential. For both male and female participants, effective methods of contraception must be used throughout the study and for 3 months following the last dose. To be considered of non-childbearing potential, postmenopausal women must be amenorrheic for at least 12 months naturally (not in the setting of post chemotherapy) or participants must be surgically sterile.', ' Must have received prior anthracycline and taxane therapy unless clinically contraindicated', 'Exclusion Criteria:', " Significant medical illness that in the investigator's opinion cannot be adequately controlled with appropriate therapy or would compromise the participant's ability to tolerate this therapy", ' Women who are pregnant or lactating', ' Radiation, chemotherapy, or immunotherapy or any other approved anticancer therapy 2 weeks prior to cycle 1 day 1', ' Major surgery within 4 weeks before Day 1', ' Unstable cardiovascular function: Electrocardiogram (ECG) abnormalities requiring treatment, or congestive heart failure (CHF) of New York Hearth Association (NYHA) Class 3; myocardial infarction (MI) within 3 months', ' Uncontrolled infection requiring parenteral antibiotics, antivirals, or antifungals within one week prior to first dose. Potential participants with controlled infection or on prophylactic antibiotics are permitted in the study.', ' Known history of HIV', ' Known active hepatitis A, B, or C infection that requires treatment', ' Any underlying condition that would significantly interfere with the absorption of an oral medication', ' Grade >2 peripheral neuropathy at baseline (within 14 days prior to cycle 1 day 1)', ' Participation in an investigational anti-cancer study within 3 weeks prior to Cycle 1 Day 1', ' Coagulation problems and active major bleeding within 4 weeks prior to C1D1 (peptic ulcer, epistaxis, spontaneous bleeding)', ' Active central nervous system (CNS) malignancy. Asymptomatic small lesions are not considered active. Treated lesions may be considered inactive if they are stable for at least 3 months.', ' Radiation, chemotherapy, or immunotherapy or any other anticancer therapy 2 weeks prior to Cycle 1 Day 1 or radio-immunotherapy 4 weeks prior to Cycle 1 Day 1', ' Have not recovered to Grade 1 or to their baseline from clinically significant adverse effects'], 'Results': ['Outcome Measurement: ', ' Clinical Benefit Rate', ' Complete Response (CR) + Partial Response (PR) + Stable Disease (SD) 12 weeks of selinexor in patients with triple negative breast cancer (TNBC), according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. CR: Disappearance of all target lesions; PR: At least a 30% decrease in the sum of the diameter (LD) of target lesions, taking as reference the baseline sum LD; Progressive Disease (PD): At least a 20% increase in the sum of the LD of target lesions, taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions; SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum LD since the treatment started.', ' Time frame: Up to 10 months', 'Results 1: ', ' Arm/Group Title: Selinexor Treatment', ' Arm/Group Description: Ten patients were treated with oral selinexor 60 mg twice per week (on days 1 and 3) on a schedule of 3 weeks on and 1 week off, each four-week cycle.', ' Overall Number of Participants Analyzed: 10', ' Measure Type: Count of Participants', ' Unit of Measure: Participants Complete Response: 0 0.0%', ' Partial Response: 0 0.0%', ' Stable Disease: 3 30.0%', ' Progressive Disease: 7 70.0%'], 'Adverse Events': ['Adverse Events 1:', ' Total: 3/10 (30.00%)', ' Sinus tachycardia * 1/10 (10.00%)', ' Blurred vision * 1/10 (10.00%)', ' Memory impairment * 1/10 (10.00%)', ' Dyspnea * 2/10 (20.00%)']}

{'Clinical Trial ID': 'NCT00490646', 'Intervention': ['INTERVENTION 1: ', ' Trastuzumab 2 mg/kg + Ixabepilone 40 mg/m^2 IV', ' trastuzumab 4 mg/kg loading dose, then 2 mg/kg weekly + ixabepilone 40 mg/m^2 intravenous (IV) over 3 hours once every 21 days (using a 21-day cycle); until disease progression or unacceptable toxicity.', 'INTERVENTION 2: ', ' Trastuzumab 2 mg/kg + Docetaxel 100 mg/m^2 IV', ' trastuzumab 4 mg/kg loading dose, then 2 mg/kg weekly + docetaxel 100 mg/m^2 IV over 1 hour once every 21 days (using a 21-day cycle); until disease progression or unacceptable toxicity.'], 'Eligibility': ['Inclusion Criteria:', ' Locally advanced or metastatic HER2+ breast cancer not previously treated with chemotherapy or trastuzumab.', ' Subjects who had received prior (neo)adjuvant chemotherapy or trastuzumab were eligible except if they relapsed within 12 months after the last dose of a taxane or trastuzumab given as (neo)adjuvant therapy.', ' Measurable disease', ' Left Ventricular Ejection Fraction (LVEF) 50%', 'Exclusion Criteria:', ' Prior chemotherapy or trastuzumab for metastatic breast cancer (MBC)', ' Relapse within 1 year after (neo)adjuvant taxane or trastuzumab', ' Neuropathy > Grade 1', ' Significant cardiovascular disease', ' Any brain metastases'], 'Results': ['Outcome Measurement: ', ' Percentage of Participants With Objective Response (OR; Assessed by Response Evaluation Criteria in Solid Tumors [RECIST] Version 1.1)', ' Percentage of participants with best overall response (BOR) of either complete response (CR) or partial response (PR) according to RECIST version 1.1 as determined by the investigator. CR: Disappearance of all evidence of target and non-target lesions. PR: At least 30% reduction from baseline in the sum of the longest diameter (LD) of all lesions. CR and PR criteria should be met again after 4 weeks and before 6 weeks after initial assessment. A two-sided confidence interval (CI) was computed using the Clopper-Pearson method.', ' Time frame: Assessed every 6 weeks from initiation of study therapy up to 12 months; then every 3 months until disease progression (maximum time that any participant was on therapy was 108 weeks)', 'Results 1: ', ' Arm/Group Title: Trastuzumab 2 mg/kg + Ixabepilone 40 mg/m^2 IV', ' Arm/Group Description: trastuzumab 4 mg/kg loading dose, then 2 mg/kg weekly + ixabepilone 40 mg/m^2 intravenous (IV) over 3 hours once every 21 days (using a 21-day cycle); until disease progression or unacceptable toxicity.', ' Overall Number of Participants Analyzed: 25', ' Measure Type: Number', ' Unit of Measure: percentage of participants 60.0 (38.7 to 78.9)', 'Results 2: ', ' Arm/Group Title: Trastuzumab 2 mg/kg + Docetaxel 100 mg/m^2 IV', ' Arm/Group Description: trastuzumab 4 mg/kg loading dose, then 2 mg/kg weekly + docetaxel 100 mg/m^2 IV over 1 hour once every 21 days (using a 21-day cycle); until disease progression or unacceptable toxicity.', ' Overall Number of Participants Analyzed: 25', ' Measure Type: Number', ' Unit of Measure: percentage of participants 52.0 (31.3 to 72.2)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 13/24 (54.17%)', ' FEBRILE NEUTROPENIA 5/24 (20.83%)', ' HAEMATOTOXICITY 0/24 (0.00%)', ' NEUTROPENIA 3/24 (12.50%)', ' LYMPHADENOPATHY 0/24 (0.00%)', ' PERICARDIAL EFFUSION 1/24 (4.17%)', ' ATRIAL FIBRILLATION 1/24 (4.17%)', ' APLASIA 0/24 (0.00%)', ' NAUSEA 0/24 (0.00%)', ' PYREXIA 1/24 (4.17%)', ' EXTRAVASATION 0/24 (0.00%)', ' CHOLECYSTITIS 1/24 (4.17%)', ' PATHOLOGICAL FRACTURE 1/24 (4.17%)', 'Adverse Events 2:', ' Total: 6/24 (25.00%)', ' FEBRILE NEUTROPENIA 0/24 (0.00%)', ' HAEMATOTOXICITY 1/24 (4.17%)', ' NEUTROPENIA 0/24 (0.00%)', ' LYMPHADENOPATHY 1/24 (4.17%)', ' PERICARDIAL EFFUSION 0/24 (0.00%)', ' ATRIAL FIBRILLATION 0/24 (0.00%)', ' APLASIA 1/24 (4.17%)', ' NAUSEA 1/24 (4.17%)', ' PYREXIA 0/24 (0.00%)', ' EXTRAVASATION 1/24 (4.17%)', ' CHOLECYSTITIS 0/24 (0.00%)', ' PATHOLOGICAL FRACTURE 0/24 (0.00%)']}

8720143a-2611-4502-a5ee-da4e641df918

Single

Intervention

NCT02186015

Women in cohort A and B of the primary trial with serum 25 (OH)D greater than or equal to 30 ng/ml did not receive weekly supplementation of cholecalciferol.

Contradiction

{'Clinical Trial ID': 'NCT02186015', 'Intervention': ['INTERVENTION 1: ', ' Cholecalciferol', ' Enrolled women received 50,000 IUs weekly supplementation of cholecalciferol for 8 weeks.', 'INTERVENTION 2: ', ' No Cholecalciferol', ' Enrolled women with serum 25 (OH)D greater than or equal to 30 ng/ml received no intervention.'], 'Eligibility': ['Inclusion Criteria:', ' Metastatic breast cancer (Stage IV)', ' Histologically confirmed estrogen receptor positive disease', ' Female', ' Serum 25(OH) <30 ng/ml', ' Age 18 years', ' Pre or post-menopausal', ' ECOG Performance status 0-2', ' Adequate organ function as defined as GFR> 30 mls/min and serum calcium 10.4 mg/dl', ' Any race/ethnicity', ' English speaking', ' No changes to MBC treatments within 30 days of enrollment and/or deemed clinically stable by their treating physician', ' Willingness to sign a written informed consent and complete questionnaires', ' Cease ingestion of vitamin D supplementation not study related', 'Exclusion Criteria:', ' Women with Stage I-III breast cancer', ' Serum 25(OH)D levels 30 ng/ml', ' Untreated CNS involvement', ' History of kidney stones', ' History of renal failure', ' History of hyperparathyroidism', ' History of hypersensitivity to vitamin D', ' Non-English speaking', ' Currently pregnant or lactating, or anticipating pregnancy', ' Unwilling to cease ingestion of calcium supplements (>1000 mg/d)', ' Unwilling or unable to complete informed consent or study questionnaires', ' Psychiatric or other clinical conditions that preclude study compliance', ' Other important medical or safety considerations at the discretion of the investigator and/or study physician, including non-compliance with the study therapy or other activities'], 'Results': ['Outcome Measurement: ', ' Change in Serum 25(OH)D', " Change in laboratory serum value of 25(OH)D at 8 weeks post-supplementation for participants who received weekly supplementation of 50,000 IUs of vitamin D3. Change is expressed as laboratory serum value of 25(OH)D at 8 weeks minus baseline. Change was not assessed for participants in the 'no cholecalciferol' arm since they did not receive weekly supplementation and were not followed over time.", ' Time frame: 0, 8 weeks', 'Results 1: ', ' Arm/Group Title: Cholecalciferol', ' Arm/Group Description: Enrolled women received 50,000 IUs weekly supplementation of cholecalciferol for 8 weeks.', ' Overall Number of Participants Analyzed: 10', ' Median (Inter-Quartile Range)', ' Unit of Measure: ng/ml 32 (22 to 40)', 'Results 2: ', ' Arm/Group Title: No Cholecalciferol', ' Arm/Group Description: Enrolled women with serum 25 (OH)D greater than or equal to 30 ng/ml received no intervention.', ' Overall Number of Participants Analyzed: 0', ' Median (Inter-Quartile Range)', ' Unit of Measure: ng/ml '], 'Adverse Events': ['Adverse Events 1:', ' Total: 0/11 (0.00%)', 'Adverse Events 2:', ' Total: ']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

0fdda7a2-4119-40a7-84f3-6c5c6077df49

Single

Adverse Events

NCT01273896

There was twice as many Cardiac adverse events as cases of Dyspnea in cohort 1 of the primary trial.

Contradiction

{'Clinical Trial ID': 'NCT01273896', 'Intervention': ['INTERVENTION 1: ', ' STA-9090', ' This will be a monotherapy, open-label phase 2 study of STA-9090 in patients who have metastatic breast cancer.', ' STA-9090: All patients will receive 200 mg/m2 of STA-9090 once weekly by a 1-hour IV infusion for three consecutive weeks followed by a 1 week dose-free interval. Subjects tolerating therapy may continue on study until disease progression.'], 'Eligibility': ['Inclusion Criteria:', ' Male and Female patients must be at least 18 years of age', ' Pathologically confirmed diagnosis of breast cancer', ' Metastatic or advanced stage breast cancer', ' Prior treatment with at least one and no more than three lines of biologic and/or chemotherapy for metastatic breast cancer (excluding hormonal therapy)', ' Patients with HER2+ disease must have received prior treatment with Trastuzumab', ' Patients with ER and/or PR+ disease must have received prior treatment with hormonal therapy', ' Off cytotoxic chemotherapy or biologic therapy (excluding Hormonal therapy) 3 weeks', ' Measurable disease by RECIST 1.1', ' Central nervous system metastases are permitted if treated and radiographically and clinically stable for at least 4 weeks prior to first dose of STA-9090', ' Eastern Cooperative Oncology Group (ECOG) Performance Status 0 or 1', ' Life expectancy of at least 3 months', ' Adequate hematologic function as defined by:', ' Absolute neutrophil count 1,500 cells/μL', ' Platelets 100,000/μL', ' Hemoglobin 9.0g/dL', ' Adequate hepatic function as defined by:', ' Serum bilirubin 1.5 X upper limit of normal (ULN);', ' Adequate renal function as defined by a serum creatinine 1.5 x ULN', ' AST, ALT, and alkaline phosphatase 3 × ULN except for:', ' Patients with hepatic metastases: ALT and AST 5 × ULN', ' Patients with hepatic and/or bone metastases: alkaline phosphatase 5 × ULN', " Patients with Gilbert's disease: serum bilirubin < 5 mg/dL", ' Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures', ' Female subjects of childbearing potential and males must agree to use adequate contraception (e.g., hormonal or barrier method of birth control; abstinence) for the duration of study treatment', ' Female subjects of childbearing age must have a negative serum pregnancy test at study entry.', 'Exclusion Criteria:', ' Surgery, radiotherapy, or lesion ablative procedure to the only area of measurable disease', ' Major surgery within 4 weeks prior to first dose of STA-9090', ' Poor peripheral venous access for study drug administration. Study drug administration via indwelling catheters allowed only if the catheter is made of silicone material.', ' History of severe (grade 3 or 4) allergic or hypersensitivity reactions to excipients (e.g., Polyethylene glycol [PEG] 300 and Polysorbate 80)', ' Baseline QTc > 470 msec', ' Ventricular ejection fraction (EF) <50% at baseline', ' Treatment with chronic immunosuppressants (e.g., cyclosporine following transplantation)', ' Women who are pregnant or lactating', ' Uncontrolled intercurrent illness including, but not limited to, human immunodeficiency virus (HIV)-positive subjects receiving combination antiretroviral therapy, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, ventricular arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements', ' Other medications, or severe acute/chronic medical or psychiatric condition, or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results in the judgment of the investigator', ' Seizure disorder or requirement for seizure medication', ' Prior treatment with an HSP90 inhibitor', ' persistent adverse events of prior therapies that are > 1 grade 1 in severity', ' history of or current coronary artery disease, myocardial infarction, angina pectoris, angioplasty or coronary bypass surgery', ' history of or current uncontrolled dysrhythmias, or requirement for antiarrhythmic medications, or Grade 2 or greater left bundle branch block', ' New York Heart Association class II/III/IV congestive heart failure with a history of dyspnea, orthopnea, or edema that requires current treatment with angiotensin converting enzyme inhibitors, angiotensin II receptor blockers, beta blockers or diuretics'], 'Results': ['Outcome Measurement: ', ' Overall Response Rate', ' To determine the overall response rate using RECIST v 1.1 criteria, defined as PR +CR.using RECIST v 1.1 criteria, defined as Partial response + complete response', ' Time frame: Radiological imaging studies to evaluate tumor status will be repeated during the rest week (Days 22 to 28) of every third cycle', 'Results 1: ', ' Arm/Group Title: STA-9090', ' Arm/Group Description: This will be a monotherapy, open-label phase 2 study of STA-9090 in patients who have metastatic breast cancer.', ' STA-9090: All patients will receive 200 mg/m2 of STA-9090 once weekly by a 1-hour IV infusion for three consecutive weeks followed by a 1 week dose-free interval. Subjects tolerating therapy may continue on study until disease progression.', ' Overall Number of Participants Analyzed: 20', ' Measure Type: Number', ' Unit of Measure: participants 20'], 'Adverse Events': ['Adverse Events 1:', ' Total: 6/22 (27.27%)', ' Cardiac General, other1/22 (4.55%)', ' Pain - Abdomen NOS1/22 (4.55%)', ' Death not assoc w CTCAE term- Death NOS1/22 (4.55%)', ' Death not assoc w CTCAE term-Disease prog NOS1/22 (4.55%)', ' Liver dysfunction/failure1/22 (4.55%)', ' Sodium, low (hyponatremia)1/22 (4.55%)', ' Dyspnea (shortness of breath)2/22 (9.09%)']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

e7eae332-6b6a-41e0-aa31-86a781fd373f

Single

Intervention

NCT01439945

In the primary trial Low Dose Magnesium Oxide is 400 mg/day less than high dose Magnesium Oxide.

Entailment

{'Clinical Trial ID': 'NCT01439945', 'Intervention': ['INTERVENTION 1: ', ' Low Dose Magnesium Oxide (800 mg/Day)', ' Week 2:', ' Patients take one 400 mg tablet of magnesium oxide orally (PO) daily (QD).', ' Week 3:', ' Patients take two 400 mg tablet of magnesium oxide orally (PO) daily (QD).', ' Weeks 4-9:', ' Patients take two 400 mg tablet of magnesium oxide orally (PO) daily (QD).', 'INTERVENTION 2: ', ' High Dose Magnesium Oxide (1200 mg/Day)', ' Week 2:', ' Patients take one 400 mg tablet of magnesium oxide orally (PO) daily (QD).', ' Week 3:', ' Patients take two 400 mg tablet of magnesium oxide orally (PO) daily (QD).', ' Weeks 4-9:', ' Patients take three 400 mg tablet of magnesium oxide orally (PO) daily (QD).'], 'Eligibility': ['DISEASE CHARACTERISTICS:', ' Women with a history of breast cancer (currently without malignant disease)', ' Bothersome hot flashes (defined by their occurrence 28 times per week and of sufficient severity to make the patient desire therapeutic intervention)', ' Presence of hot flashes for 30 days prior to study registration', ' Willingness to provide the biologic specimens as required by the protocol', ' Hormone receptor status not specified', ' PATIENT CHARACTERISTICS:', ' Women who are postmenopausal as defined by absence of a period in the past 12 months or bilateral oophorectomy', ' Women with at least one ovary but without a uterus should be deemed postmenopausal by either age over 55 or a combination of estrogen within a postmenopausal range (per local lab) and FSH over 40 mIU/mL', ' No women of childbearing potential or who are premenopausal', ' Creatinine clearance > 30 mL/min', ' Ability to complete questionnaire(s) by themselves or with assistance', ' ECOG performance status 0 or 1', ' No history of allergic or other adverse reaction to magnesium', ' No diabetes', ' No patients with conditions that are implicated in decreased absorption of magnesium (e.g., Crohn disease, ETOH abuse)', ' No patients who have diarrhea where magnesium might make it worse (per provider discretion)', ' PRIOR CONCURRENT THERAPY:', ' None of the following current ( 28 days prior to registration) or planned therapies (tamoxifen, raloxifene, or aromatase inhibitors are allowed, but the patient must have been on a constant dose for 28 days and must not be expected to stop the medication during the study period):', ' Antineoplastic chemotherapy (trastuzumab or lapatinib are allowed)', ' Androgens', ' Estrogens (any delivery route)', ' Progestational agents', ' No prior use of magnesium for hot flashes', ' No current or planned use of gabapentin (for any reasons) or antidepressants (for any reasons) or other agents for treating hot flashes (except stable dose of vitamin E is allowed as long as it was started > 30 days prior to study registration and are to be continued through the study period; soy is allowed, if it is planned to be continued at the same dose during the study period)', ' No current use of magnesium for any indication (except one standard multiple vitamin dose is allowed per day)', ' Not taking diuretics, corticosteroids, bile acid sequestrants, and other prescription and over-the-counter medications that may affect magnesium levels', ' No current ( 7 days prior to registration) or planned use of other non-drug therapies for managing hot flashes, such as acupuncture or yoga (use of these therapies for other reasons is allowed)'], 'Results': ['Outcome Measurement: ', ' The Intra-patient Changes of Weekly Hot Flash Activity From Baseline During the Treatment Period.', ' The primary endpoint is the intra-patient changes of weekly hot flash activity from baseline during the treatment period. The hot flash activity will be measured by the weekly average hot flash score, which is a composite entity of both frequency and severity of hot flashes.', ' The hot flash severity is graded from 1 to 4 (1=mild, 2=moderate, 3=severe, and 4=very severe). The daily hot flash score is computed by multiplying the mean grade of severity by the frequency during every 24 hour period. Therefore, a score of zero is the lowest possible score and can be interpreted as having no hot flashes. The weekly hot flash score was calculated by adding all scores for the week.', ' The mean Hot Flash Score for each week for each group is reported and a repeated measures analysis is reported comparing each dose level group to the Placebo group.', ' Time frame: Baseline to Week 8', 'Results 1: ', ' Arm/Group Title: Low Dose Magnesium Oxide (800 mg/Day)', ' Arm/Group Description: Week 2:', ' Patients take one 400 mg tablet of magnesium oxide orally (PO) daily (QD).', ' Week 3:', ' Patients take two 400 mg tablet of magnesium oxide orally (PO) daily (QD).', ' Weeks 4-9:', ' Patients take two 400 mg tablet of magnesium oxide orally (PO) daily (QD).', ' Overall Number of Participants Analyzed: 88', ' Mean (Standard Deviation)', ' Unit of Measure: units on a scale Baseline: 81 participants', ' 16.02 (9.62)', ' Week 1: 81 participants', ' 14.28 (9.26)', ' Week 2: 79 participants', ' 12.68 (8.87)', ' Week 3: 78 participants', ' 12.29 (9.79)', ' Week 4: 78 participants', ' 11.73 (10.35)', ' Week 5: 75 participants', ' 11.77 (10.86)', ' Week 6: 71 participants', ' 11.61 (10.46)', ' Week 7: 71 participants', ' 11.92 (11.26)', ' Week 8: 69 participants', ' 12.17 (10.88)', 'Results 2: ', ' Arm/Group Title: High Dose Magnesium Oxide (1200 mg/Day)', ' Arm/Group Description: Week 2:', ' Patients take one 400 mg tablet of magnesium oxide orally (PO) daily (QD).', ' Week 3:', ' Patients take two 400 mg tablet of magnesium oxide orally (PO) daily (QD).', ' Weeks 4-9:', ' Patients take three 400 mg tablet of magnesium oxide orally (PO) daily (QD).', ' Overall Number of Participants Analyzed: 88', ' Mean (Standard Deviation)', ' Unit of Measure: units on a scale Baseline: 81 participants', ' 15.35 (10.53)', ' Week 1: 78 participants', ' 14.47 (11.10)', ' Week 2: 78 participants', ' 12.59 (10.01)', ' Week 3: 76 participants', ' 11.32 (10.72)', ' Week 4: 73 participants', ' 10.14 (8.61)', ' Week 5: 67 participants', ' 9.73 (9.19)', ' Week 6: 67 participants', ' 9.44 (8.99)', ' Week 7: 67 participants', ' 9.37 (9.24)', ' Week 8: 66 participants', ' 9.06 (8.87)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 0/92 (0.00%)', ' Diarrhea 0/92 (0.00%)', 'Adverse Events 2:', ' Total: 1/93 (1.08%)', ' Diarrhea 1/93 (1.08%)']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

9a52d5d4-ff71-42ee-8672-ec4ac3cfd591

Comparison

Intervention

NCT01735175

NCT01216319

the secondary trial and the primary trial are both testing Biodesign interventions.

Contradiction

{'Clinical Trial ID': 'NCT01735175', 'Intervention': ['INTERVENTION 1: ', ' LA-EP2006', ' During each chemotherapy cycle eligible patients receive LA-EP2006 s.c. post chemotherapy application.', ' LA-EP2006: Eligible patients are scheduled to receive six cycles of chemotherapy every three weeks. During each chemotherapy cycle pegfilgrastim is injected s.c. post chemotherapy application.', 'INTERVENTION 2: ', ' Neulasta®', ' During each chemotherapy cycle eligible patients receive Neulasta® s.c. post chemotherapy application.', ' Neulasta®: Eligible patients are scheduled to receive six cycles of chemotherapy every three weeks. During each chemotherapy cycle pegfilgrastim is injected s.c. post chemotherapy application.'], 'Eligibility': ['Inclusion Criteria:', ' histologically proven breast cancer', ' eligible for six cycles of neoadjuvant or adjuvant chemotherapy', 'Exclusion Criteria:', ' concurrent or prior chemotherapy for breast cancer', ' concurrent or prior anti-cancer treatment for breast cancer such as endocrine therapy, immunotherapy, monoclonal antibodies, and/or biological therapy', ' concurrent prophylactic antibiotics', ' previous therapy with any G-CSF (granulocyte-colony stimulating factor) product', ' Other protocol-defined inclusion/exclusion criteria may apply.'], 'Results': ['Outcome Measurement: ', ' Mean Duration of Severe Neutropenia (DSN) During Cycle 1 of Chemotherapy', ' Mean duration of severe neutropenia, defined as number of consecutive days with ANC <0.5 × 10^9 cells/L (grade 4 neutropenia).', ' Time frame: 21 days (Cycle 1 of chemotherapy treatment)', 'Results 1: ', ' Arm/Group Title: LA-EP2006', ' Arm/Group Description: During each chemotherapy cycle eligible patients receive LA-EP2006 s.c. post chemotherapy application.', ' LA-EP2006: Eligible patients are scheduled to receive six cycles of chemotherapy every three weeks. During each chemotherapy cycle pegfilgrastim is injected s.c. post chemotherapy application.', ' Overall Number of Participants Analyzed: 159', ' Mean (Standard Deviation)', ' Unit of Measure: days FAS: 155 participants', ' 0.75 (0.878)', ' PP: 146 participants', ' 0.75 (0.875)', 'Results 2: ', ' Arm/Group Title: Neulasta ', ' Arm/Group Description: During each chemotherapy cycle eligible patients receive Neulasta s.c. post chemotherapy application.', ' Neulasta : Eligible patients are scheduled to receive six cycles of chemotherapy every three weeks. During each chemotherapy cycle pegfilgrastim is injected s.c. post chemotherapy application.', ' Overall Number of Participants Analyzed: 157', ' Mean (Standard Deviation)', ' Unit of Measure: days FAS: 155 participants', ' 0.83 (0.898)', ' PP: 149 participants', ' 0.79 (0.872)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 16/159 (10.06%)', ' Febrile neutropenia 9/159 (5.66%)', ' Neutropenia 3/159 (1.89%)', ' Anemia 1/159 (0.63%)', ' Leukopenia 0/159 (0.00%)', ' Pancytopenia 0/159 (0.00%)', ' Thrombocytopenia 0/159 (0.00%)', ' Cardio-respiratory arrest 2/159 (1.26%)', ' Cardiac arrest 1/159 (0.63%)', ' Diarrhea 0/159 (0.00%)', ' Gastritis 1/159 (0.63%)', ' Nausea 1/159 (0.63%)', ' Vomiting 0/159 (0.00%)', 'Adverse Events 2:', ' Total: 21/157 (13.38%)', ' Febrile neutropenia 12/157 (7.64%)', ' Neutropenia 6/157 (3.82%)', ' Anemia 2/157 (1.27%)', ' Leukopenia 1/157 (0.64%)', ' Pancytopenia 1/157 (0.64%)', ' Thrombocytopenia 1/157 (0.64%)', ' Cardio-respiratory arrest 0/157 (0.00%)', ' Cardiac arrest 0/157 (0.00%)', ' Diarrhea 1/157 (0.64%)', ' Gastritis 0/157 (0.00%)', ' Nausea 0/157 (0.00%)', ' Vomiting 1/157 (0.64%)']}

{'Clinical Trial ID': 'NCT01216319', 'Intervention': ['INTERVENTION 1: ', ' Nipple Reconstruction Cylinder', ' Nipple reconstruction: Biodesign® Nipple Reconstruction Cylinder'], 'Eligibility': ['Inclusion Criteria:', ' Patient presents with a history of breast cancer, having previously completed either uni- or bi-lateral breast removal and reconstruction.', ' Patient presents with a desire to obtain nipple reconstruction', ' Patient is at least 18 years of age', ' And other inclusion criteria', 'Exclusion Criteria:', ' Patient is not medically fit enough for surgery under local anesthesia', ' Patient is currently smoking, using tobacco products, or nicotine products (i.e. patch, gum, or nasal spray)', ' Patient is pregnant, breastfeeding or planning further pregnancy during the study period', ' Patient has physical allergies or cultural objections to the receipt of porcine products', ' And other exclusion criteria'], 'Results': ['Outcome Measurement: ', ' Percent Nipple Projection at 12 Months Compared to Baseline (1 Week Post-procedure)', ' [Not Specified]', ' Time frame: 12 months', 'Results 1: ', ' Arm/Group Title: Nipple Reconstruction Cylinder', ' Arm/Group Description: Nipple reconstruction: Biodesign Nipple Reconstruction Cylinder', ' Overall Number of Participants Analyzed: 44', ' Overall Number of Units Analyzed', ' Type of Units Analyzed: Nipples Mean (Standard Deviation)Unit of Measure: percentage of projection vs baseline: 37.3 (17.5)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 1/50 (2.00%)', ' Metastatic breast cancer 1/50 (2.00%)']}

c09b9f7c-2d22-4c44-a79d-32929530dd9e

Single

Results

NCT00003199

The patient group with the highest percent of PFS at 5 months in the primary trial was Stage IIIB patients, and the worst was Stage IV Disease patients.

Contradiction

{'Clinical Trial ID': 'NCT00003199', 'Intervention': ['INTERVENTION 1: ', ' TX/Maintenance Therapy for Stage IIIB/IV Breast Cancer', ' See Detailed Description.', ' tamoxifen citrate: Given orally', ' busulfan: Given orally', ' thiotepa: Given IV', ' melphalan: Given IV', ' aldesleukin: Given SC', ' sargramostim: Given SC', ' peripheral blood stem cell transplantation: Undergo autologous peripheral blood stem cell infusion', ' radiation therapy: May undergo radiotherapy after completion of IL-2/GM-CSF'], 'Eligibility': ['Inclusion Criteria:', ' Patients with inflammatory (stage IIIb) or responsive stage IV breast cancer with metastasis to soft tissue and/or bone; responsive stage IV disease is defined as patients who achieve a PR (>= 50% reduction in measurable tumor burden) or CR following initial chemotherapy for metastatic disease or patients with locally recurrent disease (chest wall/axillary nodes) who are rendered disease-free following surgery or radiation therapy without receiving chemotherapy; bone disease is categorized as responsive if there is demonstrated sclerosis of prior lesions with no new lesions', ' Patients should have received 4-7 cycles of an Adriamycin and/or taxane-based regimen for stage IIIb or stage IV disease; locally recurrent (chest wall/axillary nodes) patients rendered NED by RT or surgery do not need to receive chemotherapy for stage IV disease prior to Cytoxan/Taxol', ' Patient has received Cytoxan 4 gm/m^2 x 1 and Taxol 250 mg/m^2 x 1 per FHCRC protocol 506.03; Cytoxan/Taxol must be given after all other chemotherapy is completed and before transplant', " Stem cells were collected after mobilization with Cytoxan/Taxol or after mobilization from an FHCRC approved cytokine protocol; if syngeneic collection, PBSC's were collected by using G-CSF according to FHCRC protocol 753; patient has an adequate number of peripheral blood stem cells stored (>= 2.5 x 10^6 CD34+ cells/kg)", ' The patient must have the capacity to give informed consent; the patient must have signed an approved consent form conforming with federal and institutional guidelines', ' Hepatic function: Bilirubin =< 2 mg%; SGOT or SGPT =< 2.5 x institutional normal', ' Renal function: Creatinine =< 2.0 mg/dl or a creatinine clearance >= 50 mg/min', ' Pre-Study tests have been performed as outlined in the Study Calendar', ' Patients will begin IL-2/GM-CSF therapy if they meet the following criteria post-transplant:', ' Can start therapy 30 to 100 days after transplant', ' Karnofsky performance status > 60', ' ANC > 1,000 cells/mm^3 and platelets > 30,000/cells/mm^3 (transfusion independent) for at least 5 days before starting therapy', ' Total bilirubin =< 2.5 x upper limit of normal', ' SGOT =< 2.5 x upper limit of normal', ' Creatinine =< 2.0 mg/dl', 'Exclusion Criteria:', ' Patients with a Karnofsky Performance Score less than 70', ' Patients with a left ventricular ejection fraction less than 50 % (LVEF must be performed in patients with symptoms of CHF, abnormal cardiac exam or history of Adriamycin therapy total dose > 400 mg/m^2)', ' Patient is pregnant', ' Patient is seropositive for the human immunodeficiency virus', ' Patients with a history of seizures', ' Patients with hypersensitivity to E.coli preparations', ' Patients with active auto-immune disease', ' Patients with clinically significant pulmonary disease, i.e., diffusion capacity corrected < 60% of predicted; patients with pulmonary problems should be evaluated with appropriate pulmonary studies and/or consult', ' Patients with a history of CNS lesion (brain or carcinoid meningitis)', ' Patients with significant active infection precluding transplant', ' Patients who have had more than one prior chemotherapy regimen for stage IV disease or a prior transplant for any stage disease', ' Patients who have had CD34+ selection of their PBSC products', ' Patients will not receive IL-2/GM-CSF therapy if they:', ' Are > 100 days from transplant', ' Have documented disease progression after transplant', ' Have an active infection', ' Manifested cardiac complications during the initial transplant period, including arrhythmias (that required therapy), congestive heart failure, angina, myocardial infarct, or decreased LVEF to < 45%', ' Currently have pericardial effusions, pleural effusions or ascites', ' Manifested pulmonary toxicity during the initial transplant period and have a diffusion capacity corrected =< 60%', ' Are on steroids', ' Currently have a Grade 3 toxicity from BuMelTT', ' If the patient does not wish to receive the therapy'], 'Results': ['Outcome Measurement: ', ' Event-free Survival', ' Event-free survival of patients treated for inflammatory (Stage IIIb) and responsive stage IV breast cancer with BUMELTT and PBSC support and low dose immunotherapy with IL2 and GM-CSF.', ' Time frame: 11 years', 'Results 1: ', ' Arm/Group Title: TX/Maintenance Therapy for Stage IIIB/IV Breast Cancer', ' Arm/Group Description: See Detailed Description.', ' tamoxifen citrate: Given orally', ' busulfan: Given orally', ' thiotepa: Given IV', ' melphalan: Given IV', ' aldesleukin: Given SC', ' sargramostim: Given SC', ' peripheral blood stem cell transplantation: Undergo autologous peripheral blood stem cell infusion', ' radiation therapy: May undergo radiotherapy after completion of IL-2/GM-CSF', ' Overall Number of Participants Analyzed: 50', ' Measure Type: Count of Participants', ' Unit of Measure: Participants Stage IIIB Disease: 18 participants', ' 11 61.1%', ' Stage IV Disease: 32 participants', '9 28.1%'], 'Adverse Events': ['Adverse Events 1:', ' Total: 2/50 (4.00%)', ' Prolonged hospitalization for post-transplant complications [1]1/50 (2.00%)', ' Pulmonary Emboli [2]1/50 (2.00%)']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

6f143256-52e4-40b7-950c-5c892f8632b9

Single

Eligibility

NCT00217399

To be included in the primary trial, patients must have at least 1 unidimensionally measurable lesion, and must meet some specific size conditions.

Entailment

{'Clinical Trial ID': 'NCT00217399', 'Intervention': ['INTERVENTION 1: ', ' Sorafenib and Anastrozole', ' All patients receive sorafenib and anastrozole.'], 'Eligibility': ['Inclusion Criteria:', ' Histologically or cytologically confirmed breast cancer', ' Metastatic disease', ' Measurable disease, defined as >=1 unidimensionally measurable lesion, including >= 1 of the following:', ' Lesion >= 10 mm on CT scan (5 mm sections)', ' Lesion >= 20 mm on CT scan or MRI (10 mm sections)', ' Bone disease that is >= 10 mm on MRI', ' Lytic bone lesions that are >= 10 mm on CT scan (with 5 mm sections) OR >= 20 mm on plain film or CT scan (with 10 mm sections)', ' Lesion >= 10 mm on physical exam', ' Patients must have received >= 1 prior aromatase inhibitor in either the adjuvant or metastatic setting and must have had either disease recurrence or disease progression on a prior aromatase inhibitor therapy', ' No brain metastases diagnosed within the past 6 months OR previously untreated brain metastases', ' Estrogen receptor-positive and/or progesterone receptor-positive, defined as > 1% staining by immunohistochemistry or > 10 fmol/mg of protein by radio-ligand dextran-coated steroid binding assay', ' Postmenopausal, as defined by 1 of the following:', ' Prior bilateral oophorectomy', ' No menses for >= 12 months in patients with an intact uterus', ' Follicle-stimulating hormone (FSH) in postmenopausal range in patients < 60 years of age who have had a prior hysterectomy or have been amenorrheic for >= 3 months', ' Age >= 60 years', ' Pre- or perimenopausal patients receiving monthly injections of goserelin at a dose of 3.6 mg are eligible', ' ECOG 0-2', ' More than 3 months', ' Absolute neutrophil count >= 1,500/mm3 Platelet count >= 100,000/mm3 No bleeding diathesis', ' Bilirubin =< 1.5 times upper limit of normal (ULN AST and ALT =< 2.5 times ULN', ' Systolic blood pressure (BP) < 150 mm Hg and diastolic BP < 100 mm Hg on at least one reading prior to study entry No uncontrolled hypertension', ' None of the following within the past 6 months:', ' Symptomatic congestive heart failure', ' Unstable angina pectoris', ' Myocardial infarction', ' Cardiac arrhythmia with hemodynamic compromise', ' Not pregnant or nursing', ' Able to swallow oral medication', ' No known HIV positivity', ' No ongoing or active infection', ' No psychiatric illness or social situation that would preclude study compliance', ' No other active invasive malignancy within the past 5 years except nonmelanoma skin cancer or treated carcinoma in situ of the cervix', ' No other uncontrolled illness', ' More than 4 weeks since prior chemotherapy', ' No more than 2 prior chemotherapy regimens for metastatic disease', ' At least 8 weeks since prior anastrozole therapy', ' Concurrent steroids allowed if dose is stable', ' More than 4 weeks since prior radiotherapy', ' More than 4 weeks since prior major surgery', ' Recovered from prior therapy', ' No prior sorafenib', ' No concurrent therapeutic anticoagulation', ' Concurrent prophylactic anticoagulation (i.e., low-dose warfarin) for venous or arterial access devices allowed provided PT and PTT are =< 1.5 times ULN', ' No concurrent agents that may interact with sorafenib, including any of the following:', " Hypericum perforatum (St. John's wort)", ' Rifampin', ' P450 CYP3A4 enzyme-inducing anticonvulsants (e.g., phenytoin, carbamazepine, or phenobarbital)', ' No other concurrent investigational agents', 'Exclusion Criteria:', ' estrogen receptor status unknown', ' history of myocardial infarction within 6 months', ' performance status 3', ' performance status 4', ' premenopausal', ' progesterone receptor status unknown', 'HIV positive'], 'Results': ['Outcome Measurement: ', ' Complete Response + Partial Response + Stable Disease > 24 Weeks', ' Clinical Outcome measured using Response Evaluation Criteria In Solid Tumors (RECIST,)V1.0, and assessed by MRI or CT: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Stable Disease (SD), a tumor that is neither growing nor shrinking.', ' A patient has clinical benefit from treatment if CR + PR + SD > 24 weeks.', ' Time frame: 24 weeks', 'Results 1: ', ' Arm/Group Title: Sorafenib and Anastrozole', ' Arm/Group Description: All patients receive sorafenib and anastrozole.', ' Overall Number of Participants Analyzed: 35', ' Measure Type: Number', ' Unit of Measure: participants 35'], 'Adverse Events': ['Adverse Events 1:', ' Total: 12/35 (34.29%)', ' hand-foot syndome * 12/35 (34.29%)']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

d2718f05-1d35-4c84-a054-06a3fe4a0a9c

Single

Adverse Events

NCT01427933

Neutropenia was the most common adverse event for patients in cohort 1 of the primary trial.

Entailment

{'Clinical Trial ID': 'NCT01427933', 'Intervention': ['INTERVENTION 1: ', ' Ramucirumab and Eribulin', ' Ramucirumab (IMC-1121B) 10 mg/kg administered by intravenous (IV) infusion on Day 1 of each 3-week cycle', ' Eribulin 1.4 mg/m² administered by IV bolus on Day 1 and Day 8 of each 3-week cycle', 'INTERVENTION 2: ', ' Eribulin Monotherapy', ' Eribulin 1.4 mg/m² administered by IV bolus on Day 1 and Day 8 of each 3-week cycle'], 'Eligibility': ['Inclusion Criteria:', ' Have histologically or cytologically confirmed invasive breast cancer which at the time of study entry is either locally recurrent disease not amenable to curative therapy or Stage IV disease (American Joint Committee on Cancer Staging Criteria for breast cancer)', ' Have measurable and/or nonmeasurable disease per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1)', ' Have received at least 2 but not more than 4 prior cytotoxic chemotherapy regimens in the locally recurrent or metastatic setting', ' Have received prior treatment with both anthracyclines and taxanes, either in the metastatic, adjuvant or neoadjuvant setting', ' Have received Human Epidermal Growth Factor Receptor 2 (HER-2) directed treatment; or are not a candidate for HER-2-directed treatment if the patient has HER-2 positive disease', ' Have completed any prior radiotherapy and/or hormonal therapy at least 1 week prior to randomization and have recovered from all clinically significant treatment-related toxicities', ' Have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1', ' Have left ventricular ejection fraction within normal limits', ' Have discontinued all previous chemotherapy treatments for cancer at least 3 weeks prior to randomization and recovered from clinically significant toxic effects', ' Have resolution to Grade less than or equal to 1 [by the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), Version 4.0] of all clinically significant toxicities of prior chemotherapy, surgery, radiotherapy, or hormonal therapy with the exception of peripheral neuropathy, which must have resolved to Grade less than or equal to 2', ' Have adequate hematologic, hepatic, renal, and coagulation function', ' Test negative for pregnancy', ' Have a life expectancy of at least 3 months', 'Exclusion Criteria:', ' Have a concurrent active other malignancy other than adequately treated non-melanomatous skin cancer or other noninvasive or in situ neoplasms', ' Are currently enrolled in, or recently discontinued from, a clinical trial involving an investigational product, or concurrently enrolled in any other type of medical research judged not to be medically compatible with the study', ' Have received investigational therapy within 3 weeks prior to randomization', ' Have received prior ramucirumab or eribulin', ' Have a known sensitivity to agents of similar biologic composition as ramucirumab, halichondrin B and/or halichondrin B chemical derivative', ' Have received bevacizumab within 6 weeks prior to randomization', ' Have uncontrolled or poorly controlled hypertension', ' Have congenital prolonged QTc syndrome (or have a family history) or prolongation of QTc at baseline', ' Have a history of additional risk factors for torsades de pointes within the last year prior to randomization', ' Have an implantable pacemaker or automatic implantable cardioverter defibrillator', ' Have bradycardia', ' Have an acute/subacute bowel obstruction or history of chronic diarrhea requiring ongoing medical intervention within 6 months prior to randomization', ' Have a history of uncontrolled hereditary or acquired bleeding or thrombotic disorders', ' Have experienced a Grade 3 or greater bleeding event within 3 months prior to randomization', ' Have experienced any Grade 3 or greater arterial thromboembolic events within 6 months prior to randomization, or venous thromboembolic event within 3 months prior to randomization', ' Have undergone major surgery within 4 weeks prior to randomization or subcutaneous venous access device placement within 7 days prior to randomization', ' Have a planned major surgery to be performed during the course of the trial', ' Have uncontrolled metabolic conditions', ' Have an ongoing or active infection requiring parenteral antibiotic, antifungal, or antiviral therapy', ' Have known human immunodeficiency virus (HIV) infection or acquired immunodeficiency syndrome (AIDS)', ' Have pulmonary lymphangitic involvement that results in pulmonary dysfunction requiring active treatment including the use of oxygen', ' Have received a prior allogeneic organ or tissue transplantation', ' Have had a serious nonhealing wound, ulcer, or bone fracture within 4 weeks prior to randomization', ' Have known leptomeningeal metastases', ' Have cirrhosis (Child-Pugh Level B or worse) or cirrhosis (any degree) and a history of hepatic encephalopathy or clinically meaningful ascites'], 'Results': ['Outcome Measurement: ', ' Progression-Free Survival (PFS)', ' PFS was defined as time from date of randomization until the date of objectively determined progression defined by Response Evaluation Criteria in Solid Tumors (RECIST v1.1) criteria or death from any cause, whichever is first. Progressive disease (PD) defined as 20% increase in sum of diameter (SOD) of target lesion with the sum demonstrating an increase of 5 mm; appearance of 1 new lesions or unequivocal progression of non-target lesions. Participants with no baseline disease assessment were censored at randomization date, regardless of whether or not objectively determined PD or death was observed; participants not known to have died or to have objective progression as of data inclusion cutoff date were censored at last post baseline radiological assessment date or randomization date, if there was no post baseline radiological assessment.', ' Time frame: Start of treatment until documented disease progression or death from any cause up to 16.5 months', 'Results 1: ', ' Arm/Group Title: Ramucirumab and Eribulin', ' Arm/Group Description: Ramucirumab (IMC-1121B) 10 mg/kg administered by intravenous (IV) infusion on Day 1 of each 3-week cycle', ' Eribulin 1.4 mg/m administered by IV bolus on Day 1 and Day 8 of each 3-week cycle', ' Overall Number of Participants Analyzed: 71', ' Median (95% Confidence Interval)', ' Unit of Measure: months 4.4 (3.1 to 6.7)', 'Results 2: ', ' Arm/Group Title: Eribulin Monotherapy', ' Arm/Group Description: Eribulin 1.4 mg/m administered by IV bolus on Day 1 and Day 8 of each 3-week cycle', ' Overall Number of Participants Analyzed: 70', ' Median (95% Confidence Interval)', ' Unit of Measure: months 4.1 (3.2 to 5.6)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 26/69 (37.68%)', ' Anaemia 2/69 (2.90%)', ' Febrile neutropenia 3/69 (4.35%)', ' Neutropenia 4/69 (5.80%)', ' Cardiac arrest 1/69 (1.45%)', ' Cardiac failure congestive 1/69 (1.45%)', ' Cardiac tamponade 1/69 (1.45%)', ' Pericardial effusion 1/69 (1.45%)', ' Abdominal pain 1/69 (1.45%)', ' Ascites 2/69 (2.90%)', ' Colitis 1/69 (1.45%)', ' Gastritis 1/69 (1.45%)', ' Gastritis erosive 1/69 (1.45%)', 'Adverse Events 2:', ' Total: 12/65 (18.46%)', ' Anaemia 0/65 (0.00%)', ' Febrile neutropenia 1/65 (1.54%)', ' Neutropenia 1/65 (1.54%)', ' Cardiac arrest 0/65 (0.00%)', ' Cardiac failure congestive 0/65 (0.00%)', ' Cardiac tamponade 0/65 (0.00%)', ' Pericardial effusion 0/65 (0.00%)', ' Abdominal pain 2/65 (3.08%)', ' Ascites 2/65 (3.08%)', ' Colitis 0/65 (0.00%)', ' Gastritis 0/65 (0.00%)', ' Gastritis erosive 0/65 (0.00%)']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

7f49cafd-3a27-4fc8-872d-914b9176442e

Single

Adverse Events

NCT01998906

The same number of cases of Neutropenia and Pancytopenia are observed in patients from cohort 1 of the primary trial.

Entailment

{'Clinical Trial ID': 'NCT01998906', 'Intervention': ['INTERVENTION 1: ', ' HER2+ TC', ' Participants with HER2+ breast cancer received treatment as follows:', ' Cycles 1-3 (3-week cycles): trastuzumab 8 mg/kg, IV on Day 1 (Cycle 1 only; 6 mg/kg in Cycles 2 and 3), doxorubicin 60 mg/m^2, IV, and paclitaxel 150 mg/m^2, IV, on Day 1 followed by 2 weeks off.', ' Cycles 4-7 (3-week cycles): trastuzumab 6 mg/kg, IV, paclitaxel 175 mg/m^2, IV, on Day 1, followed by 2 weeks off.', ' Cycles 8-10 (3-week cycles): trastuzumab 6 mg/kg, IV, on Day 1 and cyclophosphamide 600 mg/m^2, IV, methotrexate 40 mg/m^2, IV, and 5-fluorouracil 600 mg/m^2, IV, (collectively CMF) on Days 1 and 8, followed by 2 weeks off.', ' Cycles 11-17 (3-week cycles): postoperatively, participants received trastuzumab 6 mg/kg IV on Day 1, followed by 2 weeks off for maximum of 17 overall cycles with trastuzumab. Adjuvant tamoxifen, 20 mg/day was administered for up to 5 years.', 'INTERVENTION 2: ', ' HER2+ C', ' Participants with HER2+ breast cancer received treatment as follows:', ' Cycles 1-3 (3-week cycles): doxorubicin 60 mg/m^2, IV and paclitaxel 150 mg/m^2, IV, on Day 1 followed by 2 weeks off.', ' Cycles 4-7 (3-week cycles): paclitaxel 175 mg/m^2, IV, on Day 1, followed by 2 weeks off.', ' Cycles 8-10 (3-week cycles): cyclophosphamide 600 mg/m^2, IV, methotrexate 40 mg/m^2, IV, and 5-fluorouracil 600 mg/m^2, IV, on Days 1 and 8, followed by 1 week off.'], 'Eligibility': ['Inclusion Criteria:', ' female patients, >=18 years of age, with locally advanced breast cancer.', 'Exclusion Criteria:', ' previous therapy for any invasive malignancy.'], 'Results': ['Outcome Measurement: ', ' Event-Free Survival (EFS) - Percentage of Participants With an Event', ' EFS was defined as the time between randomization and date of documented occurrence of disease recurrence or progression (local, regional, distant or contralateral) or death due to any cause.', ' Time frame: Baseline (BL), Presurgery: Day 1 (Cycles 1-7) and Days 1 and 8 (Cycles 8-10); Postsurgery: Day 1 (Cycles 1-17); every 6 months up to 60 months after last dose of study drug; yearly thereafter', 'Results 1: ', ' Arm/Group Title: HER2+ TC', ' Arm/Group Description: Participants with HER2+ breast cancer received treatment as follows:', ' Cycles 1-3 (3-week cycles): trastuzumab 8 mg/kg, IV on Day 1 (Cycle 1 only; 6 mg/kg in Cycles 2 and 3), doxorubicin 60 mg/m^2, IV, and paclitaxel 150 mg/m^2, IV, on Day 1 followed by 2 weeks off.', ' Cycles 4-7 (3-week cycles): trastuzumab 6 mg/kg, IV, paclitaxel 175 mg/m^2, IV, on Day 1, followed by 2 weeks off.', ' Cycles 8-10 (3-week cycles): trastuzumab 6 mg/kg, IV, on Day 1 and cyclophosphamide 600 mg/m^2, IV, methotrexate 40 mg/m^2, IV, and 5-fluorouracil 600 mg/m^2, IV, (collectively CMF) on Days 1 and 8, followed by 2 weeks off.', ' Cycles 11-17 (3-week cycles): postoperatively, participants received trastuzumab 6 mg/kg IV on Day 1, followed by 2 weeks off for maximum of 17 overall cycles with trastuzumab. Adjuvant tamoxifen, 20 mg/day was administered for up to 5 years.', ' Overall Number of Participants Analyzed: 115', ' Measure Type: Number', ' Unit of Measure: percentage of participants 40.0', 'Results 2: ', ' Arm/Group Title: HER2+ C', ' Arm/Group Description: Participants with HER2+ breast cancer received treatment as follows:', ' Cycles 1-3 (3-week cycles): doxorubicin 60 mg/m^2, IV and paclitaxel 150 mg/m^2, IV, on Day 1 followed by 2 weeks off.', ' Cycles 4-7 (3-week cycles): paclitaxel 175 mg/m^2, IV, on Day 1, followed by 2 weeks off.', ' Cycles 8-10 (3-week cycles): cyclophosphamide 600 mg/m^2, IV, methotrexate 40 mg/m^2, IV, and 5-fluorouracil 600 mg/m^2, IV, on Days 1 and 8, followed by 1 week off.', ' Overall Number of Participants Analyzed: 116', ' Measure Type: Number', ' Unit of Measure: percentage of participants 50.9'], 'Adverse Events': ['Adverse Events 1:', ' Total: 18/115 (15.65%)', ' Febrile neutropenia * 7/115 (6.09%)', ' Neutropenia * 1/115 (0.87%)', ' Pancytopenia * 1/115 (0.87%)', ' Diarrhoea * 0/115 (0.00%)', ' Nausea * 0/115 (0.00%)', ' Stomatitis * 0/115 (0.00%)', ' Vomiting * 1/115 (0.87%)', ' Asthenia * 1/115 (0.87%)', ' Mucosal inflammation * 0/115 (0.00%)', ' Pyrexia * 3/115 (2.61%)', ' Gastrointestinal infection * 1/115 (0.87%)', 'Adverse Events 2:', ' Total: 8/112 (7.14%)', ' Febrile neutropenia * 3/112 (2.68%)', ' Neutropenia * 2/112 (1.79%)', ' Pancytopenia * 0/112 (0.00%)', ' Diarrhoea * 2/112 (1.79%)', ' Nausea * 2/112 (1.79%)', ' Stomatitis * 1/112 (0.89%)', ' Vomiting * 1/112 (0.89%)', ' Asthenia * 0/112 (0.00%)', ' Mucosal inflammation * 1/112 (0.89%)', ' Pyrexia * 0/112 (0.00%)', ' Gastrointestinal infection * 0/112 (0.00%)']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

2e84c5ba-2de9-42a1-8e75-44f6d5e9ef25

Comparison

Eligibility

NCT00428922

NCT00499083

Patients with prior radiotherapy for the treatment of stage 4 cancer over 5 years ago, are not eligible for either the primary trial or the secondary trial.

Contradiction

{'Clinical Trial ID': 'NCT00428922', 'Intervention': ['INTERVENTION 1: ', ' Trastuzumab, Bevacizumab, and Docetaxel', ' Trastuzumab [6mg/kg], Bevacizumab [15mg/kg], and Docetaxel [75 mg/M²]'], 'Eligibility': ['Inclusion Criteria:', ' Histologically confirmed breast cancer with evidence of metastatic disease', ' HER2 3+ or FISH (fluorescent in situ hybridization)+', ' Age 18 years', ' No prior trastuzumab, except as given in the adjuvant or neoadjuvant setting.', ' No prior chemotherapy in the metastatic setting.', 'Exclusion Criteria:', ' CNS (central nervous system) metastases', ' Prior radiation therapy within the last 4 weeks', ' Pregnant (positive pregnancy test) or lactating women', ' Major surgical procedure, open biopsy, non-healing wounds, or significant traumatic injury within 28 days prior to starting study or anticipation of need for major surgical procedure during the study', ' Minor surgical procedures such as fine needle aspirations or core biopsies within 7 days prior to start of study.'], 'Results': ['Outcome Measurement: ', ' Progression-free Survival (PFS) and to Evaluate Safety of the Trastuzumab, Bevacizumab and Docetaxel Regimen.', ' The trial was designed as a single-stage phase II rather then usual two-stage design because of the progression free survival (PFS) primary endpoint, as it is impractical to wait to assess PFS for patients in the first stage. We will consider a PFS of 50% at twelve months (median PFS of 12 months) or less uninteresting and a PFS of 70% at twelve months (median PFS of twenty months) worthy of pursuing the regimen in a future trials. The single-stage design is as follows: p0=0.50, p1=0.70, α=0.10, β= 0.10. This leads to a total sample size of 39 patients, 24 or higher of who are progression-free at 12 months.', ' Time frame: up to 3 years', 'Results 1: ', ' Arm/Group Title: Trastuzumab, Bevacizumab, and Docetaxel', ' Arm/Group Description: Trastuzumab [6mg/kg], Bevacizumab [15mg/kg], and Docetaxel [75 mg/M ]', ' Overall Number of Participants Analyzed: 26', ' Median (95% Confidence Interval)', ' Unit of Measure: months 14.3 (9.3 to 35)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 0/26 (0.00%)']}

{'Clinical Trial ID': 'NCT00499083', 'Intervention': ['INTERVENTION 1: ', ' Vaccine', ' Patients with HER-2/neu negative tumors received therapeutic autologous dendritic cells: injected into the primary breast mass or palpable axillary node, one week after the first, second and third T treatments.', ' Adjuvant hormone therapy for patients having tumors with estrogen and/or progesterone receptors. Premenopausal patients will be treated with tamoxifen. Post or perimenopausal women may receive tamoxifen or an aromatase inhibitor.', ' Patients received 4 cycles of paclitaxel: 175 mg/m2 (IV), followed by 4 cycles of cyclophosphamide: 600 mg/m2 IV and doxorubicin hydrochloride: 60 mg/m2 IV in a bi-weekly dose dense fashion', ' All patients had pre-treatment biopsy and second tumor biopsy after 4 cycles of paclitaxel to evaluate responses to the dendritic cell injections.'], 'Eligibility': ['DISEASE CHARACTERISTICS:', ' Histologically confirmed invasive breast cancer meeting the following criteria:', ' Primary tumor 3 cm by mammography, ultrasound, or palpation AND/OR palpable axillary lymph nodes > 1 cm', ' Survivin- and/or carcinoembryonic antigen-positive by IHC', ' Tumor must be localized by exam or ultrasound to allow tumor injection', ' No stage IV or metastatic disease', ' HER2/neu-negative tumor by IHC', ' If 2+ or in the indeterminate range, further testing of HER2/neu overexpression by fluorescent in situ hybridization (FISH) is required', ' Hormone receptor status known', ' PATIENT CHARACTERISTICS:', ' Female', ' Pre-, peri-, or postmenopausal', ' ECOG performance status 0-1', ' Not pregnant or nursing', ' Negative pregnancy test', ' Fertile patients must use effective contraception during and for up to 6 months following completion of study therapy', ' ANC 1,500/mm³', ' Platelet count 100,000/mm³', ' Alkaline phosphatase 1.5 times upper limit of normal (ULN)', ' Total bilirubin 1.5 times ULN', ' AST and ALT 1.5 times ULN', ' Creatinine < 1.5 times ULN', ' No active serious infections', ' No prior malignancy except adequately treated basal cell or squamous cell skin cancer, noninvasive carcinoma, or other cancer from which the patient has been disease free for 5 years', ' No comorbidity or condition that would interfere with study assessments and procedures or preclude study participation', ' PRIOR CONCURRENT THERAPY:', ' No prior chemotherapy or radiotherapy'], 'Results': ['Outcome Measurement: ', ' Number of Patients With Pathological Complete Response', ' Assessed by the institutional pathologist.', ' Grade 1: disappearance of all tumor on microscopic assessment in the breast and LNs', ' Grade 2: presence of in situ carcinoma only in the breast, no invasive tumor, and no tumor found in the LNs', ' Grade 3: presence of invasive carcinoma with stromal alteration, such as sclerosis or fibrosis', ' Grade 4: no or few modifications of the tumor appearance', ' Time frame: At definitive surgery.', 'Results 1: ', ' Arm/Group Title: Vaccine', ' Arm/Group Description: Patients with HER-2/neu negative tumors received therapeutic autologous dendritic cells: injected into the primary breast mass or palpable axillary node, one week after the first, second and third T treatments.', ' Adjuvant hormone therapy for patients having tumors with estrogen and/or progesterone receptors. Premenopausal patients will be treated with tamoxifen. Post or perimenopausal women may receive tamoxifen or an aromatase inhibitor.', ' Patients received 4 cycles of paclitaxel: 175 mg/m2 (IV), followed by 4 cycles of cyclophosphamide: 600 mg/m2 IV and doxorubicin hydrochloride: 60 mg/m2 IV in a bi-weekly dose dense fashion', ' All patients had pre-treatment biopsy and second tumor biopsy after 4 cycles of paclitaxel to evaluate responses to the dendritic cell injections.', ' Overall Number of Participants Analyzed: 14', ' Measure Type: Number', ' Unit of Measure: participants 2'], 'Adverse Events': ['Adverse Events 1:', ' Total: 1/3 (33.33%)', ' Febrile neutropenia 1/3 (33.33%)']}

3bf314d0-2cd6-4331-ad4e-6aa7961d6cd8

Comparison

Eligibility

NCT00365599

NCT01771666

Black men with and ECOG <=2, with ANC >1.5 x 10^9/L, PLT >100 x 10^9/L and no prior history of blood clots are eligible for the primary trial but excluded from the secondary trial

Entailment

{'Clinical Trial ID': 'NCT00365599', 'Intervention': ['INTERVENTION 1: ', ' Vorinostat and Tamoxifen', ' Vorinostat and Tamoxifen as outlined in Intervention Descriptions'], 'Eligibility': ['Inclusion Criteria:', ' Patients must have cytologically/histologically documented locally advanced or metastatic breast cancer with either:', ' Progression on treatment with any aromatase inhibitor for metastatic disease;', ' Recurrence while on adjuvant aromatase inhibitors or within 12 months of completion;', ' Recurrence after having completed adjuvant tamoxifen for at least 12 months;', ' Patient who are not candidates for or are intolerant of aromatase inhibitor treatment;', ' Patients are allowed (but not required) to have one prior chemotherapy regimen for metastatic disease.', ' Tumors must express estrogen or progesterone receptor.', ' Patients are eligible regardless of the menopausal status.', ' Age > 18 years old', ' Patients must have Eastern Cooperative Oncology Group (ECOG) performance status 0-2.', ' Patients must be able to give informed consent and able to follow guidelines given in the study.', ' Patients must have acceptable organ function, as defined by the following laboratory parameters: white blood count (WBC) >3.0 x 10^9/L; absolute neutrophil count (ANC) >1.5 x 10^9/L; hemoglobin (Hgb) >10.0g/dL; platelets (PLT) >100 x 10^9/L, Bilirubin < 2.0 mg/dl, aspartate aminotransferase/alanine aminotransferase (AST/ALT) < 2.5 X upper limit of normal (ULN), Creatinine <1.8 mg/dl (Creatinine clearance >60 ml/min).', ' Women of childbearing age must have a negative pregnancy test. All patients of reproductive potential must use an effective method of contraception during the study and 6 months following termination of treatment. (Not applicable to patients with bilateral oophorectomy and/or hysterectomy or to female patients who are older than 50 years and have not had a menstrual cycle in more than one year.', ' Patients must have measurable disease by RECIST criteria by staging studies performed within 30 days of enrollment. For patients with bone only disease: For this protocol isolated bone lesions can be classified as target lesions if they are measurable by MRI at screening and must be followed by MRI.', ' Both men and women of all races and ethnic groups are eligible for this trial.', 'Exclusion Criteria:', ' Patients must not have received tamoxifen for metastatic disease.', ' Patients must not have evidence of significant active infection (e.g., pneumonia, cellulitis, wound abscess, etc.) at time of study entry.', ' Patients must be disease-free of prior invasive malignancies for > 5 years with the exception of: curatively-treated basal cell or squamous cell carcinoma of the skin, carcinoma in situ of the cervix.', ' Pregnant and breast-feeding women are excluded from the study because effects on the fetus are unknown and there may be a risk of increased fetal wastage.', ' Patients with uncontrolled central nervous system (CNS) metastasis or a history of seizures are excluded. Patients with stable CNS metastasis (either surgically resected, treated with gamma knife or stable for 3 months following whole brain radiation therapy [WBRT] are eligible). Patients with stable brain metastases will need an MRI within 4 weeks prior to start of therapy.', ' Patients may not be receiving any other investigational agents and must have stopped all other histone deacetylase inhibitors (including Valproic acid) or other hormonal therapies.', ' Patients must have discontinued their prior therapies for breast cancer and radiation therapy for a minimum of 3 weeks, patient is excluded if radiation therapy was given to a single measurable lesion and the disease is otherwise not measurable.', ' Patients are excluded if they have any known hypersensitivity reaction to tamoxifen.', ' Patient with a history of blood clots are not eligible.', ' Women who have abnormal vaginal bleeding and/or endometrial hyperplasia or cancer are not eligible.', ' Patients with evidence of visceral crisis are not eligible for this study.'], 'Results': ['Outcome Measurement: ', ' Number of Participants With Objective Response (OR)', ' The Objective Response Rate. Response and progression were evaluated in this study using the new international criteria proposed by the Response Evaluation Criteria in Solid Tumors (RECIST). Changes in only the largest diameter (unidimensional measurement) of the tumor lesions are used in the RECIST criteria. For the purposes of this study, patients were evaluated for response every 8 weeks. In addition to a baseline scan, confirmatory scans were also obtained 4 weeks following initial documentation of objective response.', ' Time frame: 24 weeks', 'Results 1: ', ' Arm/Group Title: Vorinostat and Tamoxifen', ' Arm/Group Description: Vorinostat and Tamoxifen as outlined in Intervention Descriptions', ' Overall Number of Participants Analyzed: 43', ' Measure Type: Number', ' Unit of Measure: participants 8'], 'Adverse Events': ['Adverse Events 1:', ' Total: 4/43 (9.30%)', ' Hemoglobin [1]1/43 (2.33%)', ' Hemorrhage/Bleeding [2]1/43 (2.33%)', ' Neutrophils/granulocytes (ANC/AGC) [3]1/43 (2.33%)', ' Platelets [4]1/43 (2.33%)', ' Anorexia [5]1/43 (2.33%)', ' Sodium, serum-low (hyponatremia) [1]1/43 (2.33%)', ' Thrombosis/thrombus/embolism [6]2/43 (4.65%)']}

{'Clinical Trial ID': 'NCT01771666', 'Intervention': ['INTERVENTION 1: ', ' ISB and IC-Green Dye', ' The dose of Isosulfan blue (ISB) dye is 3 to 5 mL and Indocyanine green solution will be started at 1 mg/mL. If fluorescence is not detected with this dose, then it will be increased by 50%. A gamma probe [Neoprobe 2010] will be used to localize the sentinel lymph nodes in the axilla.'], 'Eligibility': ['Inclusion Criteria:', ' Ability to understand and the willingness to sign a written informed consent document.', ' Signed written informed consent.', ' Women undergoing sentinel lymph node biopsy.', ' Women with breast cancer with known or suspected lymph node involvement.', ' Women undergoing sentinel node identification and completion axillary lymph node dissection.', ' Women of 18 years of age or older.', ' Eastern Cooperative Oncology Group (ECOG) or Karnofsky Performance Status 0,1,2.', ' Complete Blood Count (CBC) and basic Metabolic Panel within 6 months', 'Exclusion Criteria:', ' History of liver or kidney failure will not be eligible.', ' Allergies to iodine containing products will not be eligible.', ' Women who are pregnant will not be eligible.', ' Psychiatric or addictive disorders or other conditions that, in the opinion of the investigator, would preclude the patient from meeting the study requirements.'], 'Results': ['Outcome Measurement: ', ' Agreement of Labeling Between Isosulfan Blue (IS-BLUE) and Indocyanine Green (IC-GREEN)', ' Number of women with agreement of the two dies [ie, isosulfan blue (IS-BLUE) and indocyanine green (IC-GREEN)] on all nodes examined in the lymphatics and arm-draining lymph nodes, during nodal staging procedures for surgery to treat breast cancer with curative intent.', 'Time frame: 1 day', 'Results 1: ', ' Arm/Group Title: ISB and IC-Green Dye', ' Arm/Group Description: The dose of Isosulfan blue (ISB) dye is 3 to 5 mL and Indocyanine green solution will be started at 1 mg/mL. If fluorescence is not detected with this dose, then it will be increased by 50%. A gamma probe [Neoprobe 2010] will be used to localize the sentinel lymph nodes in the axilla.', ' Overall Number of Participants Analyzed: 23', ' Measure Type: Count of Participants', ' Unit of Measure: Participants 8 34.8%'], 'Adverse Events': ['Adverse Events 1:', ' Total: 0/23 (0.00%)']}

4ab00376-83a4-467e-8a1e-6b8b1643a8f0

Comparison

Adverse Events

NCT01565499

NCT01234402

None of the patients in the primary trial were recorded as having heart related adverse events, whereas many patients in the secondary trial experienced several different heart related issues.

Entailment

{'Clinical Trial ID': 'NCT01565499', 'Intervention': ['INTERVENTION 1: ', ' Nab-Paclitaxel', ' The patients will be included to receive 3 weekly nab-paclitaxel doses of 150 mg/m2 with one week of rest for 4 cycles.', 'Nab-paclitaxel'], 'Eligibility': ['Inclusion Criteria:', ' Female patients with histologically confirmed diagnosis of primary unilateral invasive early breast cancer with longest tumor size in breast 2cm, or < 2 cm with axillary involvement. In case of a multifocal tumor (tumor foci located in the same quadrant) the largest lesion must be 2cm (unless axillary involvement) and is designated as the "target" lesion for all subsequent tumor evaluations.', ' The breast tumors must be ER positive: more than 1% of stained tumor cells by immuno-histochemistry (IHC), and HER2 negative: 0, or 1+ score by IHC, or 2+ with fluorescence in situ hybridization (FISH)/chromogenic in situ hybridization (CISH) negative for HER2 amplification (defined as a ratio of HER2/neu copies to chromosome 17 centromere (CEP17) signals <1.8), according to the local laboratory).', ' Are clear candidates to receive chemotherapy by the investigator criteria.', ' Are at least 18 years of age.', ' Have at least one unidimensionally measurable lesion by RECIST [65] version 1.1, measured by mammogram.', ' Have adequate performance status: Eastern Cooperative Oncology Group (ECOG) <2', ' Have adequate renal and liver function and bone marrow reserve as follows:', ' Bone marrow: absolute neutrophil count (ANC) > or = 1.500/mm3 (1.5 x 109/L); platelet count > or = 100.000/mm3 (100.0 x 109/L); and hemoglobin > or = 9 g/dL.', ' Hepatic: bilirubin < or = 1.5 times the upper limit of normal (x ULN); alkaline phosphatase (ALP), aspartate transaminase (AST), and alanine transaminase (ALT) < or = 2.5 * ULN and Albumin 2.5 g/dL.', ' Renal: serum creatinine < 1.5 x ULN.', ' Exhibit patient compliance and geographic proximity that allow for adequate follow-up', ' Entry informed consent form signed by the patient.', 'Exclusion Criteria:', ' Inflammatory breast cancer (T4d) and supraclavicular lymph nodes (N3)', ' Synchronous contralateral or multicentric breast cancer.', ' Clinical or radiologic evidence of metastatic disease. Chest examination by x-ray or CT-scan, abdominal examination by CT-scan, bone examination by bone scan as well as other radiological methods in case of suspicion must be performed before enrollment in order to rule out metastasis.', ' Second primary malignancy, except adequately treated carcinoma in situ of the cervix, stage I colon cancer, non-invasive melanoma, basal or squamous cell carcinomas of the skin, ipsilateral ductal carcinoma in-situ (DCIS) of the breast and lobular carcinoma in-situ (LCIS) of the breast; unless that prior malignancy was diagnosed and definitively treated more than 5 years ago with no subsequent evidence of recurrence.', ' Prior or concurrent anti-cancer therapy for current disease (hormone therapy, chemotherapy, radiotherapy, immunotherapy, biological therapy other than the trial therapies).', ' Concurrent treatment with any hormonal treatment either for osteoporosis or as replacement therapy.', ' Patients with known hypersensitivity to nab-paclitaxel or any of its components.', ' Previous neuropathy grade >1 according to the NCI-CTCAE vs 4.03 criteria', ' Have received treatment within the last 4 weeks with a drug that has not received regulatory approval for any indication at the time of study entry.', ' Have any serious concomitant systemic disorder incompatible with the study (at the discretion of investigator).', ' Patient is pregnant or breast feeding or planning to become pregnant within the six months after the end of treatment. Women with child-bearing potential must be performed a pregnancy serum or urine testing within 7 days prior to study entry according to institutional standards and should use an adequate non-hormonal contraceptive method (intra-uterine contraceptive device, barrier method of contraception in conjunction with spermicidal jelly or surgically sterilized) during treatment with study drugs and within the six months after the end of treatment.'], 'Results': ['Outcome Measurement: ', ' The Residual Cancer Burden Grade III (RCB-III).', ' The RCB-III was reported, including a 95% confidence interval. The estimate of the RCB-III was calculated as follows:', ' Overall Response Rate = Number of patients with RCB-III / Intent to treat (ITT) population', ' Time frame: After surgery, up to 4 months', 'Results 1: ', ' Arm/Group Title: Nab-Paclitaxel', ' Arm/Group Description: The patients will be included to receive 3 weekly nab-paclitaxel doses of 150 mg/m2 with one week of rest for 4 cycles.', ' Nab-paclitaxel', ' Overall Number of Participants Analyzed: 81', ' Measure Type: Count of Participants', ' Unit of Measure: Participants RCB III: Extensive residual disease (>3.28): 23 28.4%', ' RCB II: Moderate residual disease (1.36-3.28): 37 45.7%', ' RCB I: Minimal residual disease (>0-1.36): 14 17.3%', ' RCB 0: No residual disease (0): 6 7.4%', 'Unknown: 1 1.2%'], 'Adverse Events': ['Adverse Events 1:', ' Total: 6/81 (7.41%)', ' Colitis [1]1/81 (1.23%)', ' Multiple Sclerosis Relapse 1/81 (1.23%)', ' Neurotoxicity [2]2/81 (2.47%)', ' Community-acquired pneumonia 1/81 (1.23%)', ' Local Infection Reservoir Area 1/81 (1.23%)']}

{'Clinical Trial ID': 'NCT01234402', 'Intervention': ['INTERVENTION 1: ', ' Ramucirumab + Capecitabine', ' Participants received 10 milligram per kilogram (mg/kg) Ramucirumab intravenously on day 1 of 21 days cycle along with 1000 milligram per square meter (mg/m^2) of Capecitabine twice daily orally on days 1 to 14 of 21 days cycle.', 'INTERVENTION 2: ', ' Icrucumab + Capecitabine', ' Participants received 12 mg/kg Icrucumab intravenously on day 1 and day 8 of 21 day cycle along with 1000 mg/m^2 of Capecitabine twice daily orally on days 1 to 14 of 21 days cycle.'], 'Eligibility': ['Inclusion Criteria:', ' The participant has histologically or cytologically confirmed breast cancer which at the time of study entry is either Stage III disease not amenable to curative therapy or Stage IV disease', ' Has measurable or nonmeasurable disease', ' Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1', ' Has received prior anthracycline therapy', ' Has received prior taxane therapy', ' Participants with human epidermal growth factor receptor-2 (HER2) positive disease must have progressed on or following trastuzumab', ' Participants with hormone receptor-positive disease must have progressed on or following hormone therapy', ' Has received 3 prior chemotherapy regimens in any setting (a regimen is defined as any agent[s] that has been administered for more than 1 cycle; sequential neoadjuvant/adjuvant treatment is considered 1 regimen)', ' Has completed any prior radiotherapy 4 weeks prior to randomization', ' Has completed any prior hormonal therapy 2 weeks prior to randomization', ' Has adverse events (AEs) that have resolved to Grade 1 by the National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0 (NCI-CTCAE v 4.0) from all clinically significant toxic effects of prior chemotherapy, surgery, radiotherapy,or hormonal therapy', ' Has adequate hematologic, coagulation, hepatic and renal function', ' Does not have:', ' cirrhosis at a level of Child-Pugh B (or worse) or', ' cirrhosis (any degree) and a history of hepatic encephalopathy or ascites resulting from cirrhosis and requiring ongoing treatment with diuretics and/or paracentesis', ' Has urinary protein is 1+ on dipstick or routine urinalysis; if urine protein 2+, a 24-hour urine collection must demonstrate < 1000 mg of protein in 24 hours to allow participation in the study', ' Agrees to use adequate contraception during the study period and for 12 weeks after the last dose of study medication', 'Exclusion Criteria:', ' Has a concurrent active malignancy other than adequately treated nonmelanomatous skin cancer, curatively treated cervical carcinoma in situ, or other noninvasive carcinoma or in situ neoplasm. A participant with previous history of malignancy is eligible, provided that there has been a disease-free interval for > 3 years', ' Has a known sensitivity to capecitabine, any of its components, or other drugs formulated with polysorbate 80', ' Has a known sensitivity to 5-fluorouracil (5-FU)', ' Has a known dihydropyrimidine dehydrogenase deficiency', ' Has received prior capecitabine treatment for advanced breast cancer', ' Has received investigational therapy within 2 weeks prior to randomization', ' Has received bevacizumab within 4 weeks prior to randomization', ' Has received more than 1 prior antiangiogenic agent for breast cancer', ' Has a known sensitivity to agents of similar biologic composition as ramucirumab DP or Icrucumab (IMC-18F1), or other agents that specifically target vascular endothelial growth factor (VEGF)', ' Has an acute/subacute bowel obstruction or history of chronic diarrhea requiring ongoing medical intervention', ' Has a history of uncontrolled hereditary or acquired bleeding or thrombotic disorders', ' Has experienced a Grade 3 bleeding event within 3 months prior to randomization', ' Is receiving prophylactic or therapeutic anticoagulation with warfarin or any other oral anticoagulant', ' Has an uncontrolled intercurrent illness, including, but not limited to uncontrolled hypertension, symptomatic anemia, symptomatic congestive heart failure, unstable angina pectoris, symptomatic or poorly controlled cardiac arrhythmia, psychiatric illness/social situations, or any other serious uncontrolled medical disorder in the opinion of the investigator', ' Has experienced any arterial thrombotic or thromboembolic events, including, but not limited to myocardial infarction, transient ischemic attack, or cerebrovascular accident within 6 months prior to randomization', ' Has brain metastases, uncontrolled spinal cord compression, or leptomeningeal disease', ' Has an ongoing or active infection requiring parenteral antibiotic, antifungal, or antiviral therapy', ' Has received a prior allogeneic organ or tissue transplantation', ' Has undergone major surgery within 4 weeks prior to randomization, or subcutaneous venous access device placement within 7 days prior to randomization', ' Has had a serious nonhealing wound, ulcer, or bone fracture within 4 weeks prior to randomization', ' Has known HIV or AIDS infection', ' Has an elective or planned major surgery to be performed during the course of the trial', ' Participant is pregnant or lactating'], 'Results': ['Outcome Measurement: ', ' Progression-Free Survival (PFS)', ' PFS is defined as the time from the date of randomization until the date of objectively determined progression as defined by Response Evaluation Criteria in Solid Tumors (RECIST v1.1) or death from any cause, whichever is first. Disease progression is defined as 20% increase in the sum of diameters of target lesions, taking as reference smallest sum on study (included baseline sum if that was the smallest on study); sum must have demonstrated an absolute increase of 5 millimeter (mm) and the appearance of 1 new lesions was progression. Participants who did not progress, were lost to follow-up, or had missed 2 or more scheduled tumor assessments were censored at the day of their last adequate tumor assessment.', ' Time frame: From Date of Randomization until Disease Progression or Death Due to Any Cause (Up To 97 weeks)', 'Results 1: ', ' Arm/Group Title: Ramucirumab + Capecitabine', ' Arm/Group Description: Participants received 10 milligram per kilogram (mg/kg) Ramucirumab intravenously on day 1 of 21 days cycle along with 1000 milligram per square meter (mg/m^2) of Capecitabine twice daily orally on days 1 to 14 of 21 days cycle.', ' Overall Number of Participants Analyzed: 52', ' Median (95% Confidence Interval)', ' Unit of Measure: Weeks 22.1 (12.1 to 36.1)', 'Results 2: ', ' Arm/Group Title: Icrucumab + Capecitabine', ' Arm/Group Description: Participants received 12 mg/kg Icrucumab intravenously on day 1 and day 8 of 21 day cycle along with 1000 mg/m^2 of Capecitabine twice daily orally on days 1 to 14 of 21 days cycle.', ' Overall Number of Participants Analyzed: 49', ' Median (95% Confidence Interval)', ' Unit of Measure: Weeks 7.3 (6.3 to 13.0)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 20/52 (38.46%)', ' Anaemia 0/52 (0.00%)', ' Pancytopenia 1/52 (1.92%)', ' Acute myocardial infarction 0/52 (0.00%)', ' Atrial fibrillation 0/52 (0.00%)', ' Cardiac failure 1/52 (1.92%)', ' Cardiogenic shock 1/52 (1.92%)', ' Palpitations 0/52 (0.00%)', ' Pericardial effusion 0/52 (0.00%)', ' Right ventricular failure 1/52 (1.92%)', ' Abdominal pain 0/52 (0.00%)', ' Ascites 3/52 (5.77%)', 'Adverse Events 2:', ' Total: 25/49 (51.02%)', ' Anaemia 2/49 (4.08%)', ' Pancytopenia 0/49 (0.00%)', ' Acute myocardial infarction 1/49 (2.04%)', ' Atrial fibrillation 1/49 (2.04%)', ' Cardiac failure 0/49 (0.00%)', ' Cardiogenic shock 0/49 (0.00%)', ' Palpitations 1/49 (2.04%)', ' Pericardial effusion 4/49 (8.16%)', ' Right ventricular failure 0/49 (0.00%)', ' Abdominal pain 1/49 (2.04%)', ' Ascites 0/49 (0.00%)']}

e2d8e4b2-d5dc-404c-98a5-2a6799dd29c1

Comparison

Intervention

NCT02699983

NCT00994279

Neither the primary trial or the secondary trial require participants to practice yoga.

Contradiction

{'Clinical Trial ID': 'NCT02699983', 'Intervention': ['INTERVENTION 1: ', ' Group I (SparkPeople Program)', ' Participants receive training on how to use the SparkPeople website, self-monitor their diet using the SparkPeople tool, and to self-monitor their activity daily using the Fitbit monitoring device.', ' Participants receive weekly motivational reminders to log into the website for 3 months via email, text, or phone, based on patient preference (active phase). Participants then enter the maintenance phase for 3 months without reminders.', ' Behavioral Dietary Intervention: Use SparkPeople web-based program', ' Exercise Intervention: Use Fitbit monitor and SparkPeople web-based program', ' Activity Monitoring Device: Wear Fitbit activity monitoring device', 'INTERVENTION 2: ', ' Group II (Wait List)', ' Participants receive the weight loss handout and a Fitbit activity monitor. After 6 months, participants receive the SparkPeople treatment.', ' Exercise Intervention: Use Fitbit monitor', ' Activity Monitoring Device: Wear Fitbit activity monitoring device'], 'Eligibility': ['Inclusion Criteria:', ' Patients must have evidence of histologically confirmed breast cancer, stage 0, I, II or III, and be at least 2 years post diagnosis', ' Patient is self-identified as African-American', ' Patient is overweight or obese (body mass index [BMI] >= 25 kg/m^2)', ' Patient is able to understand and read English', ' Patient must have home internet or smartphone access', ' Patient must give informed consent for this new study', 'Exclusion Criteria:', " Patient has a serious medical condition (e.g., stroke, liver or renal failure, congestive heart failure, myocardial infarction or cardiac surgery in past year, angina pectoris) that would compromise the safety of the patient or compromise the patient's ability to complete the study, at the discretion of the investigator", " Patient has serious psychiatric condition (e.g., bipolar disorder, schizophrenia or other psychosis, bulimia or anorexia nervosa, suicide attempt within 6 months or current active suicidal ideation) that would compromise the patient's ability to complete the study, at the discretion of the investigator", ' Patient has severe disabilities limiting moderate physical activity, such as severe orthopedic conditions', ' Patient is planning major surgery within the next 6 months', ' Patient is taking medications or supplements for weight loss currently or within the past 3 months', ' Patient has successfully lost 5% of body weight in the previous 6 months or has had bariatric surgery', ' Patient is pregnant, breastfeeding, has given birth within the last 3 months or planning pregnancy within the next 12 months; if participant becomes pregnant during the course of the study, she will be removed from further participation', ' Patient is anticipating leaving the area within the next 12 months'], 'Results': ['Outcome Measurement: ', ' Recruitment Rate', ' Number of eligible participants who were enrolled and randomly assigned. Feasibility is defined as >= 75% recruitment rate.', ' Time frame: 12 months', 'Results 1: ', ' Arm/Group Title: Group I (SparkPeople Program)', ' Arm/Group Description: Participants receive training on how to use the SparkPeople website, self-monitor their diet using the SparkPeople tool, and to self-monitor their activity daily using the Fitbit monitoring device.', ' Participants receive weekly motivational reminders to log into the website for 3 months via email, text, or phone, based on patient preference (active phase). Participants then enter the maintenance phase for 3 months without reminders.', ' Behavioral Dietary Intervention: Use SparkPeople web-based program', ' Exercise Intervention: Use Fitbit monitor and SparkPeople web-based program', ' Activity Monitoring Device: Wear Fitbit activity monitoring device', ' Overall Number of Participants Analyzed: 23', ' Measure Type: Count of Participants', ' Unit of Measure: Participants 18 78.3%', 'Results 2: ', ' Arm/Group Title: Group II (Wait List)', ' Arm/Group Description: Participants receive the weight loss handout and a Fitbit activity monitor. After 6 months, participants receive the SparkPeople treatment.', ' Exercise Intervention: Use Fitbit monitor', ' Activity Monitoring Device: Wear Fitbit activity monitoring device', ' Overall Number of Participants Analyzed: 22', ' Measure Type: Count of Participants', ' Unit of Measure: Participants 17 77.3%'], 'Adverse Events': ['Adverse Events 1:', ' Total: 0/18 (0.00%)', 'Adverse Events 2:', ' Total: 0/17 (0.00%)']}

{'Clinical Trial ID': 'NCT00994279', 'Intervention': ['INTERVENTION 1: ', ' Arm 1: Yoga Intervention', ' Yoga Intervention', ' Yoga: Yoga sessions', 'INTERVENTION 2: ', ' Arm 2: Educational Wellness Group', ' Educational Wellness Group', ' Education: Educational Wellness Group'], 'Eligibility': ['Inclusion Criteria:', ' Women will be eligible if they are:', ' Scheduled to begin chemotherapy treatment within 3 weeks of study registration, or able to start Yoga/Wellness sessions prior to second chemotherapy treatment.', ' 18 years of age.', ' Physically able to attend yoga classes (simply meaning that they can physically make it to the intervention session and are able to sit on a chair or lie on the floor) (ECOG Performance Status rating 0-2; Zubrod et al., 1960).', ' Diagnosed with breast cancer Stages I-III.', ' Chemotherapy is anticipated to continue during the 10 weeks of the study intervention.', ' 2-8 weeks post-completion of breast surgery (unless receiving neoadjuvant chemotherapy).', ' Ability to understand and the willingness to sign a written informed consent document.', 'Exclusion Criteria:', ' Have practiced yoga on a regular basis (at least once a week) within the past 4 weeks to recruit women who are not already regularly practicing yoga. Given that the benefits of yoga are likely more immediate than long-term, however, we will enroll women who have previously had a yoga practice.', ' Are being treated with surgery and/or radiation therapy and/or hormonal treatment only and/or Herceptin therapy only (no chemotherapy).', ' Anticipate undergoing surgery related to their breast cancer or receipt of radiation therapy during the study period.', ' Have regularly engaged in moderate (activity that makes you breathe somewhat harder than normal; may include carrying light loads, bicycling at a regular pace, fast walking, tennis, easy swimming, or popular or folk dancing) or vigorous (activity that causes heavy breathing, sweating, rapid fatigue; it can only be sustained for very short periods of time, like running or swimming strongly) physical activity at least 3-5 days per week (on average) within the past 4 weeks.', ' Pregnant women will not be excluded from this study because the study intervention(s) pose no risk of potential for teratogenic or abortifacient effects. In fact, gentle yoga practice is quite safe for pregnant women and poses can be slightly modified, if needed. The anticipated number of pregnant women eligible to enroll is minimal.'], 'Results': ['Outcome Measurement: ', ' Retention', ' Proportion of participants completing the 10 week study', ' Time frame: 10 weeks', 'Results 1: ', ' Arm/Group Title: Arm 1: Yoga Intervention', ' Arm/Group Description: Yoga Intervention', ' Yoga: Yoga sessions', ' Overall Number of Participants Analyzed: 22', ' Measure Type: Number', ' Unit of Measure: percentage of participants 82 (60 to 95)', 'Results 2: ', ' Arm/Group Title: Arm 2: Educational Wellness Group', ' Arm/Group Description: Educational Wellness Group', ' Education: Educational Wellness Group', ' Overall Number of Participants Analyzed: 18', ' Measure Type: Number', ' Unit of Measure: percentage of participants 89 (65 to 99)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 1/21 (4.76%)', ' Febrile Neutropenia 0/21 (0.00%)', ' Heart Failure 1/21 (4.76%)', 'Adverse Events 2:', ' Total: 1/17 (5.88%)', ' Febrile Neutropenia 1/17 (5.88%)', ' Heart Failure 0/17 (0.00%)']}

407369fa-92ba-4994-8a0f-d372995f3241

Comparison

Results

NCT01004172

NCT00802945

the primary trial and the secondary trial both evaluate response rates, however the primary trial studies CNS response, whereas the secondary trial studies tumor response, additionally, they test different treatments.

Entailment

{'Clinical Trial ID': 'NCT01004172', 'Intervention': ['INTERVENTION 1: ', ' Carboplatin, Bevacizumab, Trastuzumab (if HER2+)', ' Participants received treatment until disease progression in either CNS or non-CNS site. Cycle duration is 28 days.', ' carboplatin: AUC=5 dose given intravenously on day 8 of cycle one and Day 1 of each subsequent cycle', ' bevacizumab: 15 mg/kg dose given intravenously on day 1 of each cycle', ' trastuzumab*: 6 mg/kg dose given intravenously on day 8 of each cycle for patients with HER2-positive breast cancer only', ' *8mg/kg loading dose in cycle 1 for some participants', ' HER-2: human epidermal growth factor receptor 2'], 'Eligibility': ['Inclusion Criteria:', ' Histologically or cytologically confirmed invasive breast cancer, with metastatic disease. patients without pathologic or cytologic confirmation of metastatic disease should have unequivocal evidence of metastasis by physical exam or radiologic study', ' Measurable disease. Patients must have measurable CNS disease, defined as at least one parenchymal brain lesion that can be accurately measured in at least one dimension with longest dimension >/= 10mm by local radiology review', " New or progressive CNS lesions, as assessed by the patient's treating physician", ' No increase in corticosteroid dose in the week prior to the baseline brain MRI', ' 18 years of age or older', ' Life expectancy of greater than 12 weeks', ' Eastern Cooperative Oncology Group Performance Score (ECOG PS) performance status 0-2', ' Normal organ and marrow function as outlined in the protocol', ' Left ventricular ejection fraction >/= 50%, as determined by radionuclide ventriculography (RVG) or echocardiogram within 60 days prior to initiation of protocol therapy', ' Prior carboplatin is allowed if it was not given in conjunction with bevacizumab', ' Prior trastuzumab is allowed', ' No prior bevacizumab since diagnosis of CNS metastases or within 6 months prior to diagnosis of CNS metastases', ' Women of child-bearing potential and men must agree to use adequate contraception prior to study entry and for the duration of study participation', 'Exclusion Criteria:', ' Patients who have had chemotherapy within 14 days prior to entering the study, or those who have not recovered adequately from adverse events due to agents administered earlier', ' Patients may not receive any concurrent investigational agents while on study', ' Patients may not receive any cancer-directed concurrent therapy , such as concurrent chemotherapy, radiotherapy, or hormonal therapy while on study. Concurrent treatment with bisphosphonates is allowed', ' History of Grade 3 or 4 allergic reactions attributed to compounds of similar or identical biologic composition to bevacizumab, carboplatin, or trastuzumab', ' Known contraindication to MRI with gadolinium contrast, such as cardiac pacemaker, shrapnel, or ocular foreign body', ' Leptomeningeal carcinomatosis as the only site of CNS involvement', ' More than 2 seizures over last 4 weeks prior to study entry', ' Grade 1 or higher CNS hemorrhage on baseline brain MRI', ' History of grade 2 or higher CNS hemorrhage within 12 months of study entry', ' Inadequately controlled hypertension', ' Prior history of hypertensive crisis or hypertensive encephalopathy', ' New York Heart Association (NYHA) Grade II or greater congestive heart failure', ' History of myocardial infraction or unstable angina within 6 months prior to day 1', ' Significant vascular disease within 6 months prior to day 1', ' History of hemoptysis within 1 month prior to day 1', ' Evidence of bleeding diathesis or significant coagulopathy', ' Current, ongoing treatment with full-dose warfarin or its equivalent', ' Use of aspirin (>325 mg/day) within 10 days prior to day 1', ' Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to day 1 or anticipation of need for major surgical procedure during the course of the study.', ' Core biopsy or other minor surgical procedure, excluding placement of a vascular access device, within 7 days prior to day 1', ' History of abdominal fistula or gastrointestinal perforation within 6 months prior to day 1', ' Serious, non-healing wound, active ulcer, or untreated bone fracture', ' Proteinuria as demonstrated by a urine protein-creatinine ratio >/= 1.0 at screening', ' Known hypersensitivity to any component of bevacizumab', ' Pregnancy or lactation'], 'Results': ['Outcome Measurement: ', ' Central Nervous System (CNS) Objective Response Rate', ' CNS objective response rate is the percentage of participants that achieve CNS complete or partial response as follows:', ' CNS complete response (CR) is achieved if all of the following are satisfied:', ' Complete resolution of all measurable (>= 1 cm in longest dimension [LD]) and non-measurable brain metastases', ' No new CNS lesions (defined as any new lesion >= 6 mm in LD)', ' Stable or decreasing steroid dose', ' No new/progressive tumor-related neurologic signs or symptoms', ' No progression of extra-CNS disease as assessed by RECIST', ' CNS partial response (PR) is achieved if all of the following are satisfied:', ' ->/= 50% reduction in the volumetric sum of all measurable (>/= 1 cm in LD) brain metastases compared to baseline', ' No progression on non-measurable lesions', ' No new CNS lesions (defined as any new lesion >/= 6 mm in LD)', ' Stable or decreasing steroid dose', ' No new/progressive tumor-related neurologic signs or symptoms', ' No progression of extra-CNS disease as assessed by RECIST', ' Time frame: Response was evaluated radiologically at baseline and every 2 cycles on treatment. Treatment duration for this study cohort was a median (range) of 8 cycles (1-20) which approximates months given the 4 week cycle length.', 'Results 1: ', ' Arm/Group Title: Carboplatin, Bevacizumab, Trastuzumab (if HER2+)', ' Arm/Group Description: Participants received treatment until disease progression in either CNS or non-CNS site. Cycle duration is 28 days.', ' carboplatin: AUC=5 dose given intravenously on day 8 of cycle one and Day 1 of each subsequent cycle', ' bevacizumab: 15 mg/kg dose given intravenously on day 1 of each cycle', ' trastuzumab*: 6 mg/kg dose given intravenously on day 8 of each cycle for patients with HER2-positive breast cancer only', ' *8mg/kg loading dose in cycle 1 for some participants', ' HER-2: human epidermal growth factor receptor 2', ' Overall Number of Participants Analyzed: 38', ' Measure Type: Number', ' Unit of Measure: percentage of participants 63 (47 to 77)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 16/38 (42.11%)', ' Hemoglobin 1/38 (2.63%)', ' Ocular-other 1/38 (2.63%)', ' Fatigue 6/38 (15.79%)', ' Leukocytes 1/38 (2.63%)', ' Neutrophils 3/38 (7.89%)', ' Platelets 4/38 (10.53%)', ' ALT, SGPT 1/38 (2.63%)', ' AST, SGOT 2/38 (5.26%)', ' Hypercalcemia 1/38 (2.63%)', ' Hyponatremia 1/38 (2.63%)', ' Nonneuropathic generalized weakness 1/38 (2.63%)', ' Joint, pain 1/38 (2.63%)']}

{'Clinical Trial ID': 'NCT00802945', 'Intervention': ['INTERVENTION 1: ', ' NKTR-102 14 Day', ' NKTR-102: NKTR-102 given on a q14 day schedule', 'INTERVENTION 2: ', ' NKTR-102 21 Days', ' NKTR-102: NKTR-102 given on a q21 day schedule'], 'Eligibility': ['Inclusion Criteria:', ' Inoperable metastatic or locally advanced breast cancer', ' No more than 2 prior chemotherapy regimens given in a metastatic or locally advanced setting and prior treatment in the metastatic setting must have included a taxane', 'Exclusion Criteria:', ' Patients who have had chemotherapy or radiotherapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) prior to Day 1 of Cycle 1', ' Patients who have had any major surgery within 4 weeks prior to Day 1 of Cycle or minor surgery within 2 weeks prior to Day 1 of Cycle 1'], 'Results': ['Outcome Measurement: ', ' Objective Response Rate (ORR)', ' Per Response Evaluation Criteria In Solid Tumors (RECIST v1.0) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), at least a 30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.', ' Time frame: Up to 2 years.', 'Results 1: ', ' Arm/Group Title: NKTR-102 14 Day', ' Arm/Group Description: NKTR-102: NKTR-102 given on a q14 day schedule', ' Overall Number of Participants Analyzed: 35', ' Measure Type: Number', ' Unit of Measure: percentage of subjects 28.6 (14.6 to 46.3)', 'Results 2: ', ' Arm/Group Title: NKTR-102 21 Days', ' Arm/Group Description: NKTR-102: NKTR-102 given on a q21 day schedule', ' Overall Number of Participants Analyzed: 35', ' Measure Type: Number', ' Unit of Measure: percentage of subjects 35 (14.6 to 46.3)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 18/35 (51.43%)', ' Anaemia * 0/35 (0.00%)', ' Febrile Neutropenia * 0/35 (0.00%)', ' Neutropenia * 1/35 (2.86%)', ' Vision Blurred * 1/35 (2.86%)', ' Abdominal Pain * 1/35 (2.86%)', ' Abdominal Pain Lower * 1/35 (2.86%)', ' Constipation * 0/35 (0.00%)', ' Diarrhoea * 6/35 (17.14%)', ' Ileitis * 0/35 (0.00%)', ' Nausea * 2/35 (5.71%)', ' Small Intestinal Obstruction * 0/35 (0.00%)', 'Adverse Events 2:', ' Total: 15/35 (42.86%)', ' Anaemia * 1/35 (2.86%)', ' Febrile Neutropenia * 1/35 (2.86%)', ' Neutropenia * 0/35 (0.00%)', ' Vision Blurred * 0/35 (0.00%)', ' Abdominal Pain * 0/35 (0.00%)', ' Abdominal Pain Lower * 0/35 (0.00%)', ' Constipation * 1/35 (2.86%)', ' Diarrhoea * 4/35 (11.43%)', ' Ileitis * 1/35 (2.86%)', ' Nausea * 0/35 (0.00%)', ' Small Intestinal Obstruction * 1/35 (2.86%)']}

05e50a3d-d5b2-4fe6-9709-c884c89c5f71

Single

Adverse Events

NCT00546104

1 patient in the primary trial suffered from a blood clot blocking their blood vessels.

Entailment

{'Clinical Trial ID': 'NCT00546104', 'Intervention': ['INTERVENTION 1: ', ' Dasatinib', '50mg-100mg po BID'], 'Eligibility': ['Inclusion Criteria:', ' Measurable Stage IV or inoperable Stage III advanced breast cancer.', ' There is no limit on the number of prior therapies.', ' At least 3 weeks since prior chemotherapy, biological or hormonal therapy.', ' At least 2 weeks since surgical biopsy.', ' At least 3 weeks since major (open thoracic/abdominal/cardiac) surgery.', ' No central nervous system (CNS) metastases except solitary brain metastasis', ' No cardiac dysfunction', ' left ventricular ejection fraction (LVEF) 50% as determined by multiple gated acquisition scan (MUGA)/echocardiogram', ' Adequate blood counts', ' Normal liver and kidney function', ' Negative serum pregnancy test.', ' Able to provide informed consent', 'Exclusion Criteria:', ' Pregnant or breast feeding.', ' Prior treatment with dasatinib.', ' Bone as the only site of disease.', ' Significant gastrointestinal bleeding', ' Septicemia, infection, acute hepatitis, hypokalemia, or hypomagnesemia'], 'Results': ['Outcome Measurement: ', ' Estimation of the Proportion of Progression-free Patients at 16 Wks.', ' Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or measurable increase in a non-target lesion, or the appearance of new lesions, or similar definition as appropriate.', ' Proportion progression-free at 16 weeks.From first day of study related treatment with Dasatinib until the date of first documented progression or date of death from any cause, whichever came first.', ' Time frame: 16 weeks', 'Results 1: ', ' Arm/Group Title: Dasatinib', ' Arm/Group Description: 50mg-100mg po BID', ' Overall Number of Participants Analyzed: 31', ' Measure Type: Number', ' Unit of Measure: percentage of participants 0 (0 to 20)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 10/31 (32.26%)', ' Edema, limb 1/31 (3.23%)', ' Thrombosis1/31 (3.23%)', ' diarrhea1/31 (3.23%)', ' Pain 2/31 (6.45%)', ' Pain, back1/31 (3.23%)', ' Pain, extrimity limb 1/31 (3.23%)', ' Syncope 1/31 (3.23%)', ' Pain, chest/thorax1/31 (3.23%)', ' hyponatremia 1/31 (3.23%)', ' fever1/31 (3.23%)', ' AST 1/31 (3.23%)', ' infection1/31 (3.23%)', ' Anorexia 1/31 (3.23%)', ' Dyspnea 2/31 (6.45%)']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

59fd53e4-b38c-4018-bafc-6fd7f7becebe

Single

Adverse Events

NCT01926886

There were no cases of Cellulitis, Nausea or Anaemia in the primary trial.

Entailment

{'Clinical Trial ID': 'NCT01926886', 'Intervention': ['INTERVENTION 1: ', ' Trastuzumab', ' Participants received trastuzumab IV infusion at initial loading dose of 8 mg/kg BW for q3w regimen as a part of neo adjuvant treatment before entering in the study and then recommended maintenance dose of 6 mg/kg BW q3w for the first 3 cycles (Cycles 7-9) in hospital followed by SC administration of trastuzumab at a fixed dose of 600 mg q3w for next 3 cycles (Cycles 10-12) at hospital and SC administration of trastuzumab at a fixed dose of 600 mg q3w at home for the next 6 cycles (Cycles 13-18) (Each cycle=21 days).'], 'Eligibility': ['Inclusion Criteria:', ' Histologically confirmed non-metastatic primary invasive adenocarcinoma of the breast', ' HER2-positive disease immunohistochemistry (IHC)3+ or in situ hybridization (ISH) positive, in line with local reimbursement criteria and determined in a local laboratory that is experienced/certified in HER2-expression testing using an accurate and validated assay', ' Eastern Cooperative Oncology Group (ECOG) performance status 0-1', ' Hormonal therapy will be allowed as per institutional guidelines', ' Left ventricular ejection fraction (LVEF) of greater than or equal to (>/=) 50% measured by echocardiography (ECHO) or multiple gated acquisition (MUGA) scan prior to first dose of trastuzumab SC, or, for those who were receiving trastuzumab when beginning the study, documented results within an acceptable limit from a cardiac assessment within 3 months prior to enrollment', ' Participants have completed the first 6 cycles of trastuzumab IV as part of the (neo)adjuvant treatment', ' No evidence of residual, locally recurrent or metastatic disease after completion of surgery and chemotherapy, (neo-adjuvant or adjuvant)', ' Use of concurrent curative radiotherapy will be permitted', 'Exclusion Criteria:', ' History of other malignancy which could affect compliance with the protocol or interpretation of results. Participants with curatively treated carcinoma in situ of the cervix or basal cell carcinoma, and patients with other curatively treated malignancies who have been disease-free for at least 5 years, are eligible', ' Participants with severe dyspnea at rest or requiring supplementary oxygen therapy', ' Participants with other concurrent serious diseases that may interfere with planned treatment, including severe pulmonary conditions/illness', ' Serious cardiac illness or medical conditions that would preclude the use of trastuzumab, specifically: history of documented congestive heart failure (CHF), high-risk uncontrolled arrhythmias, angina pectoris requiring medication, clinically significant valvular disease, evidence of transmural infarction on electrocardiogram (ECG), diagnosed poorly controlled hypertension', ' Known infection with human immunodeficiency virus (HIV), active hepatitis B virus (HBV) or hepatitis C virus (HCV)', ' Pregnant or lactating women', ' Women of childbearing potential and male participants with partners of childbearing potential who are unable or unwilling to use adequate contraceptive measures during study treatment', ' Concurrent enrollment in another clinical trial using an investigational anti-cancer treatment, including hormonal therapy, bisphosphonate therapy and immunotherapy, within 28 days prior to the first dose of study treatment', ' Known hypersensitivity to trastuzumab, murine proteins, to any of the excipients of Herceptin including hyaluronidase, or the adhesive of the SC device, or a history of severe allergic or immunological reactions, e.g. difficult to control asthma', ' Inadequate bone marrow, hepatic or renal function'], 'Results': ['Outcome Measurement: ', ' Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)', ' An AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. AEs included both serious and non- serious AEs. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. An emergent AE was defined as occurring within 35 days after last treatment administration.', ' Time frame: Up to 45 months', 'Results 1: ', ' Arm/Group Title: Trastuzumab', ' Arm/Group Description: Participants received trastuzumab IV infusion at initial loading dose of 8 mg/kg BW for q3w regimen as a part of neo adjuvant treatment before entering in the study and then recommended maintenance dose of 6 mg/kg BW q3w for the first 3 cycles (Cycles 7-9) in hospital followed by SC administration of trastuzumab at a fixed dose of 600 mg q3w for next 3 cycles (Cycles 10-12) at hospital and SC administration of trastuzumab at a fixed dose of 600 mg q3w at home for the next 6 cycles (Cycles 13-18) (Each cycle=21 days).', ' Overall Number of Participants Analyzed: 101', ' Measure Type: Number', ' Unit of Measure: percentage of participants Emergent AEs: 90.1', ' Emergent SAEs: 7.9'], 'Adverse Events': ['Adverse Events 1:', ' Total: 8/101 (7.92%)', ' Vertigo * 1/101 (0.99%)', ' Infected lymphocele * 1/101 (0.99%)', ' Ejection fraction decreased * 5/101 (4.95%)', ' Lymphoedema * 1/101 (0.99%)']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

c17eaeab-4e99-4cc4-8681-ae6ccddba572

Single

Eligibility

NCT00952692

Candidates for the primary trial must have adequate renal and hepatic function, and must not be currently receiving amiodarone or have received amiodarone in the 6 months

Entailment

{'Clinical Trial ID': 'NCT00952692', 'Intervention': ['INTERVENTION 1: ', ' dHER2 + AS15 ASCI + Lapatinib', ' Patients will receive dHER2 ASCI injections IM every 2 weeks for 2 cycles . In between cycles there is 4 weeks without vaccine. The daily dose of lapatinib is 5 tablets (1250 mg of lapatinib) taken orally at approximately the same time each day for 43 weeks while on study.'], 'Eligibility': ['Inclusion Criteria:', ' The following criteria are to be checked at the time of study entry. The patients may only be included in the study if ALL of the following statements are FULLFILLED:', ' The patient (male or female) is at least 18 years old at the time of signature of the informed consent form.', ' Written informed consent has been obtained from the patient prior to the performance of any protocol-specific procedure.', ' The patient is diagnosed with confirmed invasive breast cancer with stage IV disease.', ' Note: If the metastatic disease is restricted to a solitary lesion, its neoplastic nature should be confirmed by cytology or histology.', ' The patient has documented disease progression or relapse following at least one prior standard therapy with trastuzumab (alone or in combination with chemotherapy).', ' Patients with prior lapatinib use are eligible. Furthermore,', ' The administration of the chemotherapeutic agent(s) should have been stopped for at least 28 days by the time of the first ASCI administration.', ' The administration of trastuzumab alone could be maintained after chemotherapy, but the last dose of trastuzumab should not have been given less than three weeks before the first ASCI administration.', ' The patient will not be given trastuzumab during the trial.', ' For metastatic patients whose disease is ER+ and/or PR+ the following criteria should be met:', ' Patients with visceral disease that requires chemotherapy (eg., patients with liver or lung metastases).', ' Rapidly progressing or life threatening disease, as determined by the investigator.', ' Patients who received hormonal therapy and are no longer benefiting from this therapy.', ' A tumor lesion from the patient biopsied before or during screening shows either:', ' Overexpression of the HER2 protein, as determined by immunohistochemistry (IHC, with result IHC 3+) or', ' Amplification of the HER2 gene as determined by FISH (at least 4 fold i.e. at least 8 copies).', ' Note: Overexpression/amplification measurements must be performed on a metastatic lesion in all cases where such a lesion is sufficiently easily accessible. If however such a biopsy is not possible, then these measurements can be performed on the primary tumor. Use of the primary tumor is to be documented and justified.', ' Ten FFPE tissue sections of the tumor on which the HER2 overexpression/amplification has been done -if available-may be requested. These may be used to retrospectively carry out part of the translational research (i.e. analysis of EGF receptor activity and of the presence of immune effector cells, refer to Section 7).', ' The patient has at least one measurable lesion according to RECIST criteria.', ' The patient has ECOG status of 0 or 1.', ' The patient has adequate bone marrow reserve as indicated by:', ' White blood cell count >/= 3,000/mm3.', ' Neutrophil count >/= 1,500/mm3.', ' Platelet count >/= 100,000/mm3.', ' Hemoglobin levels >/= 10.0 g/dl.', ' The patient has adequate renal function as shown by the creatinine levels (i.e. within the normal range).', ' The patient has adequate hepatic function as shown by serum bilirubin levels i.e:', ' Serum bilirubin levels within the normal limits.', ' Both AST and ALT levels <1.5 times the ULN. Note: However, for patients with liver metastasis, a serum bilirubin level <1.5 times the ULN and both AST and ALT levels <3 times the ULN will be accepted.', ' The patient has a baseline Left Ventricular Ejection Fraction (LVEF) measured by MUGA scan equal to or greater than the LLN for the radiology facility.', ' If the patient is female, she must be of non-childbearing potential, i.e. have a current tubal ligation, hysterectomy, ovariectomy or be post-menopausal, or if she is of childbearing potential, she must practice adequate contraception for 30 days prior to treatment, have a negative pregnancy test and continue such precautions for two months after completion of the study treatment.', ' Adequate contraception is defined as a contraceptive method with failure rate of less than 1% per year when used consistently and correctly (when applicable, as mentioned in the product label) for example abstinence, combined or progestogen oral contraceptives, injectable progestogen, implants of levonorgestrel, oestrogenic vaginal ring, percutaneous contraceptive patches or intrauterine device (IUD) or intrauterine system (IUS), vasectomy with documented azoospermia of the sole male partner or double barrier method (condom or occlusive cap plus spermicidal agent).', ' For azoospermia, "documented" refers to the outcome of the investigator\'s/ designee\'s medical examination of the subject or review of the subject\'s medical history for study eligibility, as obtained via a verbal interview with the subject or from the subject\'s medical records.', ' Post-menopause: Menopause is the age associated with complete cessation of menstrual cycles, menses, and implies the loss of reproductive potential by ovarian failure. A practical definition accepts menopause after 1 year without menses with an appropriate clinical profile at the appropriate age e.g. > 45 years.', ' Able to swallow and retain oral medication.', ' In the view of the investigator, the patient can and will comply with the requirements of the protocol.', 'Exclusion Criteria:', ' The following criteria should be checked at the time of study entry. If any apply, the patient must not be included in the study:', ' The patient has received > 300 mg/m2 doxorubicin (cumulative dose) or > 600 mg/m2 epirubicin (cumulative dose).', ' The patient is receiving treatment with bisphosphonate UNLESS the biphosphonate treatment was initiated more than three weeks before the first ASCI administration. (See also section 5.3.2.).', ' The patient has received any investigational or non-registered product (drug or vaccine) other than the study treatment(s) within 30 days preceding the first dose of study treatment, or planned use during the study period.', ' The patient is currently receiving amiodarone or has received amiodarone in the 6 months prior to screening.', ' The patient requires concomitant treatment with systemic corticosteroids or any immunosuppressive agents. The use of prednisone, or equivalent, <0.5 mg/kg/day (absolute maximum 40 mg/day), or inhaled corticosteroids or topical steroids is permitted.', ' The patient has a malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel.', ' Patients with ulcerative colitis.', ' The patient has known coronary artery disease, arrhythmia requiring treatment, clinically significant valvular disease, cardiomegaly on chest X-ray, ventricular hypertrophy (found by ECG) or previous myocardial infarction.', ' The patient has any acute or chronic, clinically significant pulmonary, cardiovascular, hepatic or renal functional abnormality, as determined by physical examination or laboratory screening tests.', " The patient has current active hepatic or biliary's disease (with exception of patients with Gilbert's syndrome, asymptomatic gallstones, liver metastases or stable chronic liver disease per investigator assessment).", ' The patient presents with autoimmune disease (vitiligo and autoimmune thyroid disease is not an exclusion criterion).', ' The patient has a known family history of congenital or hereditary immunodeficiency.', ' The patient has any uncontrolled bleeding disorder or coagulation disorder or thrombocytopenia or pro-thrombotic disorder.', ' The patient has a history of anaphylaxis or severe allergic reaction to vaccines or unknown allergens.', ' The patient has a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to Lapatinib. These include other anilinoquinazolines, such as gefitinib (Iressa), erlotinib (Tarceva), or other chemically related compounds or excipients.', ' The patient is known to be positive for the Human Immunodeficiency Virus (HIV).', ' The patient has (or has had) previous or concomitant malignancies at other sites except effectively treated:', ' Non-melanoma skin cancers or carcinoma in situ of the cervix', ' Malignancy that has been in remission for > 2 years and is considered highly likely to have been cured.', ' The patient has any psychiatric or addictive disorder that may compromise her ability to give informed consent, or to comply with the trial procedures.', " The patient has any other condition that in the opinion of the investigator might jeopardize the patient's safety or ability to comply with the requirements of the study.", ' The patient is pregnant or lactating.'], 'Results': ['Outcome Measurement: ', ' The Safety of dHER2+AS15 ASCI When Administered in Combination With Lapatinib Measured by Occurrence of Severe Toxicities (According to CTCAE, Version 3.0)', ' [Not Specified]', ' Time frame: 26 weeks', 'Results 1: ', ' Arm/Group Title: dHER2 + AS15 ASCI + Lapatinib', ' Arm/Group Description: Patients will receive dHER2 ASCI injections IM every 2 weeks for 2 cycles . In between cycles there is 4 weeks without vaccine. The daily dose of lapatinib is 5 tablets (1250 mg of lapatinib) taken orally at approximately the same time each day for 43 weeks while on study.', ' Overall Number of Participants Analyzed: 12', ' Measure Type: Count of Participants', ' Unit of Measure: Participants 0 0.0%'], 'Adverse Events': ['Adverse Events 1:', ' Total: 2/12 (16.67%)', ' pulmonary embolism 1/12 (8.33%)', ' chest pain 1/12 (8.33%)']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

621d06ac-12dd-42c2-a012-15c1d94a4f0b

Single

Adverse Events

NCT00193063

In the primary trial patient cohort, 3 different types of infections are observed, these are pneumonia, urinary tract and Athlete's foot.

Contradiction

{'Clinical Trial ID': 'NCT00193063', 'Intervention': ['INTERVENTION 1: ', ' Gemcitabine/Trastuzumab', ' All patients entering this trial received treatment with a combination of gemcitabine and trastuzumab. Gemcitabine 1000 mg/m2 was administered intravenously on days 1, 8,and 15 of a 28-day cycle. Trastuzumab was administered as a 4 mg/kg intravenous loading dose on day 1 and subsequently at a dose of 2 mg/kg on a weekly basis.'], 'Eligibility': ['Inclusion Criteria:', ' To be included in this study, you must meet the following criteria:', ' Her-2 positive metastatic breast cancer confirmed by biopsy', ' Measurable disease', ' Able to perform activities of daily living without considerable', ' No previous chemotherapy with gemcitabine', ' No more than one prior chemotherapy regimen for metastatic breast cancer', ' Adequate bone marrow, liver and renal function', ' Normal heart function', ' Give written informed consent prior to entering this study.', 'Exclusion Criteria:', ' You cannot participate in this study if any of the following apply to you:', ' Received previous treatment with gemcitabine', ' History of brain metastases', ' Serious underlying medical conditions', ' Please note: There are additional inclusion/exclusion criteria. The study center will determine if you meet all of the criteria. If you do not qualify for the trial, study personnel will explain the reasons. If you do qualify, study personnel will explain the trial in detail and answer any questions you may have.'], 'Results': ['Outcome Measurement: ', ' Overall Response Rate (ORR)', ' The Percentage of Patients Who Experience an Objective Benefit From Treatment. Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI or CT: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.', ' Time frame: 18 Months', 'Results 1: ', ' Arm/Group Title: Gemcitabine/Trastuzumab', ' Arm/Group Description: All patients entering this trial received treatment with a combination of gemcitabine and trastuzumab. Gemcitabine 1000 mg/m2 was administered intravenously on days 1, 8,and 15 of a 28-day cycle. Trastuzumab was administered as a 4 mg/kg intravenous loading dose on day 1 and subsequently at a dose of 2 mg/kg on a weekly basis.', ' Overall Number of Participants Analyzed: 37', ' Measure Type: Number', ' Unit of Measure: percentage of participants 30 (17 to 46)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 14/41 (34.15%)', ' Cardiac ischemia/infarction 2/41 (4.88%)', ' Duodenal ulcer 1/41 (2.44%)', ' Vomiting 2/41 (4.88%)', ' Fever 2/41 (4.88%)', ' Death NOS 1/41 (2.44%)', ' Liver failure 1/41 (2.44%)', ' Infection - pneumonia 2/41 (4.88%)', ' Infection - port site 2/41 (4.88%)', ' Infection - urinary tract 1/41 (2.44%)', ' Disease progression 3/41 (7.32%)', ' Confusion 1/41 (2.44%)']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

021e79d2-ce70-43cf-aac9-fa8d4c8d3770

Single

Intervention

NCT00486525

The difference between the two cohorts of the primary trial is that cohort 1 participated in a Hatha yoga, whereas cohort 2 abstained from yoga.

Entailment

{'Clinical Trial ID': 'NCT00486525', 'Intervention': ['INTERVENTION 1: ', ' Arm I: Yoga Therapy', ' Patients participated in a Hatha yoga session over 90 minutes twice weekly for 12 weeks. Patients were also encouraged to practice yoga at home. Patients recorded their total home/class practice time in weekly logs.', 'INTERVENTION 2: ', ' Arm II: Wait-List', ' Wait-listed women were told to continue performing their usual activities, and to refrain from beginning any yoga practice. After their final assessment they were offered the yoga classes.'], 'Eligibility': ['DISEASE CHARACTERISTICS:', ' Stage 0-IIIA breast cancer survivor', ' Completed cancer treatment within the past 36 months (except for tamoxifen/aromatase inhibitors)', ' At least 2 months since prior surgery, adjuvant therapy, or radiotherapy, whichever occurred last', ' Women who are not currently practicing yoga and have not participated in any of the following activities:', ' Meditation, tai chi, or related activities', ' Yoga or tai chi within the past 6 months', ' Had classes for or practiced yoga for more than 3 months', ' Women who typically engage in a total of 5 or more hours of vigorous physical activity per week are not eligible', ' No inflammatory breast cancer', ' PATIENT CHARACTERISTICS:', 'Inclusion criteria:', ' Hemoglobin 10 g/dL (patients with a hemoglobin of < 10 g/dL may be retested in 6 weeks after treatment of anemia and allowed to participate in study if blood counts recovered)', ' Physically able to fully participate in yoga intervention', 'Exclusion criteria:', ' Inability to comfortably get up and down from the floor 2-3 times in a session', ' Breathing problems requiring use of oxygen', ' Problems walking without a cane or walker assistance', ' Prior knee or hip replacement with limited movement in the joint', ' Inability to comfortably lie on the stomach', ' Alcohol, or drug abuse', ' Diagnosis of any of the following conditions:', ' Diabetes', ' Chronic obstructive pulmonary disease', ' Uncontrolled hypertension', ' Evidence of liver or kidney failure', ' Symptomatic ischemic heart disease', ' Significant visual or auditory problems', ' Mental disorder or cognitive impairment', ' Notable serious cardiovascular history (e.g., prior life-threatening abnormal heart rhythms)', ' Other medical conditions involving the immune system such as autoimmune and/or inflammatory diseases including rheumatoid arthritis and ulcerative colitis', ' History of breast or any other cancer, except basal or squamous cell skin cancer', ' PRIOR CONCURRENT THERAPY:', ' See Disease Characteristics', ' No regular use of medications with major immunological consequences (e.g., steroids)'], 'Results': ['Outcome Measurement: ', ' Stimulated ln (TNF-a)', ' log-transformed Lipopolysaccharide (LPS) stimulated Tumor Necrosis Factor-alpha (TNF-alpha)', ' Time frame: Immediately post-treatment and 3 months post-treatment', 'Results 1: ', ' Arm/Group Title: Arm I: Yoga Therapy', ' Arm/Group Description: Patients participated in a Hatha yoga session over 90 minutes twice weekly for 12 weeks. Patients were also encouraged to practice yoga at home. Patients recorded their total home/class practice time in weekly logs.', ' Overall Number of Participants Analyzed: 92', ' Least Squares Mean (Standard Error)', ' Unit of Measure: ln (pg/mL) Immediately post-treatment: 8.31 (0.041)', ' 3 months post-treatment: 8.31 (0.042)', 'Results 2: ', ' Arm/Group Title: Arm II: Wait-List', ' Arm/Group Description: Wait-listed women were told to continue performing their usual activities, and to refrain from beginning any yoga practice. After their final assessment they were offered the yoga classes.', ' Overall Number of Participants Analyzed: 84', ' Least Squares Mean (Standard Error)', ' Unit of Measure: ln (pg/mL) Immediately post-treatment: 8.39 (0.040)', ' 3 months post-treatment: 8.44 (0.043)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 0/100 (0.00%)', 'Adverse Events 2:', ' Total: 0/100 (0.00%)']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

06aa0fbc-fe49-4715-88cc-507646f6323f

Comparison

Eligibility

NCT00754325

NCT00399529

the secondary trial and the primary trial both accept patients with progesterone receptors(PgR+) adenocarcinoma of the breast.

Contradiction

{'Clinical Trial ID': 'NCT00754325', 'Intervention': ['INTERVENTION 1: ', ' Fulvestrant and Dasatinib', ' Arm 1: Participants in this group received a drug regimen that consisted of both fulvestrant and dasatinib.', ' Fulvestrant: Intramuscular injection (IM), loading dose (500 mg) on Day 1 followed by 500 mg on Day 15 of Cycle 1 (28-day cycle). In subsequent cycles, 500 mg IM administered on Day 1, up to 2 years.', ' Dasatinib: Tablets, Oral, 100 mg, once daily (QD), up to 2 years', 'INTERVENTION 2: ', ' Fulvestrant', ' Arm 2: Participants in this group received a drug regimen that consisted of fulvestrant only.', ' Fulvestrant: Intramuscular injection (IM), loading dose (500 mg) on Day 1 followed by 500 mg on Day 15 of Cycle 1 (28-day cycle). In subsequent cycles, 500 mg IM administered on Day 1, up to 2 years.'], 'Eligibility': ['For more information regarding Bristol-Myers Squibb (BMS) clinical trial participation, please visit www.BMSStudyConnect.com.', 'Inclusion Criteria:', ' Histologically confirmed hormone receptor positive (HR+) [(estrogen receptor (ER+) and/or progesterone receptors(PgR+)] breast cancer according to immunohistochemistry (IHC)', ' Measureable or evaluable-only disease', ' human epidermal growth factor receptor 2+ (HER2+) or HER2- breast cancer', ' Males and females 18 years of age', ' Females are post menopausal or surgically sterile', ' Recurrent or progressive advanced breast cancer (locally-advanced or metastatic), that has progressed: (a) during or within 12 months after completion of adjuvant Aromatase Inhibitor (AI) treatment OR (b) during AI treatment in advanced setting (metastatic therapy)', 'Exclusion Criteria:', ' Pregnant or breast feeding', ' >1 chemotherapy regimen for advanced disease', ' Pleural or pericardial effusion', ' Serious cardiac condition'], 'Results': ['Outcome Measurement: ', ' Number of Participants With Disease Progression (PD) or Death', ' This endpoint evaluated the progression free survival (PFS) of participants amongst the total evaluable population. Progression free survival (PFS) was defined as the time from randomization to either the date the subject was first recorded as having PD (even if the subject went off treatment because of toxicity), or the date of death if the subject died due to any causes before progression. Participants with no recorded post-baseline tumor assessment had PFS censored at the day of randomization. Participants lost to follow-up were censored at the last date of contact. Participants that had not progressed or died had PFS censored at the date of last follow-up.', ' Time frame: Date of randomization to date of initial disease progression, or date of death (whichever occurs first), up to January 2014 (approximately 5 years)', 'Results 1: ', ' Arm/Group Title: Fulvestrant and Dasatinib', ' Arm/Group Description: Arm 1: Participants in this group received a drug regimen that consisted of both fulvestrant and dasatinib.', ' Fulvestrant: Intramuscular injection (IM), loading dose (500 mg) on Day 1 followed by 500 mg on Day 15 of Cycle 1 (28-day cycle). In subsequent cycles, 500 mg IM administered on Day 1, up to 2 years.', ' Dasatinib: Tablets, Oral, 100 mg, once daily (QD), up to 2 years', ' Overall Number of Participants Analyzed: 50', ' Measure Type: Number', ' Unit of Measure: participants 35', 'Results 2: ', ' Arm/Group Title: Fulvestrant', ' Arm/Group Description: Arm 2: Participants in this group received a drug regimen that consisted of fulvestrant only.', ' Fulvestrant: Intramuscular injection (IM), loading dose (500 mg) on Day 1 followed by 500 mg on Day 15 of Cycle 1 (28-day cycle). In subsequent cycles, 500 mg IM administered on Day 1, up to 2 years.', ' Overall Number of Participants Analyzed: 49', ' Measure Type: Number', ' Unit of Measure: participants 40'], 'Adverse Events': ['Adverse Events 1:', ' Total: 14/50 (28.00%)', ' Angina Pectoris 0/50 (0.00%)', ' Hypertension 1/50 (2.00%)', ' Coagulation Time Increased 0/50 (0.00%)', ' Bowel Obstruction 1/50 (2.00%)', ' Dehydration 0/50 (0.00%)', ' Diarrhea 1/50 (2.00%)', ' Nausea 3/50 (6.00%)', ' Nausea and Vomiting 0/50 (0.00%)', ' Obstruction Bowel 2/50 (4.00%)', ' Vomiting 3/50 (6.00%)', ' Weakness Generalized 0/50 (0.00%)', ' Cholecystitis 1/50 (2.00%)', 'Adverse Events 2:', ' Total: 11/49 (22.45%)', ' Angina Pectoris 1/49 (2.04%)', ' Hypertension 0/49 (0.00%)', ' Coagulation Time Increased 1/49 (2.04%)', ' Bowel Obstruction 0/49 (0.00%)', ' Dehydration 1/49 (2.04%)', ' Diarrhea 0/49 (0.00%)', ' Nausea 0/49 (0.00%)', ' Nausea and Vomiting 1/49 (2.04%)', ' Obstruction Bowel 0/49 (0.00%)', ' Vomiting 0/49 (0.00%)', ' Weakness Generalized 1/49 (2.04%)', ' Cholecystitis 0/49 (0.00%)']}

{'Clinical Trial ID': 'NCT00399529', 'Intervention': ['INTERVENTION 1: ', ' Allo GM-CSF-secreting Vaccine, Trastuzumab, Cyclophosphamide', ' Allogeneic GM-CSF-secreting breast cancer vaccine : the vaccine containing a mixture of two GM-CSF-secreting allogeneic breast cancer cell lines (two parts 2T47D-V and one part 3SKBR3-7 mixed in a fixed dose of 5 X 10^8 cells for each patient and each vaccination cycle) given intradermally every 4-6 weeks for 3 cycles and then a 4th dose given 6-8 months after beginning the study.', ' Cyclophosphamide : 300 mg/m^2 given intravenously every 4-6 weeks for 3 cycles and then once 6-8 months after beginning the study', ' Trastuzumab : An initial loading dose of 4 mg/kg for participants beginning treatment with Trastuzumab, otherwise 2 mg/kg given every week intravenously'], 'Eligibility': ['Inclusion Criteria:', ' Patients with histologically confirmed HER-2/neu-overexpressing adenocarcinoma of the breast; this is defined as HER-2+ by immunohistochemistry (IHC) 3+ staining or Fluorescence In-Situ Hybridization (FISH). Prior adjuvant Trastuzumab therapy is permitted. Patients must not be eligible for therapy of known curative potential for metastatic breast cancer if it is identified during the course of the study.', ' Patients may have measurable or evaluable disease.', ' Stable central nervous system (CNS) disease that has been adequately treated and is not under active treatment allowed.', ' Age 18 years or older.', ' Able to give informed consent.', ' Patients with an Eastern Cooperative Oncology Group (ECOG) performance score of 0 or 1.', ' No systemic oral steroids administered within 28 days prior to initiating treatment on protocol. Topical, ocular, and nasal steroids are allowed, as are those applied to mucus membranes.', " No prior or currently active autoimmune disease requiring management with systemic immunosuppression. This includes inflammatory bowel disease, systemic vasculitis, scleroderma, psoriasis, multiple sclerosis, hemolytic anemia or immune-mediated thrombocytopenia, rheumatoid arthritis, systemic lupus erythematosus, Sjogren's syndrome, sarcoidosis, or other rheumatologic disease. Asthma or chronic obstructive pulmonary disease that does not require daily systemic corticosteroids is acceptable.", ' Not pregnant, and on appropriate birth control if of child-bearing potential.', ' No history of other malignancies within the prior five years (excluding a history of carcinoma in situ of the cervix, superficial non-melanoma skin cancer, and superficial bladder cancer).', ' Adequate bone marrow reserve with absolute neutrophil count (ANC) > 1000 and platelets > 100,000.', ' Adequate renal function with serum creatinine < 2.0.', " Adequate hepatic reserve with serum bilirubin < 2.0, aspartate transaminase (AST) and alanine aminotransferase (ALT) < 2X the upper limit of normal, and alkaline phosphatase < 5X the upper limit of normal. Serum bilirubin > 2.0 is acceptable in the setting of known Gilbert's syndrome.", ' Adequate cardiac reserve with a cardiac ejection fraction within the lower limit of facility normal by MUGA, or 45% by echocardiogram.', ' No active major medical or psychosocial problems that could be complicated by study participation.', ' HIV negative.', 'Exclusion Criteria:', ' No histologic documentation of breast adenocarcinoma.', ' Breast adenocarcinoma that is not amplified for HER-2/neu gene expression by at least 2-fold by FISH analysis, or that is less than IHC 3+ when FISH negative.', ' Cardiac dysfunction documented by an ejection fraction less than the lower limit of the facility normal by multi-gated acquisition (MUGA) scan, or 45% by echocardiogram.', ' Symptomatic intrinsic lung disease or extensive tumor involvement of the lungs resulting in dyspnea at rest.', ' History of autoimmune disease as detailed above.', ' Systemic oral corticosteroid treatment within 28 days prior to initiating treatment on study.', ' Uncontrolled medical problems.', ' Evidence of active acute or chronic infection.', ' Chemotherapy, radiation therapy, or biologic therapy (except Trastuzumab) within 28 days prior to initiating treatment on study. Hormonal therapy and supportive therapy with bisphosphonates will be allowed.', ' Participation in an investigational new drug trial within 28 days prior to initiating treatment on study.', ' Pregnant or breast feeding.', ' Hepatic, renal, or bone marrow dysfunction as detailed above.', ' Concurrent malignancy or history of other malignancy within the last five years except as noted above.', ' Corn allergy.', ' Known severe hypersensitivity to Trastuzumab (excluding mild to moderate infusion reactions that are easily managed and do not recur).'], 'Results': ['Outcome Measurement: ', ' Number of Participants With Adverse Events', ' Safety is measured as the number of patients that experienced adverse events related to study drug.', ' Time frame: From first dose through 30 days after last dose of study drug, up to 9 months', 'Results 1: ', ' Arm/Group Title: Allo GM-CSF-secreting Vaccine, Trastuzumab, Cyclophosphamide', ' Arm/Group Description: Allogeneic GM-CSF-secreting breast cancer vaccine : the vaccine containing a mixture of two GM-CSF-secreting allogeneic breast cancer cell lines (two parts 2T47D-V and one part 3SKBR3-7 mixed in a fixed dose of 5 X 10^8 cells for each patient and each vaccination cycle) given intradermally every 4-6 weeks for 3 cycles and then a 4th dose given 6-8 months after beginning the study.', ' Cyclophosphamide : 300 mg/m^2 given intravenously every 4-6 weeks for 3 cycles and then once 6-8 months after beginning the study', ' Trastuzumab : An initial loading dose of 4 mg/kg for participants beginning treatment with Trastuzumab, otherwise 2 mg/kg given every week intravenously', ' Overall Number of Participants Analyzed: 20', ' Measure Type: Count of Participants', ' Unit of Measure: Participants Fatigue: 8 40.0%', ' Urticaria: 7 35.0%', ' Pruritus: 6 30.0%', ' Fever: 5 25.0%', ' Flu-like symptoms: 4 20.0%', ' Lymphadenopathy: 4 20.0%', ' Abdominal pain: 3 15.0%', ' Rash: 3 15.0%', ' Malaise: 3 15.0%', ' Chills: 3 15.0%', ' Dizziness: 2 10.0%', ' Anorexia: 1 5.0%', ' Erythema: 1 5.0%', ' Headache: 1 5.0%', ' Nausea: 1 5.0%', ' Arm pain: 1 5.0%', ' Cancer site pain: 1 5.0%', ' Leg pain: 1 5.0%', ' Groin tightness: 1 5.0%', ' Erythema at vaccine sites: 20 100.0%', ' Pruritus at vaccine sites: 20 100.0%', ' Induration at vaccine sites: 20 100.0%', ' Pain at vaccine sties: 17 85.0%', ' Rash at vaccine sites: 7 35.0%', ' Blister at vaccine sites: 5 25.0%', ' Hyperpigmentation at vaccine sites: 4 20.0%', ' Bruising at vaccine sites: 3 15.0%', ' Edema at vaccine sites: 2 10.0%', 'Vaccine site flare: 2 10.0%'], 'Adverse Events': ['Adverse Events 1:', ' Total: 1/20 (5.00%)', ' Urticaria *1/20 (5.00%)']}

21947261-bbef-4d3a-adda-02bb4a91a3ca

Comparison

Adverse Events

NCT00617942

NCT00388726

the secondary trial had a lower total number of patients experiencing adverse events compared to the primary trial.

Contradiction

{'Clinical Trial ID': 'NCT00617942', 'Intervention': ['INTERVENTION 1: ', ' Cohort 1', '[Not Specified]', 'INTERVENTION 2: ', ' Cohort 2', '[Not Specified]'], 'Eligibility': ['Inclusion Criteria:', ' Histologically documented adenocarcinoma of the breast', ' ANC > 1000 cells', ' Female; age > 18; Zubrod PS 0-1', ' Platelets > 100,000', ' Stage IIA-IIIB disease', ' Total bilirubin < or = ULN', ' No evidence of metastatic disease Not pregnant or lactating', ' No prior systemic therapy for this breast cancer', ' Serum Creatinine < 1.5 mg/dl or Creat Cl > 30 ml/min', ' Serum ALT < 2.5 x ULN', ' ER, PR and HER2 status required', ' LVEF (MUGA/echo)WNL', ' No baseline > 2 neuropathy', ' Hemoglobin > 9.0 gm/dl', ' HER2+, defined by IHC 3+ or FISH ratio > 2.0'], 'Results': ['Outcome Measurement: ', ' Number of Patients With Complete Pathologic Response Rate, Observed Following Treatment With q3week Carboplatin, Weekly Abraxane and Weekly Trastuzumab in Resectable and Unresectable LABC;', ' These numbers represent patients with a RCB score of zero (0). RCB stands for residual cancer burden.', 'Time frame: 1 year', 'Results 1: ', ' Arm/Group Title: Cohort 1', ' Arm/Group Description: [Not Specified]', ' Overall Number of Participants Analyzed: 37', ' Measure Type: Number', ' Unit of Measure: participants 12', 'Results 2: ', ' Arm/Group Title: Cohort 2', ' Arm/Group Description: [Not Specified]', ' Overall Number of Participants Analyzed: 23', ' Measure Type: Number', ' Unit of Measure: participants 13'], 'Adverse Events': ['Adverse Events 1:', ' Total: 7/37 (18.92%)', ' gr 3port infection, 1/37 (2.70%)', ' flu 1/37 (2.70%)', ' Febrile Neutropenia 1/37 (2.70%)', ' gr 4 sepsis, intubated [1]1/37 (2.70%)', ' Diarrhea gr 2, Nausea gr 3, infection gr 3 1/37 (2.70%)', ' infection normal ANC/viral grade 1 1/37 (2.70%)', ' Dehydration 3, Diarrhea 3, Vomit 3, HGB3, Nausea 3, K 3, Dyspnea 2 1/37 (2.70%)', ' gr 3cellulitis - breast 1/37 (2.70%)', 'Adverse Events 2:', ' Total: 8/23 (34.78%)', ' gr 3port infection, 0/23 (0.00%)', ' flu 0/23 (0.00%)', ' Febrile Neutropenia 0/23 (0.00%)', ' gr 4 sepsis, intubated [1]0/23 (0.00%)', ' Diarrhea gr 2, Nausea gr 3, infection gr 3 0/23 (0.00%)', ' infection normal ANC/viral grade 1 0/23 (0.00%)', ' Dehydration 3, Diarrhea 3, Vomit 3, HGB3, Nausea 3, K 3, Dyspnea 2 0/23 (0.00%)', ' gr 3cellulitis - breast 0/23 (0.00%)']}

{'Clinical Trial ID': 'NCT00388726', 'Intervention': ['INTERVENTION 1: ', ' Eribulin Mesylate 1.4 mg/kg^2', ' Eribulin Mesylate 1.4 mg/kg^2 on Days 1 and 8', 'INTERVENTION 2: ', " Treatment of Physician's Choice", " Treatment of Physician's Choice"], 'Eligibility': ['Inclusion Criteria:', ' Female patients with histologically or cytologically confirmed carcinoma of the breast.', ' Every effort should be made to make paraffin embedded tissue or slides from the diagnostic biopsy or surgical specimen available for confirmation of diagnosis.', ' Patients with locally recurrent or metastatic disease who have received at least two (and not more than five) prior chemotherapeutic regimens for breast cancer, at least two of which were administered for treatment of locally recurrent and/or metastatic disease.', ' Prior therapy must be documented by the following criteria prior to entry onto study:', ' Regimens must have included an anthracycline (e.g., doxorubicin, epirubicin) and a taxane (e.g., paclitaxel, docetaxel) in any combination or order. Treatment with any of these agents is not required if they are contraindicated for a certain patient.', ' One or two of these regimens may have been administered as adjuvant and/or neoadjuvant therapy, but at least 2 must have been given for relapsed or metastatic disease.', ' Patients must have proved refractory to the most recent chemotherapy, documented by progression on or within six (6) months of therapy.', ' Patients with Human Epidermal Growth Factor 2 (HER2/neu) positive tumors may additionally have been treated with trastuzumab.', ' Patients may have additionally been treated with anti-hormonal therapy.', ' Resolution of all chemotherapy or radiation-related toxicities to Grade 1 severity or lower, except for stable sensory neuropathy <= Grade 2 and alopecia.', ' Age >= 18 years.', ' Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2.', ' Life expectancy of >= 3 months.', ' Adequate renal function as evidenced by serum creatinine <= 2.0 mg/dL or calculated creatinine clearance >= 40 mL/min per the Cockcroft and Gault formula.', ' Adequate bone marrow function as evidenced by absolute neutrophil count (ANC) >= 1.5 x 10^9/L, hemoglobin >= 10.0 g/dL (a hemoglobin <10.0 g/dL is acceptable if it is corrected by growth factor or transfusion), and platelet count >= 100 x 10^9/L.', ' Adequate liver function as evidenced by bilirubin <= 1.5 times the upper limits of normal (ULN) and alkaline phosphatase, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) <= 3 x ULN (in the case of liver metastases <= 5 x ULN), unless there are bone metastases, in which case liver specific alkaline phosphatase must be separated from the total and used to assess the liver function instead of the total alkaline phosphatase. In case alkaline phosphatase is >3 x ULN (in absence of liver metastases) or > 5 x ULN (in presence of liver metastases) AND patient is known to have bone metastases, the liver specific alkaline phosphatase must be separated from the total and used to assess the liver function instead of the total alkaline phosphatase.', ' Patients willing and able to comply with the study protocol for the duration of the study.', ' Written informed consent prior to any study-specific screening procedures with the understanding that the patient may withdraw consent at any time without prejudice.', ' EXCLUSION CRITERIA', ' Patients who have received any of the following treatments within the specified period before E7389 or TPC treatment start:', ' chemotherapy, radiation, trastuzumab or hormonal therapy within three weeks.', ' any investigational drug within four weeks.', ' Radiation therapy encompassing > 30% of marrow.', ' Prior treatment with mitomycin C or nitrosourea.', ' Pulmonary lymphangitic involvement that results in pulmonary dysfunction requiring active treatment, including the use of oxygen.', ' Patients with brain or subdural metastases are not eligible, unless they have completed local therapy and have discontinued the use of corticosteroids for this indication for at least 4 weeks before starting treatment in this study. Any signs (e.g., radiologic) and/or symptoms of brain metastases must be stable for at least 4 weeks before starting study treatment; radiographic stability should be determined by comparing a contrast-enhanced computed tomography or magnetic resonance imaging brain scan performed during screening to a prior scan performed at least 4 weeks earlier.', ' Patients with meningeal carcinomatosis.', ' Patients who are receiving anti-coagulant therapy with warfarin or related compounds, other than for line patency, and cannot be changed to heparin-based therapy if randomized to E7389 are not eligible. If a patient is to continue on mini-dose warfarin, then the prothrombin time (PT) or international normalized ratio (INR) must be closely monitored.', ' Women who are pregnant or breast-feeding; women of childbearing potential with either a positive pregnancy test at screening or no pregnancy test; women of childbearing potential unless (1) surgically sterile or (2) using adequate measures of contraception in the opinion of the Investigator. Perimenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential.', ' Severe/uncontrolled intercurrent illness/infection.', ' Significant cardiovascular impairment (history of congestive heart failure > New York Heart Association grade II, unstable angina or myocardial infarction within the past six months, or serious cardiac arrhythmia).', ' Patients with organ allografts requiring immunosuppression.', ' Patients with known positive HIV status.', ' Patients who have had a prior malignancy, other than previous breast cancer, carcinoma in situ of the cervix, or non-melanoma skin cancer, unless the prior malignancy was diagnosed and definitively treated >= 5 years previously with no subsequent evidence of recurrence.', ' Patients with pre-existing neuropathy > Grade 2.', ' Patients with a hypersensitivity to halichondrin B and/or halichondrin B chemical derivative.', ' Patients who participated in a prior E7389 clinical trial whether or not E7389 was received.', " Patients with other significant disease or disorders that, in the Investigator's opinion, would exclude the patient from the study."], 'Results': ['Outcome Measurement: ', ' Overall Survival', ' Defined as the time from the date of randomization until the date of death from any cause.', ' Time frame: From date of randomization until death from any cause', 'Results 1: ', ' Arm/Group Title: Eribulin Mesylate 1.4 mg/kg^2', ' Arm/Group Description: Eribulin Mesylate 1.4 mg/kg^2 on Days 1 and 8', ' Overall Number of Participants Analyzed: 508', ' Median (Full Range)', ' Unit of Measure: Days 399 (360 to 434)', 'Results 2: ', " Arm/Group Title: Treatment of Physician's Choice", " Arm/Group Description: Treatment of Physician's Choice", ' Overall Number of Participants Analyzed: 254', ' Median (Full Range)', ' Unit of Measure: Days 324 (282 to 380)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 130/503 (25.84%)', ' Febrile Neutropenia21/503 (4.17%)', ' Neutropenia9/503 (1.79%)', ' Anaemia1/503 (0.20%)', ' Pancytopenia1/503 (0.20%)', ' Pericardial Effusion2/503 (0.40%)', ' Cardiac Failure1/503 (0.20%)', ' Extrasystoles0/503 (0.00%)', ' Vertigo1/503 (0.20%)', ' Nausea7/503 (1.39%)', ' Vomiting5/503 (0.99%)', ' Diarrhoea1/503 (0.20%)', ' Abdominal Pain1/503 (0.20%)', ' Ascites1/503 (0.20%)', 'Adverse Events 2:', ' Total: 64/247 (25.91%)', ' Febrile Neutropenia3/247 (1.21%)', ' Neutropenia0/247 (0.00%)', ' Anaemia2/247 (0.81%)', ' Pancytopenia0/247 (0.00%)', ' Pericardial Effusion0/247 (0.00%)', ' Cardiac Failure0/247 (0.00%)', ' Extrasystoles1/247 (0.40%)', ' Vertigo0/247 (0.00%)', ' Nausea2/247 (0.81%)', ' Vomiting1/247 (0.40%)', ' Diarrhoea4/247 (1.62%)', ' Abdominal Pain3/247 (1.21%)', ' Ascites2/247 (0.81%)']}

71daae7c-3ee5-4451-91e2-273d8ff55aae

Single

Adverse Events

NCT00203502

Every single patient in the primary trial experienced at least 1 adverse event.

Entailment

{'Clinical Trial ID': 'NCT00203502', 'Intervention': ['INTERVENTION 1: ', ' Intervention: Drug:Docetaxel + Cyclophosphamide + Avastin', ' Docetaxel 75mg/m2 + Cyclophosphamide 500 mg/m2', ' + Avastin 15 mg/kg', ' Q 3 weeks X 4 cycles', ' Bevacizumab/Avastin: IV 15mg/kg 21 days', ' Cyclophosphamide: 500mg per meter squared, IV every 21 days', ' Doxorubicin: 60 mg per meter squared, IV every 21 days'], 'Eligibility': ['Inclusion Criteria:', ' The diagnosis of breast cancer established by biopsy.', ' Normal kidney function', ' Normal LVEF evaluated by MUGA Scan', ' >18 years of age', ' Good performance status defined by ECOG scale of 0 or 1', ' Consent', ' Women of childbearing potential must have a negative pregnancy test.', ' Use of effective means of contraception in subjects of child-bearing potential while on treatment and for at least 3 months thereafter.', ' Peripheral Neuropathy: must be < grade 1', ' Hematologic (minimal values)', ' Absolute neutrophil count >1,500/mm3', ' Hemoglobin >8.0 g/dl', ' Platelet count >100,000/mm3', ' Hepatic', ' Total bilirubin <ULN', ' AST, ALT, Alkaline Phosphatase must be within range', 'Exclusion Criteria:', ' Patients with locally advanced breast cancer with skin ulcerations', ' Stage IV breast cancer', ' Inflammatory breast cancer', ' Allergy to any component of the treatment regimen', ' Women who are breast feeding', ' Pregnancy or refusal to use effective contraception', ' Inability to comply with study and/or follow-up procedures.', ' Current, recent, or planned participation in a experimental drug study', ' Blood pressure of >150/100 mmHg. Essential hypertension well controlled with anti hypertensives is not an exclusion criterion.', ' unstable angina', ' New York Heart Association Grade II or greater congestive heart failure', ' history of myocardial infarction within 6 months', ' history of stroke within 6 months', ' Clinical significant peripheral vascular disease', ' Evidence of bleeding diathesis or coagulopathy', ' Presence of central nervous system or brain metastasis', ' major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to day 0', ' Minor surgical procedure such as fine needle aspirations or core biopsy within 7 days prior to day 0', ' Pregnant or lactating', ' Urine protein: creatinine ratio >1.0 at screening', ' History of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to Day 0', ' Serious, non-healing wound, ulcer, or bone fracture'], 'Results': ['Outcome Measurement: ', ' Percentage of Participants With Pathological Complete Response.', ' Pathological complete response was defined as the absence of residual invasive and in situ cancer on hematoxylin and eosin evaluation of the resected breast.', ' Time frame: Participants were assessed during surgery, an average of one hour', 'Results 1: ', ' Arm/Group Title: Intervention: Drug:Docetaxel + Cyclophosphamide + Avastin', ' Arm/Group Description: Docetaxel 75mg/m2 + Cyclophosphamide 500 mg/m2', ' + Avastin 15 mg/kg', ' Q 3 weeks X 4 cycles', ' Bevacizumab/Avastin: IV 15mg/kg 21 days', ' Cyclophosphamide: 500mg per meter squared, IV every 21 days', ' Doxorubicin: 60 mg per meter squared, IV every 21 days', ' Overall Number of Participants Analyzed: 39', ' Measure Type: Number', ' Unit of Measure: percentage of evaluable patients 41 (27.7 to 55.4)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 39/39 (100.00%)', ' Febrile Neutropenia 1/39 (2.56%)', ' Heart failure 1/39 (2.56%)', ' Diarrhea 3/39 (7.69%)', ' Nausea/vomiting 4/39 (10.26%)', ' Mucositis 3/39 (7.69%)', ' Fatigue 4/39 (10.26%)', ' infection 3/39 (7.69%)', ' Urinary tract infection 2/39 (5.13%)', ' Musculoskeletal pain 6/39 (15.38%)', ' Syncope 1/39 (2.56%)', ' Insomnia 3/39 (7.69%)', ' Anxiety 2/39 (5.13%)']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

4a14a8f4-c9c2-4aa2-85bc-caa1f9820e37

Single

Adverse Events

NCT01644890

Throughout the primary trial, one patient developed issues with their vision.

Entailment

{'Clinical Trial ID': 'NCT01644890', 'Intervention': ['INTERVENTION 1: ', ' NK105', ' received NK105 (65 mg/m^2) on days 1, 8 and 15 of a 28-day cycle', 'INTERVENTION 2: ', ' Paclitaxel', ' received Paclitaxel (80 mg/m^2) on days 1, 8 and 15 of a 28-day cycle'], 'Eligibility': ['Inclusion Criteria:', ' Written informed consent of the patient signed by herself.', ' Histologically confirmed metastatic or recurrent adenocarcinoma of the breast.', ' Aged 20 to 74 at the time of informed consent.', 'Exclusion Criteria:', ' Prior systemic chemotherapy with taxane anticancer drugs for metastatic or recurrent breast cancer.'], 'Results': ['Outcome Measurement: ', ' Progression Free Survival', ' PFS is defined as the period from the day of randomization until the first observation of lesion progression or death from any cause. Disease progression is defined as PD according to RECIST Ver. 1.1.', ' Assessment period was from the day of randomisation until the first observation of lesion progression or death', ' Time frame: Baseline, every 6 weeks of study treatment period, and end of study,', 'Results 1: ', ' Arm/Group Title: NK105', ' Arm/Group Description: received NK105 (65 mg/m^2) on days 1, 8 and 15 of a 28-day cycle', ' Overall Number of Participants Analyzed: 211', ' Median (95% Confidence Interval)', ' Unit of Measure: months 8.4 (7.0 to 9.9)', 'Results 2: ', ' Arm/Group Title: Paclitaxel', ' Arm/Group Description: received Paclitaxel (80 mg/m^2) on days 1, 8 and 15 of a 28-day cycle', ' Overall Number of Participants Analyzed: 211', ' Median (95% Confidence Interval)', ' Unit of Measure: months 8.5 (6.9 to 11.5)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 34/214 (15.89%)', ' Leukocytosis 0/214 (0.00%)', ' Atrial fibrillation 0/214 (0.00%)', ' Cardiac failure congestive 0/214 (0.00%)', ' Pericardial effusion 1/214 (0.47%)', ' Cataract 0/214 (0.00%)', ' Macular fibrosis 0/214 (0.00%)', ' Constipation 2/214 (0.93%)', ' Diarrhoea 2/214 (0.93%)', ' Enterocolitis 0/214 (0.00%)', ' Ileus 1/214 (0.47%)', ' Nausea 3/214 (1.40%)', 'Adverse Events 2:', ' Total: 27/213 (12.68%)', ' Leukocytosis 1/213 (0.47%)', ' Atrial fibrillation 1/213 (0.47%)', ' Cardiac failure congestive 1/213 (0.47%)', ' Pericardial effusion 0/213 (0.00%)', ' Cataract 1/213 (0.47%)', ' Macular fibrosis 1/213 (0.47%)', ' Constipation 1/213 (0.47%)', ' Diarrhoea 1/213 (0.47%)', ' Enterocolitis 1/213 (0.47%)', ' Ileus 0/213 (0.00%)', ' Nausea 0/213 (0.00%)']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

7d22937b-9823-45fa-a914-261f993e4d64

Single

Adverse Events

NCT01940497

There were 3 more allergic reactions observed in cohort 1 of the primary trial than cohort 2.

Contradiction

{'Clinical Trial ID': 'NCT01940497', 'Intervention': ['INTERVENTION 1: ', ' Trastuzumab (Vial): Adjuvant', ' Participants received trastuzumab 600 mg subcutaneously using a vial every 3 weeks (1 cycle) for 1 year (4 cycles in combination with adjuvant chemotherapy [consisting of doxorubicin, paclitaxel or docetaxel] and 14 cycles administered alone).', 'INTERVENTION 2: ', ' Trastuzumab (Vial): Neoadjuvant', ' Participants received trastuzumab 600 mg subcutaneously using a vial every 3 weeks (1 cycle) for 1 year (4 cycles in combination with neoadjuvant chemotherapy [consisting of doxorubicin, paclitaxel or docetaxel] and 14 cycles administered alone).'], 'Eligibility': ['Inclusion Criteria:', ' Histologically confirmed non-metastatic primary invasive adenocarcinoma of the breast. Stage of disease: T1-4 (T describes size of tumour from 1 to 4), N0-3 (N describes nearby lymph nodes), M0 (M describes distant metastasis)', ' HER2-positive disease immunohistochemistry (IHC) 3+ or in situ hybridization (ISH) positive', ' Eastern Cooperative Oncology Group (ECOG) performance status 0-1', ' Left ventricular ejection fraction (LVEF) of greater than or equal to (>=) 55 percent (%) measured by echocardiography (ECHO) or multiple gated acquisition (MUGA) scan prior to first dose of trastuzumab SC', ' Intact skin at site of SC injection on the thigh', 'Exclusion Criteria:', ' History of other malignancy, except for participants with curatively treated carcinoma in situ of the cervix or basal cell carcinoma and participants with other curatively treated malignancies, other than breast cancer, who have been disease-free for at least 5 years', ' Severe dyspnea at rest or requiring supplementary oxygen therapy', ' Concurrent serious diseases that may interfere with planned treatment, including severe pulmonary conditions/illness', ' Serious cardiac illness or medical conditions that would preclude the use of trastuzumab, specifically: history of documented congestive heart failure (CHF), high-risk uncontrolled arrhythmias, angina pectoris requiring medication, clinically significant valvular disease, evidence of transmural infarction on electrocardiogram (ECG), diagnosed poorly controlled hypertension', ' Known infection with human immunodeficiency virus (HIV), active hepatitis B virus (HBV) or hepatitis C virus (HCV)', ' Pregnant or lactating women', ' Concurrent enrolment in another clinical trial using an investigational anti-cancer treatment, including hormonal therapy, bisphosphonate therapy and immunotherapy, within 28 days prior to the first dose of study treatment', ' Known hypersensitivity to trastuzumab, murine proteins, to any of the excipients of Herceptin including hyaluronidase, or the adhesive of the SC device (for Cohort B), or a history of severe allergic or immunological reactions, for example, difficulty to control asthma', ' Inadequate bone marrow, hepatic or renal function', ' Hormonal treatment concomitant with chemotherapy (allowed in adjuvant phase with adjuvant trastuzumab SC)', ' Pre-existing motor or sensory neuropathy of Grade greater than (>) 1', ' Synchronous bilateral invasive breast cancer'], 'Results': ['Outcome Measurement: ', ' Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs)', ' An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. TEAEs were the AEs occurring from starting on the day of or after first administration of trastuzumab and within 28 days after last dose of trastuzumab. Data for this outcome measure were analyzed and reported by adjuvant versus neoadjuvant chemotherapy groups within each treatment arm.', ' Time frame: Day 1 up to 28 days after last dose of trastuzumab (up to approximately 1 year)', 'Results 1: ', ' Arm/Group Title: Trastuzumab (Vial): Adjuvant', ' Arm/Group Description: Participants received trastuzumab 600 mg subcutaneously using a vial every 3 weeks (1 cycle) for 1 year (4 cycles in combination with adjuvant chemotherapy [consisting of doxorubicin, paclitaxel or docetaxel] and 14 cycles administered alone).', ' Overall Number of Participants Analyzed: 95', ' Measure Type: Number', ' Unit of Measure: Percentage of Participants 98.9', 'Results 2: ', ' Arm/Group Title: Trastuzumab (Vial): Neoadjuvant', ' Arm/Group Description: Participants received trastuzumab 600 mg subcutaneously using a vial every 3 weeks (1 cycle) for 1 year (4 cycles in combination with neoadjuvant chemotherapy [consisting of doxorubicin, paclitaxel or docetaxel] and 14 cycles administered alone).', ' Overall Number of Participants Analyzed: 20', ' Measure Type: Number', ' Unit of Measure: Percentage of Participants 100.0'], 'Adverse Events': ['Adverse Events 1:', ' Total: 5/95 (5.26%)', ' Febrile neutropenia 0/95 (0.00%)', ' Neutropenia 0/95 (0.00%)', ' Atrial fibrillation 0/95 (0.00%)', ' Pleuropericarditis 0/95 (0.00%)', ' Vomiting 0/95 (0.00%)', ' Pryexia 0/95 (0.00%)', ' Anaphylactic shock 1/95 (1.05%)', ' Gastroenteritis 0/95 (0.00%)', ' Fibula fracture 1/95 (1.05%)', ' Tibia fracture 1/95 (1.05%)', ' Intervertebral disc protrusion 0/95 (0.00%)', 'Adverse Events 2:', ' Total: 3/20 (15.00%)', ' Febrile neutropenia 0/20 (0.00%)', ' Neutropenia 0/20 (0.00%)', ' Atrial fibrillation 1/20 (5.00%)', ' Pleuropericarditis 1/20 (5.00%)', ' Vomiting 0/20 (0.00%)', ' Pryexia 0/20 (0.00%)', ' Anaphylactic shock 0/20 (0.00%)', ' Gastroenteritis 1/20 (5.00%)', ' Fibula fracture 0/20 (0.00%)', ' Tibia fracture 0/20 (0.00%)', ' Intervertebral disc protrusion 1/20 (5.00%)']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

507a4189-4905-4752-8348-d715a5ce3962

Single

Results

NCT00096356

the primary trial results indicate that CoQ10 reduces the level of fatigue experienced by patients compared to a placebo.

Entailment

{'Clinical Trial ID': 'NCT00096356', 'Intervention': ['INTERVENTION 1: ', ' Arm 1 - CoQ10 & Vitamin E', ' CoQ10 100mg capsule combined with Vitamin E 100 IU taken orally three times per day.', 'INTERVENTION 2: ', ' Arm 2 - Placebo & Vitamin E', ' Placebo-Vitamin E 100 mg/day in 3 doses'], 'Eligibility': ['Inclusion Criteria:', ' Signed consent', ' Hg > 11g/dl; supportive measures (erythropoietin, transfusion, iron therapy) should be utilized to assist with maintaining Hgb levels', ' Total cholesterol > 160mg/dL.', ' Female with primary cancer diagnosis (breast)', ' Planned adjuvant chemotherapy (neoadjuvant chemotherapy is excluded)', ' KPS > 60', ' Bilirubin < 1.5 x ULN', ' SGOT < 2.5 x ULN', ' SGPT < 2.5 x ULN', 'Exclusion Criteria:', ' Recent involuntary weight loss (> 5% of body weight in the past 3 months)', ' Statin therapy - current or planned during study. Below is a list of some commonly used statin drugs.(Note: This is a helpful guide, not a complete list.)', ' Atorvastatin (Lipitor)', ' Cerivastatin', ' Fluvastatin (Lescol)', ' Lovastatin (Mevacor, Altocor, Advicor)', ' Mevastatin', ' Pravastatin (Pravachol)', ' Rosuvastatin', ' Simvastatin (Zocor)', ' Current or planned use of the following medications for fatigue', ' Corticosteroids (intermittent use as part of chemotherapy regimen is allowed)', ' Amphetamines or other stimulants including methylphenidate (Ritalin)or modafinil (Provigil)', ' Patients diagnosed with uncontrolled hypertension', ' Breast cancer patients who are male', ' Pregnant women are excluded from participation in this study. A Serum pregnancy test is required within 1 week of registration if the patient is a woman of childbearing potential.', ' Anticoagulant therapy - current or planned during study (except for maintenance of catheter patency)', ' Patients with uncontrolled thyroid dysfunction'], 'Results': ['Outcome Measurement: ', ' Effects of Coenzyme Q10 on Fatigue (as Measured by POMS-F) 24 Weeks Following Randomization', ' POMS-F is the Profile of Mood States - fatigue scale. It ranges from 0 to 28; higher values indicate greater fatigue.', ' Time frame: 24 weeks', 'Results 1: ', ' Arm/Group Title: Arm 1 - CoQ10 & Vitamin E', ' Arm/Group Description: CoQ10 100mg capsule combined with Vitamin E 100 IU taken orally three times per day.', ' Overall Number of Participants Analyzed: 122', ' Least Squares Mean (Standard Error)', ' Unit of Measure: units on a scale 6.96 (0.71)', 'Results 2: ', ' Arm/Group Title: Arm 2 - Placebo & Vitamin E', ' Arm/Group Description: Placebo-Vitamin E 100 mg/day in 3 doses', ' Overall Number of Participants Analyzed: 114', ' Least Squares Mean (Standard Error)', ' Unit of Measure: units on a scale 8.33 (0.79)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 22/100 (22.00%)', ' ANC 11/100 (11.00%)', ' WBC 4/100 (4.00%)', ' anemia 1/100 (1.00%)', ' hypotension 1/100 (1.00%)', ' L vent sy d 0/100 (0.00%)', ' chest pain 0/100 (0.00%)', ' constipation 1/100 (1.00%)', ' diarrhea 3/100 (3.00%)', ' ileus 1/100 (1.00%)', ' vomiting 1/100 (1.00%)', ' abd pain 0/100 (0.00%)', ' nausea 1/100 (1.00%)', ' allergic reaction 1/100 (1.00%)', ' fatigue 1/100 (1.00%)', 'Adverse Events 2:', ' Total: 15/93 (16.13%)', ' ANC 4/93 (4.30%)', ' WBC 2/93 (2.15%)', ' anemia 0/93 (0.00%)', ' hypotension 0/93 (0.00%)', ' L vent sy d 1/93 (1.08%)', ' chest pain 1/93 (1.08%)', ' constipation 1/93 (1.08%)', ' diarrhea 2/93 (2.15%)', ' ileus 0/93 (0.00%)', ' vomiting 1/93 (1.08%)', ' abd pain 1/93 (1.08%)', ' nausea 3/93 (3.23%)', ' allergic reaction 0/93 (0.00%)', ' fatigue 3/93 (3.23%)', ' fever 1/93 (1.08%)']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

24001e83-6a8c-4f67-9c24-55dc285c4cc2

Single

Intervention

NCT00513695

filgrastim is the only drug in the primary trial given by subcutaneous injection.

Entailment

{'Clinical Trial ID': 'NCT00513695', 'Intervention': ['INTERVENTION 1: ', ' Treatment (Neoadjuvant Chemotherapy Before Surgery)', ' Patients receive neoadjuvant chemotherapy comprising sunitinib malate PO once daily and paclitaxel IV over 1 hour once weekly for 8-12 weeks in the absence of disease progression or unacceptable toxicity. Beginning within 3 weeks of completion of sunitinib malate and paclitaxel, patients receive doxorubicin IV once weekly for 15 weeks, cyclophosphamide PO once daily for 15 weeks, and filgrastim SC on days 2-7 for 16 weeks in the absence of disease progression or unacceptable toxicity. Beginning 3-6 weeks after completion of chemotherapy, patients undergo surgery.', ' sunitinib malate: Given PO', ' paclitaxel: Given IV', ' doxorubicin hydrochloride: Given IV', ' cyclophosphamide: Given PO', ' filgrastim: Given SC', ' therapeutic conventional surgery: Undergo surgery', ' laboratory biomarker analysis: Correlative studies', ' flow cytometry: Correlative studies'], 'Eligibility': ['Inclusion Criteria:', ' Be informed of the investigational nature of the study and all pertinent aspects of the trial and must sign and give written consent in accordance with institutional and federal guidelines', " Have a histologically-confirmed diagnosis of breast cancer that is locally advanced or inflammatory; inflammatory breast cancer is defined as erythema and peau d'orange involving half or more of the breast with a histologic diagnosis of breast cancer; the finding of focal dermal lymphatic involvement on histology does not constitute inflammatory breast cancer", ' Have selected stage IIB (T3, N0, M0) or IIIA (T3, N1-2, M0 or T0-2, N2, M0) disease judged primarily unresectable by an experienced breast surgeon or otherwise deemed appropriate candidates for neoadjuvant treatment or stage IIIB (T4, any N, M0) or stage IIIC (any T, N3, M0) disease', ' Patients must have a performance status of 0-2 by Zubrod criteria', ' Absolute neutrophil count (ANC) >= 1,500 cells/mm^3', ' Platelet count >= 100,000 cells/mm^3', ' Serum creatinine =< 1.5 x institutional upper limit of normal (IULN)', ' Bilirubin =< 2.0', ' Serum glutamic oxaloacetic transaminase (SGOT)/serum glutamic pyruvic transaminase (SGPT)/alkaline phosphatase =< 2.0 x IULN', ' Have a multi gated acquisition scan (MUGA) or echocardiogram scan performed within 3 months prior to enrollment and have a left ventricular ejection fraction (LVEF) % greater than the institutional lower limit of normal', ' Be willing and able to comply with scheduled visits, treatment plan, laboratory tests and other trial procedures', 'Exclusion Criteria:', ' Have evidence of distant metastases', ' Have tumors that overexpress human epidermal growth factor receptor 2 (HER2)/neu as evidenced by 3+ staining by immunohistochemistry or gene amplification by fluorescent in situ hybridization (FISH)', ' Have received any prior chemotherapy or hormonal therapy for breast cancer', ' Have received prior radiation therapy or prior definitive surgery for breast cancer', ' Have a clinical diagnosis of congestive heart failure or angina pectoris or any of the following within the 6 months prior to study drug administration:, myocardial infarction, coronary/peripheral artery bypass graft, cerebrovascular accident or transient ischemic attack, or pulmonary embolism', ' Have ongoing cardiac dysrhythmias of National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Events (CTCAE) version 3.0 grade >= 2', ' Have uncontrolled hypertension (>150/100 mm Hg despite optimal medical therapy)', ' Have pre-existing thyroid abnormality with thyroid function that cannot be maintained in the normal range with medication', ' Have a known, active infection', ' Have any prior malignancy except for adequately treated basal cell or squamous cell skin cancer, any in situ cancer, adequately treated stage I or II cancer from which the patient is currently in complete remission or any other cancer from which the patient has been disease-free for 5 years', ' Human immunodeficiency virus (HIV) positive', ' Are receiving or planning to receive any concurrent anticancer therapy while receiving protocol treatment', ' Are receiving or planning to receive concurrent treatment on another clinical trial (supportive care trials or non-treatment trials, e.g. quality of life (QOL) are allowed; participation in the companion imaging trial, dynamic contrast enhanced-magnetic resonance imaging (DCE-MRI) and fludeoxyglucose F 18 positron emission tomography (FDG PET) with Kinetic Analysis to Monitor Breast Cancer Response to Neoadjuvant Sunitinib and Metronomic Chemotherapy is also allowed)', ' Be pregnant or breast feeding; female subjects must be surgically sterile or be postmenopausal, or must agree to use effective contraception during the period of therapy; all female subjects with reproductive potential must have a negative pregnancy test (serum or urine) prior to enrollment; male subjects must be surgically sterile or must agree to use effective contraception during the period of therapy; the definition of effective contraception will be based on the judgment of the principal investigator or a designated associate', ' Have other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration, or may interfere with the interpretation of study results, and in the judgment of the investigator would make the subject inappropriate for entry into this study'], 'Results': ['Outcome Measurement: ', ' Microscopic Pathologic CR (pCR) Rate', ' Defined as no evidence of microscopic invasive tumor present at primary tumor site in the surgical specimen and calculated with exact 90% binomial confidence interval.', ' Time frame: At the time of surgery', 'Results 1: ', ' Arm/Group Title: Treatment (Neoadjuvant Chemotherapy Before Surgery)', ' Arm/Group Description: Patients receive neoadjuvant chemotherapy comprising sunitinib malate PO once daily and paclitaxel IV over 1 hour once weekly for 8-12 weeks in the absence of disease progression or unacceptable toxicity. Beginning within 3 weeks of completion of sunitinib malate and paclitaxel, patients receive doxorubicin IV once weekly for 15 weeks, cyclophosphamide PO once daily for 15 weeks, and filgrastim SC on days 2-7 for 16 weeks in the absence of disease progression or unacceptable toxicity. Beginning 3-6 weeks after completion of chemotherapy, patients undergo surgery.', ' sunitinib malate: Given PO', ' paclitaxel: Given IV', ' doxorubicin hydrochloride: Given IV', ' cyclophosphamide: Given PO', ' filgrastim: Given SC', ' therapeutic conventional surgery: Undergo surgery', ' laboratory biomarker analysis: Correlative studies', ' flow cytometry: Correlative studies', ' Overall Number of Participants Analyzed: 63', ' Measure Type: Number', ' Unit of Measure: percent of evaluable participants 27 (18 to 39)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 47/68 (69.12%)', ' Neutropenia (ANC)47/68 (69.12%)', ' Leucopenia23/68 (33.82%)', ' Anemia15/68 (22.06%)', ' Diarrhea3/68 (4.41%)', ' Nausea1/68 (1.47%)', ' Fatigue3/68 (4.41%)', ' Pain2/68 (2.94%)', ' ALT elevation4/68 (5.88%)', ' Sensory Neuropathy3/68 (4.41%)', ' Mucositis7/68 (10.29%)', 'Rash1/68 (1.47%)']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

d179396d-94fe-465f-a4f1-e7c3291a0a9a

Comparison

Adverse Events

NCT00796978

NCT01276041

More patients in the secondary trial suffered from oedema in their limbs, compared to patients in the primary trial.

Entailment

{'Clinical Trial ID': 'NCT00796978', 'Intervention': ['INTERVENTION 1: ', ' Trastuzumab', ' trastuzumab: Trastuzumab (Herceptin®) IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks for up to 52 weeks in the absence of disease progression or unacceptable toxicity.', ' laboratory biomarker analysis: Blood is collected every 6 weeks during treatment. Samples are assessed for plasma cardiac markers (N-terminal brain natriuretic protein and troponin-I) and pro-inflammatory cytokines (interleukin-6 and tumor necrosis factor-α).', ' adjuvant therapy: Patients receive trastuzumab (Herceptin®) IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks for up to 52 weeks in the absence of disease progression or unacceptable toxicity.', ' quality-of-life assessment: Patients complete Quality of Life and Quality of Health and Comprehensive Geriatric assessments of functional, cognitive, and mental status changes at baseline, weeks 26, and 52.'], 'Eligibility': ['Inclusion Criteria:', ' Histologically confirmed adenocarcinoma of the breast', ' Immunohistochemical staining for Her2 protein of 3+ intensity or Her2 gene amplification of 2.0 by FISH testing.', ' Life expectancy > 6 months', ' ECOG performance status 2', ' Node positive disease irrespective of tumor size', ' Node negative disease:', ' TNM Stage (AJCC Cancer Staging Manual 6th edition) T1b-T4, N0-3, M0, irrespective of hormonal status', ' Baseline LVEF lower limit of normal for a particular institution', ' Complete surgical removal of invasive cancer by mastectomy or lumpectomy', ' Complete staging work-up with CT of chest, abdomen, and pelvis plus bone scan or alternatively with PET scan for stage II and higher disease, or as determined by symptoms for all other stages. Additional staging work-up as per symptoms.', ' Adequate bone marrow function as indicated by the following:', ' ANC >1000/µL', ' Platelets 100,000/µL', ' Hemoglobin >10 g/dL', ' Adequate liver function, as indicated by bilirubin 1.5 x upper limit of normal (ULN) Adequate renal function, as indicated by creatinine 1.5 x ULN', ' AST or ALT <2 x ULN unless related to primary disease.', ' Signed informed consent', 'Exclusion Criteria:', ' Enrollment after more than 120 days from the last day of mastectomy or lumpectomy', ' Patients able to tolerate and willing to receive chemotherapy', ' Prior chemotherapy for current malignancy', ' Prior herceptin therapy', ' Active cardiac disease', ' Myocardial infarction (asymptomatic changes on EKG suggestive of old MI is not an exclusion)', ' Angina pectoris requiring anti-anginal treatment', ' Documented congestive heart failure (CHF)', ' Current use of any therapy specifically for CHF', ' Cardiac arrhythmia requiring medication', ' Current uncontrolled hypertension (diastolic >100 mmHg or systolic > 200 mmHg)', ' Clinically significant valvular abnormality (associated with New York Heart Association (NYHA) class II, III, or IV symptoms)', ' Clinically significant pericardial effusion (associated with New York Heart Association (NYHA) class II, III, or IV symptoms)', ' Past cardiac disease', ' Prior myocardial infarction (asymptomatic changes on EKG suggestive of old MI is not an exclusion)', ' Prior history of CHF', ' History of cardiomyopathy', ' Other diseases and conditions', ' Evidence of metastatic breast cancer (clinical or radiological evidence)', ' Active infection', ' Concomitant malignancies or previous malignancies within the last 3 years, with the exception of adequately treated basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix.', ' Hypersensitivity to trastuzumab'], 'Results': ['Outcome Measurement: ', ' Percent of Participants Experiencing Cardiac Events at 1 Year', ' Number of participants that experience cardiac events that include cardiac death due to congestive heart failure (CHF), Myocardial infarction (MI) or documented arrhythmia, death without definitive cause, or signs and symptoms of CHF as defined by New York Heart Association (NYHA) class III or IV symptoms.', ' Time frame: At 1 year', 'Results 1: ', ' Arm/Group Title: Trastuzumab', ' Arm/Group Description: trastuzumab: Trastuzumab (Herceptin ) IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks for up to 52 weeks in the absence of disease progression or unacceptable toxicity.', ' laboratory biomarker analysis: Blood is collected every 6 weeks during treatment. Samples are assessed for plasma cardiac markers (N-terminal brain natriuretic protein and troponin-I) and pro-inflammatory cytokines (interleukin-6 and tumor necrosis factor-α).', ' adjuvant therapy: Patients receive trastuzumab (Herceptin ) IV over 30-90 minutes on day 1. Treatment repeats every 3 weeks for up to 52 weeks in the absence of disease progression or unacceptable toxicity.', ' quality-of-life assessment: Patients complete Quality of Life and Quality of Health and Comprehensive Geriatric assessments of functional, cognitive, and mental status changes at baseline, weeks 26, and 52.', ' Overall Number of Participants Analyzed: 55', ' Measure Type: Number', ' Unit of Measure: percentage of participants 3.6 (0.09 to 13.8)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 8/56 (14.29%)', ' Platelets * 1/56 (1.79%)', ' Heart failure * 1/56 (1.79%)', ' Left ventricular systolic dysfunction * 1/56 (1.79%)', ' Dehydration * 1/56 (1.79%)', ' Diarrhea * 1/56 (1.79%)', ' Infection with normal ANC or Grade 1 or 2 neutrophils - Bladder (urinary) * 1/56 (1.79%)', ' Sodium, serum-low (hyponatremia) * 1/56 (1.79%)', ' Fracture * 2/56 (3.57%)']}

{'Clinical Trial ID': 'NCT01276041', 'Intervention': ['INTERVENTION 1: ', ' Pertuzumab in Combination With Trastuzumab and Paclitaxel', ' This is a phase II study of pertuzumab in combination with trastuzumab and paclitaxel for the treatment of patients with Stage IV HER2 (+) breast cancer.'], 'Eligibility': ['Inclusion Criteria:', ' Age 18', ' Stage IV HER2 (+) breast cancer.', ' Histologically documented HER2 (+) breast cancer as defined as IHC 3+ or FISH amplification of 2.0 of primary or metastatic site; results from the local lab are acceptable. (Optional tumor sample collection from primary or metastatic site may be obtained for HER2 testing at MSKCC).', ' ECOG performance 0 -1 (Appendix A)', " 0-1 prior treatment in the metastatic setting (ie: hormone, chemotherapy, biologic, targeted agents). Prior anthracycline, paclitaxel, and trastuzumab in the adjuvant setting are allowed. If the patient has one trastuzumab-based treatment in the metastatic setting and is given a break (even intermittently) from the partner drug given with trastuzumab and is continued on trastuzumab alone, this would still be considered as one treatment. For example, if the patient was given paclitaxel + trastuzumab and was later continued on trastuzumab alone or then restarted on paclitaxel + trastuzumab (at the physician's discretion for any reason), the regimen paclitaxel + trastuzumab followed by trastuzumab alone (or followed by paclitaxel + trastuzumab again) may be considered as one treatment.", ' Measurable or non-measurable disease. Measurable lesions are defined as those that can be measured accurately in at least one diameter, that is 20 mm using conventional imaging techniques (including incremental CT) or 10 mm using spiral CT equipment and a lymph node 15 mm along the short axis. Non-measurable lesions are all other lesions, including small lesions (longest diameter <10mm pathological a lymph nodes with 10 to less than 15mm along the short axis, bony metastases, leptomeningeal disease, ascites, pleural/pericardial effusions, inflammatory breast cancer, lymphangitis carcinomatosis, and heavily calcified and cystic/necrotic lesions.', ' LVEF 50%', ' Hematologic parameters: white blood cell (WBC) count of 3000/ul, absolute neutrophil count (ANC) 1500/ul, platelets 100,000/ul, hemoglobin 10.0 g/dl', ' Non-hematologic parameters: bilirubin 1.5 mg/dl, AST/ALT 2.5 x upper limit of normal (ULN), alkaline phosphatase 5 x ULN.', ' Creatinine 1.5 mg/dl', ' Patients with stable and treated brain lesions of a duration of 2 months may be enrolled.', 'Exclusion Criteria:', ' History of prior cardiac morbidities within 12 months (unstable angina, myocardial infarction, CHF, uncontrolled ventricular arrhythmias)', ' Prior pertuzumab', ' History of prior G 3 hypersensitivity (HSR) or any toxicity to trastuzumab that warranted permanent cessation of this antibody', ' History of prior G 3 HSR or any toxicity to paclitaxel warranted permanent cessation of this chemotherapy', ' > G 2 peripheral neuropathy', ' Patients with a history of chronic hepatitis B or C should be excluded from the study as paclitaxel is potentially hepatotoxic', 'Pregnant patients'], 'Results': ['Outcome Measurement: ', ' Percentage of Patients Who Are Progression Free at 6 Months or Later.', ' Patients who are considered progression-free at 6 months are deemed successes. Failures are those patients who progressed before the 6 month mark. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions', ' Time frame: 6 months', 'Results 1: ', ' Arm/Group Title: Pertuzumab in Combination With Trastuzumab and Paclitaxel', ' Arm/Group Description: This is a phase II study of pertuzumab in combination with trastuzumab and paclitaxel for the treatment of patients with Stage IV HER2 (+) breast cancer.', ' Overall Number of Participants Analyzed: 70', ' Measure Type: Number', ' Unit of Measure: percentage of partcipants 86 (75 to 93)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 18/70 (25.71%)', ' Cardiac arrest 1/70 (1.43%)', ' Pericardial effusion 1/70 (1.43%)', ' Ear pain 1/70 (1.43%)', ' Blurred vision 1/70 (1.43%)', ' Eye disorders - Other, specify 2/70 (2.86%)', ' Abdominal Pain 5/70 (7.14%)', ' Colitis 1/70 (1.43%)', ' Diarrhea 2/70 (2.86%)', ' Nausea 2/70 (2.86%)', ' Death NOS 1/70 (1.43%)', ' Edema limbs 1/70 (1.43%)', ' Fatigue 3/70 (4.29%)']}

4b893eeb-80a4-4a83-8df5-b5c668ce55b1

Single

Adverse Events

NCT00448279

In total there were more adverse events in cohort 1 of the primary trial, than in cohort 2.

Entailment

{'Clinical Trial ID': 'NCT00448279', 'Intervention': ['INTERVENTION 1: ', ' Chemotherapy Alone', " Participants received chemotherapy until disease progression, unacceptable toxicity, or death; the schedule and dose at the investigator's discretion and per local prescribing guidelines and standard center practice. Allowed chemotherapy regimens included paclitaxel, gemcitabine, platinum compounds, docetaxel, capecitabine, or vinorelbine.", 'INTERVENTION 2: ', ' Chemotherapy + Trastuzumab', " Participants received trastuzumab at either 2 mg/kg, IV, every 7 days, or 6 mg/kg, IV, every 3 weeks, per the investigator's discretion. Participants also received chemotherapy; the schedule and dose at the investigator's discretion and per local prescribing guidelines and standard center practice. Allowed chemotherapy regimens included paclitaxel, gemcitabine, platinum compounds, docetaxel, capecitabine, or vinorelbine. Study treatment was administered until disease progression, unacceptable toxicity, or death."], 'Eligibility': ['Inclusion Criteria:', ' female patients, >=18 years of age;', ' metastatic breast cancer;', ' HER2 overexpression (IHC 3+ and/or FISH positive);', ' disease progression during or after previous 1st line chemotherapy plus Herceptin;', ' scheduled to receive 2nd line chemotherapy.', 'Exclusion Criteria:', ' incompatibility with previous Herceptin therapy;', 'pregnancy.'], 'Results': ['Outcome Measurement: ', ' Progression-Free Survival (PFS) - Percentage of Participants With an Event', ' PFS was defined as the time from randomization to the date of documented disease progression according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, or the date of occurrence of a second primary cancer, or date of death from any cause, whichever comes first. Participants were censored at the last tumour evaluation.', ' Time frame: Baseline (BL) and every 8 weeks thereafter', 'Results 1: ', ' Arm/Group Title: Chemotherapy Alone', " Arm/Group Description: Participants received chemotherapy until disease progression, unacceptable toxicity, or death; the schedule and dose at the investigator's discretion and per local prescribing guidelines and standard center practice. Allowed chemotherapy regimens included paclitaxel, gemcitabine, platinum compounds, docetaxel, capecitabine, or vinorelbine.", ' Overall Number of Participants Analyzed: 29', ' Measure Type: Number', ' Unit of Measure: percentage of participants 58.6', 'Results 2: ', ' Arm/Group Title: Chemotherapy + Trastuzumab', " Arm/Group Description: Participants received trastuzumab at either 2 mg/kg, IV, every 7 days, or 6 mg/kg, IV, every 3 weeks, per the investigator's discretion. Participants also received chemotherapy; the schedule and dose at the investigator's discretion and per local prescribing guidelines and standard center practice. Allowed chemotherapy regimens included paclitaxel, gemcitabine, platinum compounds, docetaxel, capecitabine, or vinorelbine. Study treatment was administered until disease progression, unacceptable toxicity, or death.", ' Overall Number of Participants Analyzed: 29', ' Measure Type: Number', ' Unit of Measure: percentage of participants 58.6'], 'Adverse Events': ['Adverse Events 1:', ' Total: 4/26 (15.38%)', ' Febrile neutropenia * 1/26 (3.85%)', ' Gastric volvulus * 20/26 (0.00%)', ' General Malaise * 21/26 (3.85%)', ' Hospitalisation for intrapleuric chemotherapy and thoracentesis * 21/26 (3.85%)', ' Acute renal failure * 21/26 (3.85%)', 'Adverse Events 2:', ' Total: 1/28 (3.57%)', ' Febrile neutropenia * 0/28 (0.00%)', ' Gastric volvulus * 21/28 (3.57%)', ' General Malaise * 20/28 (0.00%)', ' Hospitalisation for intrapleuric chemotherapy and thoracentesis * 20/28 (0.00%)', ' Acute renal failure * 20/28 (0.00%)']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

44cd16f5-6638-4d82-9121-1941eb8ce4b5

Comparison

Intervention

NCT01697345

NCT00513292

Fluorouracil, epirubicin, and cyclophosphamide (FEC) are used in both cohorts of the secondary trial, but not in cohort 1 of the primary trial.

Entailment

{'Clinical Trial ID': 'NCT01697345', 'Intervention': ['INTERVENTION 1: ', ' FSFI Total Score (Pretest)', ' Administered to participants prior to starting vaginal testosterone therapy.', 'INTERVENTION 2: ', ' FSFI Total Score (Postteset)', ' Testosterone USP micronized powder supplied by Medisca Pharmacy was compounded by Precision Compounding pharmacy as testosterone 0.3% per 0.5 milliliters (mL) in pharmabase cream. The compounded testosterone vaginal cream was supplied in pre-filled syringes and each 0.5 mL dose delivered 300 mcg of testosterone daily. The cream was applied to the vaginal opening once daily for four weeks (28 days).'], 'Eligibility': ['Inclusion Criteria:', ' Women with breast cancer', ' Currently taking an aromatase inhibitor (AI)', ' Age > 50 years of age', ' Postmenopausal, or two years since last menstrual cycle', ' Urogenital/vulvovaginal symptoms such as vaginal dryness and pain with intercourse', ' Changes in sexual health quality of life/sexual functioning since starting AI therapy', 'Exclusion Criteria:', ' The use of other treatments for breast cancer such as chemotherapy or radiation within the past 12 months', ' A known sensitivity to medications containing testosterone', ' The use of exogenous hormone replacement therapy (HRT) in the past three months, including systemic and local estrogen or testosterone therapy'], 'Results': ['Outcome Measurement: ', ' Total Female Sexual Function Index (FSFI) Score', ' The Female Sexual Function Index (FSFI) questionnaire was administered to participants prior to starting vaginal testosterone therapy and the survey was repeated after using the study drug for 4 weeks. The participants served as their own controls. The FSFI assesses six domains of sexual functioning (desire, arousal, lubrication, orgasm, satisfaction, and pain) over the past 4 weeks. The sum of all domain scores equals the total FSFI score. The total FSFI score ranges from 2-36 and a total FSFI score < 26.5 suggests female sexual dysfunction.', ' Time frame: Baseline, 4 weeks', 'Results 1: ', ' Arm/Group Title: FSFI Total Score (Pretest)', ' Arm/Group Description: Administered to participants prior to starting vaginal testosterone therapy.', ' Overall Number of Participants Analyzed: 12', ' Mean (Standard Deviation)', ' Unit of Measure: units on a scale 8.691 (3.803)', 'Results 2: ', ' Arm/Group Title: FSFI Total Score (Postteset)', ' Arm/Group Description: Testosterone USP micronized powder supplied by Medisca Pharmacy was compounded by Precision Compounding pharmacy as testosterone 0.3% per 0.5 milliliters (mL) in pharmabase cream. The compounded testosterone vaginal cream was supplied in pre-filled syringes and each 0.5 mL dose delivered 300 mcg of testosterone daily. The cream was applied to the vaginal opening once daily for four weeks (28 days).', ' Overall Number of Participants Analyzed: 12', ' Mean (Standard Deviation)', ' Unit of Measure: units on a scale 18.783 (7.050)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 0/13 (0.00%)', 'Adverse Events 2:', ' ']}

{'Clinical Trial ID': 'NCT00513292', 'Intervention': ['INTERVENTION 1: ', ' FEC-75 Then Paclitaxel/Trastuzumab', ' Patients receive Fluorouracil, epirubicin, and cyclophosphamide (FEC) comprising fluorouracil IV, epirubicin hydrochloride IV, and cyclophosphamide IV on day 1. Treatment repeats every 21 days for 4 courses. Beginning 21 days after completion of FEC, patients receive paclitaxel IV once weekly and trastuzumab (Herceptin) IV once weekly for 12 weeks. Within 6 weeks after completion of paclitaxel and trastuzumab, patients undergo surgery. Beginning 3-4 weeks after surgery, patients receive trastuzumab IV once every 3 weeks for up to 52 weeks. epirubicin hydrochloride: Given IV, cyclophosphamide: Given IV, paclitaxel: Given IV, trastuzumab: Given IV, therapeutic conventional surgery: Undergo surgery, laboratory biomarker analysis: Correlative studies', 'INTERVENTION 2: ', ' Paclitaxel/Trastuzumab Then Trastuzumab/FEC-75', ' Patients receive paclitaxel IV once weekly and trastuzumab IV once weekly for 12 weeks. Beginning 7 days after the completion of paclitaxel and trastuzumab, patients receive FEC comprising fluorouracil IV, epirubicin IV, and cyclophosphamide IV on day 1. Treatment repeats every 21 days for 4 courses. Patients also receive trastuzumab IV once weekly for an additional 12 weeks. Within 6 weeks after completion of FEC and trastuzumab, patients undergo surgery. Beginning 3-4 weeks after surgery, patients receive trastuzumab as in arm I. epirubicin hydrochloride: Given IV, cyclophosphamide: Given IV, paclitaxel: Given IV, trastuzumab: Given IV, therapeutic conventional surgery: Undergo surgery, laboratory biomarker analysis: Correlative studies'], 'Eligibility': ['Inclusion Criteria:', ' Diagnosis of invasive adenocarcinoma by core needle biopsy', ' Fine needle aspiration allowed provided primary tumor size < 2 cm and lymph node metastases are present', ' Excisional biopsy of the primary tumor allowed provided biopsy-positive lymph nodes are present', ' Primary tumor 2 cm and/or 1 biopsy-positive lymph node', ' HER2-positive disease', ' Confirmation by fluorescent in situ hybridization (FISH) requires gene amplification', ' Confirmation by immunohistochemistry (IHC) requires a strongly positive (3+) staining intensity score', ' Ductal carcinoma in situ (DCIS) or synchronous DCIS of the contralateral breast regardless of prior therapy allowed', ' Synchronous invasive breast cancer not allowed', ' Ipsilateral DCIS treated by local excision with or without hormonal therapy allowed', ' Those treated with radiation therapy are not allowed', ' No definitive clinical or radiologic evidence of metastatic disease', ' No history of invasive breast cancer', ' Hormone receptor status known', ' Menopausal status not specified', ' ECOG performance status of 0 -1', ' Absolute neutrophil count 1,200/mm³', ' Platelet count 100,000/mm³', ' Total bilirubin normal unless the patient has a grade 1 bilirubin elevation (normal to 1.5 times upper limit of normal [ULN]) resulting from Gilbert disease or similar syndrome due to slow conjugation of bilirubin', ' Alkaline phosphatase 2.5 times ULN', ' AST 1.5 times ULN', ' Creatinine normal', ' Left ventricular ejection fraction (LVEF) 55 by multi gated acquisition scan (MUGA) or echocardiogram (ECHO) within the past 3 months', ' Patients with either skeletal pain or alkaline phosphatase that is > ULN but 2.5 times ULN allowed if bone scans fail to demonstrate metastatic disease', ' Suspicious findings on bone scan must be confirmed as benign by x-ray, MRI, or biopsy', ' Prior non-breast malignancies allowed if disease-free for 5 years since completion of initial treatment regimen and deemed by their physician to be at low risk for recurrence', ' Patients who had the following cancers are eligible if diagnosed and treated within the past 5 years:', ' Carcinoma in situ of the cervix', ' Colon carcinoma in situ', ' Melanoma in situ', ' Basal cell and squamous cell carcinoma of the skin', ' No cardiac disease that would preclude the use of epirubicin hydrochloride or trastuzumab (Herceptin®) including any of the following:', ' Active cardiac disease', ' Angina pectoris that requires the use of antianginal medication', ' Cardiac arrhythmia requiring medication', ' Severe conduction abnormality', ' Clinically significant valvular disease', ' Cardiomegaly on chest x-ray', ' Ventricular hypertrophy on EKG', " Patient's with poorly controlled hypertension ( i.e., diastolic greater than 100 mm/Hg)", ' Patients with hypertension that is well controlled on medication are eligible', ' History of cardiac disease', ' Myocardial infarction documented as a clinical diagnosis or by EKG or any other tests', ' Documented congestive heart failure', ' Documented cardiomyopathy', " No sensory or motor neuropathy grade 2, as defined by the NCI's CTCAE v3.0", ' Women of reproductive potential must agree to use an effective non-hormonal method of contraception during therapy', ' Women of child bearing potential must have a negative urine or serum pregnancy test within 2 weeks of registration', ' Not pregnant or nursing', ' No psychiatric or addictive disorders or other conditions that, in the opinion of the investigator, would preclude the patient from meeting the study requirements', ' No non-malignant systemic disease (e.g., cardiovascular, renal, hepatic) that would preclude treatment with either of the treatment regimens', ' No prior surgical axillary staging procedure', ' Prior non-excisional biopsy of an axillary node allowed', ' No prior treatment for this breast cancer', ' Hormonal therapy allowed if had been given for up to a total of 28 days anytime after diagnosis and before study entry', ' Hormonal therapy must stop at or before study entry and be re-started, if indicated, following surgery', ' No prior therapy with anthracyclines or taxanes for any malignancy', ' No other investigational agents within the past 30 days', ' No concurrent sex hormonal therapy (e.g., birth control pills, ovarian hormonal replacement therapy)', ' No concurrent therapy with any hormonal agent such as raloxifene, tamoxifen, or other selective estrogen receptor modulator (SERM), either for osteoporosis or breast cancer prevention'], 'Results': ['Outcome Measurement: ', ' pCR Within the Breast, Defined as no Evidence of Invasive Tumor Remaining in the Breast at Surgery Following Completion of Chemotherapy', ' Pathological complete response (pCR) rates will be based on institutional pathology reports. In the final analysis for publication, rates will be based on blinded central review of these institutional pathology reports. The Chi-squared test will be conducted at the two-sided 0.05 level. A 95% confidence interval will be computed for the difference in pCR rates.', ' Time frame: Up to 5 years', 'Results 1: ', ' Arm/Group Title: FEC-75 Then Paclitaxel/Trastuzumab', ' Arm/Group Description: Patients receive Fluorouracil, epirubicin, and cyclophosphamide (FEC) comprising fluorouracil IV, epirubicin hydrochloride IV, and cyclophosphamide IV on day 1. Treatment repeats every 21 days for 4 courses. Beginning 21 days after completion of FEC, patients receive paclitaxel IV once weekly and trastuzumab (Herceptin) IV once weekly for 12 weeks. Within 6 weeks after completion of paclitaxel and trastuzumab, patients undergo surgery. Beginning 3-4 weeks after surgery, patients receive trastuzumab IV once every 3 weeks for up to 52 weeks. epirubicin hydrochloride: Given IV, cyclophosphamide: Given IV, paclitaxel: Given IV, trastuzumab: Given IV, therapeutic conventional surgery: Undergo surgery, laboratory biomarker analysis: Correlative studies', ' Overall Number of Participants Analyzed: 138', ' Measure Type: Number', ' Unit of Measure: percentage of participants 56.5 (47.8 to 64.9)', 'Results 2: ', ' Arm/Group Title: Paclitaxel/Trastuzumab Then Trastuzumab/FEC-75', ' Arm/Group Description: Patients receive paclitaxel IV once weekly and trastuzumab IV once weekly for 12 weeks. Beginning 7 days after the completion of paclitaxel and trastuzumab, patients receive FEC comprising fluorouracil IV, epirubicin IV, and cyclophosphamide IV on day 1. Treatment repeats every 21 days for 4 courses. Patients also receive trastuzumab IV once weekly for an additional 12 weeks. Within 6 weeks after completion of FEC and trastuzumab, patients undergo surgery. Beginning 3-4 weeks after surgery, patients receive trastuzumab as in arm I. epirubicin hydrochloride: Given IV, cyclophosphamide: Given IV, paclitaxel: Given IV, trastuzumab: Given IV, therapeutic conventional surgery: Undergo surgery, laboratory biomarker analysis: Correlative studies', ' Overall Number of Participants Analyzed: 142', ' Measure Type: Number', ' Unit of Measure: percentage of participants 54.2 (45.7 to 62.6)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 19/138 (13.77%)', ' Blood disorder 1/138 (0.72%)', ' Febrile neutropenia 1/138 (0.72%)', ' Hemoglobin decreased 8/138 (5.80%)', ' Hemolysis 0/138 (0.00%)', ' Atrial fibrillation 0/138 (0.00%)', ' Left ventricular failure 3/138 (2.17%)', ' Myocardial ischemia 0/138 (0.00%)', ' Sinus tachycardia 1/138 (0.72%)', ' Supraventricular tachycardia 0/138 (0.00%)', ' Extraocular muscle paresis 0/138 (0.00%)', 'Adverse Events 2:', ' Total: 26/142 (18.31%)', ' Blood disorder 1/142 (0.70%)', ' Febrile neutropenia 3/142 (2.11%)', ' Hemoglobin decreased 11/142 (7.75%)', ' Hemolysis 1/142 (0.70%)', ' Atrial fibrillation 1/142 (0.70%)', ' Left ventricular failure 5/142 (3.52%)', ' Myocardial ischemia 1/142 (0.70%)', ' Sinus tachycardia 1/142 (0.70%)', ' Supraventricular tachycardia 1/142 (0.70%)', ' Extraocular muscle paresis 1/142 (0.70%)']}

50ac2c53-3b63-4507-8712-41f8c257b4da

Comparison

Eligibility

NCT02322814

NCT00356148

A patient with Histologically confirmed triple-negative breast cancer, with no known Brain metastases and no prior history of either autoimmune disease or cardiac dysfunction, could be eligible for both the secondary trial and the primary trial.

Entailment

{'Clinical Trial ID': 'NCT02322814', 'Intervention': ['INTERVENTION 1: ', ' Cohort I: Cobimetinib, Paclitaxel', ' Participants received a combination of cobimetinib plus paclitaxel in 28-day cycles until disease progression, unacceptable toxicity, investigator decision, death, withdrawal of consent, or completion of study.', 'INTERVENTION 2: ', ' Cohort I: Placebo, Paclitaxel', ' Participants received a combination of cobimetinib placebo plus paclitaxel in 28-day cycles until disease progression, unacceptable toxicity, investigator decision, death, withdrawal of consent, or completion of study.'], 'Eligibility': ['Inclusion Criteria:', ' Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1', ' Histologically confirmed estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and human epidermal growth factor 2 (HER2)-negative adenocarcinoma of the breast with measurable metastatic or locally advanced disease', ' Locally advanced disease must not be amenable to resection with curative intent', ' Measurable disease, according to RECIST, v1.1', ' Adequate hematologic and end organ function', ' Agreement to use highly effective contraceptive methods as stated in protocol', 'Exclusion Criteria:', ' Disease-Specific Exclusion Criteria', ' Known HER2-, ER-positive, or PR-positive breast cancer by local laboratory assessment', ' Any prior chemotherapy, hormonal, or targeted therapy, for inoperable locally advanced or metastatic triple-negative breast cancer (mTNBC)', ' Any systemic anticancer therapy within 3 weeks prior to Cycle 1, Day 1', ' Any radiation treatment to metastatic site within 28 days of Cycle 1, Day 1', ' Major surgical procedure, open biopsy, or significant traumatic injury within 30 days prior to Cycle 1, Day 1 or anticipation of need for major surgical procedure during the course of the study', ' Prior exposure to experimental treatment targeting rapidly accelerated fibrosarcoma (Raf), MAP kinase/ERK kinase (MEK), or the mitogen-activated protein kinase (MAPK) pathway', ' Brain metastases (symptomatic or nonsymptomatic) that have not been treated previously, are progressive, or require any type of therapy (e.g., radiation, surgery, or steroids) to control symptoms from brain metastases within 30 days prior to first study treatment dose', ' Cobimetinib-Specific Exclusion Criteria', ' History of or evidence of retinal pathology on ophthalmologic examination that is considered a risk factor for neurosensory retinal detachment/central serous chorioretinopathy (CSCR), retinal vein occlusion (RVO), or neovascular macular degeneration', ' Cobimetinib is metabolized by the hepatic cytochrome P3A4 (CYP3A4) enzyme. Drugs CYP3A4/5 inhibitors and inducers should be avoided', ' Atezolizumab-Specific Exclusion Criteria (Cohorts II and III Only)', ' History of severe allergic, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins', ' Known hypersensitivity or allergy to biopharmaceuticals produced in Chinese hamster ovary cells or any component of the atezolizumab formulation', ' History of autoimmune disease', ' Prior allogenic stem cell or solid organ transplantation', ' History of idiopathic pulmonary fibrosis (including pneumonitis), drug induced pneumonitis, organizing pneumonia (i.e., bronchiolitis obliterans, cryptogenic organizing pneumonia), or evidence of active pneumonitis on screening chest computed tomography (CT) scan', ' Positive test for Human Immunodeficiency Virus (HIV)', ' Active hepatitis B (defined as having a positive hepatitis B surface antigen [HBsAg] or positive hepatitis B virus [HBV] deoxyribonucleic acid [DNA] test at screening) or hepatitis C', ' Active tuberculosis', ' Receipt of a live, attenuated vaccine within 4 weeks prior to randomization or anticipation that such a live, attenuated vaccine will be required during the study', ' Prior treatment with cluster of differentiation (CD) 137 (CD137) agonists or immune checkpoint blockade therapies, including anti-cytotoxic T-lymphocyte-associated protein 4 (anti-CTLA-4), anti-programmed death-1 (anti-PD-1), or anti-programmed death ligand-1 (anti-PD-L1) therapeutic antibodies', ' Treatment with systemic immunostimulatory agents (including but not limited to interferons or Interlukin-2 [IL-2]) within 4 weeks or five half-lives of the drug (whichever is shorter) prior to randomization', ' Treatment with systemic corticosteroids or other systemic immunosuppressive medications within 2 weeks prior to randomization, or anticipated requirement for systemic immunosuppressive medications during the trial', ' Cardiac Exclusion Criteria', ' History of clinically significant cardiac dysfunction', ' Corrected QT interval at screening greater than (>) 480 milliseconds (ms) (average of triplicate screening measurements)', ' Left ventricular ejection fraction (LVEF) below the institutional lower limit of normal or below 50 percent (%), whichever is lower', ' General Exclusion Criteria', ' No other history of or ongoing malignancy that would potentially interfere with the interpretation of the pharmacodynamic or efficacy assay', ' Pregnancy (positive serum pregnancy test) or lactation', ' Uncontrolled serious medical or psychiatric illness', ' Active infection requiring IV antibiotics on Cycle 1, Day 1', ' Participants who have a history of hypersensitivity reactions to paclitaxel or other drugs formulated in Cremophor® EL (polyoxyethylated castor oil) or to nab-paclitaxel and any of the excipients'], 'Results': ['Outcome Measurement: ', ' Cohort I: Progression-Free Survival, as Determined by Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1)', ' PFS was defined as the time from randomization to the first occurrence of disease progression or relapse, as determined by the investigator, using RECIST v1.1.', ' Time frame: Randomization up to disease progression or relapse, whichever occurs first (up to approximately 3.5 years)', 'Results 1: ', ' Arm/Group Title: Cohort I: Cobimetinib, Paclitaxel', ' Arm/Group Description: Participants received a combination of cobimetinib plus paclitaxel in 28-day cycles until disease progression, unacceptable toxicity, investigator decision, death, withdrawal of consent, or completion of study.', ' Overall Number of Participants Analyzed: 43', ' Median (95% Confidence Interval)', ' Unit of Measure: Weeks 16.43 (8.14 to 31.14)', 'Results 2: ', ' Arm/Group Title: Cohort I: Placebo, Paclitaxel', ' Arm/Group Description: Participants received a combination of cobimetinib placebo plus paclitaxel in 28-day cycles until disease progression, unacceptable toxicity, investigator decision, death, withdrawal of consent, or completion of study.', ' Overall Number of Participants Analyzed: 47', ' Median (95% Confidence Interval)', ' Unit of Measure: Weeks 23.71 (18.14 to 32.14)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 6/16 (37.50%)', ' Febrile neutropenia * 0/16 (0.00%)', ' Neutropenia * 0/16 (0.00%)', ' Mitral valve incompetence * 1/16 (6.25%)', ' Cardiac failure * 0/16 (0.00%)', ' Cardiac Arrest * 0/16 (0.00%)', ' Papilloedema * 0/16 (0.00%)', ' Diarrhoea * 0/16 (0.00%)', ' Intestinal obstruction * 0/16 (0.00%)', ' Nausea * 0/16 (0.00%)', ' Vomiting * 0/16 (0.00%)', ' Pyrexia * 2/16 (12.50%)', 'Adverse Events 2:', ' Total: 9/43 (20.93%)', ' Febrile neutropenia * 1/43 (2.33%)', ' Neutropenia * 0/43 (0.00%)', ' Mitral valve incompetence * 0/43 (0.00%)', ' Cardiac failure * 1/43 (2.33%)', ' Cardiac Arrest * 0/43 (0.00%)', ' Papilloedema * 0/43 (0.00%)', ' Diarrhoea * 0/43 (0.00%)', ' Intestinal obstruction * 0/43 (0.00%)', ' Nausea * 0/43 (0.00%)', ' Vomiting * 0/43 (0.00%)', ' Pyrexia * 0/43 (0.00%)']}

{'Clinical Trial ID': 'NCT00356148', 'Intervention': ['INTERVENTION 1: ', ' Prophylaxis Group', ' patients who are BMI over 25 and receiving ampicillin/sulbactam prophylaxis', 'INTERVENTION 2: ', ' No Prophylaxis Group', ' Patients who are BMI over 25 and not receive antibiotic prophylaxis'], 'Eligibility': ['Inclusion Criteria:', ' Women at any age with early stage breast cancer (stage I-II) and American Society of Anesthesiologists (ASA) score of I-II.', 'Exclusion Criteria:', ' Ductal carcinoma in situ (DCIS; stage 0 cancer),', ' Advanced or distant metastatic stage,', ' Receiving any neoadjuvant therapy,', ' History of receiving any antibiotics within prior 3 months,', ' History of immunodeficiency,', ' Having a remote infection,', ' History of reaction to study antibiotics,', ' Denial of signing the consent form.'], 'Results': ['Outcome Measurement: ', ' Number of Patients With Body Mass Index (BMI) Over 25 Who Developed Surgical Site Infection (SSI) in Groups Who Received Antibiotic Prophylaxis (Prophylaxis Group) and no Prophylaxis (No Prophylaxis Group).', ' [Not Specified]', ' Time frame: 1 month', 'Results 1: ', ' Arm/Group Title: Prophylaxis Group', ' Arm/Group Description: patients who are BMI over 25 and receiving ampicillin/sulbactam prophylaxis', ' Overall Number of Participants Analyzed: 187', ' Measure Type: Number', ' Unit of Measure: participants 9', 'Results 2: ', ' Arm/Group Title: No Prophylaxis Group', ' Arm/Group Description: Patients who are BMI over 25 and not receive antibiotic prophylaxis', ' Overall Number of Participants Analyzed: 182', ' Measure Type: Number', ' Unit of Measure: participants 25'], 'Adverse Events': ['Adverse Events 1:', ' Total: 0/189 (0.00%)', 'Adverse Events 2:', ' Total: 0/183 (0.00%)']}

14607d45-9aef-458d-89cc-d47c62c23322

Single

Adverse Events

NCT01300351

At least 1 participant in the primary trial showed signs of poor liver function.

Entailment

{'Clinical Trial ID': 'NCT01300351', 'Intervention': ['INTERVENTION 1: ', ' Fulvestrant 500 mg', ' Fulvestrant 500 mg intramuscular (im) every 28 (± 3) days plus an additional 500 mg on Day 15 (± 3) of first month only', 'INTERVENTION 2: ', ' Fulvestrant 250 mg', ' Fulvestrant 250 mg im every 28 (± 3) days'], 'Eligibility': ['Inclusion Criteria:', ' Postmenopausal women defined as a woman who has stopped having menstrual periods', ' Breast Cancer has continued to grow after having received treatment with an anti-estrogen hormonal treatment such as tamoxifen or an aromatase inhibitor', ' Requiring hormonal treatment', ' Oestrogen-receptor positive tumour', ' Written informed consent to participate in the trial', 'Exclusion Criteria:', ' Treatment with an investigational or non-approved drug within one month', ' An existing serious disease, illness, or condition that will prevent participation or compliance with study procedures', ' A history of allergies to any active or inactive ingredients of fulvestrant (i.e. castor oil)', ' Treatment with more than one regimen of chemotherapy for advanced breast cancer', ' Treatment with more than one regimen of hormonal treatment for advanced breast cancer'], 'Results': ['Outcome Measurement: ', ' Progression-free Survival', ' Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study, or unequivocal progression of existing non-target lesions, or the appearance of new lesions, or death (by any cause in the absence of progression). The primary analysis for PFS was the log rank test stratified by last endocrine therapy received prior to fulvestrant (AO vs. AI). The treatment effect was estimated using the HR of 500 mg fulvestrant to 250 mg fulvestrant together with the corresponding 95% CI and p value.', ' Time frame: 36 months', 'Results 1: ', ' Arm/Group Title: Fulvestrant 500 mg', ' Arm/Group Description: Fulvestrant 500 mg intramuscular (im) every 28 ( 3) days plus an additional 500 mg on Day 15 ( 3) of first month only', ' Overall Number of Participants Analyzed: 111', ' Median (Inter-Quartile Range)', ' Unit of Measure: months 8.0 (2.8 to 16.6)', 'Results 2: ', ' Arm/Group Title: Fulvestrant 250 mg', ' Arm/Group Description: Fulvestrant 250 mg im every 28 ( 3) days', ' Overall Number of Participants Analyzed: 110', ' Median (Inter-Quartile Range)', ' Unit of Measure: months 4.0 (2.7 to 11.1)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 4/109 (3.67%)', ' Anaemia * 0/109 (0.00%)', ' Haemolytic uraemic syndrome * 0/109 (0.00%)', ' Leukopenia * 0/109 (0.00%)', ' Cardiac failure * 0/109 (0.00%)', ' Pyrexia * 1/109 (0.92%)', ' Hepatic function abnormal * 1/109 (0.92%)', ' Arthritis bacterial * 0/109 (0.00%)', ' Lung infection * 0/109 (0.00%)', ' Haemoglobin decreased * 1/109 (0.92%)', ' Neutrophil count decreased * 0/109 (0.00%)', 'Adverse Events 2:', ' Total: 9/110 (8.18%)', ' Anaemia * 1/110 (0.91%)', ' Haemolytic uraemic syndrome * 0/110 (0.00%)', ' Leukopenia * 0/110 (0.00%)', ' Cardiac failure * 1/110 (0.91%)', ' Pyrexia * 2/110 (1.82%)', ' Hepatic function abnormal * 0/110 (0.00%)', ' Arthritis bacterial * 2/110 (1.82%)', ' Lung infection * 0/110 (0.00%)', ' Haemoglobin decreased * 1/110 (0.91%)', ' Neutrophil count decreased * 0/110 (0.00%)']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

d2961e96-bd3b-4994-aa7e-2b310eb6204e

Single

Intervention

NCT03106077

Patients in the primary trial receive at most 200mg of IMGN853 by IV every 3 weeks.

Contradiction

{'Clinical Trial ID': 'NCT03106077', 'Intervention': ['INTERVENTION 1: ', ' Cohort A: Advanced Triple-Negative Breast Cancer (TNBC)', ' 6 mg/kg IMGN853 IV Q3W'], 'Eligibility': ['Inclusion Criteria:', ' Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1', ' Confirmed invasive triple-negative breast cancer defined as estrogen receptor (ER) < 10%; progesterone receptor (PR) < 10% by immunohistochemistry (IHC) and HER2 0-1+ by IHC or 2+, fluorescence in situ hybridization (FISH) < 2, gene copy number < 4', ' (For Cohort A) - Archived tissue available at pre-screening to confirm FR alpha+ breast cancer', ' (For Cohort A) Archived tissue available pre-screening to confirm FR alpha+ breast cancer. (For Cohort B) Confirmed FRalpha+ breast cancer defined as low FRalpha expression: >= 25% of cells having >= 1+ expression', ' (For Cohort A) Measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST). (For cohort B) Clinical or radiologic primary tumor size of at least 1.5 cm prior to enrollment onto protocol 2014-0185 (ARTEMIS). Primary tumor of at least 1.0 cm or evidence of continued lymph node involvement by imaging (ultrasound or magnetic resonance imaging [MRI]) after adriamycin-based neoadjuvant therapy', ' (For cohort B): Primary tumor sample collected before NACT started (on ARTEMIS) and underwent molecular testing for integral biomarkers including immunohistochemical assessment of FRalpha', ' (For cohort A): No limit on prior therapies for metastatic disease. (Relapse of disease within 6 months of adjuvant or neoadjuvant chemotherapy is considered 1 line of therapy for metastatic disease). (For cohort B): received at least one dose of an anthracycline-based NACT. Patients are eligible if therapy was discontinued due to disease progression or therapy intolerance. Patients with disease progression on anthracycline-based therapy should be evaluated by the surgical team. If the patient is deemed inoperable at the time of evaluation, the patient may continue to undergo protocol therapy with a goal of reduction in tumor size to become operable. If the patient is deemed at high risk of becoming inoperable by the surgical team based upon tumor size or location, the patient will be considered ineligible for study and will be recommended to go to surgery', ' (For cohort B): Primary tumor size of at least 1.0 cm by imaging (ultrasound or MRI) or evidence of continued lymph node involvement by imaging (ultrasound or MRI) after adriamycin-based neoadjuvant therapy', ' (For cohort B): Baseline multigated acquisition (MUGA) or echocardiogram showing left ventricular ejection fraction (LVEF) >= 50% within 6 weeks prior to initiation of NACT', ' (For both cohorts A and B): Absolute neutrophil count (ANC) >= 1.5 x 10^9/L', ' (For both cohorts A and B): Platelets >= 100 x 10^9/L', ' (For both cohorts A and B): Hemoglobin (Hb) > 9 G/dL', ' (For both cohorts A and B): Total serum bilirubin =< 2.0 mg/dL', ' (For both cohorts A and B): Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x upper limit of normal (ULN) (=< 5 x ULN in patients with liver metastases)', ' (For both cohorts A and B): International normalized ratio (INR) =< 2', ' (For both cohorts A and B): Serum creatinine =< 1.5 x ULN', ' (For both cohorts A and B): Serum albumin > 2', ' Signed informed consent obtained prior to any screening procedures', ' (For cohort A only): Time from prior therapy: a. Systemic anti-neoplastic therapy: five half-lives or four weeks, whichever is shorter. Hormonal therapy is not considered anti-neoplastic therapy. b. Radiotherapy: wide-field radiotherapy (e.g. > 30% of marrow-bearing bones) completed at least four weeks, or focal radiation completed at least two weeks, prior to starting study treatment', ' (For cohort B only): Patients must have at least 3 and no more than 5 weeks between anthracycline-based therapy and start of treatment with mirvetuximab soravtansine', ' (For both cohorts A and B): Patients must have resolution of toxic effect(s) of the most recent prior chemotherapy to grade 1 or less (except alopecia)', ' (For both cohorts A and B): Women of child-hearing potential (WCBP) must have a negative pregnancy test within 3 days prior to the first dose of study treatment', 'Exclusion Criteria:', ' Pregnant or lactating women', ' Patients with a history of non-compliance to medical regimens or who are considered potentially unreliable or will not be able to complete the entire study', ' (For Cohort B only): Presence of metastatic disease or prior radiation therapy of the primary breast carcinoma or axillary lymph nodes', " Women of child-bearing potential (WCBP), defined as all women capable of becoming pregnant, won't use highly effective methods of contraception during the study and 12 weeks after. Highly effective contraception methods include combination of any two of the following:", ' Placement of an intrauterine device (IUD) or intrauterine system (IUS)', ' Barrier methods of contraception: condom or occlusive cap (diaphragm or cervical/vault caps) with spermicidal foam/gel/film/cream/vaginal suppository', ' Total abstinence or', ' Male/female sterilization', ' Women are considered post-menopausal and not of child-bearing potential if they have had 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile, or have had surgical bilateral oophorectomy (with or without hysterectomy) or tubal ligation at least six weeks prior to study entry. In the case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment is she considered not of childbearing potential', ' Male patients whose sexual partner(s) are WCBP who are not willing to use adequate contraception, during the study and for 12 weeks after the end of treatment', ' Patients with > grade 1 peripheral neuropathy', " Active or chronic corneal disorder, including but not limited to the following: Sjogren's syndrome, Fuchs corneal dystrophy (requiring treatment), history of corneal transplantation, active herpetic keratitis, and also active ocular conditions requiring on-going treatment/monitoring such as wet age-related macular degeneration requiring intravitreal injections, active diabetic retinopathy with macular edema, presence of papilledema, and acquired monocular vision", ' Serious concurrent illness or clinically-relevant active infection, including, but not limited to the following:', ' Known active hepatitis B or C', ' Known human immunodeficiency virus (HIV) infection', ' Varicella-zoster virus (shingles)', ' Cytomegalovirus infection', ' Any other known concurrent infectious disease, requiring IV antibiotics within 2 weeks of study enrollment', ' Clinically-significant cardiac disease:', ' Recent myocardial infarction (=< 6 months prior to day 1)', ' Unstable angina pectoris', ' Uncontrolled congestive heart failure (New York Heart Association > class II)', ' Uncontrolled hypertension (>= Common Terminology Criteria for Adverse Events [CTCAE] version [v]4.03 grade 3)', ' Prior history of hypertensive crisis or hypertensive encephalopathy', ' Uncontrolled cardiac arrhythmias', ' Clinically-significant vascular disease (e.g. aortic aneurysm, or dissecting aneurysm)', ' Severe aortic stenosis', ' Clinically significant peripheral vascular disease', ' >= Grade 3 cardiac toxicity following prior chemotherapy', ' Corrected QT interval (QTc) > 470 for females and > 450 for males', ' History of neurological conditions that would confound assessment of treatment-emergent neuropathy', ' History of hemorrhagic or ischemic stroke within the last 6 months', ' History of cirrhotic liver disease', ' Previous clinical diagnosis of non-infectious pneumonitis or non-infectious interstitial lung disease', ' Prior hypersensitivity to monoclonal antibodies', ' Patients who have a history of another primary malignancy, with the exceptions of: non-melanoma skin cancer, and carcinoma in situ of the cervix, uteri, or breast from which the patient has been disease free for >= 3 years', ' Carcinomatous meningitis, untreated central nervous system (CNS) disease or symptomatic CNS metastasis. Patients with previously treated CNS metastasis (excluding carcinomatous meningitis) may participate if they are stable (without evidence of progression by imaging, using identical imaging modality at each assessment, for at least 4 weeks prior to first dose of study treatment), have no evidence of new or emerging CNS metastasis, and are not using steroids for at least 7 days prior to first dose of study treatment', ' History or evidence of thrombotic or hemorrhagic disorders within 6 months before first study treatment', ' Required used of folate-containing supplements (e.g. folate deficiency)'], 'Results': ['Outcome Measurement: ', ' Number of Metastatic Participants With Radiographic Response', ' Determine if Mirvetuximab Soravtansine as a Single Agent is Likely to Induce Response in at Least 20% of Patients With Metastatic Folate Receptor (FR) Alpha+ Triple Negative Breast Cancer (TNBC). Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1) for target lesions and assessed by MRI: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.', ' Time frame: From the registration to the study until disease progression or death from any cause, whichever occurred first, assessed up to 2 years', 'Results 1: ', ' Arm/Group Title: Cohort A: Advanced Triple-Negative Breast Cancer (TNBC)', ' Arm/Group Description: 6 mg/kg IMGN853 IV Q3W', ' Overall Number of Participants Analyzed: 2', ' Measure Type: Count of Participants', ' Unit of Measure: Participants 0 0.0%'], 'Adverse Events': ['Adverse Events 1:', ' Total: 0/2 (0.00%)']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

8a5d7285-f4be-4e50-9057-19f74bcc410b

Single

Adverse Events

NCT00394251

There were 4 different adverse events, for which 0 cases were recorded in cohort 1.

Entailment

{'Clinical Trial ID': 'NCT00394251', 'Intervention': ['INTERVENTION 1: ', ' ABI-007 Subset', ' 260 mg/m2 ABI-007 (Abraxane) plus Bevacizumab for 4 cycles (weeks 9-16); Bevacizumab (weeks 17-46). Weeks 1-8 are excluded from this subset.', 'INTERVENTION 2: ', ' AC --> ABI-007', ' Adriamycin and Cytoxan plus Bevacizumab for four cycles (weeks 1-8); 260 mg/m2 ABI-007 (Abraxane) plus Bevacizumab for 4 cycles (weeks 9-16); Bevacizumab (weeks 17-46).'], 'Eligibility': ['Inclusion Criteria:', ' A patient was eligible for inclusion in this study only if all of the following criteria were met:', ' Female, age greater than or equal to 18 to less than or equal to 70 years old.', ' Estrogen receptor (ER) and progesterone receptor (PR) status have been determined.', ' Operable, histologically confirmed adenocarcinoma of the breast', ' Must have met 1 of the following criteria:', ' T1-3, N1-3, M0, regardless of ER or PR status.', ' T > 2 cm, N0, M0 (T2-3N0M0), regardless of ER or PR status.', ' T > 1 cm, N0, M0 (T1cN0M0) and both ER and PR negative', ' T > 1 cm, N0, M0, ER or PR positive and grade 3', ' Patients with one sentinel lymph node metastasis 0.2-2 mm in size were not required to undergo completion axillary dissection unless only 1 sentinel lymph node was examined. This completion axillary dissection was optional if 1 out of 2 or more sentinel lymph nodes was positive for a micrometastasis. Therefore if 1 of 1 sentinel lymph node was positive for micrometastasis(0.2-2 mm), then a completion axillary dissection was required.', ' Patients with more than one sentinel node micrometastasis or 1 node with a micrometastasis > 2 mm and/or T3 disease must have undergone completion, standard axillary dissection. -Note: the following were not eligible-', " T1b,c,N0M0 and ER or PR positive and grade 1 or 2 Tx tumors (regardless of nodal status) T4 disease [i.e., patients with fixed tumors, peau d'orange skin changes, skin ulcerations, or inflammatory changes", ' Note: Sentinel lymph node micrometastasis < 0.2 mm in considered N0 disease', ' Negative surgical margins on lumpectomy or mastectomy specimen (no ink on invasive cancer and no ink on ductal carcinoma in situ [DCIS]).', ' Eastern Cooperative Oncology Group (ECOG) performance status 0-1', ' Normal electrocardiogram (ECG, as assessed by the investigator).', ' No pre-existing peripheral neuropathy.', ' It had not been longer than 84 days since the date of definitive surgery (eg, mastectomy or in the case of a breast-sparing procedure, axillary dissection).', ' Laboratory values were to be as follows:', ' White blood cell count: > or equal to 3,000/mm^3', ' Absolute neutrophil count:> or equal to 1,500/mm^3', ' Platelets:> or equal to 100,000/mm^3', ' Hemoglobin: > or equal to 8g/dL', " Bilirubin:< or equal to the institution's ULN", ' Creatinine: < or equal to 1.7 mg/dL', ' Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) and alkaline phosphatase could be up to 2.5 times the institutional ULN.', " All staging studies including physical exam, chest x-ray, and bone scan had to show no evidence of metastatic disease, including suspicious lymphadenopathy or skin nodules on physical exam. A chest x-ray and bone scan were mandatory; however, all other staging studies were at the treating physician's discretion. Any other staging test (eg, Computed Tomography [CT] scans, magnetic resonance imaging [MRI] studies, ultrasound of abdomen, Positron Emission Tomography [PET] scans must have been negative for metastatic disease. An abdominal CT scan or PET scan was mandatory for patients with liver function tests elevated above the upper limit of normal (ULN) to rule out metastatic disease. If the patient had a staging PET scan then a bone scan was not necessary, but a chest x-ray was required.", ' Patient had a negative serum pregnancy test < or equal to 14 days of the first dose of study drug (patients of childbearing potential).', ' If fertile, patient had agreed to us an acceptable method of birth control to avoid pregnancy [Note: oral contraceptives were not allowed] for the duration of chemotherapy and hormonal therapy and for 6 months thereafter.', ' If obese, a patient must have been treated with doses calculated using his/her actual body surface area (BSA) (the physician must have been comfortable treating at the full BSA dose regardless of BSA).', ' Patient had signed a Patient Informed Consent Form.', 'Exclusion Criteria:', ' A patient was not eligible for inclusion in this study if any of the following criteria applied:', ' Patients with HER-2 positive breast cancer (IHC 3+ or FISH +) who were eligible for adjuvant Herceptin therapy.', ' Stage IV breast cancer (M1 disease on TNM staging system).', ' Prior anthracycline, anthracenedione (mitoxantrone), or taxane therapy', ' Neoadjuvant therapy for this breast cancer.', ' Previous invasive cancers if treated < 5 years prior to entering this study, except basal or squamous cell carcinoma of the skin or carcinoma in situ of the cervix; the latter were not required to have occurred more than 5 years prior to study entry.', ' Prior invasive breast cancer if diagnosed < 5 years prior to entering study. Patients must have finished adjuvant hormonal therapy prior to registration. Patients with prior DCIS are eligible. Patients with DCIS who were treated with tamoxifen must have finished tamoxifen prior to registration.', ' Serious medical illness, other than that treated by this study, which would limit survival to < 4 years, or psychiatric condition that would prevent informed consent and compliance with study treatment.', ' Uncontrolled or severe cardiovascular disease including recent (< or equal to 12 months) myocardial infarction or unstable angina.', ' Active uncontrolled bacterial, viral (including clinically defined Acquired Immune Deficiency Syndrome [AIDS]), or fungal infection.', ' Patients with active or chronic hepatitis with abnormal liver function tests (LFTs) or patients who were known to be HIV positive.', ' Uncontrolled disease such as uncontrolled diabetes.', ' Any prior history of hypertensive crisis or hypertensive encephalopathy.', ' Any known central nervous system (CNS) disease.', ' Known hypersensitivity to any component of bevacizumab.', ' No history of cerebrovascular accident or transient ischemic attack at any time.', ' Active symptomatic vascular disease, e.g., aortic aneurysm or aortic dissection, and no peripheral vascular disease, e.g., claudication, within six months of study entry.', ' No major surgical procedure, open biopsy, or significant traumatic injury within 28 days and no core biopsy or minor surgical procedure (excluding placement of a vascular access device) within seven days of study entry. No anticipated need for major surgical procedure during the course of study.', ' No history of abdominal fistula, gastrointestinal perforation, or intra- abdominal process within six months of study entry.', ' No serious non-healing wound, ulcer, or bone fracture.', ' No proteinuria at screening as demonstrated by urine protein: urine creatinine (UPC) ratio of > or equal to 1.0 or urine dipstick for proteinuria > or equal to 2+ (patients discovered to have > or equal to 2+ proteinuria on dipstick urinalysis at baseline should have undergone a 24 hour urine collection and must have demonstrated < or equal to 1g of protein in 24 hours to be eligible).', ' Inadequately controlled hypertension (defined as systolic blood pressure > 150 mmHg and /or diastolic blood pressure> 100 mmHg on antihypertensive medications) or New York Heart Association (NYHA) Grade 2 or greater congestive heart failure.', ' History or coagulopathy, bleeding diathesis, therapeutic anticoagulation other than low dose or chronic acetyl salicylic acid (ASA)> or equal to 325 mg. per day. Low dose coumadin for anticoagulation of venous access device or low dose molecular weight heparin (LMWH) for deep vein thrombosis prophylaxis or low dose (325 mg or less) ASA prophylaxis are allowed, but are best avoided if the treating physician feels it is safe to do so.', ' Left Ventricular Ejection Fraction (LVEF) on cardiac echocardiography (ECHO) < 50% (or institutional lower limit of normal [LLN]) and > or equal to 74%. LVEF of greater than 75% at baseline should have been re- reviewed and/or the test repeated as it could be falsely elevated.', ' Patients who were receiving concurrent immunotherapy.', " A history of other malignancy within the last 5 years, which could affect the diagnosis or assessment of breast cancer recurrence or which could shorten a patient's survival.", ' Patient had had an organ allograft.', ' Patient was pregnant or breastfeeding.', ' Patient was unable to comply with requirements of study.', ' Patient was receiving any other investigational drugs.'], 'Results': ['Outcome Measurement: ', ' Participants With Treatment-Emergent Toxicities With a Frequency >=20% at 3 Months Post Chemotherapy', ' Toxicities are summarized using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) terms. Participants with treatment-emergent toxicities with a frequency of >=20% in any treatment arm, and participants with at least one toxicity are reported.', ' Taxane subsets (ABI-007 subset and Taxol subset treatment arms) summarize participants with treatment-emergent toxicities defined as any AEs that begin or worsen in severity grade after the start of taxane treatment (cycle 5, week 9) through 30 days after the last dose of taxane (week 20) and were ongoing 3 months after chemotherapy (month 7).', ' Entire regiments (AC --> ABI-007 and AC --> Taxol treatment arms) summarize participants with treatment-emergent toxicities defined as any AEs that begin or worsen in severity grade after the start of chemotherapy (cycle 1, week 1) through 30 days after the last dose of chemotherapy (week 20) and were ongoing 3 months after chemotherapy (month 7).', ' Time frame: Month 7', 'Results 1: ', ' Arm/Group Title: ABI-007 Subset', ' Arm/Group Description: 260 mg/m2 ABI-007 (Abraxane) plus Bevacizumab for 4 cycles (weeks 9-16); Bevacizumab (weeks 17-46). Weeks 1-8 are excluded from this subset.', ' Overall Number of Participants Analyzed: 74', ' Measure Type: Number', ' Unit of Measure: participants At least 1 AE at 3 Months: 65', ' Neurology: Neuropathy: Sensory: 36', ' Constitutional Symptoms: Fatigue: 16', ' Dermatology/Skin: Hair Loss/Alopecia (Scalp+Body): 2', ' Endocrine: Hot Flashes/Flushes: 12', ' Cardiac General: Hypertension: 4', ' Pain: Arthralgia: 7', ' Hemorrhage/Bleeding: Nasal: 11', ' Pain: Other - Extremity: 4', ' Pain: Myalgia: 10', ' Dermatology/Skin: Nail Changes: 14', ' Constitutional Symptoms: Insomnia: 3', 'Results 2: ', ' Arm/Group Title: AC --> ABI-007', ' Arm/Group Description: Adriamycin and Cytoxan plus Bevacizumab for four cycles (weeks 1-8); 260 mg/m2 ABI-007 (Abraxane) plus Bevacizumab for 4 cycles (weeks 9-16); Bevacizumab (weeks 17-46).', ' Overall Number of Participants Analyzed: 74', ' Measure Type: Number', ' Unit of Measure: participants At least 1 AE at 3 Months: 74', ' Neurology: Neuropathy: Sensory: 50', ' Constitutional Symptoms: Fatigue: 46', ' Dermatology/Skin: Hair Loss/Alopecia (Scalp+Body): 33', ' Endocrine: Hot Flashes/Flushes: 28', ' Cardiac General: Hypertension: 18', ' Pain: Arthralgia: 22', ' Hemorrhage/Bleeding: Nasal: 19', ' Pain: Other - Extremity: 15', ' Pain: Myalgia: 20', ' Dermatology/Skin: Nail Changes: 22', ' Constitutional Symptoms: Insomnia: 16'], 'Adverse Events': ['Adverse Events 1:', ' Total: 30/98 (30.61%)', ' Coagulopathy 1/98 (1.02%)', ' Febrile neutropenia 7/98 (7.14%)', ' Pancytopenia 2/98 (2.04%)', ' Cardiac failure 0/98 (0.00%)', ' Cardiac failure congestive 0/98 (0.00%)', ' Pericardial effusion 0/98 (0.00%)', ' Appendicitis perforated 1/98 (1.02%)', ' Colitis 1/98 (1.02%)', ' Ileus 1/98 (1.02%)', ' Abdominal pain upper 1/98 (1.02%)', ' Gastrointestinal haemorrhage 0/98 (0.00%)', 'Adverse Events 2:', ' Total: 21/99 (21.21%)', ' Coagulopathy 0/99 (0.00%)', ' Febrile neutropenia 5/99 (5.05%)', ' Pancytopenia 0/99 (0.00%)', ' Cardiac failure 1/99 (1.01%)', ' Cardiac failure congestive 4/99 (4.04%)', ' Pericardial effusion 1/99 (1.01%)', ' Appendicitis perforated 0/99 (0.00%)', ' Colitis 0/99 (0.00%)', ' Ileus 0/99 (0.00%)', ' Abdominal pain upper 0/99 (0.00%)', ' Gastrointestinal haemorrhage 1/99 (1.01%)']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

512990dd-45d2-4b31-b571-66735ff02308

Comparison

Adverse Events

NCT00471276

NCT00951665

Gastrointestinal haemorrhage was more common in patients from cohort 2 of the secondary trial. than cohort 1 of the primary trial .

Contradiction

{'Clinical Trial ID': 'NCT00471276', 'Intervention': ['INTERVENTION 1: ', ' Sunitinib', ' Sunitinib 37.5 milligrams (mg) daily by oral capsule in continuous daily dose (CDD) schedule. Dose adjustments, if needed, included a reduction to 25mg daily or escalation to 50mg daily anytime after Week 12.'], 'Eligibility': ['Inclusion Criteria:', ' Histologically or cytologically proven diagnosis of breast cancer', ' Metastatic or locally recurrent disease that is, in the opinion of the investigator, not amenable to resection or radiation therapy', ' Patients with at least one measurable lesion as per RECIST', 'Exclusion Criteria:', ' Inflammatory breast cancer', ' Prior treatment with VEGF inhibitors (unless in adjuvant setting at least 12 months ago)'], 'Results': ['Outcome Measurement: ', ' Number of Participants With Objective Response', ' Number of participants with objective response based assessment of confirmed complete response (CR) or confirmed partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST). CR defined as disappearance of all target lesions. PR defined as a greater than or equal to 30 percent ( 30%) decrease in sum of the longest dimensions of the target lesions taking as a reference the baseline sum longest dimensions.', ' Time frame: Baseline, Week 9, and every 8 weeks up to Month 34', 'Results 1: ', ' Arm/Group Title: Sunitinib', ' Arm/Group Description: Sunitinib 37.5 milligrams (mg) daily by oral capsule in continuous daily dose (CDD) schedule. Dose adjustments, if needed, included a reduction to 25mg daily or escalation to 50mg daily anytime after Week 12.', ' Overall Number of Participants Analyzed: 83', ' Measure Type: Number', ' Unit of Measure: Participants 7'], 'Adverse Events': ['Adverse Events 1:', ' Total: 13/83 (15.66%)', ' Cardiac failure congestive 1/83 (1.20%)', ' Hypothyroidism 1/83 (1.20%)', ' Nausea 2/83 (2.41%)', ' Vomiting 2/83 (2.41%)', ' Diarrhea 1/83 (1.20%)', ' Gastrointestinal Haemorrhage 1/83 (1.20%)', ' Asthenia 1/83 (1.20%)', ' Hyperbilirubinaemia 1/83 (1.20%)', ' Anal abscess 1/83 (1.20%)', ' Dehydration 3/83 (3.61%)', ' Decreased appetite 1/83 (1.20%)']}

{'Clinical Trial ID': 'NCT00951665', 'Intervention': ['INTERVENTION 1: ', ' Phase Ib Regimen 1', ' Participants received T-DM1 Q3W + paclitaxel QW intravenously.', 'INTERVENTION 2: ', ' Phase Ib Regimen 2', ' Participants received T-DM1 Q3W + paclitaxel QW + pertuzumab Q3W intravenously.'], 'Eligibility': ['Inclusion Criteria:', ' Histologically documented HER2-positive locally advanced or metastatic breast cancer', ' Tumor tissue blocks or 15-20 unstained tissue slides for confirmatory central laboratory HER2 status testing and other exploratory assessments', ' Prior trastuzumab in any line of therapy (Phase Ib patients only)', ' No prior T-DM1 or pertuzumab therapy', ' Measurable or evaluable disease', ' Cardiac ejection fraction >=50% by either echocardiogram or multigated acquisition scan', ' Life expectancy >= 90 days as assessed by the investigator', 'Exclusion Criteria:', ' Fewer than 21 days since the last anti-tumor therapy, including chemotherapy, biologic, experimental, immune, hormonal or radiotherapy for the treatment of breast cancer, with the following exceptions: hormone-replacement therapy or oral contraceptives are allowed; palliative radiation therapy involving <=25% of marrow-bearing bone is allowed if completed within >= 14 days prior to first study treatment', ' History of intolerance or hypersensitivity to trastuzumab and/or adverse events related to trastuzumab, murine proteins, or any of the excipients that resulted in trastuzumab being permanently discontinued', ' Peripheral neuropathy of Grade >= 2 per NCI CTCAE, Version 3.0, at the time of, or within 3 weeks prior to, the first study therapy (Phase Ib patients)', ' Peripheral neuropathy of Grade >/=1 per NCI CTCAE, Version 3.0, at the time of, or within 3 weeks prior to, the first study therapy (Phase IIa patients)', ' History of exposure to the following cumulative doses of anthracyclines: Doxorubicin > 500 mg/m^2; Liposomal doxorubicin > 900 mg/m^2; Epirubicin > 720 mg/m^2', ' History of clinically significant cardiac dysfunction', ' Brain metastases that are untreated, or progressive, or have required any type of therapy (including radiation, surgery, or steroids) to control symptoms from brain metastases within 60 days prior to the first study treatment.', ' History of other malignancy within the last 5 years, except for appropriately treated carcinoma in situ of the cervix, basal cell carcinoma, or synchronous or subsequent HER2-positive breast cancer or other malignancy with a similar expected curative outcome'], 'Results': ['Outcome Measurement: ', ' Number of Participants With Any Adverse Events (AEs), Serious Adverse Events (SAEs), AEs of Grades 3/4, and Death', ' An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered to be related to the medicinal product. An SAE is any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or results in a congenital anomaly/birth defect.', ' Time frame: Up to 30 days after the last dose of study treatment or study discontinuation/termination, whichever is later', 'Results 1: ', ' Arm/Group Title: Phase Ib Regimen 1', ' Arm/Group Description: Participants received T-DM1 Q3W + paclitaxel QW intravenously.', ' Overall Number of Participants Analyzed: 26', ' Measure Type: Number', ' Unit of Measure: participants Any AEs: 26', ' Any SAEs: 7', ' Death: 1', ' Any AEs Grade 3: 19', ' Any AEs Grade 4: 0', ' AEs leading to T-DM1 discontinuation: 3', ' AEs leading to paclitaxel discontinuation: 20', ' AEs leading to pertuzumab discontinuation: NA [1]', 'Results 2: ', ' Arm/Group Title: Phase Ib Regimen 2', ' Arm/Group Description: Participants received T-DM1 Q3W + paclitaxel QW + pertuzumab Q3W intravenously.', ' Overall Number of Participants Analyzed: 10', ' Measure Type: Number', ' Unit of Measure: participants Any AEs: 10', ' Any SAEs: 5', ' Death: 0', ' Any AEs Grade 3: 5', ' Any AEs Grade 4: 2', ' AEs leading to T-DM1 discontinuation: 1', ' AEs leading to paclitaxel discontinuation: 7', ' AEs leading to pertuzumab discontinuation: 1'], 'Adverse Events': ['Adverse Events 1:', ' Total: 7/26 (26.92%)', ' Febrile neutropenia 1/26 (3.85%)', ' Neutropenia 0/26 (0.00%)', ' Thrombocytopenia 0/26 (0.00%)', ' Cardiac failure congestive 0/26 (0.00%)', ' Extrasystoles 0/26 (0.00%)', ' Nausea 1/26 (3.85%)', ' Abdominal pain 0/26 (0.00%)', ' Constipation 0/26 (0.00%)', ' Gastrointestinal haemorrhage 0/26 (0.00%)', ' Death - unknown cause 1/26 (3.85%)', ' Thrombosis in device 0/26 (0.00%)', 'Adverse Events 2:', ' Total: 5/10 (50.00%)', ' Febrile neutropenia 0/10 (0.00%)', ' Neutropenia 0/10 (0.00%)', ' Thrombocytopenia 1/10 (10.00%)', ' Cardiac failure congestive 0/10 (0.00%)', ' Extrasystoles 0/10 (0.00%)', ' Nausea 0/10 (0.00%)', ' Abdominal pain 0/10 (0.00%)', ' Constipation 0/10 (0.00%)', ' Gastrointestinal haemorrhage 0/10 (0.00%)', ' Death - unknown cause 0/10 (0.00%)', ' Thrombosis in device 0/10 (0.00%)']}

383db144-4bcd-4ebc-989c-b6ae7d282026

Single

Adverse Events

NCT00951665

Most patients in cohort 1 of the primary trial died of unknown causes.

Contradiction

{'Clinical Trial ID': 'NCT00951665', 'Intervention': ['INTERVENTION 1: ', ' Phase Ib Regimen 1', ' Participants received T-DM1 Q3W + paclitaxel QW intravenously.', 'INTERVENTION 2: ', ' Phase Ib Regimen 2', ' Participants received T-DM1 Q3W + paclitaxel QW + pertuzumab Q3W intravenously.'], 'Eligibility': ['Inclusion Criteria:', ' Histologically documented HER2-positive locally advanced or metastatic breast cancer', ' Tumor tissue blocks or 15-20 unstained tissue slides for confirmatory central laboratory HER2 status testing and other exploratory assessments', ' Prior trastuzumab in any line of therapy (Phase Ib patients only)', ' No prior T-DM1 or pertuzumab therapy', ' Measurable or evaluable disease', ' Cardiac ejection fraction >=50% by either echocardiogram or multigated acquisition scan', ' Life expectancy >= 90 days as assessed by the investigator', 'Exclusion Criteria:', ' Fewer than 21 days since the last anti-tumor therapy, including chemotherapy, biologic, experimental, immune, hormonal or radiotherapy for the treatment of breast cancer, with the following exceptions: hormone-replacement therapy or oral contraceptives are allowed; palliative radiation therapy involving <=25% of marrow-bearing bone is allowed if completed within >= 14 days prior to first study treatment', ' History of intolerance or hypersensitivity to trastuzumab and/or adverse events related to trastuzumab, murine proteins, or any of the excipients that resulted in trastuzumab being permanently discontinued', ' Peripheral neuropathy of Grade >= 2 per NCI CTCAE, Version 3.0, at the time of, or within 3 weeks prior to, the first study therapy (Phase Ib patients)', ' Peripheral neuropathy of Grade >/=1 per NCI CTCAE, Version 3.0, at the time of, or within 3 weeks prior to, the first study therapy (Phase IIa patients)', ' History of exposure to the following cumulative doses of anthracyclines: Doxorubicin > 500 mg/m^2; Liposomal doxorubicin > 900 mg/m^2; Epirubicin > 720 mg/m^2', ' History of clinically significant cardiac dysfunction', ' Brain metastases that are untreated, or progressive, or have required any type of therapy (including radiation, surgery, or steroids) to control symptoms from brain metastases within 60 days prior to the first study treatment.', ' History of other malignancy within the last 5 years, except for appropriately treated carcinoma in situ of the cervix, basal cell carcinoma, or synchronous or subsequent HER2-positive breast cancer or other malignancy with a similar expected curative outcome'], 'Results': ['Outcome Measurement: ', ' Number of Participants With Any Adverse Events (AEs), Serious Adverse Events (SAEs), AEs of Grades 3/4, and Death', ' An AE is defined as any untoward medical occurrence in a participant or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered to be related to the medicinal product. An SAE is any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, or results in a congenital anomaly/birth defect.', ' Time frame: Up to 30 days after the last dose of study treatment or study discontinuation/termination, whichever is later', 'Results 1: ', ' Arm/Group Title: Phase Ib Regimen 1', ' Arm/Group Description: Participants received T-DM1 Q3W + paclitaxel QW intravenously.', ' Overall Number of Participants Analyzed: 26', ' Measure Type: Number', ' Unit of Measure: participants Any AEs: 26', ' Any SAEs: 7', ' Death: 1', ' Any AEs Grade 3: 19', ' Any AEs Grade 4: 0', ' AEs leading to T-DM1 discontinuation: 3', ' AEs leading to paclitaxel discontinuation: 20', ' AEs leading to pertuzumab discontinuation: NA [1]', 'Results 2: ', ' Arm/Group Title: Phase Ib Regimen 2', ' Arm/Group Description: Participants received T-DM1 Q3W + paclitaxel QW + pertuzumab Q3W intravenously.', ' Overall Number of Participants Analyzed: 10', ' Measure Type: Number', ' Unit of Measure: participants Any AEs: 10', ' Any SAEs: 5', ' Death: 0', ' Any AEs Grade 3: 5', ' Any AEs Grade 4: 2', ' AEs leading to T-DM1 discontinuation: 1', ' AEs leading to paclitaxel discontinuation: 7', ' AEs leading to pertuzumab discontinuation: 1'], 'Adverse Events': ['Adverse Events 1:', ' Total: 7/26 (26.92%)', ' Febrile neutropenia 1/26 (3.85%)', ' Neutropenia 0/26 (0.00%)', ' Thrombocytopenia 0/26 (0.00%)', ' Cardiac failure congestive 0/26 (0.00%)', ' Extrasystoles 0/26 (0.00%)', ' Nausea 1/26 (3.85%)', ' Abdominal pain 0/26 (0.00%)', ' Constipation 0/26 (0.00%)', ' Gastrointestinal haemorrhage 0/26 (0.00%)', ' Death - unknown cause 1/26 (3.85%)', ' Thrombosis in device 0/26 (0.00%)', 'Adverse Events 2:', ' Total: 5/10 (50.00%)', ' Febrile neutropenia 0/10 (0.00%)', ' Neutropenia 0/10 (0.00%)', ' Thrombocytopenia 1/10 (10.00%)', ' Cardiac failure congestive 0/10 (0.00%)', ' Extrasystoles 0/10 (0.00%)', ' Nausea 0/10 (0.00%)', ' Abdominal pain 0/10 (0.00%)', ' Constipation 0/10 (0.00%)', ' Gastrointestinal haemorrhage 0/10 (0.00%)', ' Death - unknown cause 0/10 (0.00%)', ' Thrombosis in device 0/10 (0.00%)']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

bfa07fb7-f8cb-4215-9bca-ddee8b3bea73

Single

Eligibility

NCT00328783

Patients with an FEV1 of 80% to 120% are ineligible for the primary trial.

Contradiction

{'Clinical Trial ID': 'NCT00328783', 'Intervention': ['INTERVENTION 1: ', ' Active Breathing Coordinator', ' Patients breathe through the ABC device', ' Active Breathing Coordinator (ABC) : The generated dose distributions from the free-breathing versus ABC plans will be compared to assess the volume of normal tissue, as well as target volume irradiated, utilizing dose-volume histograms.'], 'Eligibility': ['Inclusion Criteria:', ' Requiring adjuvant or post mastectomy radiation therapy with tangential fields or 3-fields', ' Adequate pulmonary function', ' Presence of 5 cc of the heart or liver with the simulation fields', ' Karnofsky Performance Status (KPS) equal to or greater than 70', 'Exclusion Criteria:', ' Pregnant women', ' Patients who have had previous ipsilateral breast or thoracic radiation therapy'], 'Results': ['Outcome Measurement: ', ' Dosimetric Evaluation Magnitude of Reduction in Irradiated Normal Tissues', ' To evaluate the magnitude of reduction in irradiated normal tissues (heart and lung) when using the Active Breathing Coordinator (ABC) in breast patients, as compared to standard, free-breathing.', ' The generated dose distributions from the free-breathing vs. ABC plans will be compared to assess the volume of normal tissue, as well as target volume irradiated, utilizing dose-volume histograms. Specifically, for the heart, the volume receiving 55 and 40 Gy will be evaluated; for the liver the volume receiving 50 and 36 Gy, and for the lung, the volume receiving 20 Gy. For the contralateral breast the volume receiving 20 Gy, 30 Gy and 50 Gy will be evaluated. Patients will be treated with the ABC device if there is at least 5 % relative reduction in the volume of a normal tissue irradiated to prescription dose.', ' Time frame: At time of radiation', 'Results 1: ', ' Arm/Group Title: Active Breathing Coordinator', ' Arm/Group Description: Patients breathe through the ABC device', ' Active Breathing Coordinator (ABC) : The generated dose distributions from the free-breathing versus ABC plans will be compared to assess the volume of normal tissue, as well as target volume irradiated, utilizing dose-volume histograms.', ' Overall Number of Participants Analyzed: 86', ' Mean (95% Confidence Interval)', ' Unit of Measure: Gy Free breathing (heart): 3.0 (2.6 to 3.3)', ' ABC (heart): 1.1 (0.9 to 1.3)', ' Free breathing (lung): 6.0 (5.3 to 6.8)', ' ABC (lung): 5.4 (4.9 to 5.9)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 0/0']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

228e80ab-84d6-4b60-9960-dcdcbd78c03c

Single

Eligibility

NCT00896649

prior hormonal treatment(s) in the metastatic or adjuvant setting is not necessary for patients in the primary trial, neither is Adequate organ function or a particular racial or ethnic background.

Contradiction

{'Clinical Trial ID': 'NCT00896649', 'Intervention': ['INTERVENTION 1: ', ' Single Arm Positron Emission Mammography and Questionnaire', ' questionnaire administration positron emission mammography', ' digital mammography: standard screening mammogram', ' questionnaire administration: Questionnaire regarding patient satisfaction with mammogram experience and with positron emission mammography experience.', ' positron emission mammography: one-time positron emission mammography to compare recall rates with that of standard mammogram'], 'Eligibility': ['Inclusion criteria:', ' DISEASE CHARACTERISTICS:', ' Scheduled to undergo screening mammogram at one of the Boston Medical Center-affiliated primary care clinics and meets 1 of the following criteria:', ' Dense breast tissue', ' At high-risk for breast cancer', ' PATIENT CHARACTERISTICS:', " Has 1 of the following racial or ethnic backgrounds based on the patient's country of birth or the mother and father's country of birth:", ' Hispanic', ' Haitian Creole', ' African American', ' Caucasian', ' PRIOR CONCURRENT THERAPY:', ' None specified', 'Exclusion criteria:', ' No history of breast cancer, palpable breast mass, abnormal nipple discharge, or other focal complaints warranting diagnostic mammogram'], 'Results': ['Outcome Measurement: ', ' Frequency of Breast Imaging Assessment Reporting and Data System (BI-RADS) "0" Call-back in Mammography vs Breast Imaging Assessment Reporting and Data System (BI-RADS) "0" in Positron Emission Mammography', ' Number of participants called back due to Breast Imaging Assessment Reporting and Data System (BI-RADS) "0" Mammogram compared to number of patients with Breast Imaging Assessment Reporting and Data System (BI-RADS) "0" in positron emission mammography', ' Breast Imaging Assessment Reporting and Data System (BI-RADS) Scale:', ' 0 = Inconclusive for malignancy; call-back in mammography', ' = normal', ' = abnormal, with no malignancy', ' = abnormal, likely benign', ' = abnormal, likely malignant', ' = malignant', ' Time frame: immediately at completion of mammogram', 'Results 1: ', ' Arm/Group Title: Single Arm Positron Emission Mammography and Questionnaire', ' Arm/Group Description: questionnaire administration positron emission mammography', ' digital mammography: standard screening mammogram', ' questionnaire administration: Questionnaire regarding patient satisfaction with mammogram experience and with positron emission mammography experience.', ' positron emission mammography: one-time positron emission mammography to compare recall rates with that of standard mammogram', ' Overall Number of Participants Analyzed: 188', ' Measure Type: Number', ' Unit of Measure: participants Number of BI-RAD "0" Mammogram: 28', ' Number of BI-RAD "0" positron emission mammograph: 27'], 'Adverse Events': ['Adverse Events 1:', ' Total: 0/188 (0.00%)']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

b7caad28-5fb2-4eb6-845e-8315cff97318

Single

Eligibility

NCT00005957

T2 N1 M0 adenocarcinoma of the breast are eligible for the primary trial.

Entailment

{'Clinical Trial ID': 'NCT00005957', 'Intervention': ['INTERVENTION 1: ', ' Standard Breast Irradiation', ' radiation therapy: Standard Breast Irradiation - A dose of 5000 cGy in 25 fractions at a rate of 200 cGy per day, 5 days a week for 5 weeks will be prescribed to the standard tangent fields.', 'INTERVENTION 2: ', ' Breast Radiation Plus Regional Radiation', ' regional radiation therapy (to the ipsilateral supraclavicular, axillary and internal mammary nodes)', ' Breast Radiation plus Regional Radiation - A dose of 5000 cGy in 25 fractions at a rate of 200 cGy per day, 5 days a week for 5 weeks will be prescribed to the modified wide tangent fields.'], 'Eligibility': ['DISEASE CHARACTERISTICS:', ' Histologically proven invasive carcinoma of the breast', ' No evidence of T4, N2-3, or M1 disease prior to surgery', ' Node positive or high-risk node negative', ' Prior breast-conserving therapy (BCT) (e.g., lumpectomy, partial mastectomy, or segmental mastectomy) and axillary node dissection or sentinel node biopsy required and must be a candidate for breast radiotherapy after BCT', ' Normally patients should have microscopically clear resection margins and those with positive margins should undergo reexcision', ' Patients with microscopically focally positive margins (defined as no greater than 3 times high power fields) are candidates for breast radiotherapy plus a boost to the lumpectomy site', ' Patients with prior sentinel node dissection eligible if node negative, but still meet high-risk criteria', ' If node positive, then a level I and II axillary dissection must be performed', ' No evidence of residual disease in axilla after dissection', ' Must be treated with currently accepted adjuvant systemic chemotherapy and/or hormonal therapy', ' High risk of regional and systemic recurrence due to one of the following:', ' Pathologically positive axillary lymph nodes', ' Pathologically negative axillary lymph nodes with one of the following:', ' Primary tumor greater than 5 cm', ' Primary tumor greater than 2 cm and less than 10 axillary lymph nodes excised and one of the following:', ' Estrogen receptor negative', ' Skarf-Bloom-Richardson grade 3', ' Lymphovascular invasion', ' Hormone receptor status:', ' Estrogen and progesterone receptor status known', ' PATIENT CHARACTERISTICS:', ' Age:', ' 16 and over', ' Sex:', ' Female', ' Menopausal status:', ' Premenopausal or postmenopausal', 'Performance status:', ' ECOG 0-2', ' Life expectancy:', ' At least 5 years', ' Hematopoietic:', ' Not specified', ' Hepatic:', ' SGOT and/or SGPT no greater than 3 times upper limit of normal (ULN)*', ' Alkaline phosphatase no greater than 3 times ULN* NOTE: * Patients with laboratory values greater than 3 times ULN may still be eligible if no metastatic disease by imaging examinations', ' Renal:', ' No serious nonmalignant renal disease', ' Cardiovascular:', ' No serious nonmalignant cardiovascular disease', ' Pulmonary:', ' No serious nonmalignant pulmonary disease', ' Other:', ' Not pregnant or nursing', ' Fertile patients must use effective contraception', ' No other serious nonmalignant disease (e.g., systemic lupus erythematosus or scleroderma) that would preclude definitive surgery or radiotherapy', ' No other malignancy except:', ' Nonmelanomatous skin cancer', ' Carcinoma in situ of the cervix or endometrium', ' Contralateral noninvasive breast cancer (unless prior radiotherapy to the contralateral breast)', ' Invasive carcinoma of the cervix, endometrium, colon, thyroid, or melanoma that was curatively treated at least 5 years prior to study participation', ' No psychiatric or addictive disorder that would preclude informed consent or study compliance', ' PRIOR CONCURRENT THERAPY:', ' Biologic therapy:', ' Not specified', ' Chemotherapy:', ' See Disease Characteristics', ' Concurrent standard adjuvant chemotherapy allowed', ' Endocrine therapy:', ' See Disease Characteristics', ' Concurrent standard adjuvant hormonal therapy allowed', ' Radiotherapy:', ' See Disease Characteristics', ' Surgery:', ' See Disease Characteristics'], 'Results': ['Outcome Measurement: ', ' Overall Survival', ' Duration of study', ' Time frame: 10 years', 'Results 1: ', ' Arm/Group Title: Standard Breast Irradiation', ' Arm/Group Description: radiation therapy: Standard Breast Irradiation - A dose of 5000 cGy in 25 fractions at a rate of 200 cGy per day, 5 days a week for 5 weeks will be prescribed to the standard tangent fields.', ' Overall Number of Participants Analyzed: 916', ' Measure Type: Number', ' Unit of Measure: percentage of alive at 10 years 82 (79 to 84)', 'Results 2: ', ' Arm/Group Title: Breast Radiation Plus Regional Radiation', ' Arm/Group Description: regional radiation therapy (to the ipsilateral supraclavicular, axillary and internal mammary nodes)', ' Breast Radiation plus Regional Radiation - A dose of 5000 cGy in 25 fractions at a rate of 200 cGy per day, 5 days a week for 5 weeks will be prescribed to the modified wide tangent fields.', ' Overall Number of Participants Analyzed: 916', ' Measure Type: Number', ' Unit of Measure: percentage of alive at 10 years 83 (80 to 85)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 1/927 (0.11%)', ' Secondary Malignancy 1/927 (0.11%)', 'Adverse Events 2:', ' Total: 3/893 (0.34%)', ' Secondary Malignancy 3/893 (0.34%)']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

73c37b9c-e7ba-4c90-b26e-23b7a65509c4

Single

Eligibility

NCT02287675

Informed consent is obligatory for entry in the primary trial.

Entailment

{'Clinical Trial ID': 'NCT02287675', 'Intervention': ['INTERVENTION 1: ', ' Lymphoseek', ' Lymphoseek (technetium Tc 99m tilmanocept) Injection is indicated for lymphatic mapping with a hand-held gamma counter to assist in the localization of lymph nodes draining a primary tumor site in patients with breast cancer or melanoma and guiding sentinel lymph node biopsy using a hand-held gamma counter in patients with clinically node negative squamous cell carcinoma of the oral cavity.', 'INTERVENTION 2: ', ' Sulfur Colloid', ' Technetium Tc 99m Sulfur Colloid Injection is a radioactive diagnostic agent indicated for use as follows:', ' In adults, to assist in the:', ' localization of lymph nodes draining a primary tumor in patients with', ' breast cancer or malignant melanoma when used with a hand-held gamma counter.', ' evaluation of peritoneovenous (LeVeen) shunt patency in adults.'], 'Eligibility': ['Inclusion Criteria:', ' The subject must be female and 18 years of age or older.', ' The subject must be a preoperative clinical Tis, T1, T2, T3, T4, as well as clinical N0 and clinical M0 breast cancer', ' The subject must have a diagnosis of primary breast cancer.', ' The subject must be a candidate for surgical intervention, either with lumpectomy and SLNB or with mastectomy and SLNB, as the treatment of her breast cancer.', ' The subject must have an Eastern Cooperative Oncology Group (ECOG) performance status of Grade 0 - 2', ' The subject must provide written informed consent with Health Insurance Portability and Accountability Act (HIPAA) authorization before participating in the study', 'Exclusion Criteria:', ' The subject has clinical or radiological or pathologic evidence of metastatic cancer, including any abnormal or enlarged clinical palpable lymph nodes or core biopsy/surgical biopsy/fine-needle-aspiration evidence of malignant cell within any lymph nodes.', ' The subject has a known hypersensitivity to vital blue dye (VBD) in a case where vital blue dye was planned for use during SLNB.', ' The subject has a positive pregnancy test or is lactating.', ' The subject has had prior surgery to the indicated breast or axilla.'], 'Results': ['Outcome Measurement: ', ' Injection Site Clearance for Lymphoseek and 99mTc-Sulfur Colloid (SC).', ' The rate of injection site clearance is the time from radiotracer injection to peak SLN radioactive level. Injection clearance rates will be determined by planar SPECT imaging and by SPECT/CT. Subjects will undergo standard sequential planar imaging at 30 to 60 seconds intervals until the sentinel lymph node is seen. Once a sentinel node is located, a SPECT/CT will be performed for higher resolution imaging in transaxial, coronal, and sagittal planes.', ' Time frame: 2 hours', 'Results 1: ', ' Arm/Group Title: Lymphoseek', ' Arm/Group Description: Lymphoseek (technetium Tc 99m tilmanocept) Injection is indicated for lymphatic mapping with a hand-held gamma counter to assist in the localization of lymph nodes draining a primary tumor site in patients with breast cancer or melanoma and guiding sentinel lymph node biopsy using a hand-held gamma counter in patients with clinically node negative squamous cell carcinoma of the oral cavity.', ' Overall Number of Participants Analyzed: 18', ' Mean (Standard Deviation)', ' Unit of Measure: minutes 1.78 (0.85)', 'Results 2: ', ' Arm/Group Title: Sulfur Colloid', ' Arm/Group Description: Technetium Tc 99m Sulfur Colloid Injection is a radioactive diagnostic agent indicated for use as follows:', ' In adults, to assist in the:', ' localization of lymph nodes draining a primary tumor in patients with', ' breast cancer or malignant melanoma when used with a hand-held gamma counter.', ' evaluation of peritoneovenous (LeVeen) shunt patency in adults.', ' Overall Number of Participants Analyzed: 22', ' Mean (Standard Deviation)', ' Unit of Measure: minutes 0.045 (0.18)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 0/18 (0.00%)', 'Adverse Events 2:', ' Total: ']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

d5b81f6c-821a-4db5-8810-9cc47a952913

Single

Results

NCT01202591

100% of patients in the primary trial suffered adverse events.

Entailment

{'Clinical Trial ID': 'NCT01202591', 'Intervention': ['INTERVENTION 1: ', ' AZD4547 80mg bd Cont + Ex 25mg', ' 80 mg AZD4547 BD continuous + 25 mg exemestane', 'INTERVENTION 2: ', ' AZD4547 40mg Cont + Ex 25mg', ' 40 mg AZD4547 BD continuous + 25 mg exemestane'], 'Eligibility': ['Inclusion Criteria:', ' Post-menopausal women (either through bilateral oophorectomy or amenorrhoeic for 24 months)', ' Histological confirmation of Breast Cancer with documented ER+ receptor status', ' Safety run-in: Relapsing during/within 12 months of completion of a single regimen of adjuvant endocrine therapy with non-steroidal AI and/ tamoxifen or progression following 1st line endocrine therapy with non-steroidal AL', ' Rand phase IIa: Received at least 1 prior endocrine therapy in the metastatic setting or have relapsed during/ within 6 months of completion of adjuvant endocrine therapy (either non-steroidal AI or tamoxifen or a combination of both). Chemotherapy administered in the adjuvant setting is permitted.', ' Rand phase IIa: Mandatory provision of tumour sample to confirm FGFR1 polysomy or gene amplification. At least one measurable lesion that can be accurately assessed by CT/MRI/x-ray at baseline and follow up visits', 'Exclusion Criteria:', ' Prior exposure to exemestane (safety run-in) / fulvestrant (randomized phase IIa), or any agent known to inhibit FGFRs.', ' More than 1 prior regimen of chemotherapy for breast cancer', ' ECG recordings that demonstrate significant abnormalities in cardiac rate, rhythm or conduction', ' History of hypersensitivity to active or inactive excipients of AZD4547 or exemestane (safety run-in ) or fulvestrant (Randomized phase), including castor oil, or drugs with a similar chemical structure or class to AZD4547 or exemestane or fulvestrant.', ' Randomized phase IIa: bleeding/blood clotting conditions that would prevent the administration of the fulvestrant injection into the buttocks'], 'Results': ['Outcome Measurement: ', ' Safety and Tolerability in Terms of Number of Patients With Adverse Events (Serious and Non-serious)', ' [Not Specified]', ' Time frame: 3 years, 10 months (Adverse events recorded from patient screening to discontinuation plus 28 days safety follow-up).', 'Results 1: ', ' Arm/Group Title: AZD4547 80mg bd Cont + Ex 25mg', ' Arm/Group Description: 80 mg AZD4547 BD continuous + 25 mg exemestane', ' Overall Number of Participants Analyzed: 5', ' Measure Type: Number', ' Unit of Measure: Participants 5', 'Results 2: ', ' Arm/Group Title: AZD4547 40mg Cont + Ex 25mg', ' Arm/Group Description: 40 mg AZD4547 BD continuous + 25 mg exemestane', ' Overall Number of Participants Analyzed: 5', ' Measure Type: Number', ' Unit of Measure: Participants 5'], 'Adverse Events': ['Adverse Events 1:', ' Total: 2/5 (40.00%)', ' ANAEMIA 0/5 (0.00%)', ' DIARRHOEA 0/5 (0.00%)', ' OESOPHAGEAL ACHALASIA 0/5 (0.00%)', ' STOMATITIS 0/5 (0.00%)', ' DEVICE DEPOSIT ISSUE 0/5 (0.00%)', ' INFLAMMATION 0/5 (0.00%)', ' GAIT DISTURBANCE 0/5 (0.00%)', ' LOWER RESPIRATORY TRACT INFECTION VIRAL 0/5 (0.00%)', ' NEUTROPENIC SEPSIS 1/5 (20.00%)', ' PLEURAL INFECTION 1/5 (20.00%)', ' PYELONEPHRITIS 0/5 (0.00%)', 'Adverse Events 2:', ' Total: 2/5 (40.00%)', ' ANAEMIA 1/5 (20.00%)', ' DIARRHOEA 0/5 (0.00%)', ' OESOPHAGEAL ACHALASIA 0/5 (0.00%)', ' STOMATITIS 0/5 (0.00%)', ' DEVICE DEPOSIT ISSUE 0/5 (0.00%)', ' INFLAMMATION 0/5 (0.00%)', ' GAIT DISTURBANCE 0/5 (0.00%)', ' LOWER RESPIRATORY TRACT INFECTION VIRAL 0/5 (0.00%)', ' NEUTROPENIC SEPSIS 0/5 (0.00%)', ' PLEURAL INFECTION 0/5 (0.00%)', ' PYELONEPHRITIS 0/5 (0.00%)']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

cdba382e-894b-4f79-a8e2-ff818746adc5

Comparison

Eligibility

NCT00971737

NCT00392392

Patients with tumors overexpressing HER-2 are eligible for the secondary trial, but not for the primary trial.

Contradiction

{'Clinical Trial ID': 'NCT00971737', 'Intervention': ['INTERVENTION 1: ', ' Cyclophosphamide and Vaccine Only', ' Patients receive cyclophosphamide IV over 30 minutes on day -1 and allogeneic GM-CSF-secreting breast cancer vaccine intradermally on day 0. Courses repeat every 4-6 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Patients then receive a fourth vaccination at 6-8 months.', ' allogeneic GM-CSF-secreting breast cancer vaccine: Given intradermally', ' cyclophosphamide: Given IV', 'INTERVENTION 2: ', ' Cyclophosphamide, Vaccine and Trastuzumab', ' Patients receive cyclophosphamide and the vaccine as in arm I and trastuzumab IV over 30-90 minutes on day -1. Courses repeat every 4-6 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Patients then receive a fourth vaccination at 6-8 months.', ' allogeneic GM-CSF-secreting breast cancer vaccine: Given intradermally', ' trastuzumab: Given IV', ' cyclophosphamide: Given IV'], 'Eligibility': ['DISEASE CHARACTERISTICS:', ' Histologically confirmed adenocarcinoma of the breast', ' Does not overexpress HER-2/neu, defined as FISH negative or 0, 1+, or 2+ by IHC', ' Stage IV disease', ' Must not be eligible for therapy of known curative potential for metastatic breast cancer', ' Measurable or evaluable disease', " Stable CNS disease allowed provided that it's adequately treated and not under active treatment", ' Hormone receptor status not specified', ' PATIENT CHARACTERISTICS:', ' Menopausal status not specified', ' ECOG performance status 0-1', ' ANC > 1,000/mm^3', ' Platelets > 100,000/mm^3', ' Serum bilirubin < 2.0 mg/dL (unless due to Gilbert syndrome)', ' AST and ALT < 2 times upper limit of normal (ULN)', ' Alkaline phosphatase < 5 times ULN', ' Serum creatinine < 2.0 mg/dL', ' Ejection fraction normal by MUGA OR 50% by echocardiogram', ' Not pregnant or nursing', ' Fertile patients must use effective contraception', ' HIV negative', ' Asthma or chronic obstructive pulmonary disease that does not require daily systemic corticosteroids allowed', ' No prior or concurrent autoimmune disease requiring management with systemic immunosuppression, including any of the following:', ' Inflammatory bowel disease', ' Systemic vasculitis', ' Scleroderma', ' Psoriasis', ' Multiple sclerosis', ' Hemolytic anemia or immune-mediated thrombocytopenia', ' Rheumatoid arthritis', ' Systemic lupus erythematosus', ' Sjogren syndrome', ' Sarcoidosis', ' Other rheumatologic disease', ' No other malignancies within the past 5 years, except carcinoma in situ of the cervix, superficial nonmelanoma skin cancer, superficial bladder cancer, or tamoxifen-related endometrial cancer that has been adequately treated', ' No active major medical or psychosocial problems that could be complicated by study participation', ' No symptomatic intrinsic lung disease or extensive tumor involvement of the lungs resulting in dyspnea at rest', ' No uncontrolled medical problems', ' No evidence of active acute or chronic infection', ' No known severe hypersensitivity to trastuzumab, except mild to moderate infusion reactions that are easily managed and do not recur', ' No allergy to corn', ' PRIOR CONCURRENT THERAPY:', ' See Disease Characteristics', ' More than 28 days since prior and no other concurrent chemotherapy, radiation therapy, or biologic therapy (except trastuzumab)', ' Concurrent endocrine therapy and supportive therapy with bisphosphonates allowed', ' More than 28 days since prior and no other concurrent participation in an investigational new drug trial', ' More than 28 days since prior and no other concurrent systemic oral steroids', ' Topical, ocular, and nasal steroids allowed', ' No prior vaccination with the allogeneic GM-CSF-secreting breast tumor vaccine'], 'Results': ['Outcome Measurement: ', ' Toxicity as Assessed by Number of Grade 3 or 4 Adverse Events', ' Number of grade 3 or 4 nonhematologic toxicity (except alopecia), or any grade 4 hematologic toxicity as defined by NCI CTCAE v3.0', ' Time frame: 3 years', 'Results 1: ', ' Arm/Group Title: Cyclophosphamide and Vaccine Only', ' Arm/Group Description: Patients receive cyclophosphamide IV over 30 minutes on day -1 and allogeneic GM-CSF-secreting breast cancer vaccine intradermally on day 0. Courses repeat every 4-6 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Patients then receive a fourth vaccination at 6-8 months.', ' allogeneic GM-CSF-secreting breast cancer vaccine: Given intradermally', ' cyclophosphamide: Given IV', ' Overall Number of Participants Analyzed: 28', ' Measure Type: Number', ' Unit of Measure: adverse events 0', 'Results 2: ', ' Arm/Group Title: Cyclophosphamide, Vaccine and Trastuzumab', ' Arm/Group Description: Patients receive cyclophosphamide and the vaccine as in arm I and trastuzumab IV over 30-90 minutes on day -1. Courses repeat every 4-6 weeks for 3 courses in the absence of disease progression or unacceptable toxicity. Patients then receive a fourth vaccination at 6-8 months.', ' allogeneic GM-CSF-secreting breast cancer vaccine: Given intradermally', ' trastuzumab: Given IV', ' cyclophosphamide: Given IV', ' Overall Number of Participants Analyzed: 30', ' Measure Type: Number', ' Unit of Measure: adverse events 2'], 'Adverse Events': ['Adverse Events 1:', ' Total: 0/30 (0.00%)', 'Adverse Events 2:', ' Total: ']}

{'Clinical Trial ID': 'NCT00392392', 'Intervention': ['INTERVENTION 1: ', ' Nab-Paclitaxel/Bevacizumab/Trastuzumab', ' Patients received treatment with nab-paclitaxel (100 mg/m2 IV days 1, 8, 15) and carboplatin (AUC 6 IV day 1) every 28 days for 6 cycles. Trastuzumab (4 mg/kg loading dose, followed by 2 mg/kg) and bevacizumab (5 mg/kg IV) were administered weekly for 23 weeks, beginning concurrently with chemotherapy. Patients then underwent either mastectomy or breast conserving surgery and pathologic treatment responses were assessed. After surgery, trastuzumab 6 mg/kg and bevacizumab 15 mg/kg were administered at 3 week intervals for a total of 52 weeks.'], 'Eligibility': ['Inclusion Criteria:', ' Female patients with histologically confirmed adenocarcinoma of the breast or inflammatory breast cancer', ' Clinical stage T 1-4, N 0-3, M0', ' FISH+ HER2 gene amplified breast cancer', ' 18 years or older', ' Normal cardiac function', ' Performance status 0-2', ' Cannot have received any prior chemotherapy for this disease or cannot have received chemotherapy for any other cancer in the past 5 years.', ' Previous diagnosis of noninvasive breast cancer is OK.', ' Must have adequate bone marrow, renal and liver function.', ' Pregnant or lactating females not allowed.', ' Preexisting peripheral neuropathy must be equal to or less than grade 1', ' Must have archived tumor tissue for tissue testing.', 'Exclusion Criteria:', ' You cannot be in this study if you any of the following:', ' History of cardiac disease, with New York Heart Association Class II or greater with congestive heart failure', ' Any heart attack, stroke or TIAs within the last 6 months or serious arrhythmias needing medication; no bleeding diathesis or coagulopathy.', ' No prior investigational drug within the last 30 days', ' No prior trastuzumab or bevacizumab therapy', ' There are additional inclusion/exclusion criteria. The study center will determine if you meet all of the criteria. If you do not qualify for the trial, study personnel will explain the reasons.'], 'Results': ['Outcome Measurement: ', ' Pathologic Complete Response Rate (PCRR), the Percentage of Patients Who Have No Evidence of Cancer in the Breast or Lymph Nodes Following Surgery', ' Pathologic complete response was defined as the absence of residual invasive cancer in the breast (pT0) and axillary lymph nodes (pN0).', ' Time frame: 18 months', 'Results 1: ', ' Arm/Group Title: Nab-Paclitaxel/Bevacizumab/Trastuzumab', ' Arm/Group Description: Patients received treatment with nab-paclitaxel (100 mg/m2 IV days 1, 8, 15) and carboplatin (AUC 6 IV day 1) every 28 days for 6 cycles. Trastuzumab (4 mg/kg loading dose, followed by 2 mg/kg) and bevacizumab (5 mg/kg IV) were administered weekly for 23 weeks, beginning concurrently with chemotherapy. Patients then underwent either mastectomy or breast conserving surgery and pathologic treatment responses were assessed. After surgery, trastuzumab 6 mg/kg and bevacizumab 15 mg/kg were administered at 3 week intervals for a total of 52 weeks.', ' Overall Number of Participants Analyzed: 27', ' Measure Type: Number', ' Unit of Measure: percentage of participants 56'], 'Adverse Events': ['Adverse Events 1:', ' Total: 8/29 (27.59%)', ' Hemorrhage - Nose 1/29 (3.45%)', ' Left Ventricular Systolic Dysfunction 1/29 (3.45%)', ' Vomiting 1/29 (3.45%)', ' Esophagitis 1/29 (3.45%)', ' Pain - Abdomen 1/29 (3.45%)', ' Pain - Chest 1/29 (3.45%)', ' Infection - Skin 1/29 (3.45%)', ' Infection - Sepsis 2/29 (6.90%)', ' Creatinine 1/29 (3.45%)', ' Wound Complication, Non-Infectious 1/29 (3.45%)']}

0093175a-38cb-4f63-b391-709ac48158b8

Single

Adverse Events

NCT00846027

None of the adverse events recorded for the primary trial occurred more than once.

Entailment

{'Clinical Trial ID': 'NCT00846027', 'Intervention': ['INTERVENTION 1: ', ' Bevacizumab + Paclitaxel + Gemcitabine', ' Participants received bevacizumab 10 mg/kg intravenously (IV), paclitaxel 150 mg/m^2 IV, and gemcitabine 2000 mg/m^2 IV on Day 1 and Day 15 of each 4-week cycle until disease progression, unacceptable toxicity, or withdrawal of consent.'], 'Eligibility': ['Inclusion Criteria:', ' Female patients, 18 years of age.', ' Breast cancer, with measurable, locally recurrent or metastatic lesions, or patients with bone metastasis only.', ' HER-2 negative disease.', ' Candidates for chemotherapy.', ' Eastern Cooperative Oncology Group (ECOG) performance status 2.', 'Exclusion Criteria:', ' Previous chemotherapy for metastatic or locally advanced breast cancer.', ' Previous radiotherapy for treatment of metastatic breast cancer.', ' Any prior adjuvant treatment with anthracyclines completed < 6 months prior to enrollment.', ' Chronic daily treatment with corticosteroids ( 10 mg/day), aspirin (> 325 mg/day) or clopidogrel (> 75mg/day).'], 'Results': ['Outcome Measurement: ', ' Progression-free Survival', ' Progression-free survival was defined as the time from enrollment in the study to the first documented disease progression using Response Evaluation Criteria In Solid Tumors (RECIST) or death from any cause, whichever occurred first.', ' Time frame: Baseline to the end of the study (up to 2 years 10 months)', 'Results 1: ', ' Arm/Group Title: Bevacizumab + Paclitaxel + Gemcitabine', ' Arm/Group Description: Participants received bevacizumab 10 mg/kg intravenously (IV), paclitaxel 150 mg/m^2 IV, and gemcitabine 2000 mg/m^2 IV on Day 1 and Day 15 of each 4-week cycle until disease progression, unacceptable toxicity, or withdrawal of consent.', ' Overall Number of Participants Analyzed: 90', ' Median (95% Confidence Interval)', ' Unit of Measure: Months 11.51 (9.01 to 17.59)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 21/82 (25.61%)', ' Neutrophils count decreased 1/82 (1.22%)', ' Cardiac ischemia/infarction 1/82 (1.22%)', ' Left ventricular systolic dysfunction 1/82 (1.22%)', ' Hypertension 1/82 (1.22%)', ' Supraventricular and nodal arrhythmia 1/82 (1.22%)', ' Anorexia 1/82 (1.22%)', ' Gastrointestinal perforation 1/82 (1.22%)', ' Vomiting 1/82 (1.22%)', ' Dehydration 1/82 (1.22%)', ' Diarrhoea 1/82 (1.22%)']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

19106207-4fa2-4cc4-8e22-6e5330bf05ce

Comparison

Intervention

NCT02597452

NCT01929395

the primary trial and the secondary trial both use 21 day cycles for their interventions up to a maximum of 10 and 4 cycles respectively.

Contradiction

{'Clinical Trial ID': 'NCT02597452', 'Intervention': ['INTERVENTION 1: ', ' Intelligent Breast Exam, iBE', ' Single Arm: Additional breast exam by a FDA approved hand-held intelligent breast exam device and a clinical breast exam during their scheduled breast screening appointment. No return visit required for participation.', ' intelligent Breast Exam, iBE: A bilateral iBE exam will be performed on the entire breast in addition to a clinical breast exam administered by a trained individual. If the patient is selected to participate in the inter-rater reliability portion of the study, the subject will undergo both the iBE and the clinical breast exams twice sequentially performed by two different separately trained individuals during the same visit.'], 'Eligibility': ['Inclusion Criteria:', ' 18 years of age and older', ' Women and men with symptomatic breast lump (either by palpation or imaging) OR', ' Asymptomatic women presenting to the imaging center for a screening mammogram', ' Signed Informed Consent', 'Exclusion Criteria:', ' Patients under 18 years of age', " Patients who previously participated in this study and are returning to the Women's Imaging Center for follow-up diagnostic tests"], 'Results': ['Outcome Measurement: ', ' Compare the Outcomes of the iBE Examinations to Clinical Breast Examinations (CBE)by Estimating the Sensitivity of the Device Using Imaging Results', ' comparing the calculated the sensitivities or the percentage of true positive breast lesions (based on imaging results) of the iBE and CBE', ' Time frame: approximately one month after imaging scan', 'Results 1: ', ' Arm/Group Title: Intelligent Breast Exam, iBE', ' Arm/Group Description: Single Arm: Additional breast exam by a FDA approved hand-held intelligent breast exam device and a clinical breast exam during their scheduled breast screening appointment. No return visit required for participation.', ' intelligent Breast Exam, iBE: A bilateral iBE exam will be performed on the entire breast in addition to a clinical breast exam administered by a trained individual. If the patient is selected to participate in the inter-rater reliability portion of the study, the subject will undergo both the iBE and the clinical breast exams twice sequentially performed by two different separately trained individuals during the same visit.', ' Overall Number of Participants Analyzed: 486', ' Measure Type: Number', ' Unit of Measure: percentage of true positive lesions 34.3'], 'Adverse Events': ['Adverse Events 1:', ' Total: 0/486 (0.00%)']}

{'Clinical Trial ID': 'NCT01929395', 'Intervention': ['INTERVENTION 1: ', ' Phase 1: Addition of Supine MRI to Conventional Imaging', ' Pre-operative supine MRI with intraoperative optical scanning and tracking (group MRI)'], 'Eligibility': ['Inclusion Criteria Phase 1', ' Age greater than/equal to 18 years', ' Histologic diagnosis of palpable invasive breast cancer or ductal carcinoma in situ', ' Patient desire to undergo breast surgery', ' 3. Patients will have provided informed consent to participate, documented by their signature on the study consent form 4. The cancer enhances on breast MRI imaging.', ' Inclusion Criteria Phase 2', ' Age greater than/equal to 18 years', ' Histologic diagnosis of invasive breast cancer or ductal carcinoma in situ', ' The tumor is visible and enhances on prone MRI and is >1 cm in greatest diameter.', ' . Determination by the surgeon that the neoplasm is non-palpable.A patient with a palpable hematoma from core biopsy, but a non-palpable neoplasm, will be eligible for study', ' Patient desire to undergo breast conserving surgery', ' Patients will have provided informed consent to participate, documented by their signature on the study consent form.The process of informed consent will be documented in the medical record and a copy of the signed consent form will be given to the patient.', ' Exclusion Criteria (Phases 1 and 2)', ' Absolute contraindication to MRI, including presence of implanted electrical device (pacemaker or neurostimulator), aneurysm clip or metallic foreign body in or near eyes', ' Severe claustrophobia', ' Contraindication to use of gadolinium based intravenous contrast, including life threatening allergy or compromised renal function (creatinine > 2.0)', ' History of median sternotomy', ' Pregnancy (Patient attestation that they are not pregnant will be acceptable, as per standard, as per standard policy for MRIs at DHMC).', ' Multicentric breast cancer, defined as two or more tumors in different quadrants of the breast. An eligibility worksheet will be completed for each patient prior to enrollment and will be signed and dated by the surgeon investigator'], 'Results': ['Outcome Measurement: ', ' The Mean Distance Between the Image-defined and Palpation-defined Edges of the Tumor.', ' Mean calculated from differences in precise distances from the nipple to the superior, inferior, medial and lateral edges of the tumor as determined from the adjusted MRI images and conventional MRI.', ' Time frame: From baseline MRI to intraoperative measurements: 30 days', 'Results 1: ', ' Arm/Group Title: Phase 1: Addition of Supine MRI to Conventional Imaging', ' Arm/Group Description: Pre-operative supine MRI with intraoperative optical scanning and tracking (group MRI)', ' Overall Number of Participants Analyzed: 18', ' Mean (Full Range)', ' Unit of Measure: mm 7.2 (0 to 19)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 0/18 (0.00%)', ' Hematoma [1]0/18 (0.00%)']}

a015685e-f744-4bb2-a6d3-893f081d6dcc

Single

Intervention

NCT01487954

All patients in the primary trial had to drink 4 cups of water, either Alkaline Water or Distilled, depending on which cohort they are in.

Contradiction

{'Clinical Trial ID': 'NCT01487954', 'Intervention': ['INTERVENTION 1: ', ' Arm I: Alkaline Water', ' Patients undergo external beam radiation therapy QD, 5 days a week for 6 weeks. Patients drink 8 ounces of alkaline water within 30 minutes immediately prior to and after undergoing radiation therapy.', ' alkaline water: Patients drink 8 ounces of alkaline water within 30 minutes immediately prior to and after undergoing radiation therapy.', ' external beam radiation therapy (EBRT): Patients undergo external beam radiation therapy QD, 5 days a week for 6 weeks.', 'INTERVENTION 2: ', ' Arm II: Distilled Water', ' Patients undergo external beam radiation therapy as in arm I. Patients also drink 8 ounces of distilled water within 30 minutes immediately prior to and after undergoing radiation therapy', ' distilled water: Patients also drink 8 ounces of distilled water within 30 minutes immediately prior to and after undergoing radiation therapy.', ' external beam radiation therapy (EBRT): Patients undergo external beam radiation therapy QD, 5 days a week for 6 weeks.'], 'Eligibility': ['Inclusion Criteria:', ' Patients must have histologically or cytologically confirmed stage 0-IV breast cancer and have a treatment plan consisting of 62Gy (31 fractions) of total breast radiation therapy to be eligible; patients are eligible if they have received any number of prior chemotherapies; patients having received chemotherapy prior to radiation will be stratified among randomization groups during the second phase of this study', ' Life expectancy of greater than 3 months', ' Eastern Cooperative Oncology Group (ECOG) performance status =< 2 (Karnofsky >= 60%)', ' Ability to understand and the willingness to sign a written informed consent document', 'Exclusion Criteria:', ' Patients receiving any investigational chemotherapeutic agents during planned radiation or any prior breast or chest wall radiation treatments are excluded', ' Patients receiving concurrent chemotherapy are excluded because of an increased relative risk of skin toxicity; patients taking daily proton-pump inhibitor or H2-blocker antacid medications are excluded because of predicted interference of alkaline water consumption and stomach pH; herceptin for the purposes of this clinical trial would be considered a chemotherapy, and as such, patients receiving herceptin chemotherapy during radiation would not be eligible for participation in this protocol', ' Patients with a history of any prior malignancy except non-melanoma skin cancer or carcinoma in-situ of the cervix not in remission for twelve months are excluded; patients with known brain metastases are excluded from this clinical trial because of their overall poor prognosis', ' Pregnancy excludes female patients from this study because radiation is potentially teratogenic and abortifacient; screening beta-hcg levels and clinically-indicated diagnostic tests will be used to determine eligibility'], 'Results': ['Outcome Measurement: ', ' Acute and Grade 2 or Higher Radiation-related Skin Toxicity as Assessed by Common Terminology Criteria for Adverse Events (CTCAE) Version 3.0', ' Information will include the type, severity, time of onset and resolution of its onset, and its probable association with the study regimen. Frequency tables will be constructed to summarize observed incidents by severity and type of toxicity during weekly radiation treatment and 1 month after radiation treatment. Observed toxicity differences among the treatment arms may be reported in frequency tables.', ' Time frame: at 1 month after treatment', 'Results 1: ', ' Arm/Group Title: Arm I: Alkaline Water', ' Arm/Group Description: Patients undergo external beam radiation therapy QD, 5 days a week for 6 weeks. Patients drink 8 ounces of alkaline water within 30 minutes immediately prior to and after undergoing radiation therapy.', ' alkaline water: Patients drink 8 ounces of alkaline water within 30 minutes immediately prior to and after undergoing radiation therapy.', ' external beam radiation therapy (EBRT): Patients undergo external beam radiation therapy QD, 5 days a week for 6 weeks.', ' Overall Number of Participants Analyzed: 29', ' Measure Type: Number', ' Unit of Measure: percentage of participants 38', 'Results 2: ', ' Arm/Group Title: Arm II: Distilled Water', ' Arm/Group Description: Patients undergo external beam radiation therapy as in arm I. Patients also drink 8 ounces of distilled water within 30 minutes immediately prior to and after undergoing radiation therapy', ' distilled water: Patients also drink 8 ounces of distilled water within 30 minutes immediately prior to and after undergoing radiation therapy.', ' external beam radiation therapy (EBRT): Patients undergo external beam radiation therapy QD, 5 days a week for 6 weeks.', ' Overall Number of Participants Analyzed: 16', ' Measure Type: Number', ' Unit of Measure: percentage of participants 38'], 'Adverse Events': ['Adverse Events 1:', ' Total: 1/29 (3.45%)', ' Skin infection * [1]0/29 (0.00%)', ' Alanine aminotransferase increased * [2]1/29 (3.45%)', ' Aspartate aminotransferase increased * [3]1/29 (3.45%)', ' Chest wall pain * [4]1/29 (3.45%)', 'Adverse Events 2:', ' Total: 1/16 (6.25%)', ' Skin infection * [1]1/16 (6.25%)', ' Alanine aminotransferase increased * [2]0/16 (0.00%)', ' Aspartate aminotransferase increased * [3]0/16 (0.00%)', ' Chest wall pain * [4]0/16 (0.00%)']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

b9578bae-6640-4ef1-ba2c-899b45c602ee

Single

Adverse Events

NCT01416389

Cohort 1 of the primary trial had more cases of urinary infections and lumbar fractures than cohort 2.

Entailment

{'Clinical Trial ID': 'NCT01416389', 'Intervention': ['INTERVENTION 1: ', ' LY2523355 + Pegfilgrastim or Filgrastim', " LY2523355 administered intravenously as a 1-hour infusion on Days 1, 2, and 3 of a 21-day Cycle for 2 Cycles. Dosage determined by calculating participant's body surface area (5 milligrams per meter squared per day [mg/m^2/day]).", ' Pegfilgrastim or filgrastim administered intravenously on Day 4 of 21-day Cycle for 2 Cycles. Dosage is determined by standard of care.', ' If at the end of 2 Cycles the participant was receiving benefit, the participant may have remained on study drug for additional cycles until a criterion for study discontinuation was met.', 'INTERVENTION 2: ', ' Ixabepilone', ' Ixabepilone administered intravenously as a 3-hour infusion on Day 1 of a 21-day Cycle for 2 Cycles.', " Dosage determined by calculating participant's body surface area (40 mg/m^2).", ' If at the end of 2 Cycles the participant was receiving benefit, the participant may have remained on study drug for additional cycles until a criterion for study discontinuation was met.'], 'Eligibility': ['Inclusion Criteria:', ' Have histologic or cytologic diagnosis of metastatic or locally recurrent breast cancer that is not amenable to therapy given with curative intent.', ' Have measurable disease defined by Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 guidelines.', ' Have received 2 or more prior standard cytotoxic chemotherapy regimens for metastatic breast cancer and be, in the opinion of the investigator, an appropriate candidate for experimental therapy. Regimens received in the neoadjuvant or adjuvant setting are not counted as prior regimens.', ' Have received a prior taxane in the neoadjuvant, adjuvant, or metastatic setting.', ' Have recovered from the acute effects of prior chemotherapy, hormonal therapy, and radiation prior to study enrollment.', ' Have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) scale.', ' Have adequate organ function.', 'Exclusion Criteria:', ' Have Common Terminology Criteria for Adverse Events (CTCAE) Grade 2 or greater (moderate or worse) peripheral neuropathy', ' Have a second primary malignancy.', ' Have symptomatic, untreated, or uncontrolled central nervous system metastases.', ' Have received autologous stem cell transplant following high-dose chemotherapy.', ' Have serious preexisting medical conditions that in the opinion of the investigator would preclude participation in this study.', ' Have active symptomatic fungal, bacterial, and/or known viral infection including active human immunodeficiency virus (HIV) or viral hepatitis.', ' Have previously received LY2523355 in another study investigating this agent or therapy with ixabepilone or an ixabepilone-containing regimen.', ' Have a history of radiation therapy involving more than 25 percent of the bone marrow.', ' Have a Fridericia corrected QT (QTcF) interval of >470 milliseconds (msec) on screening electrocardiogram (ECG).', ' Have QRS widening of >120 msec on screening ECG.', ' Cannot change or stop taking a strong Cytochrome P450 3A4 (CYP3A4) inhibitor or CYP3A4 inducer per the ixabepilone label.', ' Have hypersensitivity to drugs formulated with Cremophor® EL per the ixabepilone label.'], 'Results': ['Outcome Measurement: ', ' Change in Tumor Size (CTS) From Baseline to the End of Cycle 2', ' The log ratio of tumor size at Cycle 2 to tumor size at baseline is calculated for each participant, where the tumor size is the sum of the target lesion measurements at each assessment.', ' Time frame: Baseline up to end of Cycle 2 (Day 42)', 'Results 1: ', ' Arm/Group Title: LY2523355 + Pegfilgrastim or Filgrastim', " Arm/Group Description: LY2523355 administered intravenously as a 1-hour infusion on Days 1, 2, and 3 of a 21-day Cycle for 2 Cycles. Dosage determined by calculating participant's body surface area (5 milligrams per meter squared per day [mg/m^2/day]).", ' Pegfilgrastim or filgrastim administered intravenously on Day 4 of 21-day Cycle for 2 Cycles. Dosage is determined by standard of care.', ' If at the end of 2 Cycles the participant was receiving benefit, the participant may have remained on study drug for additional cycles until a criterion for study discontinuation was met.', ' Overall Number of Participants Analyzed: 17', ' Mean (Standard Deviation)', ' Unit of Measure: log ratio of end of Cycle 2 to baseline -0.0 (0.08)', 'Results 2: ', ' Arm/Group Title: Ixabepilone', ' Arm/Group Description: Ixabepilone administered intravenously as a 3-hour infusion on Day 1 of a 21-day Cycle for 2 Cycles.', " Dosage determined by calculating participant's body surface area (40 mg/m^2).", ' If at the end of 2 Cycles the participant was receiving benefit, the participant may have remained on study drug for additional cycles until a criterion for study discontinuation was met.', ' Overall Number of Participants Analyzed: 11', ' Mean (Standard Deviation)', ' Unit of Measure: log ratio of end of Cycle 2 to baseline -0.1 (0.37)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 5/26 (19.23%)', ' Febrile neutropenia 1/26 (3.85%)', ' Abdominal pain 0/26 (0.00%)', ' Constipation 0/26 (0.00%)', ' Nausea 1/26 (3.85%)', ' Pancreatitis 1/26 (3.85%)', ' Vomiting 2/26 (7.69%)', ' Pain 0/26 (0.00%)', ' Pneumonia 0/26 (0.00%)', ' Urinary tract infection 1/26 (3.85%)', ' Lumbar vertebral fracture 1/26 (3.85%)', ' Ammonia increased 1/26 (3.85%)', ' Hepatic encephalopathy 1/26 (3.85%)', 'Adverse Events 2:', ' Total: 4/13 (30.77%)', ' Febrile neutropenia 1/13 (7.69%)', ' Abdominal pain 1/13 (7.69%)', ' Constipation 1/13 (7.69%)', ' Nausea 0/13 (0.00%)', ' Pancreatitis 0/13 (0.00%)', ' Vomiting 0/13 (0.00%)', ' Pain 1/13 (7.69%)', ' Pneumonia 1/13 (7.69%)', ' Urinary tract infection 0/13 (0.00%)', ' Lumbar vertebral fracture 0/13 (0.00%)', ' Ammonia increased 0/13 (0.00%)', ' Hepatic encephalopathy 0/13 (0.00%)']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

405369ef-d216-4d81-a04f-46f36f466a19

Comparison

Adverse Events

NCT00559754

NCT02924883

A higher percent of patients in cohort 1 of the secondary trial experienced stomatitis, than in cohort 1 of the primary trial.

Contradiction

{'Clinical Trial ID': 'NCT00559754', 'Intervention': ['INTERVENTION 1: ', ' Doxorubicin + Cyclophosphamide/Bevacizumab + Docetaxel', ' Participants received doxorubicin 60 mg/m^2 IV followed by cyclophosphamide 600 mg/m^2 IV on Day 1, repeated every 3 weeks for a maximum of 4 cycles. Participants then received bevacizumab 15 mg/kg IV followed by docetaxel 75 mg/m^2 IV on Day 1, repeated every 3 weeks for a maximum of 4 cycles.'], 'Eligibility': ['Inclusion Criteria:', ' female patients, >=18 years of age;', ' primary HER2-negative operable breast cancer;', ' tumor >2cm in size;', ' ECOG performance status 0-1.', 'Exclusion Criteria:', ' previous treatment for breast cancer;', ' metastatic disease;', ' current or recent (within 10 days of first dose of Avastin) use of aspirin (>325mg/day) or full-dose anticoagulants for therapeutic purposes;', ' clinically significant cardiovascular disease.'], 'Results': ['Outcome Measurement: ', ' Percentage of Participants With Pathological Complete Response (pCR)', ' The percentage of participants with pCR was determined by anatomopathological study after completion of 8 cycles of study treatment. The anatomopathological study of the surgical piece was performed and assessed according to the Miller-Payne criteria: 1) the primary tumor was Grade 5 (no malignant cells identified at the location of the primary tumor (ductal carcinoma in situ may be present); 2) no involvement was identified in the lymph nodes; 3) the tumour size at evaluation of the surgical piece was 0 centimeters (cm); and 4) the pathological staging of the tumour from the surgical piece was pT0pN0pM0, the stage is not applicable (NA). It will only be considered pCR in the case of absence of invasive tumour cells in the breast and lymph nodes.', ' Time frame: After Week 24 (surgery)', 'Results 1: ', ' Arm/Group Title: Doxorubicin + Cyclophosphamide/Bevacizumab + Docetaxel', ' Arm/Group Description: Participants received doxorubicin 60 mg/m^2 IV followed by cyclophosphamide 600 mg/m^2 IV on Day 1, repeated every 3 weeks for a maximum of 4 cycles. Participants then received bevacizumab 15 mg/kg IV followed by docetaxel 75 mg/m^2 IV on Day 1, repeated every 3 weeks for a maximum of 4 cycles.', ' Overall Number of Participants Analyzed: 66', ' Measure Type: Number', ' Unit of Measure: percentage of participants 24.2 (14.5 to 36.4)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 13/72 (18.06%)', ' Neutrophils/granulocytes * 24/72 (5.56%)', ' Mucositis/stomatitis * 22/72 (2.78%)', ' Vomiting * 21/72 (1.39%)', ' Febrile neutropaenia * 6/72 (8.33%)', ' Infection with normal absolute neutrophil count (ANC) or grade 1 or 2 neutrophils * 21/72 (1.39%)']}

{'Clinical Trial ID': 'NCT02924883', 'Intervention': ['INTERVENTION 1: ', ' Trastuzumab Emtansine + Placebo', ' Placebo matched to atezolizumab followed by trastuzumab emtansine 3.6 mg/kg IV infusion on Day 1 Cycle 1 and thereafter on Day 1 of each 21-day cycle until disease progression, unmanageable toxicity, or study termination by the sponsor (up to study duration of approximately 40 months)', 'INTERVENTION 2: ', ' Trastuzumab Emtansine + Atezolizumab', ' Atezolizumab 1200 milligrams (mg) intravenous (IV) infusion followed by trastuzumab emtansine 3.6 milligrams per kilogram (mg/kg) IV infusion on Day 1 Cycle 1 and thereafter on Day 1 of each 21-day cycle until disease progression, unmanageable toxicity, or study termination by the Sponsor (up to study duration of approximately 40 months)'], 'Eligibility': ['Inclusion Criteria:', ' Archival tumor samples must be obtained from primary and/or metastatic sites', ' Able to submit tumor tissue that is evaluable for programmed death- ligand 1 (PD-L1) expression', ' HER-2 positive BC as defined by an immunohistochemistry score of 3 or gene amplified by in-situ hybridization as defined by a ratio of greater than or equal to (>=) 2.0 for the number of HER2 gene copies to the number of chromosome 17 copies', ' Histologically or cytologically confirmed invasive BC: incurable, unresectable, locally advanced BC previously treated with multimodality therapy or metastatic BC', ' Prior treatment for BC in the: adjuvant; unresectable locally advanced; or metastatic settings; which must include both, a taxane and trastuzumab (alone or in combination with another agent)', ' Progression must have occurred during or after most recent treatment for locally advanced/metastatic BC or within 6 months after completing adjuvant therapy', ' Participants must have measurable disease that is evaluable as per RECIST v1.1', ' Eastern Cooperative Oncology Group Performance Status of 0 or 1', ' Negative serum pregnancy test within 7 days of enrollment for pre-menopausal women and for women less than 12 months after the onset of menopause', ' Use of highly effective method of contraception as defined by the protocol', 'Exclusion Criteria:', ' Prior treatment with trastuzumab emtansine, cluster of differentiation 137 agonists, anti-programmed death-1, or anti-PD-L1 therapeutic antibody or pathway-targeting agents', ' Receipt of any anti-cancer drug/biologic or investigational treatment within 21 days prior to Cycle 1 Day 1 except hormone therapy, which can be given up to 7 days prior to Cycle 1 Day 1; recovery of treatment related toxicity consistent with other eligibility criteria', ' Radiation therapy within 2 weeks prior to Cycle 1, Day 1', ' History of exposure to the cumulative doses of anthracyclines', ' History of other malignancy within the previous 5 years, except for appropriately treated carcinoma in situ of the cervix, non-melanoma skin carcinoma, Stage I uterine cancer, or participants who have undergone potentially curative therapy with no evidence of disease and are deemed by the treating physician to be at low risk for recurrence', ' Cardiopulmonary dysfunction, symptomatic pleural effusion, pericardial effusion, or ascites', ' Participants with severe infection within 4 weeks prior to randomization, including but not limited to hospitalization for complications of infection, bacteremia, or severe pneumonia', ' Current severe, uncontrolled systemic disease', ' Major surgical procedure or significant traumatic injury within 28 days prior to randomization or anticipation of the need for major surgery during the course of study treatment', ' Clinically significant history of liver disease, including cirrhosis, current alcohol abuse, autoimmune hepatic disorders, sclerosis cholangitis or active infection with human immunodeficiency virus, hepatitis B virus, or hepatitis C virus', ' Need for current chronic corticosteroid therapy (>=10 mg of prednisone per day or an equivalent dose of other anti-inflammatory corticosteroids)', ' Spinal cord compression not definitively treated with surgery and/or radiation, or previously diagnosed and treated spinal cord compression without evidence that disease has been clinically stable for greater than (>) 2 weeks prior to randomization', ' Participants with known central nervous system disease', ' Leptomeningeal disease', ' History of autoimmune disease', ' Prior allogeneic stem cell or solid organ transplantation', ' Active tuberculosis', ' Receipt of a live, attenuated vaccine within 4 weeks prior to randomization or anticipation that such a live, attenuated vaccine will be required during the study', ' Treatment with systemic immunostimulatory agents within 4 weeks or five half-lives of the drug (whichever is shorter) prior to randomization', ' Treatment with systemic corticosteroids or other systemic immunosuppressive medications within 2 weeks prior to randomization, or anticipated requirement for systemic immunosuppressive medications during the trial', ' Participants who are breastfeeding, or intending to become pregnant during the study'], 'Results': ['Outcome Measurement: ', " Progression-Free Survival (PFS) as Determined by Investigator's Tumor Assessment Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 (v1.1)", ' PFS was defined as the time from randomization to the first occurrence of disease progression or death from any cause, whichever occurred first, on the basis of investigator assessments. Progression was defined as at least a 20% increase in the sum of diameters of target lesions with an absolute increase of at least 5 millimeter (mm) or the appearance of one or more new lesions.', ' Time frame: Baseline up to approximately 15 months', 'Results 1: ', ' Arm/Group Title: Trastuzumab Emtansine + Placebo', ' Arm/Group Description: Placebo matched to atezolizumab followed by trastuzumab emtansine 3.6 mg/kg IV infusion on Day 1 Cycle 1 and thereafter on Day 1 of each 21-day cycle until disease progression, unmanageable toxicity, or study termination by the sponsor (up to study duration of approximately 40 months)', ' Overall Number of Participants Analyzed: 69', ' Median (95% Confidence Interval)', ' Unit of Measure: months 6.8 (4.0 to 11.1)', 'Results 2: ', ' Arm/Group Title: Trastuzumab Emtansine + Atezolizumab', ' Arm/Group Description: Atezolizumab 1200 milligrams (mg) intravenous (IV) infusion followed by trastuzumab emtansine 3.6 milligrams per kilogram (mg/kg) IV infusion on Day 1 Cycle 1 and thereafter on Day 1 of each 21-day cycle until disease progression, unmanageable toxicity, or study termination by the Sponsor (up to study duration of approximately 40 months)', ' Overall Number of Participants Analyzed: 133', ' Median (95% Confidence Interval)', ' Unit of Measure: months 8.2 (5.8 to 10.7)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 52/133 (39.10%)', ' Thrombocytopenia 2/133 (1.50%)', ' Anaemia 1/133 (0.75%)', ' Disseminated intravascular coagulation 0/133 (0.00%)', ' Atrial thrombosis 1/133 (0.75%)', ' Cardiac failure 0/133 (0.00%)', ' Vertigo 0/133 (0.00%)', ' Vomiting 3/133 (2.26%)', ' Nausea 1/133 (0.75%)', ' Colitis 1/133 (0.75%)', ' Constipation 1/133 (0.75%)', ' Enteritis 0/133 (0.00%)', ' Abdominal pain 0/133 (0.00%)', 'Adverse Events 2:', ' Total: 16/67 (23.88%)', ' Thrombocytopenia 0/67 (0.00%)', ' Anaemia 0/67 (0.00%)', ' Disseminated intravascular coagulation 1/67 (1.49%)', ' Atrial thrombosis 0/67 (0.00%)', ' Cardiac failure 1/67 (1.49%)', ' Vertigo 1/67 (1.49%)', ' Vomiting 0/67 (0.00%)', ' Nausea 1/67 (1.49%)', ' Colitis 0/67 (0.00%)', ' Constipation 0/67 (0.00%)', ' Enteritis 1/67 (1.49%)', ' Abdominal pain 2/67 (2.99%)']}

e424c65e-7c6f-43a4-95e4-6beb705d9903

Single

Results

NCT01466270

The the primary trial placebo group had a better mean retention than the donepezil hydrochloride PO QD group.

Entailment

{'Clinical Trial ID': 'NCT01466270', 'Intervention': ['INTERVENTION 1: ', ' Arm I', ' Patients receive donepezil hydrochloride PO QD.', ' donepezil hydrochloride: Given PO', 'INTERVENTION 2: ', ' Arm II', ' Patients receive placebo PO QD.', 'Placebo: Given PO'], 'Eligibility': ['INCLUSION CRITERIA:', ' Adults >18 years old.', ' Female with history of invasive breast cancer', ' Must have completed adjuvant chemotherapy between 1 and 5 years prior to registration', ' Received at least 4 cycles of cytotoxic chemotherapy', ' Documentation of prior chemotherapy', ' Patients receiving ongoing hormonal therapy for breast cancer must be on the same hormonal agent for at least 3 months prior to study registration and continue for the duration of the study (9 months)', ' Karnofsky Performance Status must be > 60 or ECOG 0-2.', ' Use of psychotropic medications (anti-depressants, anxiolytics, sleeping aids, narcotics) is permitted. Patient will be asked to list any that have been taken within the last 3 days on the recent medication sheet.', ' Patients must be able to give informed consent to participate in the study, including signing the consent form.', ' Self-reported cognitive disruption (FACT-Cog Version 3 Perceived Cognitive Impairments sub-score of < 63)', ' Negative serum pregnancy test within 10 days prior to registration for women of child-bearing potential.', 'EXCLUSION CRITERIA:', ' Evidence or suspected recurrent or metastatic disease', " History of dementia, Alzheimer's disease, multi-infarct dementia or CVA (history of transient ischemic attack (TIA is allowed)", ' Current use of donepezil, galantamine, rivastigmine, tacrine, memantine, methylphenidate, dextroamphetamine, or any other specific cognition enhancing drugs.are not allowed. For patients who have used these medications they must not have used them within 4 weeks prior to registration.', ' Patients may not currently be taking Ketoconazole or Quinidine', ' Hypersensitivity to donepezil.', ' Use of investigational medications within the last 30 days.', ' Prior brain metastasis', ' Traumatic brain injury, multiple sclerosis or recent myocardial infarction', ' History of schizophrenia, psychosis or substance abuse', ' Untreated current severe depression. (Currently treated depression is permitted if treatment is stable.)', ' Acute severe fatigue, chronic fatigue syndrome or fibromyalgia.', ' History of hepatic or renal dysfunction or disease', ' Pregnant women are excluded from this study. The effects of donepezil on the developing human fetus at the recommended therapeutic dose are unknown. For this reason and because donepezil is known to be teratogenic, women of child-bearing potential must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her study physician immediately.', ' It is unknown whether donepezil is excreted in breast milk, for this reason women who are currently breast-feeding are not eligible for this study.'], 'Results': ['Outcome Measurement: ', ' Retention', ' Retention is the percentage of participants who stay in the study for 24 weeks.', ' Time frame: 24 Weeks', 'Results 1: ', ' Arm/Group Title: Arm I', ' Arm/Group Description: Patients receive donepezil hydrochloride PO QD.', ' donepezil hydrochloride: Given PO', ' Overall Number of Participants Analyzed: 31', ' Mean (Standard Error)', ' Unit of Measure: percentage of participants 71.0 (8.3)', 'Results 2: ', ' Arm/Group Title: Arm II', ' Arm/Group Description: Patients receive placebo PO QD.', ' Placebo: Given PO', ' Overall Number of Participants Analyzed: 31', ' Mean (Standard Error)', ' Unit of Measure: percentage of participants 80.7 (7.2)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 2/28 (7.14%)', ' Insomnia 2/28 (7.14%)', ' Pain: Chest Wall 0/28 (0.00%)', ' Muscle Cramps 0/28 (0.00%)', ' Headache 1/28 (3.57%)', 'Adverse Events 2:', ' Total: 1/30 (3.33%)', ' Insomnia 0/30 (0.00%)', ' Pain: Chest Wall 1/30 (3.33%)', ' Muscle Cramps 1/30 (3.33%)', ' Headache 0/30 (0.00%)']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

f2bd0a9c-74c4-443e-b666-0a0b3aa125e1

Single

Eligibility

NCT00072293

Patients with a nonpalpable breast lesion and 0 palpable axillary lymph nodes are eligible for the primary trial.

Entailment

{'Clinical Trial ID': 'NCT00072293', 'Intervention': ['INTERVENTION 1: ', ' Axillary Dissection', ' Patients undergo surgical resection of the primary tumor with axillary lymph node dissection following sentinel lymph node assessment.', ' Axillary lymph node dissection: Axillary lymph node dissection', 'INTERVENTION 2: ', ' No Axillary Dissection', ' Patients undergo surgical resection of the primary tumor with no axillary lymph node dissection following sentinel lymph node assessment.', ' No axillary lymph node dissection: Therapeutic conventional surgery'], 'Eligibility': ['DISEASE CHARACTERISTICS:', ' Clinical, mammographic, ultrasonographic, or pathologic diagnosis of unicentric and unifocal breast carcinoma', ' Largest tumor lesion 5 cm', ' Palpable or nonpalpable breast lesion', ' Preoperative radioactive occult lesion localization, hook wire, or other method of localization required for nonpalpable lesions', ' Prior (preoperative) or planned (intraoperative) sentinel node biopsy required', ' At least 1 micrometastatic (i.e., no greater than 2 mm) sentinel lymph node with no extracapsular extension', ' No clinical evidence of distant metastases', ' No suspicious manifestation of metastases that cannot be ruled out by x-ray, MRI, or CT scan, including the following:', ' Skeletal pain of unknown cause', ' Elevated alkaline phosphatase', ' Bone scan showing hot spots', ' No palpable axillary lymph node(s)', " No Paget's disease without invasive cancer", ' Hormone receptor status:', ' Estrogen receptor and progesterone receptor known', ' PATIENT CHARACTERISTICS:', ' Age', ' Any age', ' Sex', ' Female', ' Menopausal status', ' Any status', ' Performance status', ' Not specified', ' Life expectancy', ' Not specified', ' Hematopoietic', ' Not specified', ' Hepatic', ' See Disease Characteristics', ' Renal', ' Not specified', ' Other', ' Not pregnant or nursing', ' No other prior or concurrent malignancy except the following:', ' Adequately treated basal cell or squamous cell skin cancer', ' Adequately treated carcinoma in situ of the cervix', ' Adequately treated in situ melanoma', ' Contralateral or ipsilateral carcinoma in situ of the breast', ' No psychiatric, addictive, or other disorder that may compromise ability to give informed consent', ' Geographically accessible for follow-up', ' PRIOR CONCURRENT THERAPY:', ' Biologic therapy', ' Not specified', ' Chemotherapy', ' Not specified', ' Endocrine therapy', ' Not specified', ' Radiotherapy', ' Not specified', ' Surgery', ' See Disease Characteristics', ' Other', ' No prior systemic therapy for breast cancer', ' More than 1 year since prior chemopreventive agent'], 'Results': ['Outcome Measurement: ', ' 5-year Disease-Free Survival', ' Estimated percentage of patients alive and disease-free at 5 years from randomization, where disease-free survival is defined as the time from randomization to first evidence of invasive relapse at any site, second primary tumor (contralateral or non-breast) or death.', ' Time frame: 5-year estimate reported after a median follow-up of 60 months', 'Results 1: ', ' Arm/Group Title: Axillary Dissection', ' Arm/Group Description: Patients undergo surgical resection of the primary tumor with axillary lymph node dissection following sentinel lymph node assessment.', ' Axillary lymph node dissection: Axillary lymph node dissection', ' Overall Number of Participants Analyzed: 464', ' Measure Type: Number', ' Unit of Measure: percentage of participants 84.4', 'Results 2: ', ' Arm/Group Title: No Axillary Dissection', ' Arm/Group Description: Patients undergo surgical resection of the primary tumor with no axillary lymph node dissection following sentinel lymph node assessment.', ' No axillary lymph node dissection: Therapeutic conventional surgery', ' Overall Number of Participants Analyzed: 467', ' Measure Type: Number', ' Unit of Measure: percentage of participants 87.8'], 'Adverse Events': ['Adverse Events 1:', ' Total: 1/447 (0.22%)', ' Post-operative infection (L.axilla) 1/447 (0.22%)', 'Adverse Events 2:', ' Total: 0/453 (0.00%)', ' Post-operative infection (L.axilla) 0/453 (0.00%)']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

0bf293c5-f4fc-40f1-9bd2-8f1f781c7e4a

Comparison

Intervention

NCT01156987

NCT02234479

Participants in the primary trial are assigned an intervention depending on their HIV diagnosis, whereas in the secondary trial the interventions are randomly assigned.

Contradiction

{'Clinical Trial ID': 'NCT01156987', 'Intervention': ['INTERVENTION 1: ', ' Healthy Volunteers', ' Healthy women will be screened for Magnetic Resonance Imaging (MRI) contraindications, and then undergo contrast injection, and SWIFT acquisition.', ' Magnetic resonance imaging: Patients and healthy volunteers will be first screened for MRI contraindications. The SWIFT MRI workflow will be performed as follows:', ' an IV line is placed by nurse,', ' patient is placed in the 4 T MRI scanner at CMRR,', ' initial scout images and manual linear shims are adjusted,', ' Pre-contrast SWIFT T1 weighted images and T1 map are obtained,', ' continuous SWIFT acquisition begins immediately before contrast injection,', ' contrast injection,', ' continuous SWIFT acquisition continues for 12 min after contrast,', ' late enhancement images may also be obtained.', ' 10 and 30 patients will be scanned in the first and second year, respectively. Thresholds will be set for prospective analysis. SWIFT-DCE diagnostic performance will be compared to prior FLASH-DCE methods.', 'INTERVENTION 2: ', ' Breast Cancer Patients', ' Breast cancer patients who have suspected breast lesion that will be biopsied will be screened for Magnetic Resonance Imaging (MRI) contraindications, and then undergo contrast injection and SWIFT acquisition.', ' Magnetic resonance imaging: Patients and healthy volunteers will be first screened for MRI contraindications. The SWIFT MRI workflow will be performed as follows:', ' an IV line is placed by nurse,', ' patient is placed in the 4 T MRI scanner at CMRR,', ' initial scout images and manual linear shims are adjusted,', ' Pre-contrast SWIFT T1 weighted images and T1 map are obtained,', ' continuous SWIFT acquisition begins immediately before contrast injection,', ' contrast injection,', ' continuous SWIFT acquisition continues for 12 min after contrast,', ' late enhancement images may also be obtained.', ' 10 and 30 patients will be scanned in the first and second year, respectively. Thresholds will be set for prospective analysis. SWIFT-DCE diagnostic performance will be compar'], 'Eligibility': ['Inclusion Criteria:', ' Women with a clinically or mammographically identified suspicious breast mass that is likely to be biopsied or surgically removed.', 'Exclusion Criteria:', ' Pregnancy', ' Ferromagnetic implants', ' History of shotgun wounds and shrapnel', ' Obesity (>250 pounds)', ' Cardiac pacemaker', ' Incompatible implanted medical device', ' Severe claustrophobia', ' Major surgeries with potential of ferromagnetic implants', ' Severe asthma and allergies', ' i-STAT system, a handheld blood analyzer (I-STAT) creatinine test, estimated glomerular filtration rate (GFR) <30', ' Metallic object (greater than 2 cm in length) in the breast', ' Metallic ink tatoo within 20 cm of the breast (approximately 8 inches)'], 'Results': ['Outcome Measurement: ', ' Lesions', ' Number of lesions detected', ' Time frame: at time of read by two radiologiests, compared to biopsy within 7 days.', 'Results 1: ', ' Arm/Group Title: Healthy Volunteers', ' Arm/Group Description: Healthy women will be screened for Magnetic Resonance Imaging (MRI) contraindications, and then undergo contrast injection, and SWIFT acquisition.', ' Magnetic resonance imaging: Patients and healthy volunteers will be first screened for MRI contraindications. The SWIFT MRI workflow will be performed as follows:', ' an IV line is placed by nurse,', ' patient is placed in the 4 T MRI scanner at CMRR,', ' initial scout images and manual linear shims are adjusted,', ' Pre-contrast SWIFT T1 weighted images and T1 map are obtained,', ' continuous SWIFT acquisition begins immediately before contrast injection,', ' contrast injection,', ' continuous SWIFT acquisition continues for 12 min after contrast,', ' late enhancement images may also be obtained.', ' 10 and 30 patients will be scanned in the first and second year, respectively. Thresholds will be set for prospective analysis. SWIFT-DCE diagnostic performance will be compared to prior FLASH-DCE methods.', ' Overall Number of Participants Analyzed: 8', ' Measure Type: Number', ' Unit of Measure: lesions 0', 'Results 2: ', ' Arm/Group Title: Breast Cancer Patients', ' Arm/Group Description: Breast cancer patients who have suspected breast lesion that will be biopsied will be screened for Magnetic Resonance Imaging (MRI) contraindications, and then undergo contrast injection and SWIFT acquisition.', ' Magnetic resonance imaging: Patients and healthy volunteers will be first screened for MRI contraindications. The SWIFT MRI workflow will be performed as follows:', ' an IV line is placed by nurse,', ' patient is placed in the 4 T MRI scanner at CMRR,', ' initial scout images and manual linear shims are adjusted,', ' Pre-contrast SWIFT T1 weighted images and T1 map are obtained,', ' continuous SWIFT acquisition begins immediately before contrast injection,', ' contrast injection,', ' continuous SWIFT acquisition continues for 12 min after contrast,', ' late enhancement images may also be obtained.', ' 10 and 30 patients will be scanned in the first and second year, respectively. Thresholds will be set for prospective analysis. SWIFT-DCE diagnostic performance will be compar', ' Overall Number of Participants Analyzed: 23', ' Measure Type: Number', ' Unit of Measure: lesions 12'], 'Adverse Events': ['Adverse Events 1:', ' Total: 0/8 (0.00%)', 'Adverse Events 2:', ' Total: 0/23 (0.00%)']}

{'Clinical Trial ID': 'NCT02234479', 'Intervention': ['INTERVENTION 1: ', ' Hydrophor (Group A)', ' Group A (current standard of care): Patients will be instructed (by nurses and with printed study materials) to apply a thin layer of the Hydrophor daily, starting at the onset of radiation therapy (RT) and continuing until 2 weeks after the final RT session or until the RT site is healed (whichever is first). Hydrophor application should include the entire treatment area, including the axillae and shoulder/back area in patients treated with modified radical mastectomy. To avoid possible build-up effects, patients should not apply the Hydrophor within 4 hours of receiving RT. Patients should wash the application area daily with perfume-free soap and tap water. Patients will be asked to refrain from using other topical agents in the irradiated area.', ' Hydrophor (Group A): Rehydrates dry, chapped or chafed skin', 'May be used alone as a skin lubricant or protectant', 'INTERVENTION 2: ', ' MediHoney (Group B)', ' Group B (study target): Patients will be instructed (by nurses and with printed study materials) to apply a thin layer of the Medihoney daily, starting at the onset of RT and continuing until 2 weeks after the final RT session or until the RT site is healed (whichever is first). Medihoney application should include the entire treatment area, including the axillae and shoulder/back area in patients treated with modified radical mastectomy. To avoid possible build-up effects, patients should not apply the Medihoney within 4 hours of receiving RT. Patients should wash the application area daily with perfume-free soap and tap water. Patients will be asked to refrain from using other topical agents in the irradiated area.', " MediHoney (Group B): It helps the body's natural healing processes in three key ways which have been shown to have healing benefits:", ' Maintain a balanced environment for healing.', ' Aids in reducing dermatitis.', ' Reduce affected area pH.2-3'], 'Eligibility': ['Inclusion Criteria:', ' Breast cancer treated with either lumpectomy or mastectomy (with or without reconstruction).', ' The patient must be female.', ' Radiation therapy planned to whole breast/chestwall area (can include lymph node radiation; conventional 3D radiation, IMRT/IGRT, and hypofractionation are all allowed).', ' Age 18 years old.', 'Exclusion Criteria:', ' Previous radiation therapy to chest area that would result in overlapping radiation fields.', ' Wound care issues.', ' Patients undergoing concurrent cytotoxic chemotherapy and radiation therapy (concurrent Herceptin and/or tamoxifen/aromatase inhibitors and RT is allowed).', ' Patients receiving HDR (savi or mammosite) brachytherapy treatments.', ' Patients with an allergy and/or sensitivity to Hydrophor, honey, and/or Medihoney.', ' Immunocompromised status.', ' Age < 18 years old.'], 'Results': ['Outcome Measurement: ', ' Number of Participants Whom Received Medihoney Treatment and Were Analyzed Weekly for Skin Changes While Undergoing Radiation Therapy', ' The aim of this study is to compare the effects of Medihoney and Hydrophor on radiation dermatitis reactions in a group of women undergoing radiation therapy for breast cancer. It is hoped that the outcome of this pilot study will provide evidence supporting the use of Medihoney in preventing and treating radiation dermatitis as well as sufficient preliminary data to expand this study to larger, federally funded research (R01) looking at the beneficial aspects of Medihoney across a spectrum of radiation dermatitis and mucositis in several disease settings.', ' Time frame: 12 months', 'Results 1: ', ' Arm/Group Title: Hydrophor (Group A)', ' Arm/Group Description: Group A (current standard of care): Patients will be instructed (by nurses and with printed study materials) to apply a thin layer of the Hydrophor daily, starting at the onset of radiation therapy (RT) and continuing until 2 weeks after the final RT session or until the RT site is healed (whichever is first). Hydrophor application should include the entire treatment area, including the axillae and shoulder/back area in patients treated with modified radical mastectomy. To avoid possible build-up effects, patients should not apply the Hydrophor within 4 hours of receiving RT. Patients should wash the application area daily with perfume-free soap and tap water. Patients will be asked to refrain from using other topical agents in the irradiated area.', ' Hydrophor (Group A): Rehydrates dry, chapped or chafed skin', 'May be used alone as a skin lubricant or protectant', ' Overall Number of Participants Analyzed: 16', ' Measure Type: Number', ' Unit of Measure: participants radiation dermatitis: 15', ' hyperpigmentation: 15', 'Results 2: ', ' Arm/Group Title: MediHoney (Group B)', ' Arm/Group Description: Group B (study target): Patients will be instructed (by nurses and with printed study materials) to apply a thin layer of the Medihoney daily, starting at the onset of RT and continuing until 2 weeks after the final RT session or until the RT site is healed (whichever is first). Medihoney application should include the entire treatment area, including the axillae and shoulder/back area in patients treated with modified radical mastectomy. To avoid possible build-up effects, patients should not apply the Medihoney within 4 hours of receiving RT. Patients should wash the application area daily with perfume-free soap and tap water. Patients will be asked to refrain from using other topical agents in the irradiated area.', " MediHoney (Group B): It helps the body's natural healing processes in three key ways which have been shown to have healing benefits:", ' Maintain a balanced environment for healing.', ' Aids in reducing dermatitis.', ' Reduce affected area pH.2-3', ' Overall Number of Participants Analyzed: 18', ' Measure Type: Number', ' Unit of Measure: participants radiation dermatitis: 15', ' hyperpigmentation: 15'], 'Adverse Events': ['Adverse Events 1:', ' Total: 0/16 (0.00%)', 'Adverse Events 2:', ' Total: ']}

6843daf8-8136-4973-9bf2-62a622d5a890

Comparison

Adverse Events

NCT01828021

NCT01326481

Patients in the primary trial and the secondary trial did not have any of the same adverse events.

Entailment

{'Clinical Trial ID': 'NCT01828021', 'Intervention': ['INTERVENTION 1: ', ' Margetuximab', ' Monotherapy of Anti-HER2 monoclonal antibody', ' Margetuximab: Anti-HER2 monoclonal antibody'], 'Eligibility': ['Inclusion Criteria:', ' Histologically or cytologically confirmed invasive carcinoma of the breast', ' Treatment with at least two prior systemic therapies for advanced (unresectable locoregional or metastatic) disease', ' Evidence of HER2 oncoprotein expression at the 2+ level by central laboratory. Patients whose tumors exhibit 2+ staining by IHC are eligible for the study.', ' Patients whose tumors score 1+ by conventional IHC, are non-amplified by FISH testing, and whose tumors score > or = 10.5 by HERmark® testing, are eligible for the study.', ' Evidence of lack of HER2 oncogene amplification as determined by FISH testing by central laboratory', ' Performance Status of 0 or 1', ' Life expectancy at least 6 months', ' Measurable disease (by RECIST 1.1)', ' Acceptable laboratory parameters and organ reserve', ' Baseline left ventricular ejection fraction > or = 50%', ' Anti-cancer therapy (including conventional cytotoxic chemotherapy and/or biological therapy) and radiotherapy must be completed and any associated toxicities resolved to </= Grade 1 levels or baseline levels and at least 2 weeks must have elapsed before enrollment. Treatment with monoclonal antibodies must be completed at least 14 days before entry. Must have completed immunosuppressive medications or vaccinations before enrollment.', ' Patients who are estrogen receptor+ and/or progesterone receptor+ and who are receiving anti-hormone therapy for at least three months may continue to receive such therapy during the course of the trial', ' Eighteen (18) years of age or older', 'Exclusion Criteria:', ' Major surgery or trauma within 4 weeks', ' Known hypersensitivity to murine or recombinant proteins, polysorbate 80, or any excipient contained in the margetuximab drug formulation', ' Second primary malignancy that has not been in remission for more than 3 years', ' History of active viral, bacterial, or systemic fungal infection requiring parenteral treatment within 14 days', ' History within 3 months of deep vein thrombosis, pulmonary embolism, or stroke', ' Symptomatic or untreated central nervous system (CNS) metastatic disease. Patients with previously treated CNS metastatic disease which has been stable for at least 56 days are eligible', ' Requirement, at time of study entry, for concurrent steroids > 10 mg/day of oral prednisone or the equivalent, except steroid inhaler, nasal spray, or ophthalmic solution', ' Serious medical condition that would impair the ability to receive or tolerate margetuximab; dementia or altered mental status that would preclude provision of informed consent', ' Uncontrolled hypertension, heart disease including history of congestive heart failure, history of myocardial infarction, angina pectoris requiring medication, clinically significant valvular heart disease, high risk arrhythmias, or disease corresponding to New York Heart Association class III or IV.', ' Significant pulmonary compromise', ' Have previously been exposed to MGAH22 in this or any other trial'], 'Results': ['Outcome Measurement: ', ' Best Overall Response', ' Response based on Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria based on Cycle 2, Day 21 computed tomography (CT) scans. Response is categorized as complete response (CR): disappearance of all target lesions, confirmed at 4 weeks; partial response (PR): 30% decrease in target lesions from baseline, confirmed at 4 weeks; progressive disease (PD): 20% increase over smallest sum observed with an absolute increase of at least 5 mm, or appearance of new lesions; and stable disease (SD): neither PR or PD criteria met.', ' A Simon two-stage design was planned in which an initial cohort of 21 patients was treated. If 2 or more responses (PR or CR) are seen at the first tumor re-evaluation on day 21 of Cycle 2, the study would be expanded to include up to 41 patients (20 additional patients in Cohort 2, the second stage of the study) in order to determine whether further development of the drug is warranted (5 or more responses in 41 evaluable patients).', ' Time frame: Cycle 2, Day 21', 'Results 1: ', ' Arm/Group Title: Margetuximab', ' Arm/Group Description: Monotherapy of Anti-HER2 monoclonal antibody', ' Margetuximab: Anti-HER2 monoclonal antibody', ' Overall Number of Participants Analyzed: 22', ' Measure Type: Number', ' Unit of Measure: participants Complete Response: 0', ' Partial Response: 0', ' Stable Disease: 6', ' Progressive Disease: 12', 'Not Done: 4'], 'Adverse Events': ['Adverse Events 1:', ' Total: 6/25 (24.00%)', ' Supraventricular extrasystoles 1/25 (4.00%)', ' Ventricular extrasystoles 1/25 (4.00%)', ' Ascites 2/25 (8.00%)', ' Diarrhea 1/25 (4.00%)', ' Nausea 1/25 (4.00%)', ' Pancreatitis 1/25 (4.00%)', ' Small intestinal obstruction 1/25 (4.00%)', ' Vomiting 1/25 (4.00%)', ' Bile duct obstruction 1/25 (4.00%)', ' Portal hypertension 1/25 (4.00%)']}

{'Clinical Trial ID': 'NCT01326481', 'Intervention': ['INTERVENTION 1: ', ' Carotuximab (TRC105) Plus Capecitabine', ' All patients received TRC105 + capecitabine TRC105: IV (7.5 or 10 mg/kg weekly) Capecitabine: oral (1,000 mg/m2 BID)'], 'Eligibility': ['Inclusion Criteria:', ' Histologically proven advanced solid cancer for which curative therapy is not available (Part 1 only)', ' Histologically proven metastatic Her-2-negative breast cancer (Part 2 only)', ' Measurable disease by RECIST 1.1 criteria (Part 2 only)', ' Willing and able to consent for self to participate in study', ' Progressive or recurrent disease after prior systemic chemotherapy regimen', ' Age 18 years', ' ECOG performance status of 0 or 1', ' Resolution of all acute toxic effects of prior therapy to NCI CTCAE Grade 1 or baseline (except alopecia)', ' Adequate organ function', 'Exclusion Criteria:', ' Prior treatment with more than one systemic chemotherapy regimen for metastatic disease.', ' Prior treatment with TRC105', ' History of hypersensitivity reaction to antimetabolite therapy', ' Receipt of an investigational agent within 28 days of starting study treatment', ' Prior surgery (including open biopsy), radiation therapy or systemic therapy within 28 days of starting study treatment', ' Minor surgical procedures within 14 days prior to first dose of TRC105', ' History of brain metastasis, spinal cord compression, or carcinomatous meningitis, or new evidence of brain or leptomeningeal disease', ' Angina, MI, symptomatic congestive heart failure, cerebrovascular accident, transient ischemic attack, arterial embolism, pulmonary embolism, DVT, PTCA or CABG within the past 6 months', ' Uncontrolled chronic hypertension defined as systolic > 140 or diastolic > 90 despite optimal therapy', ' Past medical history of acquired or inherited coagulopathy including patients with known hereditary hemorrhagic telangiectasia', ' Thrombolytic or anticoagulant use (except to maintain i.v. catheters) within 10 days prior to first dose with TRC105', ' Cardiac dysrhythmias of NCI CTCAE Grade 2 within the last month', ' Hemorrhage within 28 days of starting study treatment', ' Unhealed wounds within 28 days of starting study treatment', ' History of peptic ulcer disease or gastritis within the past 6 months, unless treated for the condition and complete resolution has been documented by esophagogastroduodenoscopy (EGD) within 28 days of starting study treatment', ' Known human immunodeficiency virus (HIV) or acquired immunodeficiency syndrome (AIDS) related illness', ' Known active viral or nonviral hepatitis', ' History of hypersensitivity reaction to human or mouse antibody products', ' Lung cancer with central chest lesions', ' Pregnancy or breastfeeding'], 'Results': ['Outcome Measurement: ', ' Determine Maximum Tolerated Dose of TRC105 in Combination With Capecitabine', ' Assess safety and dose limiting toxicity by dose cohort and coding all terms utilized MedDRA version 14.1.', ' Time frame: 1.5 years', 'Results 1: ', ' Arm/Group Title: Carotuximab (TRC105) Plus Capecitabine', ' Arm/Group Description: All patients received TRC105 + capecitabine TRC105: IV (7.5 or 10 mg/kg weekly) Capecitabine: oral (1,000 mg/m2 BID)', ' Overall Number of Participants Analyzed: 6', ' Measure Type: Count of Participants', ' Unit of Measure: Participants Patients with DLT at 7.5 mg/kg: 0 0.0%', ' Patients without DLT at 7.5 mg/kg: 3 50.0%', ' Patients with DLT at 10 mg/kg: 0 0.0%', ' Patients without DLT at 10 mg/kg: 3 50.0%'], 'Adverse Events': ['Adverse Events 1:', ' Total: 6/19 (31.58%)', ' Febrile neutropenia [1]1/19 (5.26%)', ' Fatigue [1]1/19 (5.26%)', ' Pyrexia [1]1/19 (5.26%)', ' Fracture [1]1/19 (5.26%)', ' Hip Fracture [1]1/19 (5.26%)', ' Headache [2]1/19 (5.26%)']}

2687b547-c225-4838-bbcd-99212a74d815

Single

Adverse Events

NCT00759785

Only one adverse event is observed in patients from cohort 1 of the primary trial.

Entailment

{'Clinical Trial ID': 'NCT00759785', 'Intervention': ['INTERVENTION 1: ', ' ER-positive Luminal B (ER+)', ' ER-positive Luminal B participants received a single dose of dalotuzumab 20 mg/kg infused over 60-120 minutes.', 'INTERVENTION 2: ', ' Triple Negative (TN)', ' Triple Negative participants received a single dose of dalotuzumab 20 mg/kg infused over 60-120 minutes.'], 'Eligibility': ['Inclusion Criteria:', ' Participant has operable stage I-IIIa breast cancer of the following subtypes: (1) estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and human epidermal growth factor receptor 2 (HER2)-negative breast cancer; (2) ER-positive tumor meeting one of the following criteria: histologic grade 3; histologic grade 2 and PR-negative; histologic grade 2 and Ki67 antigen 10%. Tumor is at least 2 cm in diameter as assessed by physical or radiographic exam', ' Participant is female and 18 years of age', 'Exclusion Criteria:', ' Participant is pregnant, breastfeeding or planning to become pregnant while in the study', ' Participant has received prior chemotherapy, biological therapy or radiation', ' Participant has participated in a clinical trial in the last 30 days', ' Participant has a history of drug or alcohol abuse in the last year', ' Participant is human immunodeficiency virus (HIV) positive. Patient has a history of Hepatitis B or C', ' Participant has poorly controlled diabetes mellitus'], 'Results': ['Outcome Measurement: ', ' Percentage of Participants Demonstrating a Decrease in the Growth Factor Signature (GFS)', " GFS was measured by microarray analysis of the entire 101 gene signature expression. The GFS is quantified as the change in gene expression between two separate samples collected from the same participant. A log (base 10) ratio of expression in the post-dose sample was generated relative to the reference in both the Up and DOWN arms of the gene signature. A log ratio value of zero indicated no change in the expression between the two samples. GFS was calculated as the mean log ratio of genes in the UP arm minus mean log ratio of genes in the Down arm. GFS was compared for paired samples (pre-dose and post-dose) by a T-statistic calculated as the GFS divided by its standard error. Responders to therapy had a T-statistic that was smaller than the threshold 1st percentile of student's T-distribution and were counted as having a decrease in GFS.", ' Time frame: Up to 12 Days Post-dose', 'Results 1: ', ' Arm/Group Title: ER-positive Luminal B (ER+)', ' Arm/Group Description: ER-positive Luminal B participants received a single dose of dalotuzumab 20 mg/kg infused over 60-120 minutes.', ' Overall Number of Participants Analyzed: 14', ' Measure Type: Number', ' Unit of Measure: Percentage of participants 28.6 (13.1 to 49.2)', 'Results 2: ', ' Arm/Group Title: Triple Negative (TN)', ' Arm/Group Description: Triple Negative participants received a single dose of dalotuzumab 20 mg/kg infused over 60-120 minutes.', ' Overall Number of Participants Analyzed: 17', ' Measure Type: Number', ' Unit of Measure: Percentage of participants 17.6 (6.7 to 35.2)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 1/25 (4.00%)', ' Diarrhoea 0/25 (0.00%)', ' Breast abscess 0/25 (0.00%)', ' Breast cellulitis 0/25 (0.00%)', ' Syncope 1/25 (4.00%)', 'Adverse Events 2:', ' Total: 1/20 (5.00%)', ' Diarrhoea 1/20 (5.00%)', ' Breast abscess 1/20 (5.00%)', ' Breast cellulitis 1/20 (5.00%)', ' Syncope 0/20 (0.00%)']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

fadf7710-6e4d-49d6-82fc-4f3137b5e26b

Single

Adverse Events

NCT00074152

All of the adverse event cases in the primary trial occurred in patients from cohort 2.

Entailment

{'Clinical Trial ID': 'NCT00074152', 'Intervention': ['INTERVENTION 1: ', ' Arm I', ' Observation (+/- Radiation). Patients receive radiotherapy* within 6 months after surgery.', ' radiation therapy: Given within 6 months after surgery', 'INTERVENTION 2: ', ' Arm II', ' Chemotherapy (+/- Radiation). Within 10 weeks after surgery, patients receive at least 3 courses of an adjuvant chemotherapy regimen as determined by the investigator. Patients may receive radiotherapy within 6 months after surgery and after the completion of chemotherapy OR integrated with chemotherapy.', ' chemotherapy: Given within 10 weeks after surgery.'], 'Eligibility': ['DISEASE CHARACTERISTICS:', ' Histologically confirmed invasive breast cancer', ' First local and/or regional (i.e., ipsilateral axillary or internal mammary lymph node region) recurrence after primary treatment with mastectomy or lumpectomy/quadrantectomy with clear surgical margins', ' Local failure is defined as a tumor recurrence in any soft tissue of the ipsilateral conserved breast or the chest wall, mastectomy scar, and/or skin', ' Regional failure is defined as a tumor recurrence in the ipsilateral axillary lymph nodes, extranodal soft tissue of the ipsilateral axilla, and/or ipsilateral internal mammary. Regional failure does not include supraclavicular lymph nodes or tumor in the opposite breast', ' No other prior recurrence in any site, including local', ' Surgical resection of the recurrence meeting 1 of the following criteria:', ' Uninvolved ("clear") margins and planned radiotherapy with at least 40 Gy for patients who had no prior adjuvant radiotherapy', ' Mastectomy of the recurrence with uninvolved ("clear") margins after lumpectomy/quadrantectomy alone for the primary', ' Adjuvant trastuzumab (Herceptin®) therapy or other HER-2 directed therapies are allowed for patients with HER-2 positive tumors and must be declared prior to randomization', ' No evidence of distant metastasis, including ipsilateral supraclavicular lymph nodes, by x-ray or CT scan of the chest, ultrasound or CT scan of the abdomen and pelvis, or bone scintigraphy only if alkaline phosphatase is > 2 times normal or if medically indicated (e.g., bone pain)', ' No macroscopically incomplete surgery', ' No bilateral malignancy except carcinoma in situ', ' No suspicious mass in the opposite breast unless that mass has been proven by biopsy to be benign', ' No skeletal pain of unknown cause', ' No hot spots on bone scan for which metastases cannot be ruled out by x-ray, MRI, and/or CT scan', ' Hormone receptor status:', ' Determined in the recurrent tumor by immunohistochemistry and/or ligand-binding assay', ' Estrogen receptor positive or negative', ' Progesterone receptor positive or negative', ' PATIENT CHARACTERISTICS:', ' Age', ' Minimum 18 years', ' Sex', ' Female', ' Menopausal status', ' Not specified', ' Performance status', ' Not specified', ' Life expectancy', ' Not specified', ' Hematopoietic', ' Not specified', ' Hepatic', ' No elevated alkaline phosphatase', ' Renal', ' Not specified', ' Other', ' Fertile patients must use effective non-hormonal contraception', ' Medically suitable for chemotherapy of 3-6 months duration', ' No other primary malignant tumors except adequately treated carcinoma in situ of the cervix or nonmelanoma skin cancer', ' No non-malignant systemic disease that would preclude study treatment or prolong follow-up', ' No psychiatric or addictive disorder that would preclude giving informed consent', ' No history of noncompliance to medical regimens or potential for being unreliable', ' PRIOR CONCURRENT THERAPY:', ' Biologic therapy', ' Not specified', ' Chemotherapy', ' See Disease Characteristics', ' Endocrine therapy', ' Not specified', ' Radiotherapy', ' See Disease Characteristics', ' Surgery', ' See Disease Characteristics'], 'Results': ['Outcome Measurement: ', ' Disease-free Survival', ' [Not Specified]', ' Time frame: 5 years after randomization', 'Results 1: ', ' Arm/Group Title: Arm I', ' Arm/Group Description: Observation (+/- Radiation). Patients receive radiotherapy* within 6 months after surgery.', ' radiation therapy: Given within 6 months after surgery', ' Overall Number of Participants Analyzed: 77', ' Measure Type: Number', ' Unit of Measure: percentage of participants 57 (44 to 67)', 'Results 2: ', ' Arm/Group Title: Arm II', ' Arm/Group Description: Chemotherapy (+/- Radiation). Within 10 weeks after surgery, patients receive at least 3 courses of an adjuvant chemotherapy regimen as determined by the investigator. Patients may receive radiotherapy within 6 months after surgery and after the completion of chemotherapy OR integrated with chemotherapy.', ' chemotherapy: Given within 10 weeks after surgery.', ' Overall Number of Participants Analyzed: 85', ' Measure Type: Number', ' Unit of Measure: percentage of participants 69 (56 to 79)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 0/77 (0.00%)', ' Neutropenia [1]0/77 (0.00%)', ' Left ventricular dysfunction 0/77 (0.00%)', ' Cardiac ischemia 0/77 (0.00%)', ' Gastrointestinal pain 0/77 (0.00%)', ' Colitis 0/77 (0.00%)', ' Febrile neutropenia 0/77 (0.00%)', ' Pulmonary/upper respiratory infection 0/77 (0.00%)', ' Diverticulitis 0/77 (0.00%)', ' Motor neuropathy 0/77 (0.00%)', ' Endometrial mucosa thinkening 0/77 (0.00%)', 'Adverse Events 2:', ' Total: 12/85 (14.12%)', ' Neutropenia [1]1/85 (1.18%)', ' Left ventricular dysfunction 1/85 (1.18%)', ' Cardiac ischemia 2/85 (2.35%)', ' Gastrointestinal pain 1/85 (1.18%)', ' Colitis 1/85 (1.18%)', ' Febrile neutropenia 3/85 (3.53%)', ' Pulmonary/upper respiratory infection 1/85 (1.18%)', ' Diverticulitis 1/85 (1.18%)', ' Motor neuropathy 1/85 (1.18%)', ' Endometrial mucosa thinkening 1/85 (1.18%)']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

8c4e6f36-37b4-4bde-b518-08a6dc55f7a5

Single

Intervention

NCT01439945

In the primary trial Low Dose Magnesium Oxide is 5% less than high dose Magnesium Oxide.

Contradiction

{'Clinical Trial ID': 'NCT01439945', 'Intervention': ['INTERVENTION 1: ', ' Low Dose Magnesium Oxide (800 mg/Day)', ' Week 2:', ' Patients take one 400 mg tablet of magnesium oxide orally (PO) daily (QD).', ' Week 3:', ' Patients take two 400 mg tablet of magnesium oxide orally (PO) daily (QD).', ' Weeks 4-9:', ' Patients take two 400 mg tablet of magnesium oxide orally (PO) daily (QD).', 'INTERVENTION 2: ', ' High Dose Magnesium Oxide (1200 mg/Day)', ' Week 2:', ' Patients take one 400 mg tablet of magnesium oxide orally (PO) daily (QD).', ' Week 3:', ' Patients take two 400 mg tablet of magnesium oxide orally (PO) daily (QD).', ' Weeks 4-9:', ' Patients take three 400 mg tablet of magnesium oxide orally (PO) daily (QD).'], 'Eligibility': ['DISEASE CHARACTERISTICS:', ' Women with a history of breast cancer (currently without malignant disease)', ' Bothersome hot flashes (defined by their occurrence 28 times per week and of sufficient severity to make the patient desire therapeutic intervention)', ' Presence of hot flashes for 30 days prior to study registration', ' Willingness to provide the biologic specimens as required by the protocol', ' Hormone receptor status not specified', ' PATIENT CHARACTERISTICS:', ' Women who are postmenopausal as defined by absence of a period in the past 12 months or bilateral oophorectomy', ' Women with at least one ovary but without a uterus should be deemed postmenopausal by either age over 55 or a combination of estrogen within a postmenopausal range (per local lab) and FSH over 40 mIU/mL', ' No women of childbearing potential or who are premenopausal', ' Creatinine clearance > 30 mL/min', ' Ability to complete questionnaire(s) by themselves or with assistance', ' ECOG performance status 0 or 1', ' No history of allergic or other adverse reaction to magnesium', ' No diabetes', ' No patients with conditions that are implicated in decreased absorption of magnesium (e.g., Crohn disease, ETOH abuse)', ' No patients who have diarrhea where magnesium might make it worse (per provider discretion)', ' PRIOR CONCURRENT THERAPY:', ' None of the following current ( 28 days prior to registration) or planned therapies (tamoxifen, raloxifene, or aromatase inhibitors are allowed, but the patient must have been on a constant dose for 28 days and must not be expected to stop the medication during the study period):', ' Antineoplastic chemotherapy (trastuzumab or lapatinib are allowed)', ' Androgens', ' Estrogens (any delivery route)', ' Progestational agents', ' No prior use of magnesium for hot flashes', ' No current or planned use of gabapentin (for any reasons) or antidepressants (for any reasons) or other agents for treating hot flashes (except stable dose of vitamin E is allowed as long as it was started > 30 days prior to study registration and are to be continued through the study period; soy is allowed, if it is planned to be continued at the same dose during the study period)', ' No current use of magnesium for any indication (except one standard multiple vitamin dose is allowed per day)', ' Not taking diuretics, corticosteroids, bile acid sequestrants, and other prescription and over-the-counter medications that may affect magnesium levels', ' No current ( 7 days prior to registration) or planned use of other non-drug therapies for managing hot flashes, such as acupuncture or yoga (use of these therapies for other reasons is allowed)'], 'Results': ['Outcome Measurement: ', ' The Intra-patient Changes of Weekly Hot Flash Activity From Baseline During the Treatment Period.', ' The primary endpoint is the intra-patient changes of weekly hot flash activity from baseline during the treatment period. The hot flash activity will be measured by the weekly average hot flash score, which is a composite entity of both frequency and severity of hot flashes.', ' The hot flash severity is graded from 1 to 4 (1=mild, 2=moderate, 3=severe, and 4=very severe). The daily hot flash score is computed by multiplying the mean grade of severity by the frequency during every 24 hour period. Therefore, a score of zero is the lowest possible score and can be interpreted as having no hot flashes. The weekly hot flash score was calculated by adding all scores for the week.', ' The mean Hot Flash Score for each week for each group is reported and a repeated measures analysis is reported comparing each dose level group to the Placebo group.', ' Time frame: Baseline to Week 8', 'Results 1: ', ' Arm/Group Title: Low Dose Magnesium Oxide (800 mg/Day)', ' Arm/Group Description: Week 2:', ' Patients take one 400 mg tablet of magnesium oxide orally (PO) daily (QD).', ' Week 3:', ' Patients take two 400 mg tablet of magnesium oxide orally (PO) daily (QD).', ' Weeks 4-9:', ' Patients take two 400 mg tablet of magnesium oxide orally (PO) daily (QD).', ' Overall Number of Participants Analyzed: 88', ' Mean (Standard Deviation)', ' Unit of Measure: units on a scale Baseline: 81 participants', ' 16.02 (9.62)', ' Week 1: 81 participants', ' 14.28 (9.26)', ' Week 2: 79 participants', ' 12.68 (8.87)', ' Week 3: 78 participants', ' 12.29 (9.79)', ' Week 4: 78 participants', ' 11.73 (10.35)', ' Week 5: 75 participants', ' 11.77 (10.86)', ' Week 6: 71 participants', ' 11.61 (10.46)', ' Week 7: 71 participants', ' 11.92 (11.26)', ' Week 8: 69 participants', ' 12.17 (10.88)', 'Results 2: ', ' Arm/Group Title: High Dose Magnesium Oxide (1200 mg/Day)', ' Arm/Group Description: Week 2:', ' Patients take one 400 mg tablet of magnesium oxide orally (PO) daily (QD).', ' Week 3:', ' Patients take two 400 mg tablet of magnesium oxide orally (PO) daily (QD).', ' Weeks 4-9:', ' Patients take three 400 mg tablet of magnesium oxide orally (PO) daily (QD).', ' Overall Number of Participants Analyzed: 88', ' Mean (Standard Deviation)', ' Unit of Measure: units on a scale Baseline: 81 participants', ' 15.35 (10.53)', ' Week 1: 78 participants', ' 14.47 (11.10)', ' Week 2: 78 participants', ' 12.59 (10.01)', ' Week 3: 76 participants', ' 11.32 (10.72)', ' Week 4: 73 participants', ' 10.14 (8.61)', ' Week 5: 67 participants', ' 9.73 (9.19)', ' Week 6: 67 participants', ' 9.44 (8.99)', ' Week 7: 67 participants', ' 9.37 (9.24)', ' Week 8: 66 participants', ' 9.06 (8.87)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 0/92 (0.00%)', ' Diarrhea 0/92 (0.00%)', 'Adverse Events 2:', ' Total: 1/93 (1.08%)', ' Diarrhea 1/93 (1.08%)']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

6c0896ac-db42-45b4-a6e2-620a27fd321a

Single

Adverse Events

NCT00432172

All of the adverse events recorded in the primary trial occurred in patients from cohort 1.

Entailment

{'Clinical Trial ID': 'NCT00432172', 'Intervention': ['INTERVENTION 1: ', ' Group 2 (Basal) Standard Treatment', ' Epirubicin (E) 90 mg/ m2 intravenous (iv) in combination with Cyclophosphamide (C) 600 mg/ m2 iv every 21 days for 4 cycles, followed by docetaxel (D)100 mg/m2 iv every 21 days for 4 cycles.', 'INTERVENTION 2: ', ' Group 2 (Basal) Selective Treatment', ' Epirubicin (E) 90 mg/ m2 intravenous (iv) in combination with Cyclophosphamide (C) 600 mg/ m2 iv every 21 days for 4 cycles, followed by docetaxel (D)100 mg/m2 iv and carboplatin (Cb) (area under the curve = 6 mg/mL) iv every 21 days for 4 cycles.'], 'Eligibility': ['Inclusion Criteria:', ' Written informed consent.', ' Breast cancer with histological diagnosis.', ' Negative Human Epidermal Growth Factor Receptor 2 (HER2) tumours defined as immunohistochemistry (IHQ) 0,1+.', ' No evidence of suspicion of metastatic disease.', ' Age >= 18 years old.', ' Performance status (Karnofsky index) >= 80 (ECOG 0,1).', ' Adequate cardiac function by ECG in the previous 12 weeks.', ' Hematology: neutrophils >= 1,5 x10^9/l; platelets >= 100 x10^9/l; hemoglobin >= 10 g/dl.', ' Adequate hepatic function: total bilirubin <= 1x Upper Normal Limit (UNL); Aspartate aminotransferase (AST) (SGOT) and Alanine aminotransferase (ALT) (SGPT) <= 2.5 x UNL; alkaline phosphatase <= 2.5 x UNL.', ' Adequate renal function: creatinine <= 1 x UNL; creatinine clearance >= 60 ml/min.', ' Patients able to comply with study treatment and follow-up.', ' Negative pregnancy test in the previous 14 days.', 'Exclusion Criteria:', ' HER2 positive tumours (defined as IHQ 3+ or positive fluorescence in situ hybridization [FISH]).', ' Prior systemic therapy for breast cancer (immunotherapy, hormonotherapy, chemotherapy).', ' Prior treatment with anthracyclines or taxanes (paclitaxel, docetaxel) for any previous malignancy.', ' Prior radiotherapy for breast cancer.', ' Bilateral invasive breast cancer.', ' Pregnant or lactating women.', ' Previous grade >= 2 motor or sensorial neurotoxicity (National Cancer Institute Common Toxicity Criteria [NCICTC]).', ' Other serious comorbidities: congestive heart failure or unstable angina; prior history of myocardial infarction in previous year; uncontrolled hypertension (HT); high risk arrhythmias; history of significant neurological or psychiatric disorders; uncontrolled active infection; active peptic ulcer; unstable diabetes mellitus; dyspnea at rest; or chronic therapy with oxygen.', ' Previous or current history of neoplasms different from breast cancer, except for skin carcinoma, cervical in situ carcinoma, or any other tumor curatively treated and without recurrence in the last 10 years; ductal in situ carcinoma in the same breast; lobular in situ carcinoma.', ' Chronic treatment with corticosteroids.', ' Contraindications for administration of corticosteroids.', ' Concomitant treatment with other therapy for cancer.', 'Males.'], 'Results': ['Outcome Measurement: ', ' Pathological Response for Basal Group 2', ' This primary outcome only applies for the basal group 2 as per protocol. The pathological response in luminal group 1 was not pre-specified even as a Secondary Outcome. Pathological response was assessed after surgery, according to the Miller & Payne criteria, which stratifies the responses based on the proportion of remaining tumor and post-chemotherapy changes, evaluating separately the response in breast and axilla. Grades 1-4 are categorised as a partial pathological response (pPR) and grade 5 was a complete pathological response (cPR).', ' Time frame: Up to 24 weeks', 'Results 1: ', ' Arm/Group Title: Group 2 (Basal) Standard Treatment', ' Arm/Group Description: Epirubicin (E) 90 mg/ m2 intravenous (iv) in combination with Cyclophosphamide (C) 600 mg/ m2 iv every 21 days for 4 cycles, followed by docetaxel (D)100 mg/m2 iv every 21 days for 4 cycles.', ' Overall Number of Participants Analyzed: 46', ' Measure Type: Count of Participants', ' Unit of Measure: Participants Grade 5: 16 34.8%', ' Grade 4: 5 10.9%', ' Grade 3: 11 23.9%', ' Grade 2: 8 17.4%', ' Grade 1: 5 10.9%', ' Not available: 1 2.2%', 'Results 2: ', ' Arm/Group Title: Group 2 (Basal) Selective Treatment', ' Arm/Group Description: Epirubicin (E) 90 mg/ m2 intravenous (iv) in combination with Cyclophosphamide (C) 600 mg/ m2 iv every 21 days for 4 cycles, followed by docetaxel (D)100 mg/m2 iv and carboplatin (Cb) (area under the curve = 6 mg/mL) iv every 21 days for 4 cycles.', ' Overall Number of Participants Analyzed: 47', ' Measure Type: Count of Participants', ' Unit of Measure: Participants Grade 5: 14 29.8%', ' Grade 4: 11 23.4%', ' Grade 3: 8 17.0%', ' Grade 2: 9 19.1%', ' Grade 1: 4 8.5%', ' Not available: 1 2.1%'], 'Adverse Events': ['Adverse Events 1:', ' Total: 5/45 (11.11%)', ' Neutrophils/granulocytes (ANC/AGC) * [1]0/45 (0.00%)', ' Neutrophils/granulocytes (ANC/AGC) * [2]0/45 (0.00%)', ' Diabetes decompensation * 0/45 (0.00%)', ' Diarrhea * [2]0/45 (0.00%)', ' Mucositis/stomatitis and Vomiting * [3]0/45 (0.00%)', ' Pancreatitis * [4]1/45 (2.22%)', ' Febrile neutropenia * [2]3/45 (6.67%)', 'Adverse Events 2:', ' Total: 0/46 (0.00%)', ' Neutrophils/granulocytes (ANC/AGC) * [1]0/46 (0.00%)', ' Neutrophils/granulocytes (ANC/AGC) * [2]0/46 (0.00%)', ' Diabetes decompensation * 0/46 (0.00%)', ' Diarrhea * [2]0/46 (0.00%)', ' Mucositis/stomatitis and Vomiting * [3]0/46 (0.00%)', ' Pancreatitis * [4]0/46 (0.00%)', ' Febrile neutropenia * [2]0/46 (0.00%)', ' Infection pulmonary/ Upper airway NOS * [5]0/46 (0.00%)']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

3a80ba8a-265f-4931-a9a8-b7e00e372599

Comparison

Intervention

NCT01929395

NCT01857882

the primary trial only has one test cohort whereas the secondary trial has both a test and control group.

Entailment

{'Clinical Trial ID': 'NCT01929395', 'Intervention': ['INTERVENTION 1: ', ' Phase 1: Addition of Supine MRI to Conventional Imaging', ' Pre-operative supine MRI with intraoperative optical scanning and tracking (group MRI)'], 'Eligibility': ['Inclusion Criteria Phase 1', ' Age greater than/equal to 18 years', ' Histologic diagnosis of palpable invasive breast cancer or ductal carcinoma in situ', ' Patient desire to undergo breast surgery', ' 3. Patients will have provided informed consent to participate, documented by their signature on the study consent form 4. The cancer enhances on breast MRI imaging.', ' Inclusion Criteria Phase 2', ' Age greater than/equal to 18 years', ' Histologic diagnosis of invasive breast cancer or ductal carcinoma in situ', ' The tumor is visible and enhances on prone MRI and is >1 cm in greatest diameter.', ' . Determination by the surgeon that the neoplasm is non-palpable.A patient with a palpable hematoma from core biopsy, but a non-palpable neoplasm, will be eligible for study', ' Patient desire to undergo breast conserving surgery', ' Patients will have provided informed consent to participate, documented by their signature on the study consent form.The process of informed consent will be documented in the medical record and a copy of the signed consent form will be given to the patient.', ' Exclusion Criteria (Phases 1 and 2)', ' Absolute contraindication to MRI, including presence of implanted electrical device (pacemaker or neurostimulator), aneurysm clip or metallic foreign body in or near eyes', ' Severe claustrophobia', ' Contraindication to use of gadolinium based intravenous contrast, including life threatening allergy or compromised renal function (creatinine > 2.0)', ' History of median sternotomy', ' Pregnancy (Patient attestation that they are not pregnant will be acceptable, as per standard, as per standard policy for MRIs at DHMC).', ' Multicentric breast cancer, defined as two or more tumors in different quadrants of the breast. An eligibility worksheet will be completed for each patient prior to enrollment and will be signed and dated by the surgeon investigator'], 'Results': ['Outcome Measurement: ', ' The Mean Distance Between the Image-defined and Palpation-defined Edges of the Tumor.', ' Mean calculated from differences in precise distances from the nipple to the superior, inferior, medial and lateral edges of the tumor as determined from the adjusted MRI images and conventional MRI.', ' Time frame: From baseline MRI to intraoperative measurements: 30 days', 'Results 1: ', ' Arm/Group Title: Phase 1: Addition of Supine MRI to Conventional Imaging', ' Arm/Group Description: Pre-operative supine MRI with intraoperative optical scanning and tracking (group MRI)', ' Overall Number of Participants Analyzed: 18', ' Mean (Full Range)', ' Unit of Measure: mm 7.2 (0 to 19)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 0/18 (0.00%)', ' Hematoma [1]0/18 (0.00%)']}

{'Clinical Trial ID': 'NCT01857882', 'Intervention': ['INTERVENTION 1: ', ' Decision Support Workshop', ' The decision support workshop will be 2 hours in duration on the morning of the consultation and will be facilitated by a dedicated social worker from psycho-oncology.', ' Decision Support Workshop: Incorporates the key components of shared decision-making and decision support with the philosophy of delivering supportive care to cancer patients.', ' Surgeon (30 mins): treatment options for breast reconstruction with indications/ contraindications, advantages / disadvantages, expected post-operative course, aesthetic result and complications with probabilities', ' Registered nurse (30 mins): preparing for surgery, postoperative recovery and how to navigate the health care system', ' Social worker (30 mins): values clarification exercise', ' Breast reconstruction patient volunteer (30 mins) questions and answers about her personal experience', 'INTERVENTION 2: ', ' Standard Care', ' Routine pre-consultation education'], 'Eligibility': ['Inclusion Criteria:', ' Patient age: 18 - 79 years at the time of consultation', ' In situ or invasive biopsy confirmed breast adenocarcinoma', ' Considered for immediate or delayed breast reconstruction', ' First consultation for breast reconstruction', 'Exclusion Criteria:', ' Chest wall or atypical breast malignancy (ex: angiosarcoma) or inflammatory adenocarcinoma of the breast', ' Completion any phase of reconstruction, or for revision reconstruction', ' Patient cannot read or write in English.', ' Cognitive impairment or uncontrolled psychiatric diagnosis'], 'Results': ['Outcome Measurement: ', ' Decision Self-efficacy Scale', ' Decision self-efficacy (DSE) scale is a prospectively designed instrument to evaluate patient self-confidence in decision-making, including shared decision-making. It has been validated among women facing treatment decisions for osteoporosis and used in cancer patients. Psychometric evaluation has shown high levels of internal consistency (Cronbach alpha 0.90). Decision self-efficacy is correlated with decision conflict subscales of feeling informed (r = 0.47) and supported (r = 0.45). This instrument has never been tested in the breast cancer or breast reconstruction population.', ' The total score is calculated by summing the 11 items, dividing by 11 and multiplying by 25. Scores range from 0 (extremely low self-efficacy) to 100 (extremely high self-efficacy).', ' The mean and standard deviation (SD) were calculated at baseline and after the initial consultation. Change in score was defined as the difference in total score between baseline and after consultation.', ' Time frame: Change from baseline decision self-efficacy at 1 week after surgical consultation', 'Results 1: ', ' Arm/Group Title: Decision Support Workshop', ' Arm/Group Description: The decision support workshop will be 2 hours in duration on the morning of the consultation and will be facilitated by a dedicated social worker from psycho-oncology.', ' Decision Support Workshop: Incorporates the key components of shared decision-making and decision support with the philosophy of delivering supportive care to cancer patients.', ' Surgeon (30 mins): treatment options for breast reconstruction with indications/ contraindications, advantages / disadvantages, expected post-operative course, aesthetic result and complications with probabilities', ' Registered nurse (30 mins): preparing for surgery, postoperative recovery and how to navigate the health care system', ' Social worker (30 mins): values clarification exercise', ' Breast reconstruction patient volunteer (30 mins) questions and answers about her personal experience', ' Overall Number of Participants Analyzed: 20', ' Mean (Standard Deviation)', ' Unit of Measure: units on a scale 5.7 (12.8)', 'Results 2: ', ' Arm/Group Title: Standard Care', ' Arm/Group Description: Routine pre-consultation education', ' Overall Number of Participants Analyzed: 19', ' Mean (Standard Deviation)', ' Unit of Measure: units on a scale 5.1 (9.8)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 0/0', 'Adverse Events 2:', ' Total: 0/0']}

df4b98f2-7ca9-4855-8d94-d62407ff8535

Comparison

Adverse Events

NCT01015131

NCT00312208

the primary trial records instances of Rectal Hemorrhage within its patient cohort, whereas the secondary trial records Vaginal hemorrhages.

Entailment

{'Clinical Trial ID': 'NCT01015131', 'Intervention': ['INTERVENTION 1: ', ' All Participants', ' Participants who underwent 18-FLT positron emission tomography (PET) and standard of care (SOC) neo-adjuvant chemotherapy'], 'Eligibility': ['Inclusion Criteria:', ' Has newly-diagnosed stage IIB/IIIA/IIIB locally advanced breast cancer', ' Is eligible for pre-operative (neo-adjuvant) chemotherapy', 'Exclusion Criteria:', ' Has a contraindication to magnetic resonance imaging (MRI)', ' Any condition that would limit ability to undergo MRI or PET scans', ' Is a nursing mother', ' Has moderate to end-stage renal disease and is not on dialysis or has renal failure on chronic dialysis'], 'Results': ['Outcome Measurement: ', ' Change From Baseline in 18F-FLT-PET Mean Standardized Uptake Value (SUVmean) After the First Cycle of Standard of Care (SOC) Neo-adjuvant Chemotherapy.', ' Participants undergo a baseline 18F-FLT-PET/CT scan followed by a magnetic resonance imaging (MRI) scan prior to chemotherapy. These scans are repeated in approximately 2 to 3 weeks, at the end of the first cycle of chemotherapy to derive a standardized uptake value (SUV) of 18F-FLT, which is calculated from the ratio of radioactivity concentration within a region of interest, and the injected dose at the time of injection, divided by body weight. The SUVmean averages the radioactivity values within a region of interest.', ' Time frame: Baseline and up to 3 weeks', 'Results 1: ', ' Arm/Group Title: All Participants', ' Arm/Group Description: Participants who underwent 18-FLT positron emission tomography (PET) and standard of care (SOC) neo-adjuvant chemotherapy', ' Overall Number of Participants Analyzed: 36', ' Mean (Standard Deviation)', ' Unit of Measure: SUV Baseline: 2.79 (1.36)', ' End of Cycle 1: 1.78 (1.03)', ' Change from Baseline: 1.00 (0.95)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 8/44 (18.18%)', ' Febrile neutropenia4/44 (9.09%)', ' Rectal bleeding1/44 (2.27%)', ' Chest pain2/44 (4.55%)', ' Fever1/44 (2.27%)', ' Catheter site infection1/44 (2.27%)', ' Neutrophil count decreased1/44 (2.27%)', ' Dizziness1/44 (2.27%)']}

{'Clinical Trial ID': 'NCT00312208', 'Intervention': ['INTERVENTION 1: ', ' Doxorubicin + Cyclophosphamide Followed by Docetaxel (AC -> T)', ' AC x 4: Doxorubicin 60 mg/m² as an IV bolus in combination with cyclophosphamide 600 mg/m² as IV followed by docetaxel 100 mg/m² as 1 hour IV infusion on day 1 every 3 weeks for 4 cycles.', 'INTERVENTION 2: ', ' Docetaxel + Doxorubicin and Cyclophosphamide (TAC)', ' TAC x 6 : Docetaxel 75 mg/m² as 1 hour IV infusion on day 1 every 3 weeks in combination with doxorubicin 50 mg/m² as an IV bolus and cyclophosphamide 500 mg/m2 as IV on day 1 every 3 weeks. Sequence of administration is as follows: doxorubicin followed by cyclophosphamide followed by docetaxel.'], 'Eligibility': ['Inclusion Criteria :', ' Histologically proven breast cancer. Interval between definitive surgery that includes axillary lymph node dissection and registration is less than or equal to 60 days. A central pathology review may be performed post randomization for confirmation of diagnosis and molecular studies.', ' Definitive surgical treatment must be either mastectomy, or breast conserving surgery with axillary lymph node dissection for operable breast cancer (T1-3, Clinical N0-1, M0). Margins of resected specimen from definitive surgery must be histologically free of invasive adenocarcinoma and Ductal Carcinoma In Situ (DCIS). Lobular carcinoma in-situ does not count as a positive margin.', ' Histologic examination of the tumor: Invasive adenocarcinoma with at least one axillary lymph node (pN1) showing evidence of tumor among a minimum of six resected lymph nodes.', ' Tumor must show negative HER2 neu proto-oncogene overexpression by FISH (Fluorescence In Situ Hybridization). Confirmation of non overexpression will be centrally assessed by authorized BCIRG (Breast Cancer International Research Group) laboratories prior to randomization.', ' Estrogen and/or progesterone receptor analysis performed on the primary tumor prior to randomization. Results must be known at the time of randomization.(Note: Patients whose tumor is estrogen receptor negative with progesterone receptor status unknown or undetermined, must have the progesterone receptor assayed in order to determine hormonal receptor status. Patients whose tumor is progesterone receptor negative with estrogen receptor status unknown or undetermined, must have the estrogen receptor assayed in order to determine hormonal receptor status).', ' Karnofsky Performance status index > 80%.', ' Normal cardiac function must be confirmed by LVEF (Lef Ventricular Ejection Fraction) i.e. MUGA (Multi Gated Acquisition) scan or echocardiography and ECG within 3 months prior to registration. LVEF result must be above or equal to the lower limit of normal for the institution. The ECG results must be within normal limits or show no significant abnormalities.', ' Laboratory requirements: (within 14 days prior to registration)', ' Hematology:', ' Neutrophils > or = 2.0 x 10^9/L', ' Platelets > or = 100 x 10^9/L', ' Hemoglobin > or = 10 g/dL', ' Hepatic function:', ' Total bilirubin < or = 1 UNL (Upper Normal Limit)', ' ASAT (Aspartate Amino Transferase) and ALAT (Alanine Amino Transferase) < or = 2.5 UNL', ' Alkaline phosphatase < or = 5 UNL', ' Patients with ASAT and/or ALAT > 1.5 x UNL associated with alkaline phosphatase > 2.5 x UNL are not eligible for the study.', ' Renal function:', ' Creatinine < or = 175 µmol/L (2 mg/dL);', ' If limit reached, the calculated creatinine clearance should be > or = 60mL/min.', ' Complete staging work-up within 3 months prior to registration. All patients will have contralateral mammography, chest X-ray (Posteroanterior and lateral) and/or CT scan and/or MRI (Magnetic Resonance Imaging), abdominal ultrasound and/or CT scan (computerized tomography) and/or MRI, and bone scan. In case of positive bone scan, bone X-ray is mandatory to rule out the possibility of non-metastatic hot spots. Other tests may be performed as clinically indicated.', ' Negative pregnancy test (urine or serum) within 7 days prior to registration for all women of childbearing potential.', ' Exclusion Criteria :', ' Prior systemic anticancer therapy for breast cancer (immunotherapy, hormonotherapy, genetherapy , chemotherapy).', ' Prior anthracycline therapy or taxoids (paclitaxel, docetaxel) for any malignancy.', ' Prior radiation therapy for breast cancer.', ' Bilateral invasive breast cancer.', ' Pregnant, or lactating patients. Patients of childbearing potential must implement adequate non-hormonal contraceptive measures during study treatment (chemotherapy and tamoxifen therapy) and must have negative urine or serum pregnancy test within 7 days prior to registration.', ' Any T4 or N2 or known N3 or M1 breast cancer.', ' Pre-existing motor or sensory neurotoxicity of a severity > grade 2 by NCI-CTC (National Cancer Institute - Common Toxicity Criteria), version 2.0.', ' Other serious illness or medical condition:', ' congestive heart failure or unstable angina pectoris, previous history of myocardial infarction within 1 year from study entry, uncontrolled hypertension or high-risk uncontrolled arrhythmias', ' history of significant neurologic or psychiatric disorders including psychotic disorders, dementia or seizures that would prohibit the understanding and giving of informed consent', ' active uncontrolled infection', ' active peptic ulcer, unstable diabetes mellitus', ' Past or current history of neoplasm other than breast carcinoma, except for:', ' curatively treated non-melanoma skin cancer', ' carcinoma in situ of the cervix', ' other cancer curatively treated and with no evidence of disease for at least 10 years', ' ipsilateral ductal carcinoma in-situ (DCIS) of the breast', ' lobular carcinoma in-situ (LCIS) of the breast', ' Chronic treatment with corticosteroids unless initiated > 6 months prior to study entry and at low dose (< 20 mg methylprednisolone or equivalent).', ' Concurrent treatment with ovarian hormonal replacement therapy. Prior treatment should be stopped before study entry.', ' Definite contraindications for the use of corticosteroids.', ' Concurrent treatment with other experimental drugs. Participation in another clinical trial with any investigational not marketed drug within 30 days prior to study entry.', ' Concurrent treatment with any other anti-cancer therapy.', ' Current therapy with any hormonal agent such as raloxifene, tamoxifen or other selective estrogen receptor modulators (SERMs), either for osteoporosis or prevention. Patients must have discontinued these agents prior to randomization.', " The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial."], 'Results': ['Outcome Measurement: ', ' Local, Regional or Metastatic Relapse, or Second Primary Cancer, or Death From Any Cause (Disease-Free Survival)', ' The primary event is the local, regional or metastatic relapse or the date of second primary cancer or death from any cause (whichever occurs first). The primary efficacy analysis is performed on the time from randomization to this primary event. The Measured Values table below presents the numbers of patients with the event at the end of the study period.', ' Time frame: Median follow-up 65 months', 'Results 1: ', ' Arm/Group Title: Doxorubicin + Cyclophosphamide Followed by Docetaxel (AC -> T)', ' Arm/Group Description: AC x 4: Doxorubicin 60 mg/m as an IV bolus in combination with cyclophosphamide 600 mg/m as IV followed by docetaxel 100 mg/m as 1 hour IV infusion on day 1 every 3 weeks for 4 cycles.', ' Overall Number of Participants Analyzed: 1649', ' Measure Type: Number', ' Unit of Measure: Participants 356', 'Results 2: ', ' Arm/Group Title: Docetaxel + Doxorubicin and Cyclophosphamide (TAC)', ' Arm/Group Description: TAC x 6 : Docetaxel 75 mg/m as 1 hour IV infusion on day 1 every 3 weeks in combination with doxorubicin 50 mg/m as an IV bolus and cyclophosphamide 500 mg/m2 as IV on day 1 every 3 weeks. Sequence of administration is as follows: doxorubicin followed by cyclophosphamide followed by docetaxel.', ' Overall Number of Participants Analyzed: 1649', ' Measure Type: Number', ' Unit of Measure: Participants 352'], 'Adverse Events': ['Adverse Events 1:', ' Total: 331/1634 (20.26%)', ' Anemia 3/1634 (0.18%)', ' Coagulation disorders 1/1634 (0.06%)', ' Hemorrhage Vaginal 1/1634 (0.06%)', ' Leukopenia 18/1634 (1.10%)', ' Lymphadenopathy 0/1634 (0.00%)', ' Lymphedema 0/1634 (0.00%)', ' Pancytopenia 0/1634 (0.00%)', ' Thrombocytopenia 0/1634 (0.00%)', ' Arrhythmia 3/1634 (0.18%)', ' Arrhythmia Ventricular 0/1634 (0.00%)', ' Cardiomyopathy 1/1634 (0.06%)', 'Adverse Events 2:', ' Total: 520/1635 (31.80%)', ' Anemia 5/1635 (0.31%)', ' Coagulation disorders 0/1635 (0.00%)', ' Hemorrhage Vaginal 0/1635 (0.00%)', ' Leukopenia 56/1635 (3.43%)', ' Lymphadenopathy 1/1635 (0.06%)', ' Lymphedema 2/1635 (0.12%)', ' Pancytopenia 1/1635 (0.06%)', ' Thrombocytopenia 1/1635 (0.06%)', ' Arrhythmia 3/1635 (0.18%)', ' Arrhythmia Ventricular 1/1635 (0.06%)', ' Cardiomyopathy 0/1635 (0.00%)']}

5d2542fa-5482-4aff-af29-80875a0a9dcc

Comparison

Eligibility

NCT00880464

NCT00458237

HIV+ Patients are excluded from both the secondary trial and the primary trial.

Entailment

{'Clinical Trial ID': 'NCT00880464', 'Intervention': ['INTERVENTION 1: ', ' Vaccine', 'Biological/Vaccine: Autologous, Lethally Irradiated Breast Cancer Cells Vaccine will be administered on days 1, 8, 15, 29 and then every 2 weeks until the supply of vaccine runs out', ' Autologous, Lethally Irradiated Breast Cancer Cells: Vaccination with autologous tumor cells engineered by adenoviral mediated gene transfer to secrete GM-CS'], 'Eligibility': ['Inclusion Criteria:', ' Histologically or cytologically confirmed invasive breast cancer, pre-operative stages II-III per AJCC 6th edition, based on baseline evaluation by clinical examination and/or breast imaging', ' Cohort 1: At least 2cm of residual disease in sum of diameters by clinical or radiographic findings following their preoperative chemotherapy', ' Cohort 2: Patients who have not received preoperative chemotherapy must have at least 4cm of disease in the largest diameter by clinical or radiographic findings', ' Prior therapy for Cohort 1 only: Must have completed preoperative (neoadjuvant) chemotherapy with either a standard regimen (containing an anthracycline and/or a taxane) or on a clinical trial', ' HER2 positive tumors must have received at least one prior trastuzumab-based therapy, and may not receive concurrent trastuzumab therapy and vaccination', ' Must initiate hormonal therapy (if indicated), including ovarian suppression, at least 4 weeks prior to initiation of vaccinations', ' Must have completed definitive resection of primary tumor with adequated excision of gross disease. Surgery should have occured more than 28 days but within 12 weeks prior to enrollment', ' May receive concurrent hormonal therapy, such as tamoxifen, ovarian suppression, and aromatase inhibitors', ' Must have had prior banked tumor of sufficient cellular yield for vaccination', ' ECOG Performance Status 0 or 1', ' 18 years of age or older', ' Greater than 4 weeks from immunotherapy, or systemic glucocorticoid therapy', ' Adequate recovery from recent surgery and radiation therapy', 'Exclusion Criteria:', ' Uncontrolled active infection or illness', ' Other medical or psychiatric illness or social situation that would limit study compliance', ' Pregnancy or nursing mothers', ' Evidence of HIV infection', ' Previous participation in an adenovirus-based trial', ' Concurrent invasive malignancies'], 'Results': ['Outcome Measurement: ', ' Minimum Number of Vaccine Doses Created Using Participant Tumor Sample', ' Tumor samples were obtained via malignant effusion or a surgically accessible tumor nodule of 2 cm in greatest diameter. Tumor cells were processed to single cell suspension and transduced with adenoviral vector encoding human Granulocyte-macrophage colony-stimulating factor (GM-CSF). Then, the cells washed extensively and irradiated with 10,000 cGy. Over the next 14 days, sterility cultures were tested for endotoxin and mycoplasma contamination. Individual vaccine cell dose and number varied depending on the final cell yield from vaccine production. For stage II-III patients, the minimal dose was 1 x 10^5 cells and the maximal dose was 4 x 10^6 cells. For metastatic patients, the minimal dose was 1 x 10^5 cells and the maximal dose was 1 x 10^7 cells.', ' Time frame: 40 Months', 'Results 1: ', ' Arm/Group Title: Vaccine', ' Arm/Group Description: Biological/Vaccine: Autologous, Lethally Irradiated Breast Cancer Cells Vaccine will be administered on days 1, 8, 15, 29 and then every 2 weeks until the supply of vaccine runs out', ' Autologous, Lethally Irradiated Breast Cancer Cells: Vaccination with autologous tumor cells engineered by adenoviral mediated gene transfer to secrete GM-CS', ' Overall Number of Participants Analyzed: 7', ' Measure Type: Number', ' Unit of Measure: doses 6'], 'Adverse Events': ['Adverse Events 1:', ' Total: 1/7 (14.29%)', ' Fatigue 1/7 (14.29%)']}

{'Clinical Trial ID': 'NCT00458237', 'Intervention': ['INTERVENTION 1: ', ' Phase I: Everolimus (Dose Level 1) and Trastuzumab', ' Cycle duration is 21 days. Participants receive trastuzumab 6 mg/kg [8 mg/kg loading dose] IV once every three weeks and take everolimus 5 mg by mouth daily on days 1-21. Participants are treated until disease progression or unacceptable toxicity.', 'INTERVENTION 2: ', ' Phase I: Everolimus (Dose Level 2) and Trastuzumab', ' Cycle duration is 21 days. Participants receive trastuzumab 6 mg/kg [8 mg/kg loading dose] IV once every three weeks and take everolimus 10 mg by mouth daily on days 1-21. Participants are treated until disease progression or unacceptable toxicity.'], 'Eligibility': ['Inclusion Criteria:', ' Histologically or cytologically confirmed invasive breast cancer, with stage IV disease', ' Measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension as greater than or equal to 20mm with conventional techniques or as greater than or equal to 10mm with spiral CT scan.', ' Primary tumor or metastasis must overexpress HER2', ' Patient must have received 1-2 prior chemotherapeutic regiments for metastatic breast cancer and must have been off treatment for at least three weeks.', ' Patient must have received and progressed on at least 1 prior trastuzumab-containing regimen, but not more than 2, in the metastatic setting.', ' Patients may have received prior radiation therapy', ' Patients may have received hormonal therapy in the adjuvant or metastatic setting', ' 18 years of age or older', ' Life expectancy of greater than 6 months', ' Normal organ and marrow function as defined in the protocol', ' Left ventricular ejection fraction (LVEF) greater than or equal to the institutional lower limit of normal', 'Exclusion Criteria:', ' Treatment with any investigational drug within 4 weeks', ' Long-term treatment, over 3 months, with a systemic steroid or another immunosuppressive agent', ' Other malignancies within the past 3 years, except for adequately treated carcinoma of teh cervix or basal-or squamous-cell carcinoma of the skin', ' Impairment of gastrointestinal function or gastrointestinal disease that may significantly alter the absorption of RAD001', ' An active, bleeding diathesis or an oral anti-vitamin K medication', ' Prior treatment with an mTOR inhibitor', ' History of non-compliance with medical regimens', ' Unwillingness or inability to comply with the protocol', ' Major surgery within 2 weeks before study entry', ' Patients with active brain metastases or leptomeningeal carcinomatosis', ' Patients who have experienced grade 1 or grade 2 hypersensitivity reactions to prior trastuzumab therapy are eligible ONLY IF these reactions did not prevent further administration', ' Severe and/or uncontrolled intercurrent medical condition, psychiatric illness or a social situation that could limit their ability to comply with the study requirements.', ' Pregnant or breast-feeding women', ' HIV positive patients', ' Known hypersensitivity to RAD001 (everolimus) or other rapamycins'], 'Results': ['Outcome Measurement: ', ' Maximum Tolerated Dose (MTD)', ' The MTD is determined by the number of patients who experience a dose limiting toxicity (DLT). The MTD is defined as the highest dose at which fewer than one-third of patients experience a DLT. If no DLTs are observed, the MTD is not reached. Dose Limiting Toxicities (DLTs) were defined as follows (CTCAE v4.0):', ' Any grade 4 hematologic toxicity, excluding anemia.', ' Any grade 3 or 4 nonhematologic toxicity, except for nausea, vomiting, diarrhea, or hyperlipidemia that responds promptly (within 24 hours for nausea, vomiting, and diarrhea and within 1 week for hyperlipidemia) to appropriate treatment, and except for cardiac toxicity which will be assessed after 12 weeks of treatment.', ' Need to hold >1 dose of trastuzumab or > 7 doses of RAD001 within the first 3 weeks because of the presence of toxicity.', ' Time frame: Cycle One (first 21 days of treatment)', 'Results 1: ', ' Arm/Group Title: Phase I: Everolimus (Dose Level 1) and Trastuzumab', ' Arm/Group Description: Cycle duration is 21 days. Participants receive trastuzumab 6 mg/kg [8 mg/kg loading dose] IV once every three weeks and take everolimus 5 mg by mouth daily on days 1-21. Participants are treated until disease progression or unacceptable toxicity.', ' Overall Number of Participants Analyzed: 3', ' Measure Type: Number', ' Unit of Measure: participants with DLT 0', 'Results 2: ', ' Arm/Group Title: Phase I: Everolimus (Dose Level 2) and Trastuzumab', ' Arm/Group Description: Cycle duration is 21 days. Participants receive trastuzumab 6 mg/kg [8 mg/kg loading dose] IV once every three weeks and take everolimus 10 mg by mouth daily on days 1-21. Participants are treated until disease progression or unacceptable toxicity.', ' Overall Number of Participants Analyzed: 3', ' Measure Type: Number', ' Unit of Measure: participants with DLT 0'], 'Adverse Events': ['Adverse Events 1:', ' Total: 0/3 (0.00%)', ' Muco/stomatitis (symptom) oral cavity 0/3 (0.00%)', ' Fatigue 0/3 (0.00%)', ' Vascular access-Thrombosis/embolism [1]0/3 (0.00%)', ' Leukocytes 0/3 (0.00%)', ' Lymphopenia 0/3 (0.00%)', ' Neutrophils 0/3 (0.00%)', ' Platelets 0/3 (0.00%)', ' Hypokalemia 0/3 (0.00%)', ' Thrombosis/thrombus/embolism [2]0/3 (0.00%)', 'Adverse Events 2:', ' Total: 1/3 (33.33%)', ' Muco/stomatitis (symptom) oral cavity 0/3 (0.00%)', ' Fatigue 0/3 (0.00%)', ' Vascular access-Thrombosis/embolism [1]0/3 (0.00%)', ' Leukocytes 0/3 (0.00%)', ' Lymphopenia 1/3 (33.33%)', ' Neutrophils 0/3 (0.00%)', ' Platelets 0/3 (0.00%)', ' Hypokalemia 0/3 (0.00%)', ' Thrombosis/thrombus/embolism [2]0/3 (0.00%)']}

5deb8ebd-fbd2-4d84-8ad2-a1248426908b

Comparison

Eligibility

NCT00365417

NCT00853996

To be eligible for both the secondary trial and the primary trial patients must satisfy all the following conditions; alkaline phosphatase < 2 x ULN, aspartate aminotransferase <= 1.5 x ULN and Hemoglobin > 10 g/dL.

Entailment

{'Clinical Trial ID': 'NCT00365417', 'Intervention': ['INTERVENTION 1: ', ' Neoadjuvant Study Treatment', ' Doxorubicin, cyclophosphamide, and bevacizumab followed by docetaxel and capecitabine'], 'Eligibility': ['Inclusion Criteria:', ' Patients must be female.', ' The patient must be greater than/equal to 18 years old', ' The diagnosis of invasive adenocarcinoma of the breast must have been made by core needle biopsy or limited incisional biopsy.', ' Patients must have clinical Stage IIIA, IIIB, or IIIC disease (American Joint Committee on Cancer [AJCC] staging criteria) with a primary breast tumor that is greater than/equal to 2.0 cm measured by clinical exam, unless the patient has inflammatory breast carcinoma, in which case measurable disease is not required.', ' Patients must have the ability to swallow oral medication.', " The patient's Eastern Cooperative Oncology Group (ECOG) performance status must be 0 or 1.", ' At the time of study entry, blood counts must meet the following criteria:', ' Absolute neutrophil count (ANC) must be greater than/equal to 1200/mm3.', ' Platelet count must be greater than/equal to 100,000/mm^3.', ' Hemoglobin must be greater than/equal to 10 g/dL.', ' The following criteria for evidence of adequate hepatic function must be met:', " total bilirubin must be less than/equal to upper limit of normal (ULN) for the lab unless the patient has a grade 1 bilirubin elevation (greater than ULN to 1.5 x ULN) due to Gilbert's disease or similar syndrome involving slow conjugation of bilirubin; and", ' alkaline phosphatase must be less than 2.5 x ULN for the lab; and', ' aspartate aminotransferase (AST) must be less than/equal to 1.5 x ULN for the lab.', ' Alkaline phosphatase and AST may not both be greater than the ULN. For example, if the alkaline phosphatase is greater than the ULN but less than/equal to 2.5 x ULN, then the AST must be less than/equal to the ULN. If the AST is greater than the ULN but less than/equal to 1.5 x ULN, then the alkaline phosphatase must be less than/equal to ULN.', ' Patients with either skeletal pain or alkaline phosphatase that is greater than ULN but less than/equal to 2.5 x ULN are eligible for inclusion in the study if a bone scan or positron emission tomography (PET) scan does not demonstrate metastatic disease. Patients with suspicious findings on bone scan or PET scan are eligible if suspicious findings are confirmed as benign by x-ray, magnetic resonance imaging (MRI), or biopsy.', ' Patients with AST or alkaline phosphatase greater than ULN are eligible for inclusion in the study if liver imaging (computed tomography [CT], MRI, or PET scan) does not demonstrate metastatic disease and adequate hepatic function.', ' The following criteria for evidence of adequate renal function must be met:', ' Serum creatinine less than/equal to ULN for the lab.', ' Calculated creatinine clearance must be greater than 50 mL/min.', ' Urine protein/creatinine (UPC) ratio must be less than 1.0.', ' Patients must have their left ventricular ejection fraction (LVEF) assessed by multigated acquisition (MUGA) scan or echocardiogram within 3 months prior to study entry. The LVEF must be greater than/equal to the lower limit of normal (LLN) for the cardiac imaging facility performing the MUGA scan or echocardiogram. Note: If the cardiac imaging facility cannot provide a LLN, use 50% as the LLN value.', " Note: Since the pre-entry LVEF serves as the baseline for comparing subsequent LVEF assessments to determine if bevacizumab therapy can be continued following doxorubicin and cyclophosphamide (AC) and postoperatively, it is critical that this baseline study be an accurate assessment of the patient's LVEF. If the baseline LVEF is greater than 65%, the MUGA scan or echocardiogram must be repeated prior to study entry. The lower of the two LVEF values should be used as the baseline LVEF.", ' Patients must have an electrocardiogram (EKG) within 3 months prior to study entry.', 'Exclusion Criteria:', ' Tumor determined to be strongly HER2-positive by immunohistochemistry (3+) or by fluorescent in situ hybridization (positive for gene amplification).', ' Excisional biopsy for this primary tumor.', ' Synchronous bilateral invasive breast cancer.', ' Surgical axillary staging procedure prior to study entry (Exceptions: 1) fine needle aspiration (FNA) of an axillary node is permitted for any patient, and 2) although not recommended, a sentinel lymph node biopsy for patients with clinically negative axillary nodes is permitted.)', ' History of any of the following cancers:', ' Ipsilateral breast cancer: invasive, ductal carcinoma in situ (DCIS) treated with any therapy other than excision', ' Contralateral breast cancer: invasive within the past 5 years (Patients with history of DCIS or synchronous DCIS are eligible)', ' History of non-breast malignancies within the 5 years prior to study entry. Patients with the following cancers are eligible if diagnosed and treated within the previous 5 years: carcinoma in situ of the cervix, carcinoma in situ of the colon, melanoma in situ, and basal cell and squamous cell carcinoma of the skin.', ' Prior therapy with anthracyclines, taxanes, capecitabine, or bevacizumab for any malignancy.', ' Treatment including radiation therapy, chemotherapy, biotherapy, and/or hormonal therapy administered for the currently diagnosed breast cancer prior to study entry. The only exception is hormonal therapy, which may have been given for up to a total of 28 days anytime after diagnosis and before study entry. In such a case, hormonal therapy must stop at or before study entry and be re-started, if indicated, following chemotherapy.', ' Any of the following cardiac conditions:', ' angina pectoris that requires the use of anti-anginal medication;', ' history of documented congestive heart failure;', ' serious cardiac arrhythmia requiring medication;', ' severe conduction abnormality;', ' valvular disease with documented cardiac function compromise; or', ' uncontrolled hypertension defined as blood pressure greater than 150/90 on antihypertensive therapy. (Patients with hypertension that is well controlled on medication are eligible.)', ' History of myocardial infarction documented by elevated cardiac enzymes or persistent regional wall abnormalities on assessment of left ventricular (LV) function.', ' History of transient ischemic attack (TIA) or cerebrovascular accident (CVA).', ' History of other arterial thrombotic event within 12 months before study entry.', ' Symptomatic peripheral vascular disease.', ' Any significant bleeding within 6 months before study entry.', ' Serious or non-healing wound, skin ulcers, or bone fracture.', ' Gastroduodenal ulcer(s) determined by endoscopy to be active.', ' Invasive procedures defined as follows:', ' Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to planned start of study therapy. (Note: Placement of a vascular access device is not considered a major surgical procedure.)', ' Anticipation of need for major surgical procedures (other than the required breast surgery) during the course of the study.', ' Known bleeding diathesis or coagulopathy. (Patients on warfarin with an in-range international normalized ratio [INR] [usually between 2 and 3] are eligible.)', ' Other nonmalignant systemic disease (cardiovascular, renal, hepatic, diabetes, etc.) that would preclude the patient from receiving study treatment or would prevent required follow-up.', " Sensory/motor neuropathy greater than/equal to grade 2, as defined by the NCI's Common Terminology Criteria for Adverse Events Version 3.0 (CTCAE v3.0).", ' Conditions that would prohibit administration of corticosteroids.', ' History of hypersensitivity reaction to drugs formulated with polysorbate 80.', ' Therapy with any hormonal agent such as raloxifene, tamoxifen, or other selective estrogen receptor modulator (SERM), either for osteoporosis or breast cancer prevention. Patients are eligible only if these medications are discontinued prior to study entry.', ' Any sex hormonal therapy, e.g., birth control pills, ovarian hormonal replacement therapy, etc. These patients are eligible if this therapy is discontinued prior to study entry. (Women of reproductive potential must agree to use an effective non-hormonal method of contraception during study therapy and for at least 3 months after completion of bevacizumab.)', ' Pregnancy or lactation at the time of study entry.', ' Use of any investigational agent within 4 weeks prior to enrollment in the study.', ' Psychiatric or addictive disorders or other conditions that, in the opinion of the investigator, would preclude the patient from meeting the study requirements.'], 'Results': ['Outcome Measurement: ', ' Pathologic Complete Response (pCR) in the Breast', ' Measured by no histologic evidence of invasive tumor cells in the surgical breast specimen', ' Time frame: Approximately 7 months', 'Results 1: ', ' Arm/Group Title: Neoadjuvant Study Treatment', ' Arm/Group Description: Doxorubicin, cyclophosphamide, and bevacizumab followed by docetaxel and capecitabine', ' Overall Number of Participants Analyzed: 45', ' Measure Type: Number', ' Unit of Measure: participants pCR in the breast: 4', ' No pCR in the breast: 38', ' No data available: 3'], 'Adverse Events': ['Adverse Events 1:', ' Total: 14/45 (31.11%)', ' Hemoglobin 1/45 (2.22%)', ' Diarrhea 1/45 (2.22%)', ' Esophagitis 1/45 (2.22%)', ' Mucositis (clinical exam) - oral cavity 1/45 (2.22%)', ' Mucositis (functional/symptomatic) - esophagus 1/45 (2.22%)', ' Mucositis (functional/symptomatic) - oral cavity 2/45 (4.44%)', ' Insomnia 1/45 (2.22%)', ' Pain - abdominal NOS 2/45 (4.44%)', ' Pain - back 1/45 (2.22%)']}

{'Clinical Trial ID': 'NCT00853996', 'Intervention': ['INTERVENTION 1: ', ' Prevention (Acolbifene Hydrochloride)', ' Patients receive oral acolbifene hydrochloride once daily for 6 months in the absence of unacceptable toxicity.', ' acolbifene hydrochloride: Given orally'], 'Eligibility': ['Inclusion Criteria:', ' Gail risk >= 1.7% and/or relative risk >= 3 times that for 5-year age group', ' Premenopausal', ' More than 6 months since initiating or discontinuing oral contraceptives', ' At increased risk for breast cancer, as indicated by >= 1 of the following risk factors:', ' BRCA1/2 mutation characterized as deleterious or of uncertain significance', ' Prior atypical ductal hyperplasia, ductal carcinoma in situ, or lobular carcinoma in situ', ' Prior random periareolar fine needle aspiration (RPFNA) showing atypical hyperplasia', ' Family history consistent with hereditary breast cancer, as indicated by 1 of the following criteria:', ' >= 4 relatives with breast cancer', ' >= 2 relatives diagnosed with breast cancer at 50 years of age', ' Breast and ovarian cancer diagnosed in same relative', ' No suspicion for breast cancer on baseline mammogram performed between days 1-10 of menstrual cycle within 3 months prior to screening baseline RPFNA', ' Exhibits hyperplasia with or without atypia (Masood score >= 14) with >= 500 cells AND Ki-67 positivity >= 2% by RPFNA performed within 6 months prior to initiation of study drug', ' Estimated visual mammographic breast density category >= 5% on mammogram performed within 6 months prior to initiation of study drug', ' Has regular menstrual cycles (between 21 and 35 days) unless using extended regimen oral contraceptives or a contraceptive device (e.g., Mirena IUD) Values for metabolic profile and blood count within normal limits', ' Absolute granulocyte count > 1,000/mm^3', ' Platelets > 100,000/mm^3', ' Hemoglobin > 10 g/dL', ' Bilirubin < 2.0 mg/dL', ' AST < 2 times upper limit of normal (ULN)', ' Albumin > 3.0 g/dL', ' Creatinine < 1.5 mg/dL', ' Alkaline phosphatase < 2 times ULN', ' Concurrent hormonal contraceptives allowed provided patient remains on the same hormonal regimen from 3 months prior to baseline aspiration until the completion of study treatment', ' Fertile patients must use effective contraception during and for 3 months after completion of study treatment', ' Willing to ingest recommended dose of calcium and vitamin D for premenopausal bone health (1,200 mg calcium and 800 IU vitamin D daily)', ' Negative pregnancy test prior to receiving study agent', ' Exclusion Criteria', ' pregnant or nursing', ' nursing within the past 6 months', ' Known osteoporosis or severe osteopenia (T-score -2 or worse by DEXA)', ' History of symptomatic endometriosis with pelvic pain, poorly controlled migraines, or hot flashes', ' History of deep venous thrombosis', ' History of allergic reactions attributed to compounds of similar chemical or biological composition to the study agent', ' Other condition or concurrent illness that, in the opinion of the investigator, would make the patient a poor candidate for RPFNA', ' Less than 1 year since prior use of aromatase inhibitors (e.g., anastrozole, exemestane, or letrozole) or selective estrogen receptor modulators (e.g., tamoxifen citrate, raloxifene, or arzoxifene hydrochloride)', ' Other concurrent chemopreventive agents', ' Concurrent anticoagulants', ' Other concurrent investigational agents', ' Bilateral breast implants'], 'Results': ['Outcome Measurement: ', ' Change in the Percentage of Breast Epithelial Cells Expressing Ki-67, From Baseline to 6 Months', ' Change in proliferation as measured by Ki-67 immunocytochemical expression in breast epithelial cells obtained by random periareolar fine needle aspiration at baseline and at 6 months.', ' Time frame: Baseline to 6 months', 'Results 1: ', ' Arm/Group Title: Prevention (Acolbifene Hydrochloride)', ' Arm/Group Description: Patients receive oral acolbifene hydrochloride once daily for 6 months in the absence of unacceptable toxicity.', ' acolbifene hydrochloride: Given orally', ' Overall Number of Participants Analyzed: 25', ' Median (Inter-Quartile Range)', ' Unit of Measure: percentage of positive cells -3.0 (-20.2 to 2.8)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 0/25 (0.00%)']}

5f4880ac-1ce2-4b89-841b-a9918720b6ea

Single

Intervention

NCT01441596

Patients in cohort 1 of the primary trial may receive gradually increasing doses of Afatinib monotherapy from 40mg PO to 50mg PO.

Entailment

{'Clinical Trial ID': 'NCT01441596', 'Intervention': ['INTERVENTION 1: ', ' Afatinib Mono', ' Afatinib monotherapy administered orally: starting dose 40 mg per day, continuous treatment in a 3-weekly course. If well tolerated, the dose may be escalated to 50 mg.', 'INTERVENTION 2: ', ' Afatinib+Vino', ' Afatinib 40 mg per day administered orally, continuous treatment, in combination with weekly Vinorelbine 25 mg/m² administered intravenously on days 1, 8, 15 in a 3-weekly course.'], 'Eligibility': ['Inclusion criteria:', ' patients with HER2 positive breast cancer with a documented central nervous system (CNS) recurrence/progression (by imaging) during or after a HER2 inhibitor (Trastuzumab and/or Lapatinib) based therapy (no leptomeningeal carcinomatosis as the only site of CNS metastases)', ' at least one measurable and progressive lesion in the brain (=10 mm on T1-weighted, gadolinium-enhanced Magnetic Resonance Imaging). Measurable or non measurable extracranial metastases allowed.', ' previous treatment with HER2 inhibitors to be discontinued prior to first study treatment administration (at least 14 days for trastuzumab and other antibodies, at least 7 days for lapatinib).', ' previous chemotherapy and hormonal therapy (adjuvant and metastatic regimens) allowed, but chemotherapy must have been discontinued at least 14 days and hormonal therapy at least 7 days prior to first study treatment administration.', ' Patients must have recovered to baseline condition or to Common Terminology Criteria for Adverse Events (CTCAE) version 3.0 grade = 1 from any acute CTCAE v. 3.0 grade =2 side effects of previous treatments.', ' prior surgery, whole brain radiotherapy or stereotactic radiosurgery allowed provided that there is unequivocal evidence of one or more new and/or progressive brain metastases after completion of whole brain radiotherapy or stereotactic radiosurgery.', 'Exclusion criteria:', ' Prior treatment with HER2- tyrosine kinase inhibitor other than lapatinib', ' Any other current malignancy or malignancy diagnosed within the past five (5) years (other than bilateral primary breast cancer, metastases to the contralateral breast, non-melanomatous skin cancer and in situ cervical cancer).', " Significant chronic or recent acute gastrointestinal disorders with diarrhoea as a major symptom e.g. Crohn's disease, malabsorption or Common Terminology Criteria (CTC) grade =2 diarrhoea of any aetiology."], 'Results': ['Outcome Measurement: ', ' Patient Benefit Rate at 12 Weeks', ' Percentage of patients with patient benefit at week 12. Patient benefit was defined by the absence of central nervous system (CNS) disease progression according to Response Evaluation Criteria in Solid Tumours (RECIST) version 1.1 in addition to no tumour-related worsening of the neurological signs and symptoms (NSS), no tumour-related increase in corticosteroid dosage and no progression of extra CNS disease according to RECIST 1.1', ' Time frame: 12 weeks from randomisation', 'Results 1: ', ' Arm/Group Title: Afatinib Mono', ' Arm/Group Description: Afatinib monotherapy administered orally: starting dose 40 mg per day, continuous treatment in a 3-weekly course. If well tolerated, the dose may be escalated to 50 mg.', ' Overall Number of Participants Analyzed: 40', ' Measure Type: Number', ' Unit of Measure: percentage of participants 30.0 (16.6 to 46.5)', 'Results 2: ', ' Arm/Group Title: Afatinib+Vino', ' Arm/Group Description: Afatinib 40 mg per day administered orally, continuous treatment, in combination with weekly Vinorelbine 25 mg/m administered intravenously on days 1, 8, 15 in a 3-weekly course.', ' Overall Number of Participants Analyzed: 38', ' Measure Type: Number', ' Unit of Measure: percentage of participants 34.2 (19.6 to 51.4)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 18/40 (45.00%)', ' Anaemia 0/40 (0.00%)', ' Febrile neutropenia 0/40 (0.00%)', ' Progressive cerebellar degeneration 0/40 (0.00%)', ' Vertigo 0/40 (0.00%)', ' Diarrhoea 3/40 (7.50%)', ' Dysphagia 0/40 (0.00%)', ' Enteritis 0/40 (0.00%)', ' Ileus 0/40 (0.00%)', ' Intestinal obstruction 0/40 (0.00%)', ' Nausea 1/40 (2.50%)', ' Stomatitis 1/40 (2.50%)', ' Subileus 0/40 (0.00%)', ' Vomiting 3/40 (7.50%)', 'Adverse Events 2:', ' Total: 24/37 (64.86%)', ' Anaemia 1/37 (2.70%)', ' Febrile neutropenia 3/37 (8.11%)', ' Progressive cerebellar degeneration 0/37 (0.00%)', ' Vertigo 0/37 (0.00%)', ' Diarrhoea 5/37 (13.51%)', ' Dysphagia 1/37 (2.70%)', ' Enteritis 1/37 (2.70%)', ' Ileus 1/37 (2.70%)', ' Intestinal obstruction 1/37 (2.70%)', ' Nausea 0/37 (0.00%)', ' Stomatitis 1/37 (2.70%)', ' Subileus 1/37 (2.70%)', ' Vomiting 2/37 (5.41%)']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

b3aabfaa-23cb-4a75-8416-761d8574f0a4

Single

Results

NCT00524303

The Trastuzumab arm of the primary trial reported a pCR rate of 54%, significantly worse results than the Lapatinib arm which achieved a pCR rate of 45%.

Contradiction

{'Clinical Trial ID': 'NCT00524303', 'Intervention': ['INTERVENTION 1: ', ' Trastuzumab', ' Participants received trastuzumab alone (a loading dose of 4 milligrams [mg]/kilogram [kg] on Day 1, followed by a dose of 2 mg/kg on Day 1 of Week 2 and weekly thereafter). Participants were treated with trastuzumab in a 2-week run-in period. On Day 14, a second core needle biopsy was performed, followed by initiation of chemotherapy with 2 combination regimens of 4 cycles each (1 cycle=3 weeks): FEC75 (5-fluorouracil [5-FU] 500 mg/meters squared [m^2], epirubicin 75 mg/m^2, cyclophosphamide 500 mg/m^2 x 4 cycles on Day 1), then paclitaxel (80 mg/m^2 x 4 cycles on Day 1, Day 8, and Day 15) in combination with trastuzumab.', 'INTERVENTION 2: ', ' Lapatinib', ' Participants received lapatinib alone (1250 mg orally [PO] once daily [QD]). Participants were treated with lapatinib in a 2-week run-in period. On Day 14, a second core needle biopsy was performed, followed by initiation of chemotherapy with 2 combination regimens of 4 cycles each (1 cycle=3 weeks): FEC75 (5-FU 500 mg/m^2, epirubicin 75 mg/m^2, cyclophosphamide 500 mg/m^2 x 4 cycles on Day 1), then paclitaxel (80 mg/m^2 x 4 cycles on Day 1, Day 8, and Day 15) in combination with lapatinib.'], 'Eligibility': ['Inclusion Criteria:', ' Have signed an informed consent form (ICF) and a Patient Authorization Form (HIPAA).', ' Have histologically or cytologically confirmed ErbB2- (HER2/neu-) overexpressing invasive breast cancer (T2-4, N0-2).', ' ErbB2 overexpressing breast cancer, defined as one of the following definitions:', ' 3+ staining by immunohistochemistry (IHC),', ' a fluorescent in situ hybridization (FISH) result of more than six HER2 gene copies per nucleus', ' a FISH ratio of more than 2.2.', ' Have either measurable or evaluable disease.', ' Have an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-1 (Refer to Section 11.4).', ' Have LVEF within the institutional range of normal as measured by either echocardiogram (ECHO) or MUGA scans. The same modality must be used consistently throughout the study.', ' Be deemed able to tolerate 8 cycles of preoperative chemotherapy, including 4 cycles with an anthracycline (epirubicin).', ' Must be willing to undergo 2 mandatory core biopsies (4 passes each) after diagnosis to obtain tissue for biologic expression profiling. Any subject with clinically palpable residual disease may undergo an optional third biopsy to allow identification of presumed pathways of resistance to therapy. This information might be useful in providing the subject with options for other targeted therapies if definitive surgery confirms residual disease. Definitive local therapy with surgery and radiation therapy as indicated will be performed after completion of 12 weeks of paclitaxel-based chemotherapy.', ' Are able to swallow and retain oral medication (intact pill).', ' Are able to complete all screening assessments as outlined in the protocol.', ' Have adequate organ function as defined in Table 4:', ' Table 1 Baseline Laboratory Values', ' Hematologic:', ' ANC (absolute neutrophil count) >1.5 x 109/L hemoglobin >9 g/dL platelets >75 x 109/L', ' Hepatic:', ' albumin >2.5 g/dL serum bilirubin <1.25 x ULN AST / ALT <3 x ULN if no documented liver metastases AST / ALT <3 x ULN with documented liver metastases', ' Renal:', ' serum creatinine <2.0 mg/dL', ' OR - calculated creatinine clearance >40 mL/min', ' Are subjects aged >18 years with any menopausal status:', ' Non-child-bearing potential (i.e., women with functioning ovaries who have a current documented tubal ligation or hysterectomy, or women who are postmenopausal)', ' Child-bearing potential (i.e., women with functioning ovaries and no documented impairment of oviductal or uterine function that would cause sterility.) This category includes women with oligomenorrhea (severe), women who are perimenopausal, and young women who have begun to menstruate. These subjects must have a negative serum pregnancy test at screening and agree to one of the following:', " Complete abstinence from intercourse from 2 weeks prior to administration of the first dose of study medication until 28 days after the final dose of study medication; or Consistent and correct use of one of the following acceptable methods of birth control: male partner who is sterile prior to the female subject's entry into the study and is the sole sexual partner for that female subject; any intrauterine device (IUD) with a documented failure rate of less than 1% per year; oral contraceptives (either combined or progestogen only) where not contraindicated for this subject population or per local practice.; or barrier methods, including diaphragm or condom with a spermicide.", ' Please note that breast cancer subjects on this trial cannot receive injectable levonorgestrel or injectable progestogen due to the potential for an adverse effect of anti-hormonal therapies on chemotherapy administered for breast cancer [Albain, 2002]. Progestogen may also affect the proliferative rate of endocrine-responsive tumors.', 'Exclusion Criteria:', ' Have received any prior chemotherapy.', ' Had prior therapy with an ErbB1 and/or ErbB2 inhibitor.', ' Are receiving concurrent anti-cancer therapy (chemotherapy, immunotherapy, and biologic therapy) while taking study medication.', ' Have malabsorption syndrome, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel. Women with ulcerative colitis are also excluded.', " Have a concurrent disease or condition that would make the woman inappropriate for study participation, or any serious medical disorder that would interfere with the woman's safety.", ' Have an active or uncontrolled infection.', ' Have dementia, altered mental status, or any psychiatric condition that would prohibit the understanding or rendering of informed consent.', ' Have active cardiac disease, defined as one or more of the following:', ' History of uncontrolled or symptomatic angina History of arrhythmias requiring medications, or clinically significant Myocardial infarction <6 months from study entry Uncontrolled or symptomatic congestive heart failure Ejection fraction below the institutional normal limit Any other cardiac condition, which in the opinion of the treating physician, would make this protocol unreasonably hazardous for the patient', ' Are pregnant or breastfeeding.', ' Have received concurrent treatment with an investigational agent or participate in another clinical trial.', ' Have received concurrent treatment with prohibited medications (refer to Section 5.8.2 for details on prohibited medications).', ' Have used an investigational drug within 30 days or 5 half-lives, whichever is longer, preceding the first dose of study medication.', ' Have a known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to any of the agents used in this study or their excipients.', ' Are receiving therapeutic anti-coagulation therapy (i.e. warfarin, heparin).'], 'Results': ['Outcome Measurement: ', ' Percentage of Participants With Overall Pathological Complete Response (pCR) After 26 Weeks of Therapy', ' A pCR in the breast was defined as no pathologic evidence of invasive disease (residual ductal carcinoma in situ [DCIS] or lobular carcinoma in situ [LCIS] was allowed). A pCR in the axillary lymph node(s) was defined as no evidence of breast cancer cells in the lymph node (including subcapsular sinus). Overall pCR was defined as the sum of pCR in the breast and pCR in the lymph nodes. 26 weeks of therapy comprised the 2-week run-in phase, 12 weeks of treatment with FEC, and 12 weeks of treatment with Paclitaxel.', ' Time frame: Week 26', 'Results 1: ', ' Arm/Group Title: Trastuzumab', ' Arm/Group Description: Participants received trastuzumab alone (a loading dose of 4 milligrams [mg]/kilogram [kg] on Day 1, followed by a dose of 2 mg/kg on Day 1 of Week 2 and weekly thereafter). Participants were treated with trastuzumab in a 2-week run-in period. On Day 14, a second core needle biopsy was performed, followed by initiation of chemotherapy with 2 combination regimens of 4 cycles each (1 cycle=3 weeks): FEC75 (5-fluorouracil [5-FU] 500 mg/meters squared [m^2], epirubicin 75 mg/m^2, cyclophosphamide 500 mg/m^2 x 4 cycles on Day 1), then paclitaxel (80 mg/m^2 x 4 cycles on Day 1, Day 8, and Day 15) in combination with trastuzumab.', ' Overall Number of Participants Analyzed: 26', ' Measure Type: Number', ' Unit of Measure: percentage of participants 54.0', 'Results 2: ', ' Arm/Group Title: Lapatinib', ' Arm/Group Description: Participants received lapatinib alone (1250 mg orally [PO] once daily [QD]). Participants were treated with lapatinib in a 2-week run-in period. On Day 14, a second core needle biopsy was performed, followed by initiation of chemotherapy with 2 combination regimens of 4 cycles each (1 cycle=3 weeks): FEC75 (5-FU 500 mg/m^2, epirubicin 75 mg/m^2, cyclophosphamide 500 mg/m^2 x 4 cycles on Day 1), then paclitaxel (80 mg/m^2 x 4 cycles on Day 1, Day 8, and Day 15) in combination with lapatinib.', ' Overall Number of Participants Analyzed: 29', ' Measure Type: Number', ' Unit of Measure: percentage of participants 45.0'], 'Adverse Events': ['Adverse Events 1:', ' Total: 7/32 (21.88%)', ' Febrile nuetropenia 3/32 (9.38%)', ' Neutropenia 3/32 (9.38%)', ' Anaemia 1/32 (3.13%)', ' Diarrhoea 0/32 (0.00%)', ' Vomiting 0/32 (0.00%)', ' Nausea 0/32 (0.00%)', ' Stomatitis 0/32 (0.00%)', ' Pyrexia 0/32 (0.00%)', ' Chest discomfort 0/32 (0.00%)', ' Cellilitis 0/32 (0.00%)', ' Diverticulitis 0/32 (0.00%)', ' Gastroenteritis 0/32 (0.00%)', 'Adverse Events 2:', ' Total: 7/34 (20.59%)', ' Febrile nuetropenia 0/34 (0.00%)', ' Neutropenia 0/34 (0.00%)', ' Anaemia 0/34 (0.00%)', ' Diarrhoea 2/34 (5.88%)', ' Vomiting 1/34 (2.94%)', ' Nausea 0/34 (0.00%)', ' Stomatitis 0/34 (0.00%)', ' Pyrexia 3/34 (8.82%)', ' Chest discomfort 0/34 (0.00%)', ' Cellilitis 1/34 (2.94%)', ' Diverticulitis 1/34 (2.94%)', ' Gastroenteritis 0/34 (0.00%)']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

f697c2d8-e0dd-476e-8ff4-dffe053076f8

Comparison

Intervention

NCT02835625

NCT00486525

the primary trial and the secondary trial do not use chemotherapy, radiotherapy or mammography in their interventions

Contradiction

{'Clinical Trial ID': 'NCT02835625', 'Intervention': ['INTERVENTION 1: ', ' Digital Breast Tomosynthesis', ' Digital Breast Tomosynthesis + Synthetic Mammography (DBT)', ' The DBT was independently read by two radiologists. A consensus meeting decided whether to recall the woman or not.', ' Women selected for further assessment (positive screening exam) was recalled.', ' Digital Breast Tomosynthesis + Synthetic Mammography: Two-view tomosynthesis performed with GE SenoClaire 3D Breast Tomosynthesis.', 'INTERVENTION 2: ', ' Digital Mammography', ' The digital mammograms was independently read by two radiologists. A consensus meeting decided whether to recall the woman or not.', ' Women selected for further assessment (positive screening exam) was recalled.', ' Digital mammography: Two-view digital mammography performed with GE SenoClaire 3D Breast Tomosynthesis.'], 'Eligibility': ['Inclusion Criteria:', ' Informed consent', 'Exclusion Criteria:', 'Breast implants'], 'Results': ['Outcome Measurement: ', ' Number of Participants With Screen-Detected Breast Cancer', ' Comparison of rates of screen-detected breast cancer in tomosynthesis versus digital mammography as performed in a population based screening program.', ' Time frame: 36 months from start up of the trial', 'Results 1: ', ' Arm/Group Title: Digital Breast Tomosynthesis', ' Arm/Group Description: Digital Breast Tomosynthesis + Synthetic Mammography (DBT)', ' The DBT was independently read by two radiologists. A consensus meeting decided whether to recall the woman or not.', ' Women selected for further assessment (positive screening exam) was recalled.', ' Digital Breast Tomosynthesis + Synthetic Mammography: Two-view tomosynthesis performed with GE SenoClaire 3D Breast Tomosynthesis.', ' Overall Number of Participants Analyzed: 14380', ' Measure Type: Count of Participants', ' Unit of Measure: Participants 95 0.7%', 'Results 2: ', ' Arm/Group Title: Digital Mammography', ' Arm/Group Description: The digital mammograms was independently read by two radiologists. A consensus meeting decided whether to recall the woman or not.', ' Women selected for further assessment (positive screening exam) was recalled.', ' Digital mammography: Two-view digital mammography performed with GE SenoClaire 3D Breast Tomosynthesis.', ' Overall Number of Participants Analyzed: 14369', ' Measure Type: Count of Participants', ' Unit of Measure: Participants 87 0.6%'], 'Adverse Events': ['Adverse Events 1:', ' Total: 0/14734 (0.00%)', 'Adverse Events 2:', ' Total: 0/14719 (0.00%)']}

{'Clinical Trial ID': 'NCT00486525', 'Intervention': ['INTERVENTION 1: ', ' Arm I: Yoga Therapy', ' Patients participated in a Hatha yoga session over 90 minutes twice weekly for 12 weeks. Patients were also encouraged to practice yoga at home. Patients recorded their total home/class practice time in weekly logs.', 'INTERVENTION 2: ', ' Arm II: Wait-List', ' Wait-listed women were told to continue performing their usual activities, and to refrain from beginning any yoga practice. After their final assessment they were offered the yoga classes.'], 'Eligibility': ['DISEASE CHARACTERISTICS:', ' Stage 0-IIIA breast cancer survivor', ' Completed cancer treatment within the past 36 months (except for tamoxifen/aromatase inhibitors)', ' At least 2 months since prior surgery, adjuvant therapy, or radiotherapy, whichever occurred last', ' Women who are not currently practicing yoga and have not participated in any of the following activities:', ' Meditation, tai chi, or related activities', ' Yoga or tai chi within the past 6 months', ' Had classes for or practiced yoga for more than 3 months', ' Women who typically engage in a total of 5 or more hours of vigorous physical activity per week are not eligible', ' No inflammatory breast cancer', ' PATIENT CHARACTERISTICS:', 'Inclusion criteria:', ' Hemoglobin 10 g/dL (patients with a hemoglobin of < 10 g/dL may be retested in 6 weeks after treatment of anemia and allowed to participate in study if blood counts recovered)', ' Physically able to fully participate in yoga intervention', 'Exclusion criteria:', ' Inability to comfortably get up and down from the floor 2-3 times in a session', ' Breathing problems requiring use of oxygen', ' Problems walking without a cane or walker assistance', ' Prior knee or hip replacement with limited movement in the joint', ' Inability to comfortably lie on the stomach', ' Alcohol, or drug abuse', ' Diagnosis of any of the following conditions:', ' Diabetes', ' Chronic obstructive pulmonary disease', ' Uncontrolled hypertension', ' Evidence of liver or kidney failure', ' Symptomatic ischemic heart disease', ' Significant visual or auditory problems', ' Mental disorder or cognitive impairment', ' Notable serious cardiovascular history (e.g., prior life-threatening abnormal heart rhythms)', ' Other medical conditions involving the immune system such as autoimmune and/or inflammatory diseases including rheumatoid arthritis and ulcerative colitis', ' History of breast or any other cancer, except basal or squamous cell skin cancer', ' PRIOR CONCURRENT THERAPY:', ' See Disease Characteristics', ' No regular use of medications with major immunological consequences (e.g., steroids)'], 'Results': ['Outcome Measurement: ', ' Stimulated ln (TNF-a)', ' log-transformed Lipopolysaccharide (LPS) stimulated Tumor Necrosis Factor-alpha (TNF-alpha)', ' Time frame: Immediately post-treatment and 3 months post-treatment', 'Results 1: ', ' Arm/Group Title: Arm I: Yoga Therapy', ' Arm/Group Description: Patients participated in a Hatha yoga session over 90 minutes twice weekly for 12 weeks. Patients were also encouraged to practice yoga at home. Patients recorded their total home/class practice time in weekly logs.', ' Overall Number of Participants Analyzed: 92', ' Least Squares Mean (Standard Error)', ' Unit of Measure: ln (pg/mL) Immediately post-treatment: 8.31 (0.041)', ' 3 months post-treatment: 8.31 (0.042)', 'Results 2: ', ' Arm/Group Title: Arm II: Wait-List', ' Arm/Group Description: Wait-listed women were told to continue performing their usual activities, and to refrain from beginning any yoga practice. After their final assessment they were offered the yoga classes.', ' Overall Number of Participants Analyzed: 84', ' Least Squares Mean (Standard Error)', ' Unit of Measure: ln (pg/mL) Immediately post-treatment: 8.39 (0.040)', ' 3 months post-treatment: 8.44 (0.043)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 0/100 (0.00%)', 'Adverse Events 2:', ' Total: 0/100 (0.00%)']}

f2c0f753-1775-42af-94f0-b87b20156e65

Single

Eligibility

NCT01028352

Patients with aromatase inhibitor associated musculoskeletal symptoms, such as Grade 1 or above musculoskeletal pain or sensory neuropathy, are eligible for the primary trial.

Entailment

{'Clinical Trial ID': 'NCT01028352', 'Intervention': ['INTERVENTION 1: ', ' Duloxetine', ' Participants took 30 mg oral capsules once a day for 7 days, then 60 mg per mouth once per day for 21 days. After 4 weeks if pain had decreased, subjects continued 60 mg. per mouth once per day for 4 weeks. If pain had not decreased, subjects took 60 mg twice per day per mouth for 4 weeks. 5 Questionnaires were administered at baseline and every 2 weeks for 8 weeks; medication was tapered at the end of study.'], 'Eligibility': ['Inclusion Criteria:', ' Female;', ' Histologically proven stage 0-III invasive carcinoma of the breast that is ER and/or PR positive by immunohistochemical staining, who are receiving a standard dose of aromatase inhibitor (AI) therapy (letrozole 2.5mg once daily or exemestane 25mg once daily or anastrozole 1mg once daily). Women with oligometastatic disease may be included at the discretion of the principal investigator. Surgical resection, chemotherapy, and radiation therapy must have been completed at the time of study enrollment, with the exception of trastuzumab;', ' AI therapy has been ongoing for 2 weeks and treatment is expected to continue;', ' AI-associated musculoskeletal symptoms, defined as:', ' Grade 1 or higher musculoskeletal pain that developed or worsened (6 or 7 on CGICS) during AI therapy or', ' Grade 1 or higher sensory neuropathy that developed or worsened (6 or 7 on CGICS) during AI therapy;', ' Average pain of 4 on the 11-point Likert scale of question #5 of the Brief Pain Inventory;', ' ECOG performance status 0-2;', ' Willing and able to sign an informed consent document.', 'Exclusion Criteria:', ' Known hypersensitivity to duloxetine or any of the inactive ingredients;', ' New musculoskeletal pain that is due specifically to fracture or traumatic injury;', ' Treatment with monoamine oxidase inhibitors (MAO-I) within 14 days of enrollment;', ' Concurrent treatment with phenothiazines (including thioridazine), propafenone, flecainide, triptans, MAO-Is, SSRIs, SNRIs, or tricyclic antidepressants;', ' Currently primary psychiatric diagnosis (schizophrenia, psychosis) or suicidal ideation, history of bipolar disorder, or seizure disorder;', ' Chronic liver disease, end stage renal disease, or creatinine clearance < 30 mL/min as defined by the Cockroft-Gault equation;', ' Uncontrolled narrow-angle glaucoma or clinically significant coagulation disorder;', ' Pregnant or breast feeding;', ' History of alcohol or other substance abuse or dependence within the year prior to enrollment;', ' Serious or unstable medical condition that could likely lead to hospitalization during the course of the study or compromise study participation.'], 'Results': ['Outcome Measurement: ', ' Percentage of Patients Who Experience 30% Reduction in Average Pain Score From Baseline to 8 Weeks Due to Duloxetine Therapy.', ' Subjects were considered evaluable if they met all eligibility criteria and took at least one dose of duloxetine. Average pain was measured using Wisconsin Brief Pain Inventory Questionnaire.(BPI) The BPI is a 17-item patient self-rating scale that assessed sensory & reactive components of pain. The BPI uses 0 to 10 numeric rating scales for item rating.Since pain can be variable,the BPI asks patients to rate pain at completing questionnaire, and also at its worst, least, and average over the previous 24 hours. The primary endpoint is based on the 24-hour avg pain as reported on BPI.', ' Time frame: 8 weeks', 'Results 1: ', ' Arm/Group Title: Duloxetine', ' Arm/Group Description: Participants took 30 mg oral capsules once a day for 7 days, then 60 mg per mouth once per day for 21 days. After 4 weeks if pain had decreased, subjects continued 60 mg. per mouth once per day for 4 weeks. If pain had not decreased, subjects took 60 mg twice per day per mouth for 4 weeks. 5 Questionnaires were administered at baseline and every 2 weeks for 8 weeks; medication was tapered at the end of study.', ' Overall Number of Participants Analyzed: 29', ' Measure Type: Number', ' Unit of Measure: percentage of participants 72.4'], 'Adverse Events': ['Adverse Events 1:', ' Total: 0/29 (0.00%)']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

17b31c1d-db62-4628-b390-02da22512079

Comparison

Intervention

NCT00574145

NCT03167359

Radiotherapy is used in all cohorts of the primary trial and the secondary trial.

Entailment

{'Clinical Trial ID': 'NCT00574145', 'Intervention': ['INTERVENTION 1: ', ' Radiotherapy/Supportive Care (A)', ' Patients receive radiotherapy and healing touch therapy from a healing-touch therapist once a week for the duration of their radiotherapy', 'INTERVENTION 2: ', ' Control ARM (B)', ' Patients receive radiotherapy and sham healing touch therapy from a sham healing-touch therapist once a week for the duration of their radiotherapy'], 'Eligibility': ['Inclusion Criteria:', ' Histologically proven breast cancer', ' Receiving post lumpectomy or post mastectomy radiation therapy (RT)', ' Eastern Cooperative Oncology Group performance status of 0, 1 or 2', ' Prescribed a minimum of 5 weeks of RT', ' Between the ages of 21 and 75', ' Able to speak English.', ' Provides written informed consent', 'Exclusion Criteria:', ' Documented active psychiatric illness', ' Documented cognitive impairment that would preclude the ability to provide informed consent.', ' Stage IV breast cancer', ' Receiving concurrent chemotherapy and RT'], 'Results': ['Outcome Measurement: ', ' Fatigue Using the Brief Fatigue Inventory (BFI)', " 9-items with an 11-point rating scale measures intensity of fatigue (3 items, 0 = no fatigue to 10 = fatigue as bad as you can imagine) and interference of fatigue on daily life (6 items, 0 = does not interfere to 10 = completely interferes. Each participant's score is summed with a possible minimum score of 0 and a possible maximum score of 90. A mean score was then determined.", ' Time frame: 6 weeks', 'Results 1: ', ' Arm/Group Title: Radiotherapy/Supportive Care (A)', ' Arm/Group Description: Patients receive radiotherapy and healing touch therapy from a healing-touch therapist once a week for the duration of their radiotherapy', ' Overall Number of Participants Analyzed: 20', ' Mean (Standard Deviation)', ' Unit of Measure: units on a scale 2.786 (0.1963)', 'Results 2: ', ' Arm/Group Title: Control ARM (B)', ' Arm/Group Description: Patients receive radiotherapy and sham healing touch therapy from a sham healing-touch therapist once a week for the duration of their radiotherapy', ' Overall Number of Participants Analyzed: 21', ' Mean (Standard Deviation)', ' Unit of Measure: units on a scale 1.356 (0.1413)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 0/22 (0.00%)', 'Adverse Events 2:', ' Total: 0/22 (0.00%)']}

{'Clinical Trial ID': 'NCT03167359', 'Intervention': ['INTERVENTION 1: ', ' Participants With Stage 0-III Breast Cancer', ' Women with Stage 0-III breast cancer, treated with breast conserving surgery or mastectomy and clear margins, will receive 15 doses of radiation over three weeks.', ' Hypofractionated Simultaneous Integrated Boost Radiotherapy: Participants will receive radiotherapy treatments to the whole breast or chest wall to a dose of 2.66 Gy per day x 15 fractions simultaneously with a boost treatment. The boost treatment will be given on the same days as the whole breast treatment. The lumpectomy cavity + scar (in lumpectomy patients) or chest wall scar (mastectomy patients) will receive 0.54 Gy per day x 15 fractions.'], 'Eligibility': ['Inclusion Criteria:', ' Participants must have one or more of the following characteristics and be eligible for breast or chest wall with or without regional nodal radiotherapy:', ' Prior Chemotherapy for Breast Cancer', ' Greater than 25 cm of breast separation (the largest distance on an axial slice of the planning CT simulation scan between the entry and exit points of the radiation beam on the body)', ' Non-Caucasian Race', ' Less than or equal to 50 years of age', ' Requiring regional nodal irradiation without evidence of N3 disease', 'Exclusion Criteria:', ' Males will be excluded', ' Women who are pregnant or nursing a child may not take part in this study'], 'Results': ['Outcome Measurement: ', ' Number of Participants Per Cutaneous Toxicity Grade (0, 1, 2, 3, 4)', ' Cutaneous toxicity rate will be assessed by the National Cancer Institute - Common Toxicity Criteria (NCI-CTC) v.3 grading scale. THe NCI CTCAE grades go from 0 to 4. Grade 0: none. Grade 1: Mild or localized; topical intervention indicated. Grade 2: Intense or widespread; intermittent; skin changes from scratching (e.g., edema, papulation, excoriations, lichenification, oozing/crusts); limiting instrumental ADLs. Grade 3-4: Severe or life-threatening. The higher the grade, the worse the outcome.', ' Time frame: Duration of Study (Up to 18 months)', 'Results 1: ', ' Arm/Group Title: Participants With Stage 0-III Breast Cancer', ' Arm/Group Description: Women with Stage 0-III breast cancer, treated with breast conserving surgery or mastectomy and clear margins, will receive 15 doses of radiation over three weeks.', ' Hypofractionated Simultaneous Integrated Boost Radiotherapy: Participants will receive radiotherapy treatments to the whole breast or chest wall to a dose of 2.66 Gy per day x 15 fractions simultaneously with a boost treatment. The boost treatment will be given on the same days as the whole breast treatment. The lumpectomy cavity + scar (in lumpectomy patients) or chest wall scar (mastectomy patients) will receive 0.54 Gy per day x 15 fractions.', ' Overall Number of Participants Analyzed: 71', ' Measure Type: Count of Participants', ' Unit of Measure: Participants Grade 0: 60 84.5%', ' Grade 1: 11 15.5%', ' Grade 2: 0 0.0%', ' Grade 3: 0 0.0%', 'Grade 4: 0 0.0%'], 'Adverse Events': ['Adverse Events 1:', ' Total: 3/74 (4.05%)', ' Recurrance *3/74 (4.05%)']}

2e6e1044-8b4a-41f7-8319-85fc5bba4482

Comparison

Adverse Events

NCT00493649

NCT01201265

There was 1 MRSA infection in cohort 1 of the secondary trial and 4 in cohort 2 of the primary trial.

Contradiction

{'Clinical Trial ID': 'NCT00493649', 'Intervention': ['INTERVENTION 1: ', ' TOP2A-amplified Group', ' FISH ratio of TOP2A gene copy number was 2 or greater.', 'INTERVENTION 2: ', ' TOP2A-nonamplified Group', ' FISH ratio of TOP2A gene copy number was less than 2.'], 'Eligibility': ['Inclusion Criteria:', ' A woman will be eligible for inclusion in this study if she meets all of the following criteria:', ' Has HER2+ (IHC staining of 3+ [uniform, intense membrane staining of >30% of invasive tumor cells], or a FISH result of .6 HER2 gene copies per nucleus or a FISH ratio [HER2 gene signals to chromosome 17 signals] of >2.2; patients with equivocal FISH ratio results 1.8-2.2 are also eligible if 3+ IHC) (Appendix IX); Stage I, IIA, IIB, or IIIA T1-3N1-3M0 disease. At the discretion of the Treating Physician, patients with 4+ nodes with other factors such as patient choice, older age, preexisting cardiac disease with normal MUGA or ECHO may be enrolled into a separate subgroup.', ' Has operable, histologically confirmed, invasive carcinoma of the breast.', ' Has known ER and PR status', ' Has adequate tumor specimen available for FISH analysis of TOP2A status (See Appendix VII)', ' Has had no prior chemotherapy unless it was given >5 years ago for breast cancer or other cancer', ' Has an ECOG Performance Status (PS) 0-1', ' Age >18 to <70 years old.', ' Has laboratory values of: See protocol for specific details', ' Has aspartate aminotransferase (AST) or alanine aminotransferase (ALT) and alkaline phosphatase (ALP) within the ranges shown below. In determining eligibility the more abnormal of the 2 values (AST or ALT) should be used. See protocol for specific details', ' Has complete surgical resection of the primary breast tumor: either lumpectomy or mastectomy with sentinel lymph node or axillary dissection.', ' It has been <84 days since the date of definitive surgery, and there is adequate wound healing as determined by the Treating Physician', ' Has no evidence of metastatic disease by physical examination and x-ray; appropriate scans as needed by each individual patient (eg, bone scan; abdominal, chest CT; PET or PET/CT; ultrasound; or MRI should indicate no evidence of metastatic disease.', ' Has normal cardiac function as evidenced by a LVEF >50%, but must be within normal limits (WNL) by institutional standard, as determined by multiple gated acquisition (MUGA) scan. An echocardiogram (ECHO). The same modality must be used throughout the study to evaluate LVEF. Ejection fraction (EF) as determined by ECHO must be WNL by institutional standard.', ' Has a negative serum pregnancy test within 7 calendar days prior to registration (female patients of childbearing potential [not surgically sterilized and between menarche and 1 year postmenopause]).', ' If fertile, patient has agreed to use an acceptable method of birth control (barrier contraceptive) to avoid pregnancy for the duration of the study and for a period of 3 months thereafter', ' Has signed a Patient Informed Consent Form', ' Has signed a Patient Authorization Form', 'Exclusion Criteria:', ' A woman will be excluded from this study if she meets any of the following criteria:', ' Has any evidence of disease following complete surgical resection of the primary tumor and metastatic workup', " Has Stage IIIB breast cancer (T4 disease; ie, patients with fixed tumors, peau d'orange skin changes, skin ulcerations, or inflammatory changes).", ' Has Stage IV breast cancer (M1 disease on TNM staging system)', ' Had prior chemotherapy for breast cancer or other cancer within the last 5 years (no neoadjuvant chemotherapy in this study is permitted)', ' Has a history of severe hypersensitivity reaction to drugs formulated with polysorbate 80', ' Has had a myocardial infarction (MI) within 6 months of trial enrollment, or has New York Heart Association (NYHA) Class II or greater heart failure (see Appendix III), uncontrolled angina, severe uncontrolled ventricular arrhythmias, clinically significant pericardial disease, or electrocardiographic evidence of acute ischemic changes', ' Has abnormal baseline MUGA (or ECHO) (<50%, or less than institutional LLN)', ' Is receiving concurrent immunotherapy, hormonal therapy, or radiation therapy. Adjuvant hormonal therapy, if needed, may be given during radiation therapy and during treatment with trastuzumab after completion of chemotherapy.', ' Is receiving concurrent investigational therapy or has received such therapy within the past 30 calendar days', ' Has peripheral neuropathy >Grade 1', ' Has a serious uncontrolled intercurrent medical or psychiatric illness, including serious viral (including clinically defined AIDS), bacterial or fungal infection; or history of uncontrolled seizures, or diabetes, or CNS disorders deemed by the Treating Physician to be clinically significant, precluding informed consent', ' Has active hepatitis B or hepatitis C with abnormal liver function tests (LFTs) or is known to be HIV positive', ' Has a history of other malignancy within the last 5 years (except cured basal cell carcinoma of skin and carcinoma in situ of uterine cervix), which could affect the diagnosis or assessment of any of the study drugs', ' Is an obese patient to whom the Treating Physician would not be comfortable administering full doses of study drugs as calculated by the BSA. Obese patients will be treated based on actual body weight. Obese patients treated with full doses based on actual BSA are eligible', ' Is a pregnant or breastfeeding woman', ' Is deemed unable to comply with requirements of study'], 'Results': ['Outcome Measurement: ', ' Disease-free Survival (DFS) Rate at 2 Years in TOP2A-amplified and in TOP2A-nonamplified HER2+ ESBC Patients Treated With TC+H.', ' DFS was measured from the date of registration to either the date the patient was first recorded as having disease recurrence, or the date of death due to any causes before recurrence. If a patient had not recurred or died, DFS was censored at the date of last follow-up.', ' Time frame: 2 years', 'Results 1: ', ' Arm/Group Title: TOP2A-amplified Group', ' Arm/Group Description: FISH ratio of TOP2A gene copy number was 2 or greater.', ' Overall Number of Participants Analyzed: 190', ' Measure Type: Number', ' Unit of Measure: probability of disease-free survival 0.978 (0.942 to 0.992)', 'Results 2: ', ' Arm/Group Title: TOP2A-nonamplified Group', ' Arm/Group Description: FISH ratio of TOP2A gene copy number was less than 2.', ' Overall Number of Participants Analyzed: 248', ' Measure Type: Number', ' Unit of Measure: probability of disease-free survival 0.979 (0.949 to 0.991)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 51/486 (10.49%)', ' ANEMIA 1/486 (0.21%)', ' NEUTROPENIA 4/486 (0.82%)', ' FIBRILLATION ATRIAL 1/486 (0.21%)', ' ABDOMINAL PAIN 2/486 (0.41%)', ' BLOATING 1/486 (0.21%)', ' BOWEL PERFORATION 1/486 (0.21%)', ' COLITIS 1/486 (0.21%)', ' DEHYDRATION 5/486 (1.03%)', ' DIARRHEA 5/486 (1.03%)', ' GASTRIC INFLAMMATION 1/486 (0.21%)', ' NAUSEA 3/486 (0.62%)', ' NAUSEA AND VOMITING 1/486 (0.21%)', 'Adverse Events 2:', ' ']}

{'Clinical Trial ID': 'NCT01201265', 'Intervention': ['INTERVENTION 1: ', ' All Participants', ' Participants received a combination therapy of bevacizumab 15 milligram per kilogram (mg/kg) intravenous every 3 weeks with carboplatin recommended dose (area under curve [AUC]= 2) along with gemcitabine 1000 mg/ metre square (m^2) on days 1 and 8 of each 3 week cycle.'], 'Eligibility': ['Inclusion Criteria:', ' Female participants, >/= 18 years of age', ' Metastatic breast cancer', ' Estrogen receptor-, progesterone- and human epidermal growth factor receptor 2 (HER2)-negative disease', ' Treatment-naïve for metastatic breast cancer', ' Eastern Cooperative Oncology Group (ECOG) performance status 0-2', ' Adequate hematological, renal and liver function', ' Patients should have received Anthracyclines and Taxanes in the adjuvant setting', ' Women of childbearing potential must agree to use adequate contraception (per institutional standard of care) during treatment and until 6 months after the last administration of investigational products', 'Exclusion Criteria:', ' Prior first line treatment for metastatic breast cancer', ' Central nervous system (CNS) metastasis', ' Uncontrolled hypertension (> 170/95 mmHg)', ' Evidence of bleeding diathesis, coagulopathy or hemorrhage at baseline', ' Other malignancy within the last 5 years, except for adequately treated carcinoma in situ of the cervix or squamous carcinoma of the skin, or adequately controlled limited basal cell skin cancer.', ' Prior therapy with gemcitabine or carboplatin in the metastatic setting. Participants having received gemcitabine or carboplatin as part of adjuvant therapy are eligible, if recurrence was first documented >6 months after the last exposure to the drug(s)', ' Requirement of chronic use of immunosuppressive agents', ' HIV, hepatitis B or hepatitis C infection'], 'Results': ['Outcome Measurement: ', ' Progression-free Survival (PFS)', ' Progression free survival (PFS) was calculated in days from the date of registration until the earliest date of documented disease progression or death. The median PFS time with 95% confidence interval (CI) was estimated using Kaplan Meier method. The progression-free survival was assessed utilizing computer tomography (CT)/ magnetic resonance imaging (MRI)/bone scans and X-ray and Response Evaluation Criteria in Solid Tumors (RECIST) v. 1.1. Progression of disease is defined as at least 20% increase in the sum of diameters of target lesions compared to the smallest sum of diameters on-study and absolute increase of at least 5 mm, progression of existing non-target lesions, or presence of new lesions.', ' Time frame: From the date of registration until the disease progression or death (up to 1541 days).', 'Results 1: ', ' Arm/Group Title: All Participants', ' Arm/Group Description: Participants received a combination therapy of bevacizumab 15 milligram per kilogram (mg/kg) intravenous every 3 weeks with carboplatin recommended dose (area under curve [AUC]= 2) along with gemcitabine 1000 mg/ metre square (m^2) on days 1 and 8 of each 3 week cycle.', ' Overall Number of Participants Analyzed: 40', ' Median (95% Confidence Interval)', ' Unit of Measure: days 255 (157 to 465)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 17/40 (42.50%)', ' Anaemia 2/40 (5.00%)', ' Febrile Neutropenia 3/40 (7.50%)', ' Neutropenia 2/40 (5.00%)', ' Thrombocytopenia 5/40 (12.50%)', ' Pericardial Effusion 1/40 (2.50%)', ' Abdominal Pain Lower 1/40 (2.50%)', ' Disease Progression 6/40 (15.00%)', ' Fatigue 1/40 (2.50%)', ' Pyrexia 3/40 (7.50%)', ' Septic Shock 1/40 (2.50%)', ' Streptococcal Infection 1/40 (2.50%)']}

456c6011-52bb-4c8b-9e82-e5a85cbbe0e3

Single

Intervention

NCT03618017

the primary trial's intervention section does not describe the intervention dosage, frequency or duration.

Entailment

{'Clinical Trial ID': 'NCT03618017', 'Intervention': ['INTERVENTION 1: ', ' Recruitment Population', ' Pre-randomization recruitment and enrollment'], 'Eligibility': ['Inclusion Criteria:', ' Diagnosed with early Stage (0-IIB) breast cancer', ' Must be a patient of a University of Michigan Breast Cancer Oncologist', ' Must be completing primary cancer treatment and transitioning into survivorship', ' Must be able to speak, read and write in English', ' Must have access and the ability to use the internet', 'Exclusion Criteria:', ' Diagnosed with stage III or IV breast cancer', ' Unable to speak, read, and write in English'], 'Results': ['Outcome Measurement: ', ' Number of Breast Cancer Patients Successfully Recruited to Participate in the Study', ' We anticipate a response rate of 80% enrollment (n=60). We will assess the number of patients successfully recruited who enroll and complete the baseline survey.', ' Time frame: At baseline survey', 'Results 1: ', ' Arm/Group Title: Recruitment Population', ' Arm/Group Description: Pre-randomization recruitment and enrollment', ' Overall Number of Participants Analyzed: 160', ' Measure Type: Count of Participants', ' Unit of Measure: Participants 66 41.3%'], 'Adverse Events': ['Adverse Events 1:', ' Total: 0/33 (0.00%)']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

0c0324d2-0672-45cb-b715-e51e48786afb

Single

Adverse Events

NCT01421472

Over 9 patients in the primary trial suffered from adverse events associated with a low number of white blood cells present in the bloodstream.

Contradiction

{'Clinical Trial ID': 'NCT01421472', 'Intervention': ['INTERVENTION 1: ', ' HR+: MM-121+ Paclitaxel', ' Hormone-receptor positive (HR+) sub-group randomized to receive:', ' 2 week run-in of MM-121 (20 mg/kg weekly IV infusion over 60 minutes following a 40 mg/kg loading dose), followed by 4 cycles of MM-121 (20 mg/kg weekly) + Paclitaxel (80 mg/kg IV infusion weekly over 60 minutes) for 12 weeks, followed by 4 cycles of doxorubicin and cyclophosphamide (8 weeks)', 'INTERVENTION 2: ', ' HR+: Paclitaxel Only', ' Hormone-receptor positive (HR+) sub-group randomized to receive:', ' Paclitaxel (80 mg/kg IV infusion weekly over 60 minutes) for 12 weeks followed by standard dosing of doxorubicin IV plus cyclophosphamide IV, followed by surgery.'], 'Eligibility': ['Inclusion Criteria:', ' Histological confirmation of ER positive, HER2 negative invasive breast cancer (Group 1) or invasive triple-negative breast cancer (Group 2)', ' Free of metastatic disease', ' 18 years old', ' Female', ' Had no prior treatment for any cancer', ' Eligible for treatment with paclitaxel, doxorubicin and cyclophosphamide', 'Exclusion Criteria:', ' Have a history of severe allergic reactions to paclitaxel or other drugs formulated in Cremaphor® EL', ' Are pregnant or breastfeeding'], 'Results': ['Outcome Measurement: ', ' Number of Participants With Pathologic Complete Response (pCR) (Rate of pCR)', ' Pathologic Complete Response was defined as the absence of invasive cancer in the breast and lymph nodes following completion of neoadjuvant systemic therapy and reported according to the current AJCC staging system for neoadjuvant clinical studies. The endpoint was to determine the pathologic Complete Response (pCR) rates associated with weekly treatment of MM-121 plus paclitaxel followed by the combination treatment of doxorubicin plus cyclophosphamide compared with weekly paclitaxel alone followed by the combination treatment of doxorubicin plus cyclophosphamide in patients with human epidermal growth factor receptor 2 (HER2)-negative primary breast cancer.', ' Time frame: At time of surgery, an expected average of 24-26 weeks', 'Results 1: ', ' Arm/Group Title: HR+: MM-121+ Paclitaxel', ' Arm/Group Description: Hormone-receptor positive (HR+) sub-group randomized to receive:', ' 2 week run-in of MM-121 (20 mg/kg weekly IV infusion over 60 minutes following a 40 mg/kg loading dose), followed by 4 cycles of MM-121 (20 mg/kg weekly) + Paclitaxel (80 mg/kg IV infusion weekly over 60 minutes) for 12 weeks, followed by 4 cycles of doxorubicin and cyclophosphamide (8 weeks)', ' Overall Number of Participants Analyzed: 66', ' Measure Type: Number', ' Unit of Measure: participants Subjects with no pCR: 59', ' Subjects with pCR: 7', 'Results 2: ', ' Arm/Group Title: HR+: Paclitaxel Only', ' Arm/Group Description: Hormone-receptor positive (HR+) sub-group randomized to receive:', ' Paclitaxel (80 mg/kg IV infusion weekly over 60 minutes) for 12 weeks followed by standard dosing of doxorubicin IV plus cyclophosphamide IV, followed by surgery.', ' Overall Number of Participants Analyzed: 30', ' Measure Type: Number', ' Unit of Measure: participants Subjects with no pCR: 29', ' Subjects with pCR: 1'], 'Adverse Events': ['Adverse Events 1:', ' Total: 14/67 (20.90%)', ' Febrile Neutropenia * 5/67 (7.46%)', ' Anemia * 3/67 (4.48%)', ' Neutropenia * 0/67 (0.00%)', ' Leukopenia * 0/67 (0.00%)', ' Sinus Tachycardia * 0/67 (0.00%)', ' Diarrhea * 2/67 (2.99%)', ' Nausea * 1/67 (1.49%)', ' Vomiting * 1/67 (1.49%)', ' Pancreatitis * 1/67 (1.49%)', ' Pyrexia * 1/67 (1.49%)', ' Bacteremia * 0/67 (0.00%)', ' Breast Cellulutis * 0/67 (0.00%)', 'Adverse Events 2:', ' Total: 5/33 (15.15%)', ' Febrile Neutropenia * 0/33 (0.00%)', ' Anemia * 0/33 (0.00%)', ' Neutropenia * 0/33 (0.00%)', ' Leukopenia * 0/33 (0.00%)', ' Sinus Tachycardia * 0/33 (0.00%)', ' Diarrhea * 0/33 (0.00%)', ' Nausea * 1/33 (3.03%)', ' Vomiting * 1/33 (3.03%)', ' Pancreatitis * 0/33 (0.00%)', ' Pyrexia * 1/33 (3.03%)', ' Bacteremia * 0/33 (0.00%)', ' Breast Cellulutis * 0/33 (0.00%)']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

b3bd3522-8731-448a-bade-a5a350697a98

Comparison

Intervention

NCT01572038

NCT00826267

Each patient in the primary trial receives 3 different drugs, whereas in the secondary trial patients are given supportive-expressive group psychotherapy instead.

Contradiction

{'Clinical Trial ID': 'NCT01572038', 'Intervention': ['INTERVENTION 1: ', ' Pertuzumab + Trastuzumab + Taxane', " Participants received pertuzumab and trastuzumab intravenously (IV) plus taxane chemotherapy once of every 3 weeks per treatment cycle until predefined study end, unacceptable toxicity, withdrawal of consent, disease progression, or death, whichever occurred first. Taxane chemotherapy was docetaxel, paclitaxel, or nab-paclitaxel, per the investigator's choice."], 'Eligibility': ['Inclusion Criteria:', ' Histologically or cytologically confirmed adenocarcinoma of the breast with metastatic or locally recurrent disease not amenable to curative resection', ' HER2-positive breast cancer', ' Eastern cooperative Oncology Group (ECOG) performance status 0, 1 or 2', ' LVEF of at least 50 percent (%)', 'Exclusion Criteria:', ' Previous systemic non-hormonal anti-cancer therapy for metastatic or locally recurrent disease', ' Disease-free interval from completion of adjuvant or neoadjuvant systemic non-hormonal treatment to recurrence less than or equal to (</=) 6 months', ' Previous approved or investigative anti-HER2 agents in any breast cancer treatment setting, except for trastuzumab and/or lapatinib in the adjuvant or neoadjuvant setting', ' Disease progression while receiving trastuzumab and/or lapatinib in the adjuvant or neoadjuvant setting', ' History of persistent Grade 2 or higher (National Cancer Institute Common Toxicity Criteria [NCI-CTC], Version 4.0) hematological toxicity resulting from previous adjuvant or neoadjuvant therapy', ' Central nervous system (CNS) metastases', ' Current peripheral neuropathy of Grade 3 or greater (NCI-CTC, version 4.0)', ' History of other malignancy within the last 5 years prior to first study drug administration, except for carcinoma in situ of the cervix or basal cell carcinoma', ' Inadequate bone marrow, liver or renal function', ' Uncontrolled hypertension', ' Hepatitis B, hepatitis C or Human Immunodeficiency Virus (HIV) infection'], 'Results': ['Outcome Measurement: ', ' Overview of the Number of Participants With at Least One Treatment-Emergent Adverse Event, Severity Determined According to National Cancer Institute Common Terminology Criteria for Adverse Events, Version 4.0 (NCI-CTCAE v4.0)', ' Treatment-emergent adverse events (TEAEs) were adverse events (AEs) that started or worsened in severity on or after the first administration of study drug, up to and including 28 days after the last dose. The investigator graded all AEs for severity per NCI-CTCAE v4.0; if not listed, the AE was assessed as follows: Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening/disabling; Grade 5 = death. The investigator determined whether an AE was related to study drug and independently assessed severity and seriousness of each AE. TEAEs to monitor included anaphylaxis and hypersensitivity, cardiac dysfunction, diarrhoea Grade 3, pregnancy-related AEs, interstitial lung disease, infusion-/administration-related reactions, mucositis, (febrile) neutropenia, rash/skin reactions, and suspected transmission of infectious agent. TEAEs of special interest included LVEF decreased, liver enzymes increased, and suspected transmission of infectious agent by the study drug.', ' Time frame: From Baseline until 28 days after, or 7 months after (only for serious AEs related to study drug), the last dose of study treatment. The median (full range) duration of exposure to any study treatment was 16.2 (0.0-86.4) months.', 'Results 1: ', ' Arm/Group Title: Pertuzumab + Trastuzumab + Taxane', " Arm/Group Description: Participants received pertuzumab and trastuzumab intravenously (IV) plus taxane chemotherapy once of every 3 weeks per treatment cycle until predefined study end, unacceptable toxicity, withdrawal of consent, disease progression, or death, whichever occurred first. Taxane chemotherapy was docetaxel, paclitaxel, or nab-paclitaxel, per the investigator's choice.", ' Overall Number of Participants Analyzed: 1436', ' Measure Type: Count of Participants', ' Unit of Measure: Participants Any TEAE - Any Grade: 1419 98.8%', ' Any TEAE - Grade 3 or Higher ( 3): 879 61.2%', ' Any Serious TEAE: 535 37.3%', ' Any TEAE Leading to Death: 31 2.2%', ' Any TEAE Related to Pertuzumab - Any Grade: 1037 72.2%', ' Any TEAE Related to Trastuzumab - Any Grade: 946 65.9%', ' Any TEAE Related to Taxane - Any Grade: 1342 93.5%', ' Any TEAE Related to Pertuzumab - Grade 3: 286 19.9%', ' Any TEAE Related to Trastuzumab - Grade 3: 245 17.1%', ' Any TEAE Related to Taxane - Grade 3: 514 35.8%', ' Any TEAE Leading to Interruption of Pertuzumab: 334 23.3%', ' Any TEAE Leading to Interruption of Trastuzumab: 386 26.9%', ' Any TEAE Leading to Interruption of Taxane: 354 24.7%', ' Any TEAE Leading to Discontinuation of Pertuzumab: 140 9.7%', ' Any TEAE Leading to Discontinuation of Trastuzumab: 133 9.3%', ' Any TEAE Leading to Discontinuation of Taxane: 286 19.9%', ' Any TEAE to Monitor - Any Grade: 1320 91.9%', ' Any TEAE to Monitor - Grade 3: 535 37.3%', ' Any TEAE of Special Interest: 91 6.3%', ' Any TEAE Within 28 Days of Treatmt Discontinuation: 975 67.9%'], 'Adverse Events': ['Adverse Events 1:', ' Total: 535/1436 (37.26%)', ' Febrile neutropenia 71/1436 (4.94%)', ' Neutropenia 47/1436 (3.27%)', ' Anaemia 8/1436 (0.56%)', ' Leukopenia 2/1436 (0.14%)', ' Bone marrow failure 1/1436 (0.07%)', ' Febrile bone marrow aplasia 1/1436 (0.07%)', ' Thrombocytopenia 1/1436 (0.07%)', ' Cardiac failure 12/1436 (0.84%)', ' Atrial fibrillation 8/1436 (0.56%)', ' Atrial thrombosis 2/1436 (0.14%)']}

{'Clinical Trial ID': 'NCT00826267', 'Intervention': ['INTERVENTION 1: ', ' Afatinib 50 mg', ' Patients received continuous daily dosing with Afatinib 50 mg orally from Day 1 to Day 21 of each treatment course. 2 treatment courses were to be given in the trial.', 'INTERVENTION 2: ', ' Lapatinib 1500 mg', ' Patients received continuous daily dosing with Lapatinib 1500 mg orally from Day 1 to Day 21 of each treatment course. 2 treatment courses were to be given in the trial.'], 'Eligibility': ['Inclusion criteria:', ' Female, age 18 years or older.', ' Histologically proven breast cancer who have not received any prior therapy.', ' Locally advanced disease Stage IIIa with no evidence of distant metastatic disease other than anatomical site lymph nodes.', ' HER2-positive.', 'Exclusion criteria:', ' Absolute neutrophil count (ANC) less than 1500/mm3.', ' Platelet count less than 100 000/ mm3.', ' Hemoglobin level less than 9.0 g/dl.', ' Bilirubin greater than 1.5 mg/dI.', ' Aspartate amino transferase (AST) or alanine amino transferase (ALT) greater than twice the upper limit of normal.', ' Serum creatinine greater than 1.5 times of the upper normal limit.', ' Significant or recent acute gastrointestinal disorders with diarrhea', ' Pregnancy or breast-feeding.', ' Organ system dysfunction including cardiac (LVEF < 50%).', ' Prior chemotherapy, radiotherapy or hormone therapy. Previous treatment with trastuzumab, EGFR, or EGFR/HER2-inhibitors.', ' Other malignancies diagnosed within the past five years.', ' Serious active infection. HIV, active hepatitis B or C.'], 'Results': ['Outcome Measurement: ', ' Objective Response (OR)', ' Objective response (complete or partial) was assessed according to RECIST 1.0 criteria.', ' Time frame: Tumour assessments were performed at screening, day 22 and day 43.', 'Results 1: ', ' Arm/Group Title: Afatinib 50 mg', ' Arm/Group Description: Patients received continuous daily dosing with Afatinib 50 mg orally from Day 1 to Day 21 of each treatment course. 2 treatment courses were to be given in the trial.', ' Overall Number of Participants Analyzed: 10', ' Measure Type: Number', ' Unit of Measure: Percentage of participants 80.0 (44.4 to 97.5)', 'Results 2: ', ' Arm/Group Title: Lapatinib 1500 mg', ' Arm/Group Description: Patients received continuous daily dosing with Lapatinib 1500 mg orally from Day 1 to Day 21 of each treatment course. 2 treatment courses were to be given in the trial.', ' Overall Number of Participants Analyzed: 8', ' Measure Type: Number', ' Unit of Measure: Percentage of participants 75.0 (34.9 to 96.8)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 0/10 (0.00%)', 'Adverse Events 2:', ' Total: 0/8 (0.00%)']}

8607e8c1-6e99-49be-a63e-e707856c805a

Single

Results

NCT03252431

On average patients from both arms of the primary trial experienced Grade 4 Neutropenia for the same amount of time.

Entailment

{'Clinical Trial ID': 'NCT03252431', 'Intervention': ['INTERVENTION 1: ', ' F-627', ' F-627, 20 mg fixed dose pre-filled syringe, administered on Day 2 of each of 4 chemotherapy cycles.', ' F-627: single dose pre-filled syringe', 'INTERVENTION 2: ', ' Neulasta', ' 6 mg fixed dose Neulasta®, administered on Day 2 of each of 4 chemotherapy cycles', ' Neulasta: single dose pre-filled syringe'], 'Eligibility': ['Inclusion Criteria:', ' Show evidence of a personally signed and dated informed consent document indicating that the patient has been informed of all pertinent aspects of the trial.', ' Females 18 years of age.', ' Diagnosed with Stage I-III breast cancer.', ' Subject is scheduled to undergo 4 cycles of neoadjuvant or adjuvant TC chemotherapy (docetaxel, cyclophosphamide, 75, 600 mg/m2, respectively).', ' ECOG Performance status of 2.', ' WBC count 4.0 × 109/L, hemoglobin 11.5 g/dL and a platelet count 150 × 109/L.', ' Demonstrate adequate renal, hepatic, and cardiac function (liver function tests [alanine aminotransferase {ALT}, aspartate aminotransferase {AST}, alkaline phosphatase, and total bilirubin]) should be less than 2.5x the upper limits of normal (ULN). Serum creatinine should be less than 1.7x ULN.', ' All subjects must agree to use at least one of the following types of contraception: intrauterine device, implantable progesterone device, progesterone intramuscular injection, or oral contraceptive, which has been started at least one month prior to visit one and will continue for the duration of the trial. The contraceptive patch or condom use with spermicide is also acceptable forms of contraception as long as they will be used continually throughout the duration of the trial.', 'Exclusion Criteria:', ' Subject is <18 years of age.', ' Disease progression has occurred while receiving a taxane regimen.', ' Subject has undergone radiation therapy within 4 weeks of enrollment.', ' Subject has undergone bone marrow or stem-cell transplantation.', ' Subject has a history of prior malignancy other than breast cancer that is NOT in remission.', ' Subjects that have used G-CSF or any other drug that may potentiate the release of neutrophils (i.e., lithium) within 6 weeks of the screening period are excluded.', ' Subject has had chemotherapy within 180 days of screening.', ' Subject has documented congestive heart failure, cardiomyopathy or myocardial infarction by clinical diagnosis, electrocardiogram (ECG) test, or any other relevant test.', ' History of alcohol or drug abuse that would interfere with the ability to be compliant with the study procedure.', ' Unwillingness to participate in the study.', " Any underlying medical condition that, in the Investigator's opinion, would make the administration of study drug hazardous to the patient or that would obscure the interpretation of adverse events.", ' Receiving other investigational drugs or biologics within 1 month or five half lives of enrollment (if known), which ever is less.', ' Any condition, which can cause splenomegaly.', ' Chronic constipation or diarrhea, irritable bowel syndrome, inflammatory bowel disease.', ' ALT, AST, alkaline phosphatase, total bilirubin 2.5x ULN.', ' Subject with active infection, or known to be infected with chronic active Hepatitis B within the last 1 year (unless shown at the time of study entry to be Hepatitis B antigen negative), or having any history of Hepatitis C.', ' Women who are pregnant or breast-feeding.', ' Subject known to be seropositive for HIV, or who have had an AIDS defining illness or a known immunodeficiency disorder.', ' Subject with a history of tuberculosis or exposure to tuberculosis. Patients that have received a prior chest X-ray for suspicion of tuberculosis are also excluded unless they have been confirmed to be PPD negative or they had latent tuberculosis that has been previously treated.', ' Subjects with Sickle Cell disease', " Subjects with known hypersensitivity to E.coli derived proteins' pegfilgrastim' filgrastim, or any other component of the study drug."], 'Results': ['Outcome Measurement: ', ' Duration in Days of Grade 4 Neutropenia in Chemotherapy Cycle 1', ' Eligible subjects were randomized in a 1:1 ratio. Subjects were dosed with either the F 627 20 mg/dose PFS or Neulasta® 6 mg/dose as the study drug in each chemotherapy cycle. Subjects remained in their assigned treatment arm throughout the study. Subjects were dosed subcutaneously (SC) 24 to 28 hours after receiving TC chemotherapy (75 mg/m2 docetaxel + 600 mg/m2 cyclophosphamide) on Day 2 of each chemotherapy cycle that the subject underwent (up to 4 cycles). Grade 4 (severe) neutropenia was defined as ANC <0.5 × 109/L within the first 12 days of chemotherapy.', ' Time frame: The first of 4, 21-day chemotherapy cycles (average 3 weeks)', 'Results 1: ', ' Arm/Group Title: F-627', ' Arm/Group Description: F-627, 20 mg fixed dose pre-filled syringe, administered on Day 2 of each of 4 chemotherapy cycles.', ' F-627: single dose pre-filled syringe', ' Overall Number of Participants Analyzed: 197', ' Mean (Standard Deviation)', ' Unit of Measure: days 0.2 (0.51)', 'Results 2: ', ' Arm/Group Title: Neulasta', ' Arm/Group Description: 6 mg fixed dose Neulasta , administered on Day 2 of each of 4 chemotherapy cycles', ' Neulasta: single dose pre-filled syringe', ' Overall Number of Participants Analyzed: 196', ' Mean (Standard Deviation)', ' Unit of Measure: days 0.2 (0.45)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 12/197 (6.09%)', ' Febrile neutropenia 2/197 (1.02%)', ' anemia 0/197 (0.00%)', ' neutropenia 0/197 (0.00%)', ' Myocardial infarction 0/197 (0.00%)', ' fatigue 1/197 (0.51%)', ' Hepatitis toxic 0/197 (0.00%)', ' diabetic ketoacidosis 1/197 (0.51%)', ' syncope 1/197 (0.51%)', ' acute kidney injury 1/197 (0.51%)', ' pulmonary embolism 1/197 (0.51%)', ' pneumonia 2/197 (1.02%)', 'Adverse Events 2:', ' Total: 3/196 (1.53%)', ' Febrile neutropenia 0/196 (0.00%)', ' anemia 1/196 (0.51%)', ' neutropenia 1/196 (0.51%)', ' Myocardial infarction 1/196 (0.51%)', ' fatigue 0/196 (0.00%)', ' Hepatitis toxic 1/196 (0.51%)', ' diabetic ketoacidosis 0/196 (0.00%)', ' syncope 0/196 (0.00%)', ' acute kidney injury 0/196 (0.00%)', ' pulmonary embolism 0/196 (0.00%)', ' pneumonia 1/196 (0.51%)', ' angioedema 0/196 (0.00%)']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

1c26e1a7-9d77-46ff-b1c6-179ece7c190f

Single

Adverse Events

NCT00191789

In cohort 2 and 3 of the primary trial there was only case 1 of jaundice.

Contradiction

{'Clinical Trial ID': 'NCT00191789', 'Intervention': ['INTERVENTION 1: ', ' Gemcitabine+Doxorubicin+Cisplatin+Surgery', ' Gemcitabine: 1200 mg/m^2, intravenous (IV) day 1 and day 8 every 21 days x 4 cycles (1-4) then 1000 mg/m^2, IV, day 1 and day 8 every 21 days x 4 cycles (5-8).', ' Doxorubicin: 60 mg/m^2, IV, every 21 days x 4 cycles (1-4). Cisplatin: 70 mg/m^2, IV, every 21 days x 4 cycles (5-8). Surgery follows 8 cycles of chemotherapy. Extent and type of surgery is guided by tumor size, physician and/or patient decision.'], 'Eligibility': ['Inclusion Criteria:', ' Diagnosis of breast carcinoma', ' No previous chemotherapy, with bidimensionally measurable locally advanced disease', ' Adequate performance status (Karnofsky Performance Status [KPS] greater than or equal to 70), bone marrow reserves, hepatic, cardiac and renal functions.', 'Exclusion Criteria:', ' Inflammatory breast cancer', ' Pregnancy and Breast-feeding', ' Serious concomitant disorder or infection', ' Previous cancer within the last 5 years or a second primary malignancy.'], 'Results': ['Outcome Measurement: ', ' Number of Patients With Pathological Complete Response (Pathological Complete Response Rate)', ' Complete pathological response: No invasive tumor cells identified from sections from site of previous cancer. Require evidence corroborating prior presence of invasive cancer, which requires detection of abnormal fibroelastic breast stroma devoid of normal lobular units and contains foamy macrophages with moderate numbers of fibroblasts and mononuclear inflammatory cells. Presence of nondescript collagenised lobules or breast fibrous tissue is not evidence that tumor site has been adequately sampled and macroscopic assessment and sampling is needed until original neoplastic stroma identified.', ' Time frame: tumor assessment at baseline and during surgery after eight 21-day treatment cycles', 'Results 1: ', ' Arm/Group Title: Gemcitabine+Doxorubicin+Cisplatin+Surgery', ' Arm/Group Description: Gemcitabine: 1200 mg/m^2, intravenous (IV) day 1 and day 8 every 21 days x 4 cycles (1-4) then 1000 mg/m^2, IV, day 1 and day 8 every 21 days x 4 cycles (5-8).', ' Doxorubicin: 60 mg/m^2, IV, every 21 days x 4 cycles (1-4). Cisplatin: 70 mg/m^2, IV, every 21 days x 4 cycles (5-8). Surgery follows 8 cycles of chemotherapy. Extent and type of surgery is guided by tumor size, physician and/or patient decision.', ' Overall Number of Participants Analyzed: 65', ' Measure Type: Number', ' Unit of Measure: participants 13'], 'Adverse Events': ['Adverse Events 1:', ' Total: 17/65 (26.15%)', ' Febrile neutropenia 3/65 (4.62%)', ' Neutropenia 2/65 (3.08%)', ' Pancytopenia 1/65 (1.54%)', ' Thrombocytopenia 1/65 (1.54%)', ' Cardiac arrest 2/65 (3.08%)', ' Myocardial infarction 1/65 (1.54%)', ' Diarrhoea 5/65 (7.69%)', ' Stomatitis 1/65 (1.54%)', ' Vomiting 2/65 (3.08%)', ' Fatigue 1/65 (1.54%)', ' Jaundice 1/65 (1.54%)', ' Neutropenic infection 2/65 (3.08%)']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

0a156ee2-eb90-40d2-9802-27b9b4a42ff3

Comparison

Adverse Events

NCT00266110

NCT00879086

the primary trial and the secondary trial have entirely different adverse event reports.

Entailment

{'Clinical Trial ID': 'NCT00266110', 'Intervention': ['INTERVENTION 1: ', ' Dendritic Cell Vaccine', ' Therapeutic autologous dendritic cells (Dendritic Cell Vaccine) i.d. injection, 20 x 106 DCs given per treatment Trastuzumab infusion Vinorelbine ditartrate infusion', ' sargramostim: All patients will receive Leukine (GM-CSF) at 250 mcg/m2 starting one day after the administration of chemotherapy x 7 days. Patients with neutrophil counts below 1,000/mm3 on day 8 will continue GM-CSF therapy until the neutrophil count is greater than 1,000/mm3.', ' therapeutic autologous dendritic cells: patients will receive (10 x 106) peptide-pulsed DCs given by i.d injection into either axilla or the inguinal region with each peptide given into a separate site. The total dose will be 20 x 106 DCs given per treatment.', ' trastuzumab: Trastuzumab will be infused in the side-port of a freely flowing IV over 90 minutes and at 6mg/kg if the subject has not previously received Trastuzumab, or if it has been more than 30 days since any prior trastuzumab administration.'], 'Eligibility': ['PATIENT ELIGIBILITY', ' 4.1 Inclusion Criteria 4.1.1 Histologically proven metastatic breast cancer with measurable or evaluable disease per investigator discretion.', ' 4.1.2 Patients must be 18 years of age or older. Women of child bearing potential must be practicing barrier or oral contraception for the duration of the study, or documented as surgically sterile or one year post-menopausal.', ' 4.1.3 Eastern Cooperative Oncology Group (ECOG) performance status 0-2 (See Appendix A).', ' 4.1.5 Cardiac function by multigated acquisition scan (MUGA) with an ejection fraction (EF) > 45% or an echocardiogram that shows normal left ventricle (LV) function.', ' 4.1.6 Serum Creatinine < 2.0 mg/dl. 4.1.7 Hepatic transaminases (alanine aminotransferase (ALT) and aspartate aminotransferase (AST)) 3.0 times the upper limit of normal if no liver metastases or 5 times the upper limit of normal if liver metastases are present.', ' 4.1.8 Bilirubin no more than 2 times normal.', ' 4.1.9 Seronegative for HIV.', ' 4.1.10 Negative for Hepatitis B surface antigen.', ' 4.1.11 Signed and dated informed consent.', ' 4.1.12 HLA A0201+ by DNA genotyping.', ' 4.1.13 Absolute neutrophil count greater than 1,500/mm3. Platelet count greater 100,000/mm3 and hemoglobin greater than or equal to 10', ' 4.1.14. 3+ expression of HER-2/neu from original pathology (diagnostic) tumor sample by Immunohistochemistry (IHC) or 2+ expression by IHC with gene amplification by fluorescence in situ hybridization (FISH).', ' 4.1.15. Patients will be eligible even if they have failed treatment for metastatic breast cancer with trastuzumab and a chemotherapy agent other than vinorelbine or if they have progressed within 12 months of receiving adjuvant chemotherapy using trastuzumab and a taxane.', ' 4.2 Exclusion Criteria', ' 4.2.1 Patients with any serious medical, cardiac, or psychiatric condition which, in the opinion of the investigator, would make the patient unsuitable for study participation or would impede probable compliance with the protocol.', ' 4.2.2 Patients with central nervous system metastases must have stable disease for at least 3 months prior to study entry.', ' 4.2.3 Patient is currently taking steroid medications. Systemic steroid treatment is not allowed.', ' 4.2.4 Patients that have failed prior therapy with vinorelbine + trastuzumab will not be eligible for therapy.', ' 4.2.5 Patient has received hormonal or cytotoxic chemotherapy within 14 days of apheresis and within 28-30 days prior to study treatment.'], 'Results': ['Outcome Measurement: ', ' Number of Participants With Response', ' Response: Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed: Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), >=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR.', ' Time frame: 5-6 years', 'Results 1: ', ' Arm/Group Title: Dendritic Cell Vaccine', ' Arm/Group Description: Therapeutic autologous dendritic cells (Dendritic Cell Vaccine) i.d. injection, 20 x 106 DCs given per treatment Trastuzumab infusion Vinorelbine ditartrate infusion', ' sargramostim: All patients will receive Leukine (GM-CSF) at 250 mcg/m2 starting one day after the administration of chemotherapy x 7 days. Patients with neutrophil counts below 1,000/mm3 on day 8 will continue GM-CSF therapy until the neutrophil count is greater than 1,000/mm3.', ' therapeutic autologous dendritic cells: patients will receive (10 x 106) peptide-pulsed DCs given by i.d injection into either axilla or the inguinal region with each peptide given into a separate site. The total dose will be 20 x 106 DCs given per treatment.', ' trastuzumab: Trastuzumab will be infused in the side-port of a freely flowing IV over 90 minutes and at 6mg/kg if the subject has not previously received Trastuzumab, or if it has been more than 30 days since any prior trastuzumab administration.', ' Overall Number of Participants Analyzed: 17', ' Measure Type: Count of Participants', ' Unit of Measure: Participants 0 0.0%'], 'Adverse Events': ['Adverse Events 1:', ' Total: 2/17 (11.76%)', ' Nausea * 1/17 (5.88%)', ' Pain - Abdomen NOS * 1/17 (5.88%)', ' Constipation * 1/17 (5.88%)']}

{'Clinical Trial ID': 'NCT00879086', 'Intervention': ['INTERVENTION 1: ', ' Eribulin Mesylate', ' Eribulin mesylate was given at a dose of 1.4 mg/m^2 as a 2 to 5 minute IV bolus on Days 1 and 8 of a 21-day cycle during the Treatment and Extension Phases. The Treatment Phase included six cycles. Following the sixth cycle of the Treatment Phase, participants who demonstrated clinical benefit could continue treatment during the Extension Phase for an indefinite number of cycles for as long as clinical benefit was sustained (up to 211 weeks).', 'INTERVENTION 2: ', ' Ixabepilone', ' Ixabepilone was given at a starting dose of 32 or 40 mg/m^2 (as per approved labeling) as a 3-hour IV infusion on Day 1 of a 21-day cycle during the Treatment and Extension Phases. The Treatment Phase included six cycles. Following the sixth cycle of the Treatment Phase, participants who demonstrated clinical benefit could continue treatment during the Extension Phase for an indefinite number of cycles for as long as clinical benefit was sustained (up to 211 weeks).'], 'Eligibility': ['Inclusion criteria:', ' 1. Female subjects with confirmed locally recurrent or metastatic carcinoma of the breast who have received prior taxane therapy and at least one prior cytotoxic chemotherapy regimen for advanced disease.', 'Exclusion criteria:', ' Subjects who have received prior ixabepilone therapy.', ' Subjects with prior participation in an eribulin clinical study, even if not assigned to eribulin treatment.', ' Subjects with pre-existing neuropathy Grade greater than or equal to 2.', ' Subjects with a history of diabetes mellitus Type 1 or 2.', ' Subjects with bilateral mastectomy which included bilateral axillary lymph node dissection.', ' Subjects with missing digits required for vibration assessment.', ' Subjects with any other concurrent diseases or conditions that would be expected to interfere with neuropathy assessments, which may include vitamin deficiency, sequelae of cerebrovascular disease, thyroid insufficiency, lumbar or cervical radiculopathy, or alcoholic or inflammatory neuropathy.'], 'Results': ['Outcome Measurement: ', ' Percentage of Participants With Treatment-Emergent Neuropathy Adverse Events (AEs)', ' Neuropathy AEs were graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) version 3.0 and coded according to the current version of the Medical Dictionary for Regulatory Activities (MedDRA). Neuropathy AEs included the broad list of preferred terms (PTs) defined in the Standard MedDRA Query for Neuropathy and the following additional PTs: neuropathy, hyperesthesia, painful response to normal stimuli, pallanesthesia, and allodynia. If the post-baseline maximum CTCAE grade of the combined term "neuropathy" was greater than the baseline maximum CTCAE grade of the combined term, then the event was considered as treatment emergent neuropathy adverse events per CTCAE grade. For a single participant, 1) a neuropathy AE occurring more than once during the study, whether defined with the same or different MedDRA PTs, was counted only once, 2) a neuropathy AE with different CTCAE grades had only the highest grade AE counted.', ' Time frame: From administration of first dose up to approximately 5 years', 'Results 1: ', ' Arm/Group Title: Eribulin Mesylate', ' Arm/Group Description: Eribulin mesylate was given at a dose of 1.4 mg/m^2 as a 2 to 5 minute IV bolus on Days 1 and 8 of a 21-day cycle during the Treatment and Extension Phases. The Treatment Phase included six cycles. Following the sixth cycle of the Treatment Phase, participants who demonstrated clinical benefit could continue treatment during the Extension Phase for an indefinite number of cycles for as long as clinical benefit was sustained (up to 211 weeks).', ' Overall Number of Participants Analyzed: 51', ' Measure Type: Number', ' Unit of Measure: Percentage of participants 33.3 (20.8 to 47.9)', 'Results 2: ', ' Arm/Group Title: Ixabepilone', ' Arm/Group Description: Ixabepilone was given at a starting dose of 32 or 40 mg/m^2 (as per approved labeling) as a 3-hour IV infusion on Day 1 of a 21-day cycle during the Treatment and Extension Phases. The Treatment Phase included six cycles. Following the sixth cycle of the Treatment Phase, participants who demonstrated clinical benefit could continue treatment during the Extension Phase for an indefinite number of cycles for as long as clinical benefit was sustained (up to 211 weeks).', ' Overall Number of Participants Analyzed: 50', ' Measure Type: Number', ' Unit of Measure: Percentage of participants 50.0 (35.5 to 64.5)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 19/51 (37.25%)', ' Febrile neutropenia 6/51 (11.76%)', ' Anaemia 1/51 (1.96%)', ' Leukopenia 1/51 (1.96%)', ' Neutropenia 1/51 (1.96%)', ' Thrombocytopenia 0/51 (0.00%)', ' Pericarditis 1/51 (1.96%)', ' Atrial flutter 0/51 (0.00%)', ' Cardiac failure congestive 0/51 (0.00%)', ' Visual impairment 0/51 (0.00%)', ' Dysphagia 1/51 (1.96%)', ' Abdominal pain 0/51 (0.00%)', ' Chills 1/51 (1.96%)', 'Adverse Events 2:', ' Total: 17/50 (34.00%)', ' Febrile neutropenia 0/50 (0.00%)', ' Anaemia 1/50 (2.00%)', ' Leukopenia 0/50 (0.00%)', ' Neutropenia 1/50 (2.00%)', ' Thrombocytopenia 1/50 (2.00%)', ' Pericarditis 0/50 (0.00%)', ' Atrial flutter 1/50 (2.00%)', ' Cardiac failure congestive 1/50 (2.00%)', ' Visual impairment 1/50 (2.00%)', ' Dysphagia 0/50 (0.00%)', ' Abdominal pain 1/50 (2.00%)', ' Chills 0/50 (0.00%)']}

82895f11-37bf-4d03-8de2-84818d93cce0

Comparison

Adverse Events

NCT00878709

NCT02447003

the primary trial had a total of 3 patients experiencing Pancreatic Cancer, the secondary trial had 0.

Contradiction

{'Clinical Trial ID': 'NCT00878709', 'Intervention': ['INTERVENTION 1: ', ' Neratinib', ' Patients who completed prior adjuvant trastuzumab received six 40 mg neratinib tablets (240 mg) taken orally once daily with food, preferably in the morning, continuously for one year. Therapy continued until unacceptable toxicity, recurrent disease, death, or withdrawal of consent occurred.', 'INTERVENTION 2: ', ' Placebo', ' Patients who completed prior adjuvant trastuzumab received six 40 mg placebo tablets (240 mg) taken orally once daily with food, preferably in the morning, continuously for one year. Therapy continued until unacceptable toxicity, recurrent disease, death, or withdrawal of consent occurred.'], 'Eligibility': ['Inclusion Criteria:', ' Stage II through IIIC HER-2/erbB-2 positive breast cancer with node positive disease.', ' Been treated for early breast cancer with standard of care duration of trastuzumab.', ' Could have been treated neoadjuvantly but have not reached pathologic complete response.', 'Exclusion Criteria:', ' Positive clinical and radiologic assessments for local or regional recurrence of disease at the time of study entry.', ' History of heart disease.', ' Corrected QT (QTc) interval >0.45 seconds', ' History of gastrointestinal disease with diarrhea as the major symptom.'], 'Results': ['Outcome Measurement: ', ' Invasive Disease-free Survival (iDFS) in Neratinib Arm Compared to Placebo Arm at Year 2', ' Invasive disease-free survival time is defined as the time from date of randomization until the first disease recurrence of the following events: invasive ipsilateral breast tumor recurrence, invasive contralateral breast cancer, local/regional invasive recurrence, distant recurrence and death from any cause.', ' Time frame: From randomization until time of event up to 2 years', 'Results 1: ', ' Arm/Group Title: Neratinib', ' Arm/Group Description: Patients who completed prior adjuvant trastuzumab received six 40 mg neratinib tablets (240 mg) taken orally once daily with food, preferably in the morning, continuously for one year. Therapy continued until unacceptable toxicity, recurrent disease, death, or withdrawal of consent occurred.', ' Overall Number of Participants Analyzed: 1420', ' Measure Type: Number', ' Unit of Measure: percentage of participants with events 4.7', 'Results 2: ', ' Arm/Group Title: Placebo', ' Arm/Group Description: Patients who completed prior adjuvant trastuzumab received six 40 mg placebo tablets (240 mg) taken orally once daily with food, preferably in the morning, continuously for one year. Therapy continued until unacceptable toxicity, recurrent disease, death, or withdrawal of consent occurred.', ' Overall Number of Participants Analyzed: 1420', ' Measure Type: Number', ' Unit of Measure: percentage of participants with events 7.5'], 'Adverse Events': ['Adverse Events 1:', ' Total: 103/1408 (7.32%)', ' Anaemia 1/1408 (0.07%)', ' Angina pectoris 1/1408 (0.07%)', ' Myocardial infarction 1/1408 (0.07%)', ' Atrial fibrillation 0/1408 (0.00%)', ' Sinus tachycardia 0/1408 (0.00%)', ' Tachycardia 0/1408 (0.00%)', ' Vertigo 0/1408 (0.00%)', ' Diarrhoea 22/1408 (1.56%)', ' Vomiting 12/1408 (0.85%)', ' Nausea 4/1408 (0.28%)', ' Abdominal pain 2/1408 (0.14%)', ' Pancreatitis 2/1408 (0.14%)', 'Adverse Events 2:', ' Total: 85/1408 (6.04%)', ' Anaemia 1/1408 (0.07%)', ' Angina pectoris 0/1408 (0.00%)', ' Myocardial infarction 1/1408 (0.07%)', ' Atrial fibrillation 1/1408 (0.07%)', ' Sinus tachycardia 1/1408 (0.07%)', ' Tachycardia 1/1408 (0.07%)', ' Vertigo 1/1408 (0.07%)', ' Diarrhoea 1/1408 (0.07%)', ' Vomiting 1/1408 (0.07%)', ' Nausea 1/1408 (0.07%)', ' Abdominal pain 0/1408 (0.00%)', ' Pancreatitis 1/1408 (0.07%)']}

{'Clinical Trial ID': 'NCT02447003', 'Intervention': ['INTERVENTION 1: ', ' Cohort A: Pembrolizumab', ' Participants in Cohort A previously received at least one prior systemic treatment for metastatic breast cancer. Participants were administered pembrolizumab 200 mg intravenously (IV) on Day 1 of each 3-week cycle (Q3W) for up to 35 cycles (up to ~2 years).', 'INTERVENTION 2: ', ' Cohort B: Pembrolizumab', ' Participants in Cohort B previously received no prior systemic treatment for metastatic breast cancer AND had a programmed cell death-ligand 1 (PD-L1) positive tumor expression. Participants were administered pembrolizumab 200 mg IV on Day 1 of each 3-week cycle (Q3W) for up to 35 cycles (up to ~2 years).'], 'Eligibility': ['Inclusion Criteria:', ' For the purposes of this study, neoadjuvant and/or adjuvant chemotherapy regimens do not count as a prior line of therapy.', ' For second line plus monotherapy (Parts 1 and 2):', ' Has received at least one systemic treatment for metastatic breast cancer', ' Has documented disease progression on or after the most recent therapy', ' Prior treatment must include an anthracycline and a taxane in the neoadjuvant, adjuvant, or metastatic setting', ' For first line monotherapy (Part 1):', ' Has received no prior systemic treatment for metastatic breast cancer', ' Has PD-L1-positive mTNBC.', ' For second line plus monotherapy (Part 2):', ' - Has PD-L1 strong positive mTNBC', ' For all parts:', ' Has mTNBC confirmed by a central laboratory', ' For biomarker analysis, adequate newly obtained core or excisional biopsy of a not-previously-irradiated metastatic tumor lesion (mandatory)', ' Has measurable metastatic disease', ' Has Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1', ' Female participants of childbearing potential should be willing to use 2 methods of birth control or be surgically sterile, or abstain from heterosexual activity for the course of the study through 120 days after the last dose of study treatment', ' Male participants should agree to use an adequate method of contraception starting with the first dose of study treatment through 120 days after the last dose of study treatment', ' Has adequate organ function', 'Exclusion Criteria:', ' Is currently participating and receiving study treatment, or has participated in a study of an investigational agent and received study therapy or used an investigational device within 4 weeks prior to study Day 1', ' Has received prior anti-cancer monoclonal antibody (mAb) therapy for direct anti-neoplastic treatment within 4 weeks prior to study Day 1', ' Has received prior chemotherapy, targeted small molecule therapy, or radiation therapy within at least 2 weeks prior to study Day 1', ' Has not recovered (i.e., Grade 1 or at baseline) from adverse events due to agents administered within at least 2 weeks prior to study Day 1', ' Has an active autoimmune disease requiring systemic treatment in past 2 years', ' Has a diagnosis of immunodeficiency or receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of study treatment', ' Has known additional malignancy that progressed or required active treatment within the last 5 years. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin that has undergone potentially curative therapy, or in situ cervical cancer', ' Has radiographically-detectable central nervous system (CNS) metastases and/or carcinomatous meningitis', ' Has a history of (non-infectious) pneumonitis that required steroids or current pneumonitis or a history of interstitial lung disease', ' Has an active infection requiring systemic therapy', ' Has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the study', ' Is pregnant, breastfeeding, or expecting to conceive or father children within the projected duration of the study, starting with the screening visit through 120 days after the last dose of study treatment', ' Has received prior therapy with an anti-programmed cell death protein-1 (anti-PD-1), anti-PD-L1, anti-PD-L2 agent or with an agent directed to another co-inhibitory T-cell receptor (e.g. cytotoxic T-lymphocyte-associated protein-4 [CTLA-4], OX-40, CD137) or has participated in Merck MK-3475 (pembrolizumab) study', ' Has a known history of human immunodeficiency virus (HIV)', ' Has known active Hepatitis B or C', ' Has received a live vaccine within 30 days of planned start of study treatment'], 'Results': ['Outcome Measurement: ', ' Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) by Central Imaging Vendor (CIV) in All Cohort A Participants', ' ORR was defined as the percentage of participants who had a Complete Response (CR: disappearance of all target lesions) or a Partial Response (PR: 30% decrease in sum of diameters [SOD] of target lesions) per RECIST 1.1 by CIV. ORR was estimated by Agresti-Coull (A-C) method. The percentage of participants who had CR or PR is reported here as the protocol-specified ORR, for the first pembrolizumab course, assessed from enrolment/treatment initiation and analyzed by Cohort, for all participants in Cohort A. Per protocol final ORR analysis in all Cohort A participants was done at the time of final statistical efficacy analysis, with a 10-November (Nov)-2017 cutoff. Per protocol ORR per RECIST 1.1 by CIV in all Cohort A participants was planned and conducted as a pre-specified primary outcome analysis. Per protocol ORR per RECIST 1.1 by CIV in all Cohort B participants was analyzed separately as a pre-specified secondary outcome analysis and reported later in the record.', ' Time frame: Up to ~28 months (through pre-specified statistical analysis cut-off date of 10-Nov-2017)', 'Results 1: ', ' Arm/Group Title: Cohort A: Pembrolizumab', ' Arm/Group Description: Participants in Cohort A previously received at least one prior systemic treatment for metastatic breast cancer. Participants were administered pembrolizumab 200 mg intravenously (IV) on Day 1 of each 3-week cycle (Q3W) for up to 35 cycles (up to ~2 years).', ' Overall Number of Participants Analyzed: 170', ' Measure Type: Number', ' Unit of Measure: Percentage of participants 5.3 (2.7 to 9.9)', 'Results 2: ', ' Arm/Group Title: Cohort B: Pembrolizumab', ' Arm/Group Description: Participants in Cohort B previously received no prior systemic treatment for metastatic breast cancer AND had a programmed cell death-ligand 1 (PD-L1) positive tumor expression. Participants were administered pembrolizumab 200 mg IV on Day 1 of each 3-week cycle (Q3W) for up to 35 cycles (up to ~2 years).', ' Overall Number of Participants Analyzed: 0', ' Measure Type: Number', ' Unit of Measure: Percentage of participants '], 'Adverse Events': ['Adverse Events 1:', ' Total: 46/170 (27.06%)', ' Anaemia 1/170 (0.59%)', ' Febrile neutropenia 1/170 (0.59%)', ' Cardiac tamponade 1/170 (0.59%)', ' Myocarditis 1/170 (0.59%)', ' Pericardial effusion 2/170 (1.18%)', ' Pericarditis 1/170 (0.59%)', ' Colitis 1/170 (0.59%)', ' Constipation 1/170 (0.59%)', ' Diarrhoea 0/170 (0.00%)', ' Gastroenteritis eosinophilic 0/170 (0.00%)', ' Intestinal obstruction 0/170 (0.00%)', 'Adverse Events 2:', ' Total: 0/1 (0.00%)', ' Anaemia 0/1 (0.00%)', ' Febrile neutropenia 0/1 (0.00%)', ' Cardiac tamponade 0/1 (0.00%)', ' Myocarditis 0/1 (0.00%)', ' Pericardial effusion 0/1 (0.00%)', ' Pericarditis 0/1 (0.00%)', ' Colitis 0/1 (0.00%)', ' Constipation 0/1 (0.00%)', ' Diarrhoea 0/1 (0.00%)', ' Gastroenteritis eosinophilic 0/1 (0.00%)', ' Intestinal obstruction 0/1 (0.00%)', ' Nausea 0/1 (0.00%)']}

f94643de-7122-4a58-972d-b0bb7e59d441

Comparison

Intervention

NCT01869764

NCT02556632

Every participant in the secondary trial and the primary trial undergoes Laboratory Biomarker Analysis.

Entailment

{'Clinical Trial ID': 'NCT01869764', 'Intervention': ['INTERVENTION 1: ', ' Arm I (Omega-3 Fatty Acid)', ' Patients receive omega-3 fatty acid PO daily for 7-14 days.', 'omega-3 fatty acid: Given PO', ' laboratory biomarker analysis: Correlative studies', 'INTERVENTION 2: ', ' Arm II (Placebo)', ' Patients receive placebo PO daily for 7-14 days.', ' placebo: Given PO', ' laboratory biomarker analysis: Correlative studies'], 'Eligibility': ['Inclusion Criteria:', ' Newly diagnosed stage I to III breast cancer and carcinoma in situ (including lobular carcinoma in situ [LCIS] and ductal carcinoma in situ [DCIS])', ' Breast surgery (lumpectomy or mastectomy) is planned for at least 7 days from the day of enrollment', ' Ability to understand and the willingness to sign an Institutional Review Board (IRB)-approved written informed consent document', ' Tumor measures at least 1 centimeter on imaging or physical exam', 'Exclusion Criteria:', ' Any patient with surgery scheduled < 7days after biopsy', ' Patients who are unable to refrain from the use of any NSAID or full-dose acetylsalicylic acid (ASA)-containing NSAID while taking study drug', ' Patients who will receive neoadjuvant chemotherapy are not eligible', ' Patients who are currently taking omega-3 fatty acids, as they are unable to be randomized to placebo', ' Patients who have previously taken omega-3 fatty acid within 1 month prior to study enrollment', ' Patients with an allergy or known hypersensitivity to fish'], 'Results': ['Outcome Measurement: ', ' PUFA Levels in Normal and Metastatic Breast Tissue', ' Analysis of variance (ANOVA) will be used to assess the effect of omega-3 dietary supplementation on PUFA levels separately in normal and malignant breast tissue. Analysis of covariance (ANCOVA) will be used to assess the omega-3 effect in plasma and red blood cells (RBC), where the baseline levels of the PUFAs will be included as covariates. PUFA Levels analyzed were 18:2 n-6, 18:3 n-3, 20:2 n-6, 20:4 n-6, 20:3 n-3, 20:5 n-3, 22:6 n-3', ' Time frame: At time of surgery', 'Results 1: ', ' Arm/Group Title: Arm I (Omega-3 Fatty Acid)', ' Arm/Group Description: Patients receive omega-3 fatty acid PO daily for 7-14 days.', 'omega-3 fatty acid: Given PO', ' laboratory biomarker analysis: Correlative studies', ' Overall Number of Participants Analyzed: 22', ' Mean (Standard Deviation)', ' Unit of Measure: ug/ml Normal breast tissue 18:2 n-6: 22 participants', ' 60.986 (40.392)', ' Normal breast tissue 18:3 n-3: 22 participants', ' 3.232 (2.289)', ' Normal breast tissue 20:2 n-6: 22 participants', ' 1.104 (0.96)', ' Normal breast tissue 20:4 n-6: 22 participants', ' 2.221 (1.349)', ' Normal breast tissue 20:3 n-3: 22 participants', ' 0.049 (0.107)', ' Normal breast tissue 20:5 n-3: 22 participants', ' 0.027 (0.128)', ' Normal breast tissue 22:6 n-3: 22 participants', ' 0.095 (0.443)', ' Normal breast tissue n-3: 22 participants', ' 3.402 (2.572)', ' Normal breast tissue n-6: 22 participants', ' 3.421 (2.085)', ' Normal breast tissue n3/n-6 ratio: 21 participants', ' 0.948 (0.468)', ' Malignant breast tissue 18:2 n-6: 22 participants', ' 44.137 (44.544)', ' Malignant breast 18:3 n-3: 22 participants', ' 1.943 (2.162)', ' Malignant breast 20:2 n-6: 22 participants', ' 0.889 (0.886)', ' Malignant breast 20:4 n-6: 22 participants', ' 3.208 (1.948)', ' Malignant breast 20:3 n-3: 22 participants', ' 0.034 (0.087)', ' Malignant breast 20:5 n-3: 22 participants', ' 0.2 (0.665)', ' Malignant breast 22:6 n-3: 22 participants', ' 0 (0)', ' Malignant breast n-3: 22 participants', ' 2.178 (2.41)', ' Malignant breast n-6: 22 participants', ' 48.233 (46.105)', ' Malignant breast n-3/n-6 ratio: 22 participants', ' 0.029 (0.031)', ' Differences in PUFA level 18:2 n-6: 22 participants', ' -16.85 (51.043)', ' Differences in PUFA level 18:3 n-3: 22 participants', ' -1.289 (2.784)', ' Differences in PUFA level 20:2 n-6: 22 participants', ' -0.215 (0.866)', ' Differences in PUFA level 20:4 n-6: 22 participants', ' 0.986 (1.595)', ' Differences in PUFA level 20:3 n-3: 22 participants', ' -0.015 (0.105)', ' Differences in PUFA level 20:5 n-3: 22 participants', ' 0.173 (0.545)', ' Differences in PUFA level 22:6 n-3: 22 participants', ' -0.095 (0.443)', ' Difference in PUFA level n-3: 22 participants', ' -1.224 (2.794)', ' Difference in PUFA level in n-6: 22 participants', ' 44.812 (45.463)', ' Difference in n-3/n-6 ratio: 21 participants', ' -0.92 (0.45)', 'Results 2: ', ' Arm/Group Title: Arm II (Placebo)', ' Arm/Group Description: Patients receive placebo PO daily for 7-14 days.', ' placebo: Given PO', ' laboratory biomarker analysis: Correlative studies', ' Overall Number of Participants Analyzed: 19', ' Mean (Standard Deviation)', ' Unit of Measure: ug/ml Normal breast tissue 18:2 n-6: 19 participants', ' 72.762 (50.742)', ' Normal breast tissue 18:3 n-3: 19 participants', ' 3.505 (2.041)', ' Normal breast tissue 20:2 n-6: 19 participants', ' 1.008 (0.724)', ' Normal breast tissue 20:4 n-6: 19 participants', ' 2.342 (1.445)', ' Normal breast tissue 20:3 n-3: 19 participants', ' 0.038 (0.085)', ' Normal breast tissue 20:5 n-3: 19 participants', ' 0.034 (0.147)', ' Normal breast tissue 22:6 n-3: 19 participants', ' 0.061 (0.264)', ' Normal breast tissue n-3: 19 participants', ' 3.64 (2.24)', ' Normal breast tissue n-6: 19 participants', ' 3.413 (1.962)', ' Normal breast tissue n3/n-6 ratio: 19 participants', ' 1.102 (0.438)', ' Malignant breast tissue 18:2 n-6: 19 participants', ' 33.735 (31.548)', ' Malignant breast 18:3 n-3: 19 participants', ' 1.356 (1.465)', ' Malignant breast 20:2 n-6: 19 participants', ' 0.601 (0.657)', ' Malignant breast 20:4 n-6: 19 participants', ' 2.248 (1.744)', ' Malignant breast 20:3 n-3: 19 participants', ' 0 (0)', ' Malignant breast 20:5 n-3: 19 participants', ' 0 (0)', ' Malignant breast 22:6 n-3: 19 participants', ' 0 (0)', ' Malignant breast n-3: 19 participants', ' 1.357 (1.466)', ' Malignant breast n-6: 19 participants', ' 36.586 (32.856)', ' Malignant breast n-3/n-6 ratio: 19 participants', ' 0.032 (0.016)', ' Differences in PUFA level 18:2 n-6: 19 participants', ' -39.027 (38.697)', ' Differences in PUFA level 18:3 n-3: 19 participants', ' -2.149 (1.935)', ' Differences in PUFA level 20:2 n-6: 19 participants', ' -0.407 (0.514)', ' Differences in PUFA level 20:4 n-6: 19 participants', ' -0.094 (1.589)', ' Differences in PUFA level 20:3 n-3: 19 participants', ' -0.038 (0.085)', ' Differences in PUFA level 20:5 n-3: 19 participants', ' -0.034 (0.147)', ' Differences in PUFA level 22:6 n-3: 19 participants', ' -0.061 (0.264)', ' Difference in PUFA level n-3: 19 participants', ' -2.282 (2.127)', ' Difference in PUFA level in n-6: 19 participants', ' 33.173 (31.836)', ' Difference in n-3/n-6 ratio: 19 participants', ' -1.07 (0.438)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 0/28 (0.00%)', 'Adverse Events 2:', ' Total: ']}

{'Clinical Trial ID': 'NCT02556632', 'Intervention': ['INTERVENTION 1: ', ' Arm I (Curcumin-based Gel)', ' Patients apply curcumin-based gel topically TID approximately every 4-6 hours beginning on the first day of radiation therapy and continuing until 1 week after completion of radiation therapy.', 'Curcumin-based Gel: Applied topically', ' Laboratory Biomarker Analysis: Correlative studies', ' Questionnaire Administration: Ancillary studies', 'INTERVENTION 2: ', ' Arm II (HPR Plus)', ' Patients apply HPR Plus™ topically TID approximately every 4-6 hours beginning on the first day of radiation therapy and continuing until 1 week after completion of radiation therapy.', ' Dermatologic Complications Management: Apply HPR Plus topically', ' Laboratory Biomarker Analysis: Correlative studies', ' Questionnaire Administration: Ancillary studies'], 'Eligibility': ['Inclusion Criteria:', ' Subjects with a diagnosis of non-inflammatory breast cancer or carcinoma in situ', ' Subjects must be prescribed and scheduled for "conventional fractionated" RT without concurrent chemotherapy; bolus and intensity modulated radiation therapy (IMRT) are permitted; lymph node irradiation (i.e., internal mammary nodes, supraclavicular nodes, axillary nodes, etc) as part of their prescribed radiation therapy are permitted; conventional fractionated radiation therapy regimens eligible for study are described below:', ' Minimal (min) total dose: whole breast: 44 gray (Gy); breast boost: 10 Gy; tumor bed = whole breast +/- boost: 50.0 Gy; lymph nodes: 45 Gy', ' Maximal (max) total dose: whole breast: 50.4 Gy; breast boost: 20 Gy; tumor bed = whole breast +/- boost: 66.0 Gy; lymph nodes: 50.4 Gy', ' Min dose per fraction: whole breast: 1.8 Gy; breast boost: 2.0 Gy; tumor bed = whole breast +/- boost: 1.8 Gy; lymph nodes: 1.8 Gy', ' Max dose per fraction: whole breast: 2.0 Gy; breast boost: 2.0 Gy; tumor bed = whole breast +/- boost: 2.0 Gy; lymph nodes: 2.0 Gy', 'Min # of fractions: whole breast: 22 Gy; breast boost: 5 Gy; tumor bed = whole breast +/- boost: 25 Gy; lymph nodes: 25 Gy', 'Max # of fractions: whole breast: 28 Gy; breast boost: 10 Gy; tumor bed = whole breast +/- boost: 36 Gy; lymph nodes: 28 Gy', ' Min # of sessions: whole breast: 22 Gy; breast boost: 5 Gy; tumor bed = whole breast +/- boost: 25 Gy; lymph nodes: 25 Gy', ' Max # of sessions: whole breast: 28 Gy; breast boost: 10 Gy; tumor bed = whole breast +/- boost: 36 Gy; lymph nodes: 28 Gy', ' Subjects may or may not have had surgery (lumpectomy or mastectomy) prior to RT; (NOTE: surgery is not required for eligibility)', ' Subjects may have had chemotherapy prior to radiation; a minimum of two weeks is required between end of chemotherapy and start of RT', ' Subjects may be currently prescribed hormone treatment or Herceptin therapy', ' Subjects must be able to read, speak, and understand English', ' Subjects must have the ability to understand and the willingness to sign a written informed consent document', ' Subjects must agree to not use any other topical agents on skin in the radiation treatment area during the course of this trial; subjects should only use topical agents for the study (i.e., topical intervention or standard care agents) supplied by the study personnel and/or treating physician', 'Exclusion Criteria:', ' Pregnant females are ineligible; all subjects of childbearing potential will be asked if they are pregnant or could be pregnant; the patient must respond "no" to continue with radiation and to participate in this clinical study', ' Subjects with bilateral breast cancer are not eligible', ' Subjects receiving the short-course fractionation radiation therapy (i.e., 16 sessions or 20 sessions at 2.4 to 2.6 Gy fractions per session, with or without boost)', ' Subject is currently on anti-EGFR (human epidermal growth factor receptor) therapy, such as Iressa (gefitinib) or Erbitux (cetuximab, C225)', ' Previous radiation to the chest or breast', ' Subjects with breast reconstruction prior to RT', ' Previous diagnosis of radiosensitivity disorder (i.e., ataxia telangiectasia)', ' Previous diagnosis of collagen vascular disorder or vasculitis', ' Presence of unhealed surgical wounds in chest or breast region and/or breast infection', ' Current daily application of a prescribed topical product to the skin within the RT area for an unrelated skin condition that cannot be discontinued during the participation in this clinical trial', ' Presence of any active dermatological issues in radiation treatment area (i.e., fungal skin infection, dermatitis, psoriasis plaques, etc)'], 'Results': ['Outcome Measurement: ', ' Mean Radiation Dermatitis Severity (RDS) Score. Range: 0 (no Dermatitis) - 4 (Violaceous Erythema With Diffuse Desquamation Occurring in Sheets; Patchy Crusting; Superficial Ulceration)', ' The mean 1 week post-RT RDS score for each arm will be compared using ANOVA to determine if the topical interventions reduce the severity of skin reactions at the end of RT.', ' The RDS score ranges from 0-4 with higher scores indicating worse outcome.', ' Time frame: Baseline up to 1 week post radiation therapy', 'Results 1: ', ' Arm/Group Title: Arm I (Curcumin-based Gel)', ' Arm/Group Description: Patients apply curcumin-based gel topically TID approximately every 4-6 hours beginning on the first day of radiation therapy and continuing until 1 week after completion of radiation therapy.', 'Curcumin-based Gel: Applied topically', ' Laboratory Biomarker Analysis: Correlative studies', ' Questionnaire Administration: Ancillary studies', ' Overall Number of Participants Analyzed: 59', ' Mean (Standard Deviation)', ' Unit of Measure: units on a scale 2.68 (0.74)', 'Results 2: ', ' Arm/Group Title: Arm II (HPR Plus)', ' Arm/Group Description: Patients apply HPR Plus™ topically TID approximately every 4-6 hours beginning on the first day of radiation therapy and continuing until 1 week after completion of radiation therapy.', ' Dermatologic Complications Management: Apply HPR Plus topically', ' Laboratory Biomarker Analysis: Correlative studies', ' Questionnaire Administration: Ancillary studies', ' Overall Number of Participants Analyzed: 59', ' Mean (Standard Deviation)', ' Unit of Measure: units on a scale 2.64 (0.74)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 3/64 (4.69%)', ' Heart Failure * 0/64 (0.00%)', ' Radiation Dermatitis * 3/64 (4.69%)', ' Headache * 0/64 (0.00%)', ' Pleuritic pain * 0/64 (0.00%)', ' Dermatitis * 1/64 (1.56%)', 'Adverse Events 2:', ' Total: 2/65 (3.08%)', ' Heart Failure * 1/65 (1.54%)', ' Radiation Dermatitis * 1/65 (1.54%)', ' Headache * 0/65 (0.00%)', ' Pleuritic pain * 1/65 (1.54%)', ' Dermatitis * 0/65 (0.00%)']}

1485315b-3169-42a3-a672-6f7963d49a51

Single

Eligibility

NCT03719677

Potential participants will be considered regardless of the hormone receptivity of their breast cancer.

Contradiction

{'Clinical Trial ID': 'NCT03719677', 'Intervention': ['INTERVENTION 1: ', ' Habit Development Intervention', ' Treatment includes occupational therapy evaluation and consultation to address any deficits in physical function, safety, social participation and/or life roles. After the occupational therapy evaluation, the therapist delivers education on physical activity and dietary recommendations and habit development techniques, and uses behavioral skills training to develop habit plans, as well as prompts/cues, environmental modifications, and reminder text messages to reinforce engagement in the plan. The intervention is delivered through 3 face to face sessions, 9 tele coaching calls, and text messages.', ' Habit development intervention: Lifestyle behavior change intervention targeting physical activity and dietary habit development as well as improving physical and social functioning'], 'Eligibility': ['Inclusion Criteria:', ' English speaking', ' Diagnosis of stage 1-3 histologically confirmed first cancer of the breast', ' Reside in a zip code designated as rural by the United States Department of Agriculture Economic Research Service', ' Be within the initial 12 months following the end of primary treatment and meet 3 of the following 5 criteria for MetS confirmed via point-of-care testing or documentation in their medical record:', ' A large waistline > 35 inches Blood pressure > 130/85; HbA1c of 5.7%-6.4%; Triglyceride levels > 150 mg/dL; HDL cholesterol levels < 50 mg/dL', 'Exclusion Criteria:', ' Will not exclude participants based on hormone receptivity, one exception is that we will exclude HER2 positive BCS', ' Pregnant patients', ' Resistant Hypertension', ' Steroid-dependent asthma or Chronic obstructive pulmonary disease', ' Cirrhosis or hepatic failure', ' A major cardiovascular event (e.g., stroke, myocardial infarction) within the previous 90 days', ' Chronic kidney disease on renal replacement therapy', ' Type one or two diabetes', ' Stage 4 cancer; those with a secondary cancer (except for nonmelanomatous skin cancers and carcinoma of the cervix in situ)', ' Taking weight loss medications', ' Current involvement in a behavioral program', ' Neuropsychiatric disorder or dementia'], 'Results': ['Outcome Measurement: ', ' Self Reported Behavioral Automaticity Index', ' Measures changes in habit strength, scores range from 1-7 with higher scores indicating a stronger habit', ' Time frame: From week 0-2', 'Results 1: ', ' Arm/Group Title: Habit Development Intervention', ' Arm/Group Description: Treatment includes occupational therapy evaluation and consultation to address any deficits in physical function, safety, social participation and/or life roles. After the occupational therapy evaluation, the therapist delivers education on physical activity and dietary recommendations and habit development techniques, and uses behavioral skills training to develop habit plans, as well as prompts/cues, environmental modifications, and reminder text messages to reinforce engagement in the plan. The intervention is delivered through 3 face to face sessions, 9 tele coaching calls, and text messages.', ' Habit development intervention: Lifestyle behavior change intervention targeting physical activity and dietary habit development as well as improving physical and social functioning', ' Overall Number of Participants Analyzed: 7', ' Mean (Standard Deviation)', ' Unit of Measure: score on a scale Baseline: 1.6 (1.3)', ' Post test: 4.8 (2.1)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 0/7 (0.00%)']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

b4ef27ca-52b4-4af3-9b60-e9e0285e0e86

Single

Eligibility

NCT03371732

patients with Karnofsky Index = 72 are eligible for the primary trial.

Entailment

{'Clinical Trial ID': 'NCT03371732', 'Intervention': ['INTERVENTION 1: ', ' Arm 1', ' Arm 1: Motivational Intervention group', ' Motivational Intervention group: Participants in the intervention group a one-session brief motivational intervention administered by a psychologist. This intervention consist in a single adapted motivational interview lasting 20-30 minutes, based on the principles of the trans-theoretical model and on the manual for motivational therapy. It is carried out by the same psychologist, trained and supervised for this type of intervention.', 'INTERVENTION 2: ', ' Arm 2', ' Arm 2: Educational advises group', ' Educational advises group: Participants in this group benefit of brief educational advises (10 minutes interview maximum ; only on alcohol/tobacco consumption consequences on health), and received a pamphlet on the health effects of alcohol and tobacco consumption.'], 'Eligibility': ['Inclusion Criteria :', ' women with primary breast cancer, without ongoing support for substance use.', ' An AUDIT-C score >1 or more than one cigarette smoked per day.', ' Individuals able to consent to benefit of intervention focused on substance use. (Karnofsky Index >70).', ' Exclusion Criteria :', ' Patients who currently use substances for which a second-line care is already committed.', ' Patients with a Karnofsky index <70.'], 'Results': ['Outcome Measurement: ', ' Number of Patients With Individual Decrease of Tobacco Consumption at 3 Months', ' Individual decrease of 20% in the AUDIT (Alcohol Use Disorders Identification Test) score observed at 3 months', ' AUDIT test measures alcohol consumption and makes it possible to describe its profiles. Its score ranges from 0 (no consumption) to 28 (alcohol dependence).', ' Time frame: 3 months', 'Results 1: ', ' Arm/Group Title: Arm 1', ' Arm/Group Description: Arm 1: Motivational Intervention group', ' Motivational Intervention group: Participants in the intervention group a one-session brief motivational intervention administered by a psychologist. This intervention consist in a single adapted motivational interview lasting 20-30 minutes, based on the principles of the trans-theoretical model and on the manual for motivational therapy. It is carried out by the same psychologist, trained and supervised for this type of intervention.', ' Overall Number of Participants Analyzed: 48', ' Measure Type: Count of Participants', ' Unit of Measure: Participants Success: 23 47.9%', ' Success not maintained: 18 37.5%', 'Missing: 7 14.6%', 'Results 2: ', ' Arm/Group Title: Arm 2', ' Arm/Group Description: Arm 2: Educational advises group', ' Educational advises group: Participants in this group benefit of brief educational advises (10 minutes interview maximum ; only on alcohol/tobacco consumption consequences on health), and received a pamphlet on the health effects of alcohol and tobacco consumption.', ' Overall Number of Participants Analyzed: 53', ' Measure Type: Count of Participants', ' Unit of Measure: Participants Success: 19 35.8%', ' Success not maintained: 29 54.7%', 'Missing: 5 9.4%'], 'Adverse Events': ['Adverse Events 1:', ' Total: 0/0', 'Adverse Events 2:', ' Total: 0/0']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

769bb3b2-9d2d-4dad-bd59-0042c55ac1ee

Comparison

Eligibility

NCT00899574

NCT01007942

the primary trial uses different inclusion criteria for its cohorts, the secondary trial only uses one set on inclusion criteria for all cohorts.

Entailment

{'Clinical Trial ID': 'NCT00899574', 'Intervention': ['INTERVENTION 1: ', ' Imiquimod', ' Each treatment cycle consists of 8 weeks.', ' Weeks 1-8: day 1-5 of each week: 1 packet imiquimod 5% cream applied overnight, day 6-7 of each week: rest period.', ' Patients with responding or stable local disease (non-progressors) may continue to receive treatment following the same schedule (as outlined above for the first cycle) until complete tumor regression, unacceptable toxicity or progression of disease.'], 'Eligibility': ['Inclusion Criteria:', ' Patients with biopsy-confirmed breast cancer (prior histological documentation is acceptable).', ' Patients with measurable skin metastases (chest wall recurrence and/or non-chest wall skin metastases are eligible).', ' Skin metastases not suitable for or patient refusing definitive surgical resection and radiation.', ' (Cohort 1) Concurrent systemic cancer therapy (hormones, biologics or chemotherapy) is allowed if distant metastases have been non-progressing (stable or responding) on that regimen for > or = 12 weeks and skin metastases are non-responsive (stable or progressing) as assessed by the investigator.', ' (Cohort 2) Any concurrent systemic therapy is allowed', ' Age at least 18 years.', ' Eastern Cooperative Oncology Group (ECOG) performance status < or = 2.', ' Patients must have biopsy-accessible tumor (skin metastases) and agree to biopsies required by protocol.', ' Patients must have adequate organ and bone marrow function as defined below:', ' absolute neutrophil count > or = 1,500/microliter', ' hemoglobin > or = 9.5 grams/deciliter', ' platelets >or = 75,000/microliter', ' total bilirubin < or = 1.5 X institutional upper limit of normal', ' Aspartate aminotransferase (AST)/Alanine aminotransferase (ALT) < or = 2.5X institutional upper limit of normal', ' creatinine < or = 1.5 X institutional upper limit of normal', ' Informed consent.', 'Exclusion Criteria:', ' Brain metastases unless resected or irradiated and stable > or = 8 weeks.', ' Treatment with other investigational agents.', ' Patients who have received radiotherapy, high-potency corticosteroids, intralesional therapy, laser therapy or surgery other than biopsy to the target area within 4 weeks prior to first dosing of study agent.', ' Patients who have received hyperthermia to the target area within 10 weeks prior to first dosing of study agent.', ' Patients with an uncontrolled bleeding disorder.', ' Patients who will be therapeutically anticoagulated with heparins or coumadin at the time of the biopsy (they are eligible if anticoagulation can be held prior to biopsy as per investigator). Patients on aspirin and other platelet agents are eligible.', ' Patients with known immunodeficiency or receiving immunosuppressive therapies.', ' History of allergic reactions to imiquimod or its excipients.', ' Uncontrolled intercurrent medical illness or psychiatric illness/social situations that would limit compliance with study requirements.', ' Pregnancy or lactation.', ' Women of childbearing potential not using a medically acceptable means of contraception.'], 'Results': ['Outcome Measurement: ', ' Objective Response (Complete Clinical Response+ Partial Response)', ' This is defined as percentage of patients who achieved complete clinical response or partial response at end of cycle 1 of treatment. The tumor size will be measured as lesion surface area (region of interest, ROI). The response to the treatment is then evaluated as a function of post-treatment over pre-treatment ROI, expressed in percentage. Response criteria for this study are based on European Organisation for Research and Treatment of Cancer definitions for chest wall tumors: complete clinical response: absence of any detectable residual disease; partial response: <50% of ROI change.', ' Time frame: 9 weeks', 'Results 1: ', ' Arm/Group Title: Imiquimod', ' Arm/Group Description: Each treatment cycle consists of 8 weeks.', ' Weeks 1-8: day 1-5 of each week: 1 packet imiquimod 5% cream applied overnight, day 6-7 of each week: rest period.', ' Patients with responding or stable local disease (non-progressors) may continue to receive treatment following the same schedule (as outlined above for the first cycle) until complete tumor regression, unacceptable toxicity or progression of disease.', ' Overall Number of Participants Analyzed: 10', ' Measure Type: Number', ' Unit of Measure: percentage of patients 20 (3 to 56)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 0/10 (0.00%)']}

{'Clinical Trial ID': 'NCT01007942', 'Intervention': ['INTERVENTION 1: ', ' Everolimus + Vinorelbine + Trastuzumab', ' Oral everolimus (5 mg/day) + intravenous vinorelbine (25 mg/m2 weekly) + intravenous trastuzumab (2 mg/kg weekly following a 4 mg/kg loading dose on Day 1 of Cycle 1 only)', 'INTERVENTION 2: ', ' Placebo + Vinorelbine + Trastuzumab', ' Oral daily matching placebo + intravenous vinorelbine (25 mg/m2 weekly) + intravenous trastuzumab (2 mg/kg weekly following a 4 mg/kg loading dose on Day 1 of Cycle 1 only)'], 'Eligibility': ['Inclusion Criteria:', ' Histologically or cytologically confirmed invasive breast carcinoma with locally recurrent or radiological evidence of metastatic disease. Locally recurrent disease must not be amenable to resection with curative intent.', ' HER2+ status defined as IHC 3+ staining or in situ hybridization positive', ' Patients with resistance to trastuzumab', ' Prior taxane therapy', ' Patients with an ECOG performance status of 0 - 2', ' Patients with measurable disease as per RECIST criteria', ' Documentation of negative pregnancy test for patients of child bearing potential prior to enrollment within 7 days prior to randomization. Sexually active pre-menopausal women must use adequate contraceptive measures, excluding estrogen containing contraceptives, while on study;', ' Patients must meet laboratory criteria defined in the study within 21 days prior to randomization', 'Exclusion Criteria:', ' Prior mTOR inhibitors or vinca alkaloid agents for the treatment of cancer', ' More than three prior chemotherapy lines for advanced disease.', ' Symptomatic CNS metastases or evidence of leptomeningeal disease. Previously treated asymptomatic CNS metastases are allowed provided that the last treatment for CNS metastases was completed >8 weeks prior to randomization', ' Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral everolimus', ' Peripheral neuropathy grade 2 at randomization', ' Active cardiac disease', ' History of cardiac dysfunction', ' Any malignancy within 5 years prior to randomization, with the exception of adequately treated in-situ carcinoma of the cervix uteri, basal or squamous cell carcinoma or non-melanomatous skin cancer', ' Known hypersensitivity to any study medication', ' Breastfeeding or pregnant'], 'Results': ['Outcome Measurement: ', ' Progressive-free Survival (PFS) Per Investigator Assessment', ' PFS was defined as the time from the date of randomization to the date of first radiologically documented tumor progression or death from any cause, whichever occurs first. PFS primary analysis performed when 415 events were reached. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions.', ' Time frame: Every 6 weeks until disease progression or death which ever occurred first up to about 41 months', 'Results 1: ', ' Arm/Group Title: Everolimus + Vinorelbine + Trastuzumab', ' Arm/Group Description: Oral everolimus (5 mg/day) + intravenous vinorelbine (25 mg/m2 weekly) + intravenous trastuzumab (2 mg/kg weekly following a 4 mg/kg loading dose on Day 1 of Cycle 1 only)', ' Overall Number of Participants Analyzed: 284', ' Median (95% Confidence Interval)', ' Unit of Measure: months 7.00 (6.74 to 8.18)', 'Results 2: ', ' Arm/Group Title: Placebo + Vinorelbine + Trastuzumab', ' Arm/Group Description: Oral daily matching placebo + intravenous vinorelbine (25 mg/m2 weekly) + intravenous trastuzumab (2 mg/kg weekly following a 4 mg/kg loading dose on Day 1 of Cycle 1 only)', ' Overall Number of Participants Analyzed: 285', ' Median (95% Confidence Interval)', ' Unit of Measure: months 5.78 (5.49 to 6.90)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 122/280 (43.57%)', ' Agranulocytosis 0/280 (0.00%)', ' Anaemia 10/280 (3.57%)', ' Febrile neutropenia 30/280 (10.71%)', ' Immune thrombocytopenic purpura 1/280 (0.36%)', ' Leukopenia 3/280 (1.07%)', ' Neutropenia 12/280 (4.29%)', ' Thrombocytopenia 4/280 (1.43%)', ' Acute myocardial infarction 1/280 (0.36%)', ' Cardiac failure 1/280 (0.36%)', ' Cataract 2/280 (0.71%)', 'Adverse Events 2:', ' Total: 58/282 (20.57%)', ' Agranulocytosis 1/282 (0.35%)', ' Anaemia 2/282 (0.71%)', ' Febrile neutropenia 4/282 (1.42%)', ' Immune thrombocytopenic purpura 0/282 (0.00%)', ' Leukopenia 0/282 (0.00%)', ' Neutropenia 3/282 (1.06%)', ' Thrombocytopenia 1/282 (0.35%)', ' Acute myocardial infarction 0/282 (0.00%)', ' Cardiac failure 0/282 (0.00%)', ' Cataract 1/282 (0.35%)', ' Cataract subcapsular 1/282 (0.35%)']}

426196d8-44ab-4c5c-8f81-5cb12345ad69

Comparison

Adverse Events

NCT00365365

NCT00005908

the primary trial and the secondary trial only recorded one type of acute adverse event.

Contradiction

{'Clinical Trial ID': 'NCT00365365', 'Intervention': ['INTERVENTION 1: ', ' Stratum 1 (AC->T + Bevacizumab)', ' HER2-negative participants administered', ' doxorubicin and cyclophosphamide (AC) + bevacizumab for 4 cycles followed by', ' docetaxel (T) + bevacizumab for 4 cycles followed by', ' bevacizumab maintenance therapy for total of 52 weeks from date of first dose regardless of number of doses received or missed', 'INTERVENTION 2: ', ' Stratum 2 (TAC + Bevacizumab)', ' HER2-negative participants administered', ' docetaxel, doxorubicin, cyclophosphamide (TAC) + bevacizumab for 6 cycles followed by', ' bevacizumab maintenance therapy for total of 52 weeks from date of first dose regardless of number of doses received or missed'], 'Eligibility': ['The following information on clinical trials is provided for information purposes only to allow participants and physicians to have an initial discussion about the trial. This information is not intended to be complete information about the trial, to contain all considerations that may be relevant to potential participation in the trial, or to replace the advice of a personal physician or health professional.', 'Inclusion Criteria:', ' Women >/= 18 years of age.', ' Histologically proven breast cancer with an interval between definitive breast surgery that includes axillary lymph node (LN) dissection or axillary nodal evaluation and study registration of < 60 days. (Note: Cycle 1 of chemotherapy treatment may NOT be infused until > 28 days after the date of definitive breast surgery and the participant must be recovered from any clinically significant toxicity thereof.)', ' Definitive surgical treatment must be either mastectomy, or breast conserving surgery with axillary lymph node dissection (axillary lymph node evaluation can be either full axillary node dissection or sentinel LN evaluation followed by dissection if sentinel LN is positive) for operable breast cancer (pT1-4 [including inflammatory], pNO-3, and MO). Margins of resected specimen from definitive surgery must be histologically free of invasive adenocarcinoma and ductal carcinoma in-situ (DCIS). Lobular carcinoma in-situ does not count as a positive margin.', ' Subjects must be either lymph node-positive (pN1-3) or lymph node-negative (pN0) with high-risk features as determined by Investigator.', ' High-risk, lymph node-negative participants, (pN0) will be defined as subjects having invasive adenocarcinoma with either a negative sentinel node biopsy (pN0[sn]) OR negative lymph node dissection (pN0) disease AND tumor size > 2 cm or tumor size >/= 1 cm with at least one of the following factors:', ' negative estrogen receptor (ER) and negative progesterone receptor (PR) status', ' histologic and/or nuclear Grade 2-3; or', ' age < 35 years', ' HER2/neu positive or negative tumors are eligible. HER2 positivity must be documented by fluorescence in situ hybridization (FISH).', ' Estrogen and progesterone receptor status must be performed on the primary tumor prior to study entry. Results must be pending or known at the time of study entry.', ' Normal cardiac function must be confirmed by left ventricular ejection fraction (LVEF) or shortening fraction (multiple-gated acquisition [MUGA] scan or echocardiography respectively). The result must be greater than the lower limit of normal (LLN) for the institution.', ' Hematology evaluation within 2 weeks prior to study entry:', ' Absolute neutrophil count (ANC) >/= 1,500/μL', ' Platelets >/= 100,000/μL', ' Hemoglobin >/= 9 g/dL', ' Hepatic function evaluation within 2 weeks prior to study entry:', ' Total bilirubin </= ULN for the institution', ' Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) must be in the acceptable range.', ' Complete staging work-up as follows: All subjects must have an appropriate radiographic evaluation, e.g., computed tomography (CT), positron emission tomography (PET)/CT, and/or (magnetic resonance imaging) MRI of the brain, chest, abdomen and pelvis, and imaging of bone by either a bone scan or PET scan. In cases of positive bone imaging, a bone X-ray or MRI evaluation is mandatory to rule out the possibility of metastatic bone scan disease. Other tests may be performed as clinically indicated. It is recommended that all baseline staging should be completed within 35 days prior to study entry.', 'Exclusion Criteria:', ' Prior systemic anticancer therapy for breast cancer (immunotherapy, hormonotherapy, chemotherapy).', ' Prior anthracycline therapy, taxoids or platinum salts for any malignancy.', ' Prior radiation therapy for breast cancer or any radiotherapy to the chest wall for any other malignancy.', ' Bilateral invasive breast cancer.', ' Pregnant or lactating subjects', ' Cardiac disease or risk for same as judged by Investigator', ' Other serious illness or medical conditions such as (partial list- review with Investigator) history of significant neurologic or psychiatric disorders that would prohibit the understanding and giving of informed consent, active uncontrolled infection, active peptic ulcer, unstable diabetes mellitus or subjects with symptomatic, intrinsic lung disease resulting in dyspnea at rest', ' Current therapy with any hormonal agent such as raloxifene, tamoxifen, or other selective estrogen receptor modulators (SERMs), either for osteoporosis or prevention of breast cancer. Subjects must have discontinued these agents prior to study entry.', ' Concurrent treatment with ovarian hormonal replacement therapy. Prior treatment must be stopped prior to study entry.', ' Concurrent treatment with other experimental drugs. Participation in another clinical trial with any investigational non-marketed drug within 30 days prior to study entry.', ' Concurrent treatment with any other anti-cancer therapy.', ' Male subjects, as no clinical efficacy or safety data are available from phase I-II studies.', ' Chemotherapy and/or bevacizumab may not be given until > 7 days following a minor surgical procedure. Chemotherapy may be given without bevacizumab in circumstances in which the participant has recovered sufficiently to receive chemotherapy but has not yet reached a 28 day time point at which bevacizumab could be administered.'], 'Results': ['Outcome Measurement: ', ' Cardiac Safety - Number of Participants With Grade 3-4 Clinical Congestive Heart Failure (CHF)', ' Participants were evaluated for clinical CHF every 3 weeks during chemotherapy, every 3 months while on maintenance therapy, and every 3 months during the 2-year follow-up period. Left ventricular ejection fraction (LVEF) of CHF was assessed by multi-gated acquisition (MUGA) or echocardiogram (ECHO) performed midway through completion of chemotherapy according to a treatment-specific schedule, every 12 weeks during maintenance therapy, and at 6 and 24 months after completion of maintenance therapy.', ' Grade 3-4 CHF were identified through a clinical review of all study collected investigator verbatim and the Medical Dictionary for Regulatory Activities (MedDRA). The preferred terms (PT) cardiac failure congestive, cardiomyopathy, and ejection fraction decreased were associated with CHF.', ' Time frame: from the first dose of study medication up to the end of follow-up (up to 3 yrs)', 'Results 1: ', ' Arm/Group Title: Stratum 1 (AC->T + Bevacizumab)', ' Arm/Group Description: HER2-negative participants administered', ' doxorubicin and cyclophosphamide (AC) + bevacizumab for 4 cycles followed by', ' docetaxel (T) + bevacizumab for 4 cycles followed by', ' bevacizumab maintenance therapy for total of 52 weeks from date of first dose regardless of number of doses received or missed', ' Overall Number of Participants Analyzed: 78', ' Measure Type: Number', ' Unit of Measure: participants 1', 'Results 2: ', ' Arm/Group Title: Stratum 2 (TAC + Bevacizumab)', ' Arm/Group Description: HER2-negative participants administered', ' docetaxel, doxorubicin, cyclophosphamide (TAC) + bevacizumab for 6 cycles followed by', ' bevacizumab maintenance therapy for total of 52 weeks from date of first dose regardless of number of doses received or missed', ' Overall Number of Participants Analyzed: 75', ' Measure Type: Number', ' Unit of Measure: participants 3'], 'Adverse Events': ['Adverse Events 1:', ' Total: 23/78 (29.49%)', ' Febrile neutropenia * 4/78 (5.13%)', ' Neutropenia * 1/78 (1.28%)', ' Thrombocytopenia * 0/78 (0.00%)', ' Acute coronary syndrome * 1/78 (1.28%)', ' Cardiac failure congestive * 1/78 (1.28%)', ' Myocardial infarction * 1/78 (1.28%)', ' Cardiomyopathy * 0/78 (0.00%)', ' Abdominal pain * 1/78 (1.28%)', ' Diarrhoea * 1/78 (1.28%)', ' Upper gastrointestinal haemorrhage * 1/78 (1.28%)', 'Adverse Events 2:', ' Total: 24/75 (32.00%)', ' Febrile neutropenia * 8/75 (10.67%)', ' Neutropenia * 3/75 (4.00%)', ' Thrombocytopenia * 2/75 (2.67%)', ' Acute coronary syndrome * 0/75 (0.00%)', ' Cardiac failure congestive * 2/75 (2.67%)', ' Myocardial infarction * 0/75 (0.00%)', ' Cardiomyopathy * 1/75 (1.33%)', ' Abdominal pain * 0/75 (0.00%)', ' Diarrhoea * 1/75 (1.33%)', ' Upper gastrointestinal haemorrhage * 0/75 (0.00%)']}

{'Clinical Trial ID': 'NCT00005908', 'Intervention': ['INTERVENTION 1: ', ' Dose A-Cohort 1-Arm 1-Docetaxel & Capecitabine', ' Docetaxel 75 mg/m^2 intravenous day 1, capecitabine 1000 mg/m^2 orally twice daily day 2-15 for 4 cycles Once the dose was deemed to be too toxic, subsequent patients were enrolled on dose B.', 'INTERVENTION 2: ', ' Dose B-Cohort 2-Arm 2 Reduced Dose-Docetaxel & Capecitabine', ' Docetaxel 60 mg/m^2 intravenous day 1 capecitabine 937.5 mg/m^2 orally twice daily day 2-15'], 'Eligibility': ['INCLUSION CRITERIA:', ' Stage II or III breast cancer with a tumor size of greater than 2 cm. Patients with a previous biopsy are eligible provided adequate tumor tissue remains for biopsy in this study.', ' At least 18 years of age.', ' Adequate hematopoietic function as defined by absolute neutrophil count greater than 1200/mm^3 and platelet count greater than 100,000/mm^3.', ' Adequate renal function as defined by creatinine less than 1.6 mg/dL.', ' Adequate hepatic function as defined by total (T.) bilirubin less than 1.4 mg/dL and serum glutamic oxaloacetic transaminase (SGOT)/serum glutamic pyruvic transaminase (SGPT) less than 1.5 times the upper limit of normal and alkaline phosphatase less than 2.5 times upper limit of normal', ' Zubrod Performance status 0-2.', 'EXCLUSION CRITERIA:', ' Medical or psychiatric condition that, in the opinion of the Principal Investigator, would preclude chemotherapy administration. Patients may be evaluated by psychiatry or medical subspecialties as appropriate.', ' Pregnant or lactating women', ' Known bleeding disorders', ' Hypersensitivity to Tween 80 (Polysorbate)', ' Cardiac ejection fraction below normal limits, myocardial infarction within the past 12 months, or symptomatic arrhythmia requiring medical intervention.', ' Prior chemotherapy or hormonal therapy for breast cancer. Patients treated with hormonal chemoprevention (tamoxifen or raloxifene) will be eligible.', ' Active malignancy diagnosed within the last 5 years. (Cervical cancer or non-melanomatous skin cancer that has been treated with curative intent will be eligible).'], 'Results': ['Outcome Measurement: ', ' Number of Participants With Adverse Events', ' Here is the number of participants with adverse events. For the detailed list of adverse events see the adverse event module.', ' Time frame: 6 years', 'Results 1: ', ' Arm/Group Title: Dose A-Cohort 1-Arm 1-Docetaxel & Capecitabine', ' Arm/Group Description: Docetaxel 75 mg/m^2 intravenous day 1, capecitabine 1000 mg/m^2 orally twice daily day 2-15 for 4 cycles Once the dose was deemed to be too toxic, subsequent patients were enrolled on dose B.', ' Overall Number of Participants Analyzed: 9', ' Measure Type: Number', ' Unit of Measure: Participants 9', 'Results 2: ', ' Arm/Group Title: Dose B-Cohort 2-Arm 2 Reduced Dose-Docetaxel & Capecitabine', ' Arm/Group Description: Docetaxel 60 mg/m^2 intravenous day 1 capecitabine 937.5 mg/m^2 orally twice daily day 2-15', ' Overall Number of Participants Analyzed: 20', ' Measure Type: Number', ' Unit of Measure: Participants 20'], 'Adverse Events': ['Adverse Events 1:', ' Total: 29/30 (96.67%)', ' Febrile neutropenia [1]3/30 (10.00%)', ' Lymphatics 1/30 (3.33%)', ' Diarrhea (without colostomy) 5/30 (16.67%)', ' Abdominal pain or cramping 2/30 (6.67%)', ' Colitis 1/30 (3.33%)', ' Dehydration 1/30 (3.33%)', ' Nausea 1/30 (3.33%)', ' Stomatitis/pharyngitis (oral/pharyngeal/mucositis) 1/30 (3.33%)', ' Vomiting 1/30 (3.33%)', 'Adverse Events 2:', ' ']}

bcf433b6-4029-4d00-9ccf-d8d94f1722d8

Single

Results

NCT01605396

The Ridaforolimus + Dalotuzumab + Exemestane group of the primary trial had a median PFS of over 5 months.

Entailment

{'Clinical Trial ID': 'NCT01605396', 'Intervention': ['INTERVENTION 1: ', ' Ridaforolimus + Dalotuzumab + Exemestane', ' Participants received ridaforolimus 10 mg orally (PO) every 5 days (QD x 5) plus dalotuzumab 10 mg/kg intravenously (IV) every week (QW) plus exemestane 25 mg PO every day (QD) in 28-day cycles until documented disease progression or unacceptable toxicity.', 'INTERVENTION 2: ', ' Ridaforolimus + Exemestane', ' Participants received ridaforolimus 30 mg PO QD x 5 plus exemestane 25 mg PO QD treatment in 28-day cycles until documented disease progression or unacceptable toxicity.'], 'Eligibility': ['Inclusion Criteria:', ' Females with a histologically confirmed diagnosis of breast cancer that is metastatic or locally advanced (locally advanced tumors must not be amenable to', ' surgery or radiation therapy with curative intent) with the following pathological characteristics determined locally: estrogen receptor positive and Human Epidermal Growth Factor Receptor 2 (HER-2) negative, and Ki67 (a tumor marker) 15% determined by the central study laboratory', ' Post-menopausal', ' With advanced breast cancer whose disease was refractory to previous letrozole or anastrozole', ' Has at least one confirmed measurable metastatic lesion', ' Has a performance status 1 on the Eastern Cooperative Oncology Group (ECOG) performance scale', ' Has a life expectancy of at least 3 months', ' Adequate organ function', 'Exclusion Criteria:', ' Is receiving any other concurrent systemic tumor therapy, including', ' hormonal agents and HER-2 inhibitors', ' Previously received rapamycin or rapamycin analogs, including', ' ridaforolimus, temsirolimus, or everolimus', ' Received prior treatment with Insulin-like Growth Factor 1 Receptor (IGF-1R) inhibitors, Phosphatidylinositol 3-Kinase (PI3K) inhibitors, or', ' other experimental agents that target PI3K, Protein Kinase B (AKT), or Mammalian Target of Rapamycin (mTOR) pathway', ' Is receiving chronic corticosteroids administered at doses greater than', ' those used for normal replacement therapy', ' Has active brain metastasis or leptomeningeal carcinomatosis; patients', ' with adequately treated brain metastases are eligible if they meet certain criteria', ' Known allergy to macrolide antibiotics', ' Has an active infection requiring antibiotics', ' Significant or uncontrolled cardiovascular disease', ' Poorly controlled Type 1 or 2 diabetes', ' Is known to be Human Immunodeficiency Virus (HIV) positive', ' Has a known history of active hepatitis B or C. Healthy carriers of hepatitis B are not allowed on this study'], 'Results': ['Outcome Measurement: ', ' 1. Progression-free Survival (PFS) According to Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1) Based on Blinded Independent Central Review (BICR)', ' PFS was defined as the time from randomization to progressive disease, or death, whichever occurs first. Response was assessed according to RECIST 1.1 by BICR. According to RECIST 1.1, progressive disease (PD) was defined as a 20% relative increase in the sum of diameters (SOD) of target lesions, taking as reference the nadir SOD and an absolute increase of >5 mm in the SOD, or the appearance of new lesions. PFS was analyzed using the Kaplan-Meier method and median PFS (95% confidence interval [CI]) in weeks was reported for each treatment arm. Per protocol, participants remained on assigned treatment until disease progression. Participants who discontinued study treatment for reasons other than disease progression continued to be assessed by imaging until objective documentation of progression. All participants (including participants who discontinued study treatment) were followed for survival until investigator notification to discontinue.', ' Time frame: From Day 1 through last post-study efficacy follow-up (up to ~19 months)', 'Results 1: ', ' Arm/Group Title: Ridaforolimus + Dalotuzumab + Exemestane', ' Arm/Group Description: Participants received ridaforolimus 10 mg orally (PO) every 5 days (QD x 5) plus dalotuzumab 10 mg/kg intravenously (IV) every week (QW) plus exemestane 25 mg PO every day (QD) in 28-day cycles until documented disease progression or unacceptable toxicity.', ' Overall Number of Participants Analyzed: 40', ' Median (95% Confidence Interval)', ' Unit of Measure: Weeks 23.29 (8.71 to 38.43)', 'Results 2: ', ' Arm/Group Title: Ridaforolimus + Exemestane', ' Arm/Group Description: Participants received ridaforolimus 30 mg PO QD x 5 plus exemestane 25 mg PO QD treatment in 28-day cycles until documented disease progression or unacceptable toxicity.', ' Overall Number of Participants Analyzed: 40', ' Median (95% Confidence Interval)', ' Unit of Measure: Weeks 31.86 (16.00 to 39.29)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 8/39 (20.51%)', ' Myocardial infarction 0/39 (0.00%)', ' Sinus tachycardia 0/39 (0.00%)', ' Diarrhoea 1/39 (2.56%)', ' Haematochezia 0/39 (0.00%)', ' Vomiting 1/39 (2.56%)', ' Asthenia 0/39 (0.00%)', ' Disease progression 0/39 (0.00%)', ' Jaundice cholestatic 0/39 (0.00%)', ' Appendicitis 0/39 (0.00%)', ' Escherichia sepsis 1/39 (2.56%)', ' Gastroenteritis 0/39 (0.00%)', 'Adverse Events 2:', ' Total: 17/40 (42.50%)', ' Myocardial infarction 1/40 (2.50%)', ' Sinus tachycardia 1/40 (2.50%)', ' Diarrhoea 0/40 (0.00%)', ' Haematochezia 1/40 (2.50%)', ' Vomiting 1/40 (2.50%)', ' Asthenia 1/40 (2.50%)', ' Disease progression 1/40 (2.50%)', ' Jaundice cholestatic 1/40 (2.50%)', ' Appendicitis 1/40 (2.50%)', ' Escherichia sepsis 0/40 (0.00%)', ' Gastroenteritis 1/40 (2.50%)']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

1268edfc-cce2-4f07-9fbb-392341b7f399

Single

Adverse Events

NCT01276041

1 patient in the primary trial died in an event not associated with a specifc CTCAE term.

Entailment

{'Clinical Trial ID': 'NCT01276041', 'Intervention': ['INTERVENTION 1: ', ' Pertuzumab in Combination With Trastuzumab and Paclitaxel', ' This is a phase II study of pertuzumab in combination with trastuzumab and paclitaxel for the treatment of patients with Stage IV HER2 (+) breast cancer.'], 'Eligibility': ['Inclusion Criteria:', ' Age 18', ' Stage IV HER2 (+) breast cancer.', ' Histologically documented HER2 (+) breast cancer as defined as IHC 3+ or FISH amplification of 2.0 of primary or metastatic site; results from the local lab are acceptable. (Optional tumor sample collection from primary or metastatic site may be obtained for HER2 testing at MSKCC).', ' ECOG performance 0 -1 (Appendix A)', " 0-1 prior treatment in the metastatic setting (ie: hormone, chemotherapy, biologic, targeted agents). Prior anthracycline, paclitaxel, and trastuzumab in the adjuvant setting are allowed. If the patient has one trastuzumab-based treatment in the metastatic setting and is given a break (even intermittently) from the partner drug given with trastuzumab and is continued on trastuzumab alone, this would still be considered as one treatment. For example, if the patient was given paclitaxel + trastuzumab and was later continued on trastuzumab alone or then restarted on paclitaxel + trastuzumab (at the physician's discretion for any reason), the regimen paclitaxel + trastuzumab followed by trastuzumab alone (or followed by paclitaxel + trastuzumab again) may be considered as one treatment.", ' Measurable or non-measurable disease. Measurable lesions are defined as those that can be measured accurately in at least one diameter, that is 20 mm using conventional imaging techniques (including incremental CT) or 10 mm using spiral CT equipment and a lymph node 15 mm along the short axis. Non-measurable lesions are all other lesions, including small lesions (longest diameter <10mm pathological a lymph nodes with 10 to less than 15mm along the short axis, bony metastases, leptomeningeal disease, ascites, pleural/pericardial effusions, inflammatory breast cancer, lymphangitis carcinomatosis, and heavily calcified and cystic/necrotic lesions.', ' LVEF 50%', ' Hematologic parameters: white blood cell (WBC) count of 3000/ul, absolute neutrophil count (ANC) 1500/ul, platelets 100,000/ul, hemoglobin 10.0 g/dl', ' Non-hematologic parameters: bilirubin 1.5 mg/dl, AST/ALT 2.5 x upper limit of normal (ULN), alkaline phosphatase 5 x ULN.', ' Creatinine 1.5 mg/dl', ' Patients with stable and treated brain lesions of a duration of 2 months may be enrolled.', 'Exclusion Criteria:', ' History of prior cardiac morbidities within 12 months (unstable angina, myocardial infarction, CHF, uncontrolled ventricular arrhythmias)', ' Prior pertuzumab', ' History of prior G 3 hypersensitivity (HSR) or any toxicity to trastuzumab that warranted permanent cessation of this antibody', ' History of prior G 3 HSR or any toxicity to paclitaxel warranted permanent cessation of this chemotherapy', ' > G 2 peripheral neuropathy', ' Patients with a history of chronic hepatitis B or C should be excluded from the study as paclitaxel is potentially hepatotoxic', 'Pregnant patients'], 'Results': ['Outcome Measurement: ', ' Percentage of Patients Who Are Progression Free at 6 Months or Later.', ' Patients who are considered progression-free at 6 months are deemed successes. Failures are those patients who progressed before the 6 month mark. Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0), as a 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions', ' Time frame: 6 months', 'Results 1: ', ' Arm/Group Title: Pertuzumab in Combination With Trastuzumab and Paclitaxel', ' Arm/Group Description: This is a phase II study of pertuzumab in combination with trastuzumab and paclitaxel for the treatment of patients with Stage IV HER2 (+) breast cancer.', ' Overall Number of Participants Analyzed: 70', ' Measure Type: Number', ' Unit of Measure: percentage of partcipants 86 (75 to 93)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 18/70 (25.71%)', ' Cardiac arrest 1/70 (1.43%)', ' Pericardial effusion 1/70 (1.43%)', ' Ear pain 1/70 (1.43%)', ' Blurred vision 1/70 (1.43%)', ' Eye disorders - Other, specify 2/70 (2.86%)', ' Abdominal Pain 5/70 (7.14%)', ' Colitis 1/70 (1.43%)', ' Diarrhea 2/70 (2.86%)', ' Nausea 2/70 (2.86%)', ' Death NOS 1/70 (1.43%)', ' Edema limbs 1/70 (1.43%)', ' Fatigue 3/70 (4.29%)']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

58ccfd13-aa6d-4604-bf3d-c69270fe50d2

Comparison

Adverse Events

NCT00182793

NCT00509769

The majority of patients in the primary trial and the secondary trial experienced an adverse event.

Contradiction

{'Clinical Trial ID': 'NCT00182793', 'Intervention': ['INTERVENTION 1: ', ' All Patients', ' Patients undergo stem cell collection. Patients receive high-dose melphalan IV with or without trastuzumab (Herceptin®), one day later, patients undergo autologous peripheral blood stem cell (PBSC) transplantation, no more than 7 weeks later, patients proceed to course 2; OR Patients receive high-dose carboplatin, thiotepa, and cyclophosphamide IV continuously over 4 days followed by autologous PBSC transplantation. After recover from high-dose chemotherapy and autologous PBSC transplantation, patients with stage IIIB or IIIC disease undergo radiotherapy to the chest wall and lymph nodes. Patients with stage IV disease undergo radiotherapy using helical tomotherapy or standard radiotherapy to oligometastatic sites.'], 'Eligibility': ['DISEASE CHARACTERISTICS:', ' Histologically confirmed breast cancer, meeting 1 of the following stage criteria:', ' Stage IIIB or IIIC disease, meeting both of the following criteria:', ' Must have received prior neoadjuvant or adjuvant therapy', ' Must have undergone lumpectomy or mastectomy', ' Stage IV disease, meeting all of the following criteria:', ' Only 1-3 organ sites with disease involvement after induction chemotherapy', ' Achieved at least a partial response after induction chemotherapy', ' No more than 3 lesions in the organ sites combined', ' Inflammatory breast cancer allowed', ' Completed chemotherapy, surgery, or radiotherapy for breast cancer within the past 6 months', ' Hormone receptor status:', ' Not specified', ' PATIENT CHARACTERISTICS:', ' Age', ' 65 and under', ' Sex', ' Male or female', ' Menopausal status', ' Not specified', ' Performance status', ' Karnofsky 80-100%', ' Life expectancy', ' Not specified', ' Hematopoietic', ' Absolute neutrophil count 1,000/mm^3', ' Platelet count 100,000/mm^3', ' Hepatic', ' SGOT or SGPT 2 times upper limit of normal', ' Bilirubin 1.5 mg/dL', ' Renal', ' Creatinine 1.2 mg/dL', ' Creatinine clearance 70 mL/min', ' Cardiovascular', ' LVEF 55% by MUGA or echocardiogram', ' Pulmonary', ' FEV_1 60% of predicted', ' DLCO 60% of the lower limit of predicted value', ' Oxygen saturation > 92% on room air', ' Other', ' Not pregnant or nursing', ' Negative pregnancy test', ' Fertile patients must use effective contraception', ' No autoimmune disorders', ' No immunosuppressive condition', ' No other malignancy within the past 5 years', ' PRIOR CONCURRENT THERAPY:', ' Biologic therapy', ' No prior biologic therapy except trastuzumab (Herceptin®)', ' Chemotherapy', ' See Disease Characteristics', ' Endocrine therapy', ' Not specified', ' Radiotherapy', ' See Disease Characteristics', ' No prior radiotherapy to adjacent or involved sites of disease that would preclude study radiotherapy', ' Surgery', ' See Disease Characteristics', ' Other', ' No other concurrent anticancer therapy'], 'Results': ['Outcome Measurement: ', ' 5-Year Relapse-free Survival Rate', ' Estimated using the product-limit method of Kaplan and Meier. Relapse defined as appearance of any new lesions during or after protocol treatment. Whenever possible, relapses should be documented histologically.', ' Time frame: From time of initial PBPC rescue until death or disease recurrence (disease progression for patients with stage IV disease), whichever came first, up to 5 years post treatment', 'Results 1: ', ' Arm/Group Title: All Patients', ' Arm/Group Description: Patients undergo stem cell collection. Patients receive high-dose melphalan IV with or without trastuzumab (Herceptin ), one day later, patients undergo autologous peripheral blood stem cell (PBSC) transplantation, no more than 7 weeks later, patients proceed to course 2; OR Patients receive high-dose carboplatin, thiotepa, and cyclophosphamide IV continuously over 4 days followed by autologous PBSC transplantation. After recover from high-dose chemotherapy and autologous PBSC transplantation, patients with stage IIIB or IIIC disease undergo radiotherapy to the chest wall and lymph nodes. Patients with stage IV disease undergo radiotherapy using helical tomotherapy or standard radiotherapy to oligometastatic sites.', ' Overall Number of Participants Analyzed: 27', ' Median (95% Confidence Interval)', ' Unit of Measure: percentage of participants 53 (23 to 77)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 24/32 (75.00%)', ' Disseminated intravascular coagulation * 1/32 (3.13%)', ' Febrile neutropenia * 1/32 (3.13%)', ' Adrenal insufficiency * 1/32 (3.13%)', ' Endocrine disorder * 1/32 (3.13%)', ' Chills * 1/32 (3.13%)', ' Fatigue * 1/32 (3.13%)', ' Fever * 1/32 (3.13%)', ' Multi-organ failure * 1/32 (3.13%)', ' Hepatic failure * 1/32 (3.13%)', ' Infection * 1/32 (3.13%)', ' Sepsis * 1/32 (3.13%)']}

{'Clinical Trial ID': 'NCT00509769', 'Intervention': ['INTERVENTION 1: ', ' Trastuzumab Emtansine 3.6 mg/kg', " Patients received trastuzumab emtansine 3.6 mg/kg intravenously on Day 1 of each 21 day cycle for a maximum of 1 year. The total dose was dependent on the patient's weight on Day 1 of each cycle."], 'Eligibility': ['Inclusion Criteria:', ' Signed informed consent form.', ' Human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC); tissue (slides or blocks) available for HER2 confirmation.', ' History of progression on HER2-directed therapy for the treatment of HER2-positive breast cancer.', ' At least 1, and no more than 3, chemotherapy regimens for MBC.', ' Granulocyte count 1500/μL, platelet count 100,000/μL, and hemoglobin 9 g/dL.', ' Serum bilirubin 1.5 mg/dL, aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase 2.5x the upper limit of normal (ULN).', ' Serum creatinine 1.5 mg/dL or creatinine clearance 60 mL/min.', ' Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.', 'Exclusion Criteria:', ' Any chemotherapy, hormonal therapy, radiotherapy, immunotherapy, or biological therapy for the treatment of breast cancer within 2 weeks of the first study treatment.', ' Prior cumulative doxorubicin dose > 360 mg/m^2 or the equivalent.', ' History of significant cardiac disease, unstable angina, congestive heart failure (CHF), myocardial infarction, or ventricular arrythmia requiring medication.'], 'Results': ['Outcome Measurement: ', ' Objective Response Assessed by the Independent Review Facility Using Response Evaluation Criteria in Solid Tumors (RECIST)', ' Objective response was defined as a complete response (CR) or partial response (PR) determined on 2 consecutive occasions 4 weeks apart, using Response Evaluation Criteria in Solid Tumors (RECIST). CR: The disappearance of all target lesions and all non-target lesions, normalization of tumor marker level, and no new lesions. PR: Disappearance of all target lesions and persistence of 1 non-target lesions and/or the maintenance of tumor marker level above the normal limits, or, at least a 30% decrease in the sum of the longest diameter of target lesions, and no new lesions or unequivocal progression of existing non-target lesions.', ' Time frame: Randomization until the analysis data cutoff-dates of 31 Jan 2009 (6 months after the last patient was enrolled in the study) and 25 Jun 2009 (approximately 12 months after the last patient was enrolled in the study, up to 23 months)', 'Results 1: ', ' Arm/Group Title: Trastuzumab Emtansine 3.6 mg/kg', " Arm/Group Description: Patients received trastuzumab emtansine 3.6 mg/kg intravenously on Day 1 of each 21 day cycle for a maximum of 1 year. The total dose was dependent on the patient's weight on Day 1 of each cycle.", ' Overall Number of Participants Analyzed: 109', ' Measure Type: Number', ' Unit of Measure: Percentage of patients Month 6 (n=109): 25.7 (17.9 to 34.5)', ' Month 12 (n=108): 26.9 (19.2 to 35.8)'], 'Adverse Events': ['Adverse Events 1:', ' Total: 30/112 (26.79%)', ' Thrombocytopenia 1/112 (0.89%)', ' Dysphagia 1/112 (0.89%)', ' Haemorrhoidal haemorrhage 1/112 (0.89%)', ' Oesophageal stenosis 1/112 (0.89%)', ' Upper gastrointestinal haemorrhage 1/112 (0.89%)', ' Asthenia 1/112 (0.89%)', ' Disease progression 1/112 (0.89%)', ' Hepatotoxicity 1/112 (0.89%)', ' Cellulitis 3/112 (2.68%)', ' Pneumonia 2/112 (1.79%)', ' Osteomyelitis 1/112 (0.89%)']}

a6e4f4f3-72cc-4617-bf8b-7eac1c8b8249

Single

Eligibility

NCT01105312

Patients with measurable diseases are only eligible for phase 2 of the primary trial.

Contradiction

{'Clinical Trial ID': 'NCT01105312', 'Intervention': ['INTERVENTION 1: ', ' Phase I: Dose Level One', ' Each patient will receive panobinostat (LBH589) and letrozole. Patients will be administered 20 mg LBH589 PO, 3 days per week for a total of 4 weeks. Patients will also be administered letrozole 2.5 mg PO Days 1-28 every 4 weeks.', 'INTERVENTION 2: ', ' Phase I: Dose Level Two', ' Each patient will receive panobinostat (LBH589) and letrozole. Patients will be administered 30 mg LBH589 PO, 3 days per week for a total of 4 weeks. Patients will also be administered letrozole 2.5 mg PO Days 1-28 every 4 weeks.'], 'Eligibility': ['DISEASE CHARACTERISTICS:', ' Histologically confirmed breast cancer', ' Metastatic disease amenable to biopsy', ' Unresected tumor with no intention to undergo resection during study', ' Archival tissue from the primary diagnosis or fresh biopsy from metastatic cancer site required', ' Measurable or non-measurable disease for phase I study (The Phase I portion of this study closed and the Phase II portion of the study opened as per NCCTG Addendum 6, effective January 23, 2012.)', ' Measurable disease only for phase II study', ' Available tumor estrogen (ER), progesterone (PR), and HER2 status from metastatic site tested by IHC or FISH OR results from the original tumor diagnosis', ' Any ER, PR, or HER2 level (positive or negative) acceptable (phase I)', ' Triple-negative disease only (phase II)', ' ER and PR negative defined as 1% by IHC', ' HER2 negative', ' Patients with triple-negative breast cancer allowed provided there is clinical or radiographic evidence of tumor progression in the adjuvant or metastatic setting', ' No patients whose disease can be treated with known standard therapy that is potentially curative or definitely capable of extending life expectancy', ' No known CNS metastasis', ' Hormone-receptor status:', ' ER and PR positive or negative (phase I)', ' ER and PR negative (phase II)', ' PATIENT CHARACTERISTICS:', ' ECOG performance status 0-1 (phase I) or 0-2 (phase II)', ' Postmenopausal defined by 1 of the following:', ' 60 years of age', ' 45 years of age with last menstrual period 12 months prior and estradiol and follicle-stimulating hormone levels in postmenopausal range', ' Bilateral oophorectomy', ' Life expectancy 12 weeks', ' ANC 1,500/mm^3', ' Platelet count 100,000/mm^3', ' Total bilirubin normal', ' ALT and AST 3 times upper limit of normal (ULN) ( 5 times ULN if due to liver metastasis)', ' Serum creatinine 1.5 times ULN', ' TSH normal (thyroid hormone supplements allowed for patients with hypothyroidism)', ' Not pregnant or nursing', ' Fertile patients must use effective contraception', ' Willing to return to Mayo Clinic or NCCTG institution (phase II) for follow-up', ' Willing to provide blood samples for correlative research purposes', ' No uncontrolled or intercurrent illness including, but not limited to, any of the following:', ' Ongoing or active infection', ' Symptomatic congestive heart failure', ' Unstable angina pectoris', ' Cardiac arrhythmia', ' Psychiatric illness and/or social situations that would limit compliance with study requirements', ' No NYHA class III or IV cardiovascular disease', ' No known seizure disorder', ' No co-morbid systemic illnesses or other severe concurrent disease that, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens', ' No immunocompromised patients, including patients known to be HIV positive', ' Immunocompromised patients due to the use of corticosteroids allowed', ' No malignancy within the past 5 years except for nonmelanoma skin cancer or carcinoma in situ of the cervix', ' No history of myocardial infarction 6 months', ' No congenital long QT syndrome or QTcF>450 msec, including:', ' Complete left bundle block or use of a permanent cardiac pacemaker, history or presence of ventricular tachyarrhythmias, clinically significant resting bradycardia (<50 beats per minute)', ' Right bundle branch block + left anterior hemiblock (bifascicular block)', ' No congestive heart failure requiring use of maintenance therapy for life-threatening ventricular arrhythmias', ' PRIOR CONCURRENT THERAPY:', ' See Disease Characteristics', ' More than 4 weeks since prior chemotherapy or radiotherapy and fully recovered', ' No radiotherapy to > 25 % of bone marrow', ' Prior treatments allowed (phase II):', ' 0 or 1 prior chemotherapy regimens for breast cancer', ' 2 prior aromatase-inhibitor regimens (including letrozole)', ' Not currently receiving treatment in a different clinical study in which investigational procedures are performed or investigational therapies are administered', ' No other concurrent investigational agent for the primary neoplasm', ' No concurrent CYP3A4 inhibitors or inducers'], 'Results': ['Outcome Measurement: ', ' Maximum-tolerated Dose (Phase I)', " MTD is defined as the dose level below the lowest dose that induces dose limiting toxicity in at least one-third of patients (at least 2 of a maximum of 6> new patients). If dose-limiting toxicity (DLT) is not seen in any of the 3 patients, 3 new patients will be accrued and treated at the next higher dose level. If DLT are seen in 2 or 3 of 3 patients treated at a given dose level, then the next 3 patients will be treated at the next lower dose level, if only 3 patients were enrolled and treated at this lower dose level. The number of DLT's will be reported here.", ' Time frame: Up to 2.5 months', 'Results 1: ', ' Arm/Group Title: Phase I: Dose Level One', ' Arm/Group Description: Each patient will receive panobinostat (LBH589) and letrozole. Patients will be administered 20 mg LBH589 PO, 3 days per week for a total of 4 weeks. Patients will also be administered letrozole 2.5 mg PO Days 1-28 every 4 weeks.', ' Overall Number of Participants Analyzed: 6', ' Measure Type: Count of Participants', ' Unit of Measure: Participants 1 16.7%', 'Results 2: ', ' Arm/Group Title: Phase I: Dose Level Two', ' Arm/Group Description: Each patient will receive panobinostat (LBH589) and letrozole. Patients will be administered 30 mg LBH589 PO, 3 days per week for a total of 4 weeks. Patients will also be administered letrozole 2.5 mg PO Days 1-28 every 4 weeks.', ' Overall Number of Participants Analyzed: 6', ' Measure Type: Count of Participants', ' Unit of Measure: Participants 3 50.0%'], 'Adverse Events': ['Adverse Events 1:', ' Total: 4/16 (25.00%)', ' Bladder infection 0/16 (0.00%)', ' Lung infection 1/16 (6.25%)', ' Fracture 1/16 (6.25%)', ' Platelet count decreased 3/16 (18.75%)', ' White blood cell decreased 1/16 (6.25%)', ' Hypokalemia 0/16 (0.00%)', ' Hyponatremia 0/16 (0.00%)', 'Adverse Events 2:', ' Total: 1/6 (16.67%)', ' Bladder infection 1/6 (16.67%)', ' Lung infection 0/6 (0.00%)', ' Fracture 0/6 (0.00%)', ' Platelet count decreased 0/6 (0.00%)', ' White blood cell decreased 0/6 (0.00%)', ' Hypokalemia 0/6 (0.00%)', ' Hyponatremia 0/6 (0.00%)']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

8c84c96f-1635-40dc-839b-fc937ed566a2

Single

Adverse Events

NCT00320710

There was no adverse event in cohort 2 of the primary trial which occurred in more than 5% of patients.

Entailment

{'Clinical Trial ID': 'NCT00320710', 'Intervention': ['INTERVENTION 1: ', ' Zoledronic Acid Every (q) 4 Weeks', ' Participants received 4mg of zoledronic acid intravenously (IV) infusion q 4 weeks.', 'INTERVENTION 2: ', ' Zoledronic Acid q 12 Weeks', ' Participants received 4 mg zoledronic acid IV q 12 weeks and received placebo to Zometa IV at the 4 week intervals between the q 12 week zoledronic acid infusions in order to maintain the blind.'], 'Eligibility': ['Inclusion Criteria:', ' Female patients 18 years of age. Confirmed breast cancer with bone metastasis. Pretreated with Zometa®, or Aredia (pamidronate) or all sequential regimens of both, for a minimum of 9 doses;', 'Exclusion Criteria:', ' Abnormal kidney function determined by serum creatinine levels. Current active dental problems including: ongoing infection of the teeth or jawbone; current exposed bone in the mouth; and current or prior diagnosis of osteonecrosis of the jaw.', ' Recent (within 8 weeks) or planned dental or jaw surgery (e.g., extraction, implants).', " Diagnosis of metabolic bone disease other than osteoporosis (e.g., Paget's disease of bone).", ' Known hypersensitivity to Zometa. Treatment with other investigational drugs within 30 days prior to randomization.', ' Other protocol-defined exclusion criteria may have applied.'], 'Results': ['Outcome Measurement: ', ' Proportion of Patients Who Experienced at Least One Skeletal Related Event (SRE)', ' An SRE was defined as a pathologic fracture (vertebral and non-vertebral), spinal cord compression, radiation to bone or surgery to bone.', ' Time frame: 52 weeks', 'Results 1: ', ' Arm/Group Title: Zoledronic Acid Every (q) 4 Weeks', ' Arm/Group Description: Participants received 4mg of zoledronic acid intravenously (IV) infusion q 4 weeks.', ' Overall Number of Participants Analyzed: 200', ' Measure Type: Number', ' Unit of Measure: Percentage of participants 22', 'Results 2: ', ' Arm/Group Title: Zoledronic Acid q 12 Weeks', ' Arm/Group Description: Participants received 4 mg zoledronic acid IV q 12 weeks and received placebo to Zometa IV at the 4 week intervals between the q 12 week zoledronic acid infusions in order to maintain the blind.', ' Overall Number of Participants Analyzed: 203', ' Measure Type: Number', ' Unit of Measure: Percentage of participants 23.2'], 'Adverse Events': ['Adverse Events 1:', ' Total: 50/198 (25.25%)', ' Anaemia 1/198 (0.51%)', ' Febrile neutropenia 1/198 (0.51%)', ' Leukocytosis 1/198 (0.51%)', ' Leukopenia 2/198 (1.01%)', ' Neutropenia 1/198 (0.51%)', ' Pancytopenia 0/198 (0.00%)', ' Atrial fibrillation 0/198 (0.00%)', ' Cardiac failure congestive 0/198 (0.00%)', ' Palpitations 0/198 (0.00%)', ' Pericardial effusion 1/198 (0.51%)', ' Supraventricular tachycardia 1/198 (0.51%)', 'Adverse Events 2:', ' Total: 51/202 (25.25%)', ' Anaemia 3/202 (1.49%)', ' Febrile neutropenia 2/202 (0.99%)', ' Leukocytosis 0/202 (0.00%)', ' Leukopenia 0/202 (0.00%)', ' Neutropenia 0/202 (0.00%)', ' Pancytopenia 1/202 (0.50%)', ' Atrial fibrillation 1/202 (0.50%)', ' Cardiac failure congestive 1/202 (0.50%)', ' Palpitations 1/202 (0.50%)', ' Pericardial effusion 1/202 (0.50%)', ' Supraventricular tachycardia 1/202 (0.50%)']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

7b48355e-3b9c-4cca-b7fa-1cbd612d1523

Single

Eligibility

NCT00617539

Presence of Extracranial metastases is part of the exclusion critera for the primary trial.

Contradiction

{'Clinical Trial ID': 'NCT00617539', 'Intervention': ['INTERVENTION 1: ', ' Irinotecan and Temozolomide', ' irinotecan hydrochloride administered intravenously (IV) at a starting dose of 125 mg/m2 on days 1 and 15 of a 28 day cycle', ' temozolomide orally for seven days at a starting dose of 100 mg/m2 on days 1-7 and days 15-21 of a 28 day cycle'], 'Eligibility': ['DISEASE CHARACTERISTICS:', ' Histologically or cytologically confirmed breast cancer with radiographically confirmed metastases to the brain', ' Extracranial metastases allowed', ' Must have demonstrated progression of brain metastases after prior treatment for brain metastases, including any of the following:', ' External beam radiotherapy', ' Brachytherapy', ' Stereotactic radiosurgery', ' Surgery', ' Chemotherapy', ' Treatments with investigational drugs, biologics, or devices', ' Disease progression in the CNS must meet 1 of the following criteria:', ' New lesions in the CNS on an imaging study (contrast-enhanced CT scan or MRI)', ' Progressive lesions on an imaging study (contrast-enhanced CT scan or MRI)', ' New or progressive lesions that do not meet measurable disease definition allowed', ' Leptomeningeal disease allowed if concurrent progression or parenchymal brain metastases', ' Not a candidate for surgical resection and/or further stereotactic radiosurgery', ' Hormone receptor status not specified', ' PATIENT CHARACTERISTICS:', ' Menopausal status not specified', ' ECOG performance status 0-2', ' Life expectancy 1 month', ' Hemoglobin 10 g/dL (transfusion allowed)', ' ANC 1,500/mm³', ' Granulocyte count 1,500/mm³', ' Platelet count 100,000/mm³', ' Creatinine 1.5 mg/dL', ' Total bilirubin 1.5 times upper limit of normal (ULN)', ' AST and ALT 3 times ULN', ' Must be able to swallow and retain oral medications', ' No other active malignancy except for any of the following:', ' Curatively treated basal or squamous cell carcinoma of the skin', ' Carcinoma in situ of the cervix', ' Other malignancies considered disease-free', ' Not pregnant or nursing', ' Negative pregnancy test', ' Fertile patients must use effective contraception', ' No history of immediate or delayed-type hypersensitivity reaction to gadolinium contrast agents or other contraindication to gadolinium contrast', ' No other known contraindication to MRI including, but not limited to, any of the following:', ' Cardiac pacemaker', ' Implanted cardiac defibrillator', ' Brain aneurysm clips', ' Cochlear implant', ' Ocular foreign body', ' Shrapnel', ' No active or uncontrolled infection', ' PRIOR CONCURRENT THERAPY:', ' See Disease Characteristics', ' Recovered from the side effects of prior chemotherapy, surgery, or radiotherapy for extracranial disease or brain metastases', ' Concurrent trastuzumab, bisphosphonate, and/or corticosteroid therapy allowed', ' At least 1 week since prior or on current stable dose of corticosteroid therapy', ' Patients on an enzyme-inducing anti-epileptic agent (EIAE) or valproic acid are eligible if they are switched to an alternate non-EIAE medication', ' Concurrent coumadin allowed', ' No prophylactic use of filgrastim (G-CSF) during first course of treatment'], 'Results': ['Outcome Measurement: ', ' Number of Patients With Objective Treatment Response (Complete or Partial) in the CNS', ' Imaging was performed at 8-week intervals to assess response to treatment. Patients with known or suspected leptomeningeal disease were deemed to have a complete response if CSF cytology converted to negative (if positive at baseline) and all meningeal enhancement or nodularity of brain and/or spine MRI resolved. A modified RECIST 1.0 criteria was used to assess CNS response for patients with new or progressing brain metastases. In this modified RECIST criteria, CNS lesions <1cm were not considered measurable, but were considered evaluable for response and progression. Progressive disease for patients with lesions <1 cm was defined as follows: growth of a lesion from less than or equal to 5 mm to greater than or equal to 10mm; or, growth of a 6-9 mm lesion by at least 5 mm in the case of non-target parenchymal brain metastases.', ' Time frame: Baseline scan prior to study entry was performed within 14 days of cycle 1 day 1, then every 8 weeks from then until disease progression or up to 2 years', 'Results 1: ', ' Arm/Group Title: Irinotecan and Temozolomide', ' Arm/Group Description: irinotecan hydrochloride administered intravenously (IV) at a starting dose of 125 mg/m2 on days 1 and 15 of a 28 day cycle', ' temozolomide orally for seven days at a starting dose of 100 mg/m2 on days 1-7 and days 15-21 of a 28 day cycle', ' Overall Number of Participants Analyzed: 30', ' Measure Type: Count of Participants', ' Unit of Measure: Participants 2 6.7%'], 'Adverse Events': ['Adverse Events 1:', ' Total: 16/30 (53.33%)', ' Lymphopenia * 16/30 (53.33%)', ' Leukopenia * 5/30 (16.67%)', ' Neutropenia * 5/30 (16.67%)', ' Anemia * 3/30 (10.00%)', ' Thrombocytopenia * 3/30 (10.00%)', ' Vomiting * 2/30 (6.67%)', ' Nausea * 1/30 (3.33%)', ' Diarrhea * 1/30 (3.33%)', ' Dysphagia * 1/30 (3.33%)', ' Fatigue * 3/30 (10.00%)', ' Dehydration * 2/30 (6.67%)', ' Alkaline phosphatase increased * 1/30 (3.33%)']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

3d188d93-13c6-48f3-b231-dcdeef81080e

Single

Intervention

NCT01209195

Lower doses of MM-121 and Paclitaxel are utilised in cohort1 of the primary trial than in cohort 2.

Contradiction

{'Clinical Trial ID': 'NCT01209195', 'Intervention': ['INTERVENTION 1: ', ' Part 1: Dose Escalation: Cohort 1', ' MM-121 - 20 mg/kg loading dose followed by 12 mg/kg weekly IV Paclitaxel - 80mg/m2 weekly IV', 'INTERVENTION 2: ', ' Part 1: Dose Escalation: Cohort 2', ' MM-121 - 40 mg/kg loading dose followed by 20 mg/kg weekly IV', ' Paclitaxel - 80mg/m2 weekly IV'], 'Eligibility': ['Inclusion Criteria:', ' Cytological or histological confirmation of locally advanced/metastatic or recurrent epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer or endometrial cancer; OR, cytological or histological confirmation of locally advanced /metastatic Her2 non-overexpressing breast cancer', ' Eighteen years of age or above', ' Candidates for chemotherapy', ' Able to understand and sign an informed consent (or have a legal representative who is able to do so)', ' Measurable disease according to RECIST v1.1', ' ECOG Performance Score (PS) of 2', ' Willing to abstain from sexual intercourse or to use an effective form of contraception during the study and for 90 days following the last dose of MM-121', 'Exclusion Criteria:', ' Prior radiation therapy to >25% of bone marrow-bearing areas', ' Evidence of any other active malignancy', ' Active infection or fever> 38.5°C during screening visits or on the first scheduled day of dosing', ' Symptomatic CNS disease', ' Known hypersensitivity to any of the components of MM-121 or who have had hypersensitivity reactions to fully human monoclonal antibodies', ' Received treatment, within 30 days prior to the first scheduled day of dosing, with any investigational agents that have not received regulatory approval for any indication or disease state', ' Pregnant or breast feeding'], 'Results': ['Outcome Measurement: ', ' Dose Escalation: To Evaluate the Safety and Tolerability of Escalating Doses of the MM-121 Plus Paclitaxel Combination Via Reporting of Dose-limiting Toxicity (DLT)', ' To establish the safety of escalating doses of MM-121 in combination with paclitaxel in order to determine the recommended phase 2 dose. Dose-escalation conducted using standard 3+3 model to determine maximum tolerated dose. Reports of Dose-Limiting Toxicities (DLTs) were assessed to determine the MTD.', ' Time frame: From date of first dose to 30 days after termination, the longest 163 weeks', 'Results 1: ', ' Arm/Group Title: Part 1: Dose Escalation: Cohort 1', ' Arm/Group Description: MM-121 - 20 mg/kg loading dose followed by 12 mg/kg weekly IV Paclitaxel - 80mg/m2 weekly IV', ' Overall Number of Participants Analyzed: 7', ' Measure Type: Number', ' Unit of Measure: participants reporting DLTs 0', 'Results 2: ', ' Arm/Group Title: Part 1: Dose Escalation: Cohort 2', ' Arm/Group Description: MM-121 - 40 mg/kg loading dose followed by 20 mg/kg weekly IV', ' Paclitaxel - 80mg/m2 weekly IV', ' Overall Number of Participants Analyzed: 3', ' Measure Type: Number', ' Unit of Measure: participants reporting DLTs 1'], 'Adverse Events': ['Adverse Events 1:', ' Total: 4/10 (40.00%)', ' SMALL INTESTINAL OBSTRUCTION * [1]3/10 (30.00%)', ' INTESTINAL OBSTRUCTION * [1]1/10 (10.00%)', ' INTESTINAL PERFORATION * [1]1/10 (10.00%)', ' ABDOMINAL PAIN * [1]0/10 (0.00%)', ' DIARRHOEA * [1]0/10 (0.00%)', ' GASTRITIS * [1]0/10 (0.00%)', ' PEPTIC ULCER * [1]0/10 (0.00%)', ' DEATH * [1]1/10 (10.00%)', ' DISEASE PROGRESSION * [1]0/10 (0.00%)', 'Adverse Events 2:', ' Total: 12/31 (38.71%)', ' SMALL INTESTINAL OBSTRUCTION * [1]0/31 (0.00%)', ' INTESTINAL OBSTRUCTION * [1]0/31 (0.00%)', ' INTESTINAL PERFORATION * [1]0/31 (0.00%)', ' ABDOMINAL PAIN * [1]1/31 (3.23%)', ' DIARRHOEA * [1]1/31 (3.23%)', ' GASTRITIS * [1]1/31 (3.23%)', ' PEPTIC ULCER * [1]1/31 (3.23%)', ' DEATH * [1]0/31 (0.00%)', ' DISEASE PROGRESSION * [1]3/31 (9.68%)', ' FATIGUE * [1]2/31 (6.45%)']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

d7e81d80-5cbf-4969-be00-4fdf17aa4eb9

Single

Eligibility

NCT00101400

A female with Hemoglobin > 10.0 g/dl, Absolute neutrophil count 1,733/mm3, platelet count = 100,000/µl and total bilirubin > 1.6 x ULN are eligilbe for the primary trial.

Entailment

{'Clinical Trial ID': 'NCT00101400', 'Intervention': ['INTERVENTION 1: ', ' Sorafenib (Nexavar, BAY43-9006)', ' Sorafenib 400 mg administered twice daily (b.i.d.)'], 'Eligibility': ['Inclusion Criteria:', ' Age > 18 years', ' Women with prior histologically documented diagnosis of breast cancer', ' Subjects with metastatic disease who have already received and failed at least one chemotherapy regimen for metastatic disease and, if ER/PgR +ve, have failed on at least adjuvant hormonal therapy', ' Subjects for whom trastuzumab treatment is not indicated, no longer effective or refused by the subjects', ' Four weeks since the last cytotoxic chemotherapy or clear evidence of progression on hormonal therapy', ' Subjects who have at least one measurable lesion by CT (Computed Tomography) scan or MRI (Magnetic Resonance Imaging) according to modified WHO Tumour Response Criteria', ' Subjects who have an Eastern Co-operative Oncology Group (ECOG) performance status of 0, 1 or 2', ' Adequate bone marrow, liver and renal function as assessed by the following laboratory evaluations:', ' Hemoglobin > 9.0 g/dl', ' Absolute neutrophil count (ANC) > 1,500/mm3', ' Platelet count = 100,000/µl', ' Total bilirubin =1.5 x the upper limit of normal.', ' Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST) = 2.5 x upper limit of normal (=5 x upper limit of normal for subjects with liver involvement of their cancer)', ' Amylase and lipase = 1.5 x the upper limit of normal', ' Serum creatinine = 3.0 x the upper limit of normal', ' Prothrombin Time (PT) or International Normalized Ratio (INR) and Partial Thromboplastin Time (PTT) < 1.5 x upper limit of normal (subjects who receive anti-coagulation treatment with an agent such as warfarin or heparin will be allowed to participate provided that no evidence of underlying abnormality in these parameters exists)', ' Subjects who give written informed consent prior to any study specific screening procedures with the understanding that the subject has the right to withdraw from the study at any time, without prejudice', ' Life expectancy of at least 12 weeks', ' Signed informed consent must be obtained prior to any study specific procedures', 'Exclusion Criteria:', ' Previous malignancy (except for cervical carcinoma in situ, adequately treated basal cell carcinoma, or superficial bladder tumours [Ta, Tis and T1] or other malignancies curatively treated > 2 years prior to entry)', ' Congestive heart failure > New York Heart Association (NYHA) Class II', ' Cardiac arrhythmia requiring anti-arrhythmic (excluding beta blockers or digoxin)', ' Active coronary artery disease or ischaemia', ' Active clinically serious bacterial or fungal infections (> grade 2 National Cancer Institute - Common Terminology Criteria for Adverse Events (NCI-CTCAE), Version 3)', ' Known History of Human Immunodeficiency Virus (HIV) infection or chronic hepatitis B or C', ' Metastatic brain or meningeal tumors unless the subject is > 6 months from definitive therapy, has a negative imaging study within 4 weeks of study entry and is clinically stable with respect to the tumor at the time of study entry. Also the patient must not be undergoing acute steroid therapy or taper (chronic steroid therapy is acceptable provided that the dose is stable for 1 month prior to and following screening radiographic study)', ' Subjects with seizure disorders requiring medication (such as steroid or anti-epileptics)', ' History of organ allograft', " Substance abuse, medical, psychological or social conditions that may interfere with the subject's participation in the study or evaluation of the study results", ' Known or suspected allergy to the investigational agent', ' Any condition that is unstable or which could jeopardize the safety of the subject and his/her compliance in the study. Pregnant or breast-feeding subjects. Women of childbearing potential must have a negative pregnancy test performed within seven days prior to the start of study drug. Women enrolled in this trial must use adequate barrier birth control measures during the course of the trial.', ' Excluded therapies include:', ' Anti-cancer chemotherapy, hormonal therapy or immunotherapy during the study or within 4 weeks of study entry. Mytomicin or nitroureas should not be given within 6 weeks of study entry', ' Significant surgery within 4 weeks prior to the start of study drug', ' Any bone marrow transplant or stem cell rescue within 4 months of the start of study drug', ' Radiotherapy during the study or within 3 weeks of the start of drug', ' Use of biologic response modifiers, such as Granulocyte-Colony Stimulating Factor (G-CSF), within 3 weeks of study entry', ' Investigational drug therapy outside of this trial during or within 30 days prior to start of the study drug', ' Concomitant treatment with ketoconazole, itraconazole, ritonavir, or use of grapefruit juice', ' Prior use of Raf-Kinase Inhibitors (RKI), Methyl Ethyl Ketone (MEK) or farnesyl transferase inhibitors', " Concomitant treatment or use of St. John's Wort", ' Prior use of bevacizumab and all other drugs that target Vascular Endothelial Growth Factor (VEGF)/VEGF receptors'], 'Results': ['Outcome Measurement: ', ' Number of Subjects With Response (Complete or Partial)', ' Number of subjects with metastatic breast cancer treated with single agent BAY43-9006 who had best overall response assessed as complete response (CR) or partial response (PR) as per Modified World Health Organization (WHO) Tumor Response Criteria.', ' Time frame: Until 30 days after termination of active therapy', 'Results 1: ', ' Arm/Group Title: Sorafenib (Nexavar, BAY43-9006)', ' Arm/Group Description: Sorafenib 400 mg administered twice daily (b.i.d.)', ' Overall Number of Participants Analyzed: 54', ' Measure Type: Number', ' Unit of Measure: participants Complete response (CR): 0', ' Partial response (PR): 1', ' Stable disease (SD): 20', ' Progressive disease (PD): 31', 'Not evaluated: 2'], 'Adverse Events': ['Adverse Events 1:', ' Total: 22/54 (40.74%)', ' Hemoglobin * 1/54 (1.85%)', ' Coagulation - Other * 1/54 (1.85%)', ' Supraventricular Arrhythmia, Supraventricular Tachycardia * 1/54 (1.85%)', ' Cardiac General - Other * 2/54 (3.70%)', ' Anorexia * 1/54 (1.85%)', ' Ascites * 2/54 (3.70%)', ' Nausea * 2/54 (3.70%)', ' Perforation, GI, Colon * 1/54 (1.85%)', ' Vomiting * 1/54 (1.85%)']}

{'Clinical Trial ID': '', 'Intervention': '', 'Eligibility': '', 'Results': '', 'Adverse Events': ''}

2206dc2a-93da-4c11-b110-81f9c39af807